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RNA splicing defects in cancer
R. K. Bradley*
Fred Hutchinson Cancer Research Center, Seattle, WA,
United States
Alternative RNA splicing, the process whereby a single
gene can give rise to many different proteins, has long
been known to be dysregulated in many cancers. Recent
studies have provided concrete genetic evidence that spli-
cing dysregulation directly promotes cancer initiation
and progression. For example, genes encoding RNA spli-
cing factors are recurrently mutated in both hematologic
malignancies and solid tumors. However, uncovering the
specific mechanisms by which these mutations promote
tumorigenesis has proven challenging. Here, I will discuss
recent progress in establishing functional links between
somatic mutations affecting RNA splicing factors and
tumorigenesis, the promise of correct mis-splicing for can-
cer therapy, and the recent creation of CRISPR/Cas-based
technologies for conducting mRNA isoform-level genetic
screens.
R. K. Bradley: None.
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PL2.1
Evaluation of DNA methylation episignatures for diag-
nosis and phenotype correlations in 42 Mendelian neu-
rodevelopmental disorders
E. Aref-Eshghi1, J. Kerkhof1, V. Pedro2, Groupe DI France,
M. Barat-Houari3, N. Ruiz-Pallares4, M. Alders5, M.
Mannens5, P. Henneman5, R. C. Hennekam6, A. Ciolfi7, S.
Pizzi7, M. Tartaglia7, P. M. Campeau8, J. Rousseau8, M. A.
Levy1,2, L. Brick9, M. Kozenko9, T. B. Balci1,2,10, V. M.
Siu1,2, A. Stuart1, M. Kadour1,11, J. Masters1,11, K.
Takano12, T. Kleefstra13,14, N. de Leeuw13,14, M. Field15, M.
Shaw16, J. Gecz16,17, G. Merla18, P. J. Ainsworth1,2, H.















Lee20, B. R. DuPont20, R. E. Stevenson20, S. A. Skinner20,
C. E. Schwartz20, D. Genevieve4,21, B. Sadikovic1,2*
1London Health Sciences Centre, London, ON, Canada,
2Western University, London, ON, Canada, 3Universitaire de
Montpellier, Montpellier, France, 4Centre Hospitalier Uni-
versitaire de Montpellier, Montpellier, France, 5Amsterdam
University Medical Centers, Amsterdam, Netherlands, 6Uni-
versity of Amsterdam, Amsterdam, Netherlands, 7Ospedale
Pediatrico Bambino Gesù, Rome, Italy, 8University of
Montreal, Montreal, QC, Canada, 9McMaster University,
Hamilton, ON, Canada, 10Lawson Health Research Institute,
London, ON, Canada, 11St. Joseph’s Health Care, London,
ON, Canada, 12Shinshu University Hospital, Nagano, Japan,
13Radboud University Medical Center, Nijmegen, Nether-
lands, 14Donders Center for Medical Neuroscience, Nijme-
gen, Netherlands, 15Hunter Genetics, Waratah, Australia,
16The University of Adelaide, Adelaide, Australia, 17South
Australian Health and Medical Research Institute, Adelaide,
Australia, 18IRCCS-Casa Sollievo della Sofferenza, San
Giovanni Rotondo, Italy, 19Children’s Health Research
Institute, London, ON, Canada, 20Greenwood Genetic Center,
Greenwood, SC, United States, 21Montpellier University,
Montpellier, France
Introduction: Genetic syndromes frequently present with
overlapping clinical features and negative or ambiguous
genetic findings which can confound accurate diagnosis and
clinical management. An expanding number of genetic
syndromes have been shown to have unique genomic DNA
methylation patterns (episignatures).
Materials and Methods: Peripheral blood episignatures
can be used for diagnostic testing as well as for the
interpretation of ambiguous genetic test results. We present
here an approach to episignature mapping of the largest
number of genetic syndromes studied to date (n = 42), which
has allowed the identification of 34 robust disease-specific
episignatures.
Results:We examine emerging patterns of overlap, as well
as similarities and hierarchical relationships across these
episignatures to highlight their key features as related to
genetic heterogeneity, dosage effect, unaffected carrier status,
and incomplete penetrance. We demonstrate the necessity of
multiclass modeling for accurate genetic variant classification.
We demonstrate the utility of this tool in resolving ambiguous
clinical cases and identification of previously undiagnosed
cases through mass screening of a large cohort of subjects
with developmental delays and congenital anomalies. Finally,
we outline and present early data from a Canadian national
clinical trial EpiSign-CAN currently enrolling 4000 patients
to assess impact of this novel diagnostic technology on
diagnosis of neurodevelopmental conditions.
Conclusions: This study more than doubles the number
of published syndromes with DNA methylation episigna-
tures, and most significantly, opens new avenues for
accurate diagnosis and clinical assessment in individuals
affected by these disorders.
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PL2.2
Identity-by-descent detection across 487,409 British
samples reveals fine-scale population structure, evolu-
tionary history, and trait associations
J. Nait Saada1*, G. Kalantzis1, D. Shyr2, M. Robinson3,
A. Gusev4,5, P. Palamara1,6
1Department of Statistics, University of Oxford, Oxford,
United Kingdom, 2Department of Biostatistics, Harvard T.
H Chan School of Public Health, Boston, MA, United
States, 3Department of Computer Science, University of
Oxford, Oxford, United Kingdom, 4Brigham & Women’s
Hospital, Division of Genetics, Boston, MA, United States,
5Department of Medical Oncology, Dana-Farber Cancer
Institute, Boston, MA, United States, 6Wellcome Centre for
Human Genetics, University of Oxford, Oxford, United
Kingdom
The sharing of identical-by-descent (IBD) genomic seg-
ments is a key indicator of genetic relatedness between
individuals and plays an important role in a wide range of
genomic analyses. We developed a new method, called
FastSMC, that enables accurate biobank-scale detection of
IBD segments transmitted by common ancestors living up
to several hundreds of generations in the past. FastSMC
combines a fast heuristic search for IBD segments with
accurate coalescent-based likelihood calculations and esti-
mates the age of common ancestors transmitting IBD
regions. We applied FastSMC to 487,409 phased samples
from the UK Biobank and detected the presence of ~214
billion IBD segments transmitted by shared ancestors within
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the past 1,500 years. We quantified time-dependent shared
ancestry within and across 120 postcodes, obtaining a fine-
grained picture of genetic relatedness within the past two
millennia in the UK. Sharing of common ancestors strongly
correlates with geographic distance, enabling us to localise
a sample’s birth coordinates from genomic data with a
median error of 44 km. We analysed genomic regions with
unusually high density of shared ancestry, which is indi-
cative of recent positive selection, and detected 12 genome-
wide significant signals, including 7 novel sites. We found
IBD sharing to be highly predictive of the sharing of ultra-
rare variants in exome sequencing samples from the UK
Biobank, enabling us to detect 29 associations (20 of which
novel) with 7 blood-related traits. These results underscore
the importance of modelling distant relatedness to reveal
subtle population structure, recent evolutionary history, and
rare pathogenic variation.
J. Nait Saada: None. G. Kalantzis: None. D. Shyr: None.
M. Robinson: None. A. Gusev: None. P. Palamara: None.
PL2.3
Large-scale targeted sequencing identifies risk genes for
neurodevelopmental disorders
M. Kvarnung1,2*, T. Wang3, K. Hoekzema3, D. Vecchio4, H.
Wu5, A. Sulovari3, B. P. Coe3, M. A. Gillentine3,
A. B. Wilfert3, A. Lindstrand1,2, A. Nordgren1,2,
B. Anderlid1,2, J. A. Rosenfeld6,7, P. Liu6,7, ASID
Consortium3, I. E. Scheffer8,9,10, N. Brunetti-Perri11,12,
N. Rommelse13,14, D. G. Amaral15, G. W. E. Santen16,
E. Trabetti17, Z. Sedláček18, J. J. Michaelson19, E.
Courchesne20, F. R. Kooy21, The SPARK Consortium22,
C. Romano23, H. Peeters24, R. A. Bernier25, J. Gecz26,27,28,
K. Xia5,29, E. E. Eichler3,30,31, M. Nordenskjöld1,2
1Dept of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm, Sweden, 2Department of Clinical
Genetics, Karolinska University Hospital, Stockholm,
Sweden, 3Department of Genome Sciences, University of
Washington, Seattle, WA, United States, 4Rare Disease and
Medical Genetics, AcademDepartment of Pediatrics, Bam-
bino Gesu Children’s Hospital, Rome, Italy, 5Center of
Medical Genetics & Hunan Key Laboratory of Medical
Genetics, School of Life Sciences, Central South University,
Changsha, Hunan, China, 6Department of Molecular &
Human Genetics, Baylor College of Medicine, Houston, TX,
United States, 7Baylor Genetics, Houston, TX, United
States, 8Murdoch Children’s Research Institute, Melbourne,
Australia, 9Department of Paediatrics, Royal Children’s
Hospital and Department of Medicine, Austin Health,
University of Melbourne, Melbourne, Australia, 10The
Florey Institute of Neuroscience and Mental Health,
Parkville, Victoria, Australia, 11Department of
Translational Medicine, Federico II University, Naples,
Italy, 12Telethon Institute of Genetics and Medicine,
Pozzuoli, Naples, Italy, 13Department of Psychiatry,
Donders Institute for Brain, Cognition and Behaviour,
Radboud University Medical Center, Nijmegen, Nether-
lands, 14Karakter Child and Adolescent Psychiatry Center,
Nijmegen, Netherlands, 15Department of Psychiatry and
Behavioral Sciences and the MIND Institute, University of
California, Davis, Sacramento, CA, United States,
16Department of Clinical Genetics, Leiden University
Medical Center (LUMC), Leiden, Netherlands, 17Depart-
ment of Neurosciences, Biomedicine and Movement
Sciences, University of Verona, Verona, Italy, 18Depart-
ment of Biology and Medical Genetics, Charles University
2nd Faculty of Medicine and University Hospital Motol,
Prague, Czech Republic, 19Department of Psychiatry,
University of Iowa Carver College of Medicine, Iowa city,
IA, United States, 20Department of Neurosciences, UC San
Diego Autism Center, School of Medicine, University of
California San Diego, La Jolla, CA, United States,
21Department of Medical Genetics, University of Antwerp,
Antwerp, Belgium, 22Simons Foundation, New York, NY,
United States, 23Oasi Research Institute-IRCCS, Troina,
Italy, 24Centre for Human Genetics, KU Leuven and Leuven
Autism Research (LAuRes), Leuven, Belgium, 25Department
of Psychiatry and Behavioral Sciences, University of
Washington, Seattle, WA, United States, 26Adelaide Medical
School and the Robinson Research Institute, the University
of Adelaide, South Australia, Australia, 27Genetics and
Molecular Pathology, SA Pathology, Adelaide, South
Australia, Australia, 28South Australian Health and Med-
ical Research Institute, Adelaide, South Australia, Austra-
lia, 29CAS Center for Excellence in Brain Science and
Intelligences Technology (CEBSIT), Chinese Academy of
Sciences, Shanghai, China, 30Howard Hughes Medical
Institute, University of Washington, Seattle, WA, United
States, 31Corresponding author, Seattle, WA, United States
Introduction: Large-scale exome sequencing studies have
identified hundreds of genes with significant excess of de
novo mutations (DNMs) in neurodevelopmental disorders
(NDDs). In this collaborative study, we assessed 125 can-
didate and high-confidence genes in a large cohort of
NDD cases.
Materials and Methods:We targeted 63 candidate genes
for resequencing among 16,321 NDD cases and an
additional 62 high-confidence genes in 6,211 NDD cases.
In order to test for significance at the level of case-control
mutation burden and integrating with previously published
data, we assessed these genes among NDD cases and
compared the mutation burden to nonpsychiatric controls
from ExAC. These genes were assessed also in a combined
set of 17,426 NDD parent-child trios. Furthermore,
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thorough phenotype studies for seven of the genes with
evidence of mutational burden were performed in a subset
of the patients.
Results: We identified 48 genes (25 newly reported) with
a significant burden of ultra-rare (MAF < 0.01%) severe
mutations. Among the 125 targeted genes, we show that 90
genes are also enriched for DNMs in parent-child trios. We
here focus on seven genes (CTCF, HNRNPU, KCNQ3,
ZBTB18, TCF12, SPEN and LEO1) for detailed clinical
descriptions to delineate the associated phenotypes and
clinical presentation of these specific and newly described
neurodevelopmental disorders.
M. Kvarnung: None. T. Wang: None. K. Hoekzema: None.
D. Vecchio: None. H. Wu: None. A. Sulovari: None. B. P.
Coe: None. M. A. Gillentine: None. A. B. Wilfert: None. A.
Lindstrand: None. A. Nordgren: None. B. Anderlid: None. J.
A. Rosenfeld: None. P. Liu: None. -. ASID Consortium:
None. I. E. Scheffer: None. N. Brunetti-Perri: None. N.
Rommelse: None. D. G. Amaral: None. G. W. E. Santen:
None. E. Trabetti: None. Z. Sedláček: None. J. J. Michaelson:
None. E. Courchesne: None. F. R. Kooy: None. -. The
SPARK Consortium: None. C. Romano: None. H. Peeters:
None. R. A. Bernier: None. J. Gecz: None. K. Xia: None. E.
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PL2.4
Genomic and transcriptomic profiling of malformations
of cortical development: from tissue to single-cell
resolution
S. Baldassari1,2,3*, M. Chipaux4, E. Marsan1,2,3, S. Ferrand-
Sorbets4, G. Dorfmüller4, H. Adle-Biassette5,6,7, S.
Baulac1,2,3
1ICM Institut du Cerveau et de la Moelle épinière, Paris,
France, 2Sorbonne Université, UPMC Univ Paris 06, UMR
S 1127, INSERM, U1127, Paris, France, 3CNRS, UMR
7225, Paris, France, 4Department of Pediatric Neurosur-
gery, Rothschild Foundation Hospital, Paris, France,
5INSERM UMR 1141, Hôpital Robert-Debré, Paris,
France, 6Faculté de Médecine Denis Diderot, Université
Paris 7, Paris, France, 7Service d’Anatomie et de Cytologie
Pathologiques, Hôpital Lariboisière, APHP, Paris, France
Introduction: Malformations of cortical brain development,
such as focal cortical dysplasia (FCD) and hemi-
megalencephaly (HME), are important causes of severe
pediatric drug-resistant epilepsies subjected to neurosurgery.
At neuropathological assessment, FCD-II subtype is char-
acterized by enlarged dysmorphic neurons (DNs) and balloon
cells (BCs) due to mTOR pathway hyperactivation.
Methods and Results: We performed ultra-deep targeted
gene sequencing on matched blood-brain resected samples
to search for low-allele frequency variants in a panel
of mTOR pathway and FCD genes in 99 FCD patients. We
report that ~30% of FCD-I patients carried somatic loss-of-
function SLC35A2-variants and ~60% of FCD-II/HME
patients presented somatic gain-of-function MTOR, AKT3,
PIK3CA and RHEB-variants or two-hit, germline and
somatic loss-of function DEPDC5, NPRL3, TSC1 and
TSC2 variants. Analysis by droplet digital PCR of
microdissected cells demonstrated that only DNs and BCs
in FCD-II/HME carry the pathogenic variants, and that loss-
of-heterozygosity in DNs in DEPDC5-mutated cases
represents a mutational mechanism in FCD. Global
unsupervised analysis of RNAseq from frozen bulk tissues
from 20 mutated patients showed clusters independent of
the nature of the variant/gene. We therefore performed
single-nuclei RNAseq from mutated frozen resected brain
tissues to better resolve the mosaic nature of the lesions and
investigate the cellular heterogeneity characterizing FCD.
Cell-type specific transcriptomic profiling revealed novel
insights into epilepsy pathogenic mechanisms.
Conclusions: Our novel findings represent an important
advancement in understanding the genetic etiology and
mechanisms underlying epilepsies associated to malforma-
tions of the cortical development. This work was funded by
the ERC grant n.682345 and Easi-Genomics Access grant
S. Baldassari: None. M. Chipaux: None. E. Marsan:
None. S. Ferrand-Sorbets: None. G. Dorfmüller: None. H.
Adle-Biassette: None. S. Baulac: None.
PL2.5
TAD-shuffling at the FGF8 locus causes Split-Hand/
Foot Malformation type 3
G. Cova1,2*, R. Schöpflin1, R. Falcone1, B. Timmermann1, L.
Wittler1, O. Zuffardi3, M. Spielmann1,2, S. Mundlos1,2
1Max Planck Institute for Molecular Genetics, Berlin,
Germany, 2Institute for Medical Genetics and Human
Genetics, Charité - Universitätsmedizin Berlin, Berlin,
Germany, 3Department of Molecular Medicine, University
of Pavia, Pavia, Italy
In recent years chromosome conformation capture assays
such as Hi-C revealed that mammalian genomes are orga-
nized in genomic units called topologically associated
domains (TADs). TADs provide the regulatory scaffold for
physical contacts between regulatory elements and their
target genes. Structural variations, such as duplications,
deletions and inversions, can result in disruptions of TAD
structures, gene misexpression and consequently in human
diseases. Split-Hand/Foot Malformation type 3 is a rare
congenital limb defect affecting the central digits of hands
and feet and has been associated with tandem duplications
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at the FGF8 locus. In order to investigate the molecular
pathomechanism underlying this disease we mapped 25
duplications and one inversion at the FGF8 locus and we
generated mice carrying the corresponding rearrangements
using the CRISPR/Cas9 system. Capture Hi-C maps span-
ning the Fgf8 locus revealed the presence of ectopic inter-
actions between the Fgf8 endogenous regulatory elements
and an unrelated gene within the locus in mutant mice
compared to wild-type. We showed that both in the tandem
duplications and the inversion, the Fgf8 enhancers are
relocated into a new TAD causing misexpression of the
neighbouring gene in an Fgf8-like pattern in the limb bud.
This ectopic expression in the apical ectodermal ridge of
developing limbs is associated with the limb phenotype
observed in mice and in human patients. Therefore, our
functional data show that TAD-shuffling at the Fgf8 locus is
the cause of this human limb malformation syndrome and
further highlight this new mutational mechanism and its role
in human disease.
G. Cova: None. R. Schöpflin: None. R. Falcone: None. B.
Timmermann: None. L. Wittler: None. O. Zuffardi: None.
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The enrichment of breakpoints in late-replicating
chromatin provides novel insights into chromoanagen-
esis mechanisms
N. Chatron1,2,3*, G. Giannuzzi3, P. Rollat-Farnier1,4,
F. Diguet1,2, E. Porcu3, T. Yammine1,2, K. UGUEN5,
Z. Bellil1,2, J. Lauer Zillhardt6, A. Sorlin7, F. Ader8,
A. Afenjar9, J. Andrieux10, C. Bardel4, E. Calpena11,
S. Chantot-Bastaraud12, P. Callier7, N. Chelloug13,
E. Chopin14, M. Cordier1, C. Dubourg15,16, L. Faivre17,
F. Girard18, S. Heide19, Y. Herenger20, S. Jaillard21,
B. Keren19, S. J. L. Knight22, J. Lespinasse23, L. Lohmann24,
N. Marle7, R. Maroofian25, A. Masurel-Paulet17,
M. Mathieu-Dramard26, C. Metay27, A. T. Pagnamenta22,
M. Portnoï12, F. Prieur28, M. Rio29, J. Siffroi30,
S. Valence31,32, J. C. Taylor22, A. O. M. Wilkie11,
P. Edery1,2, A. Reymond3, D. Sanlaville1,2, C. Schluth-
Bolard1,2
1Service de Génétique, Hospices Civils de Lyon, Lyon,
France, 2Equipe GENDEV, CRNL, INSERM U1028, CNRS
UMR5292 UCBL1, Lyon, France, 3Center for Integrative
Genomics, University of Lausanne, Lausanne, Switzerland,
4Cellule Bioinformatique Plateforme NGS, Hospices Civils de
Lyon, Lyon, France, 5Service de Génétique, CHU Brest,
Brest, France, 6Unité de Diagnostic Préimplantatoire,
Laboratoires de Diagnostic Génétique, Hôpitaux Universi-
taires de Strasbourg, Strasbourg, France, 7Laboratoire de
génétique chromosomique et moléculaire, CHU de Dijon,
Dijon, France, 8AP-HP, Département de Génétique médicale,
Cardiogénétique et myogénétique moléculaire et cellulaire,
Hôpital de la Pitié-Salpêtrière, Paris, France, 9AP-HP,
Département de Génétique médicale, UF de Génétique
clinique, hôpital d’Enfants Armand Trousseau, Paris, France,
10CHRU de Lille, Service de génétique, Hôpital Jeanne de
Flandre, Lille, France, 11Clinical Genetics Group, MRC
Weatherall Institute of Molecular Medicine, University of
Oxford, Oxford, United Kingdom, 12AP-HP, Département de
Génétique médicale, UF de Génétique chromosomique,
hôpital d’Enfants Armand Trousseau, Paris, France,
13Laboratoire de cytogénétique, Service de génétique médi-
cale, CHRU Tours, Tours, France, 14Centre de Biotechno-
logie Cellulaire, Hospices Civils de Lyon, Lyon, France,
15Service de Génétique Moléculaire et Génomique médicale,
CHU Rennes, Rennes, France, 16IGDR, CNRS UMR 6290,
Université de Rennes 1, Rennes, France, 17Centre de
génétique, Hôpital d’enfants, CHU de Dijon, Dijon, France,
18Laboratoire de cytogénétique constitutionnelle et prénatale,
CHU Strasbourg, Strasbourg, France, 19APHP, Département
de Génétique et Centre de Référence Déficiences Intellec-
tuelles de Causes Rares, Hôpital de la Pitié-Salpêtrière,
Paris, France, 20Service de génétique médicale, CHRU
Tours, Tours, France, 21Service de cytogénétique et biologie
cellulaire, CHU Rennes, Rennes, France, 22Oxford NIHR
Biomedical Research Centre, Wellcome Centre for Human
Genetics, University of Oxford, Oxford, United Kingdom,
23Service de génétique, CH Métropole Savoie, Chambéry,
France, 24Département de génétique, Laboratoire CERBA,
Saint-Ouen l’Aumône, France, 25Institute of Neurology,
University College London, London, United Kingdom, 26Ser-
vice de génétique clinique et oncogénétique, CHU Amiens-
Picardie, Amiens, France, 27AP-HP, Hôpital Henri Mondor,
Créteil, France, 28Service de Génétique Clinique, Chromo-
somique et Moléculaire, CHU Hôpital Nord, Saint-Etienne,
France, 29AP-HP, Service de Génétique Médicale, Hôpital
Necker-Enfants Malades, Paris, France, 30AP-HP, Départe-
ment de Génétique médicale, UF de Génétique chromosomi-
que, hôpital d’Enfants Armand Trousseau, Paris, Paris,
France, 31Sorbonne Université, GRC n°19, pathologies
Congénitales du Cervelet-LeucoDystrophies, Paris, France,
32AP-HP, Hôpital Armand Trousseau; GHUEP, Service de
Neurologie Pédiatrique, Paris, France
The rise of pangenomic molecular assays allowed uncovering
complex rearrangements named chromoanagenesis that were
hypothesized to result from catastrophic shattering events.
Constitutional cases have typically been reported individually
preventing identification of common features and uncovering
the mechanisms at play. We characterized 20 new chro-
moanagenesis and discovered yet-undescribed features. While
literature differentiates chromothripsis and its shattering event
repaired through non-homologous end joining from
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chromoanasynthesis born to aberrant replicative processes,
we identified shattered chromosomes repaired through a
combination of mechanisms. In particular, three samples
present with “rearrangement hubs” comprising a fragmented
kilobase-long sequence threaded throughout the rearrange-
ment. To assess the mechanisms at play, we merged our data
with those of 20 published constitutional complex chromo-
somal rearrangement cases. We evaluated if the distribution of
their 1033 combined breakpoints was distinctive using boot-
strap simulations and found that breakpoints tend to keep
away from haplosensitive genes suggesting selective pressure.
We then compared their distribution with that of 13,310 and
468 breakpoints of cancer complex chromosomal rearrange-
ments and constitutional simple rearrangement samples,
respectively. Both complex rearrangement groups showed
breakpoint enrichment in late replicating regions suggesting
similar origins for constitutional and cancer cases. Simple
rearrangement breakpoints but not complex ones were
depleted from lamina-associated domains (LADs), possibly as
a consequence of reduced mobility of DNA ends bound to
lamina. The enrichment of breakpoints in late-replicating
chromatin for both constitutional and cancer chromoanagen-
esis provides an orthogonal support to the premature chro-
mosome condensation hypothesis that was put forward to
explain chromoanagenesis.
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None. F. Diguet: None. E. Porcu: None. T. Yammine: None.
K. Uguen: None. Z. Bellil: None. J. Lauer Zillhardt: None. A.
Sorlin: None. F. Ader: None. A. Afenjar: None. J. Andrieux:
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None. R. Maroofian: None. A. Masurel-Paulet: None. M.
Mathieu-Dramard: None. C. Metay: None. A. T. Pagnamenta:
None. M. Portnoï: None. F. Prieur: None. M. Rio: None. J.
Siffroi: None. S. Valence: None. J. C. Taylor: None. A. O. M.
Wilkie: None. P. Edery: None. A. Reymond: None. D.
Sanlaville: None. C. Schluth-Bolard: None.




University of Plymouth (retired), Plymouth, United Kingdom
The definition of genetic counselling includes the important
terms, ‘psychological’ and ‘adaptation’. While practising
clinically, I started my research work because I wondered
what made a difference to the family’s ability to cope and
adapt. In this presentation I will discuss early work that
influenced me, my own research journey and thoughts for the
future of research in genetic counselling. My own studies,
undertaken from 1994 to 2019, have reinforced my belief that,
although communicating scientific information is important,
addressing the psychological issues that inevitably arise
alongside a genetic diagnosis is essential to enable the family
to adjust and adapt the information to their own lives. My
doctoral study, for example, showed that people had difficulty
in applying the scientific information to their personal cir-
cumstances unless they believed that the practitioner related to
them as an individual, and that improving psychological
peace of mind was a major motivator for those using genetic
services. Despite the clinical advances of the past four dec-
ades, studies still indicate that family members fail to com-
municate genetic risk to each other, that genetic decision
making can still be fraught with distress and ambivalence and
a proportion of those who could benefit from screening and/or
treatment fail to seek it. I would argue that addressing these
issues still falls within the remit of genetic health profes-
sionals, particularly genetic counsellors, but there is a dearth
of research, particularly using qualitative methods, to inform
current practice. Genetic counsellors can be overwhelmed by
the ever-expanding body of genomic science underpinning
our work. However, there is a continuing challenge for
counsellors in this ultra-information era to offer psychological
support to family members to enable information to be uti-
lised, support family communication and to reach those who
are unaware of their options. I emphasise the need for more
applied research, especially addressing questions initiated by




S01 What to Expect from Prenatal Diagnosis
S01.1
Prenatal Genomic Approach to Genetic Diseases of Bone
D. Krakow*
UCLA, Los Angeles, CA, United States
Skeletal dysplasia are a heterogenous group of mendelian
disorders that often present in the prenatal period. With the
expansion of available genomic technologies, many of these
techniques have been applied to both the preimplantation and
prenatal periods. These methodologies include noninvasive
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prenatal testing for de novo or dominantly inherited skeletal
disorders, couple screening for recessively inherited skeletal
diseases, PGT for familial inherited disorders. microarray
analysis for copy number variation, gene panels for skeletal
dysplasias and related diseases, and exome analysis. The
disease genes have been identified for most of the >460
established skeletal dysplasias, thus affording the opportunity
to address the molecular basis of most of the skeletal disorders
that will present in the prenatal period. Use of exome analysis
has identified previously unappreciated prenatal onset dis-
orders, expanding the number of defined skeletal disorders.
However, in spite of the advances in genomic technologies,
the mainstay of prenatal diagnosis remains prenatal ultrasound
evaluation. Most cases of skeletal dysplasia are detected by
prenatal ultrasound and appreciation of the ultrasound find-
ings helps guide diagnosis and genomic analyses. Key ultra-
sound findings including lethality can help guide management
pending the results of molecular diagnosis.
D. Krakow: None.
S01.2
Pandora’s Pregnancy - A new Era for Prenatal Genetic
Testing
Y. Hashiloni-Dolev1*, T. Nov-Klaiman2, A. Raz3
1Ben-Gurion University of the Negav, Israel, Tel Aviv,
Israel, 2Ben-Gurion University of the Negav, Israel,
Munich, Israel, 3Ben-Gurion University of the Negav,
Israel, Be’er Sheva, Israel
The talk is based on conceptual analysis of seminal works
that shaped the socio-ethical discourse surrounding the
experiences of parents as well as professionals with prenatal
diagnosis in the last thirty years. It delineates a shift from
the "traditional" technologies of karyotyping in PND to the
current phase of advanced genetic technologies including
non-invasive prenatal testing (NIPT), chromosomal micro-
array analysis (CMA) and whole-exome sequencing (WES)
with their higher detection rate and related abundance of
uncertain data. The talk will consider the implications of
this new era of PND for patients and health professionals by
drawing on previous studies documenting how probability
and uncertainty affect informed consent/choice, health risks
communication, customer satisfaction and decision-making,
and parent-child bonding. I will argue that these changes
move us beyond the idioms and realities of the "tentative
pregnancy" and "moral pioneering", to uncertainty, prob-
ability-based counseling and moral/translational gambling. I
will conclude by discussing what is needed to maintain
hope in the era of Pandora’s pregnancy.
Y. Hashiloni-Dolev: None. T. Nov-Klaiman: None. A.
Raz: None.
S02 Liquid Biopsy for Early Detection of Cancer
S02.1
Methylation Patterns of Plasma DNA in Health and
Disease
Y. Dor*
The Hebrew University of Jerusalem, Jerusalem, Israel
Each cell type has a unique and stable DNA methylation
pattern, reflecting its gene expression program. We have
established a comprehensive atlas of tissue and cell type-
specific human methylomes, allowing to define multiple
loci that are unmethylated or methylated specifically in a
given cell type. We are using these loci as biomarkers to
identify the tissue origins of cfDNA, and to infer physio-
logic and pathologic tissue dynamics. I will discuss exam-
ples for the use of tissue specific cfDNA methylation
patterns including the detection of cardiomyocyte cfDNA
after myocardial infarction and in sepsis; the detection of
tissue-specific cfDNA in patients with early and late stage
cancer; and a dissection of the phenomenon of elevated




What ancient humans can teach us about modern
genetic variation
J. Kelso1,2*
1Leipzig, Germany, 2Max Planck Institute for Evolutionary
Anthropology, Leipzig, Germany
Recent technological advances have made it possible to
recover genome sequences from a number of archaic and
early modern humans. These genomes offer a unique
opportunity to identify genetic changes that have come to
fixation or reached high frequency in modern humans since
the divergence from our common ancestor with Neandertals
and Denisovans. Analyses of these archaic genomes have
also provided direct evidence for interbreeding between
early modern and archaic humans. As a result all present-
day people outside of Africa carry approximately 2%
Neandertal DNA, and some populations, largely in Oceania,
also carry DNA from Denisovans. This introgressed DNA
has been shown to have both positive and negative out-
comes for present-day carriers: underlying apparently
adaptive phenotypes as well as influencing disease risk. In
recent work we have identified Neandertal haplotypes that
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are likely of archaic origin and determined the likely
functional consequences of these haplotypes using public
genome, gene expression, and phenotype datasets. We have
also used simulations, as well as the distribution of Nean-
dertal DNA in ancient modern humans, to understand how
selection has acted on Neandertal introgressed sequences
over the last 45,000 years.
S04 Public and Patient Engagement
S04.1
The Patient’s Role in New Disease Gene Discovery
C. P. Schaaf*
University Hospital Heidelberg, Heidelberg, Germany
The practice of clinical genetics has been revolutionised by
the implementation of next generation sequencing. Novel
disease genes are recognised on a weekly basis, and the
number of OMIM-listed disease-gene associations con-
tinues to increase steadily.
What are the characteristics of “patient no.1”, and how do
you engage with your patient families to work together
beyond the initial disease gene discovery?
Here, we highlight the discovery of Schaaf-Yang
syndrome, a rare neurodevelopment disorder caused by
truncating mutations in MAGEL2, a protein-coding gene
within the Prader-Willi syndrome domain on chromosome
15q11.2. We highlight ongoing physician-patient interac-
tions, leading to a deeper understanding of disease
phenotype, genotype-phenotype interactions, but also
molecular mechanisms and avenues towards therapeutic
development.
C. P. Schaaf: None.
S04.2
Experiences with public engagement: Estonian Bio-
bank’s example
A. Allik1,2*, A. Metspalu2, L. Leitsalu2, L. Milani2
1Tartu, Estonia, 2Estonian Genome Center, Institute of
Genomics, University of Tartu, Tartu, Estonia
Introduction: The Estonian government launched a pro-
gram in 2018 to map the microarray-based genotypes of
100,000 out of 1.3 million inhabitants. The goal of this
initiative was to introduce the collected genotype data in
Estonia’s upgraded healthcare system for delivering perso-
nalized medicine information. Estonia’s healthcare system
has been revolutionized by innovative e-solutions and has
become beneficial for patients, doctors, hospitals, and also
the government for its convenient accessibility and rea-
sonable maintenance costs. Each citizen in Estonia has an
online e-Health record that can be accessed with the per-
son’s electronic ID-card which makes the e-Health medical
record system secure and the information easily accessible
to authorized individuals. The project has been a huge
challenge for the Estonian Biobank, considering that the
first set of 52,000 biobank participants were recruited over a
10-year period (2002-2011). The new recruitment started in
2018, afterwards an additional 150+ thousand people have
joined the biobank. In total, the biobank participants cover
approximately 20% of the adult population of Estonia. Long
before the new recruitment, in 2015, Estonian Biobank
started providing personalized genetic feedback to the bio-
bank participants and an interest towards it is huge. by now
Around 3000 people have received their feedback reports
by now. As a result, the government of Estonia has laun-
ched the Personalized medicine program and invested 5,
million € for developing state-of-the-art digital decision
support system to use the gathered genomic information in
the Estonian healthcare system.
Methods: In order to recruit an additional 15% of the
adult population of Estonia, traditional marketing tools
were applied to gain public attention and support to
benefit the nationwide project with a minimized budget.
Our approaches included: explaining the benefits of using
the genetic information in healthcare system by public
media, involving social media influencers, and arranging
social media challenges to draw the attention and raise
interest to the project. Enrolment consisted of digitally
signed consents using Estonian ID-card systems, and
blood sample donations collected through a wide network
of pharmacies.
Results: By the end of 2019, there are 200,000+ biobank
participants, increasing the biobank cohort from previous
5% to 20% of adult population of Estonia in less than
two years.
Conclusion: A lot can be done if you think out-of-the-
box! The approaches we used and experiences gained
throughout this project can be successfully used by other
countries.
A. Metspalu: None. L. Leitsalu: None. L. Milani: None.
S04.3
My DNA, whose business is it anyway? A Citizen Forum
on the Societal Impact of Genomics
W. Van Hoof*, C. Mayeur
Sciensano, Brussels, Belgium
Precision medicine, personalized screening, prevention,
ever-expanding commercial services and the need for
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massive data sharing in genomics have led to a need to
engage the public in a discussion on the governance of
genomic information. Therefore, Sciensano and the King
Baudouin Foundation organized a Belgium citizen forum
on the ethical, legal, and societal implications (ELSI)
surrounding the use of genomic information. This delib-
erative forum resulted in policy recommendations for the
Belgian Minister of Public Health, related experts and
stakeholders. The citizen forum consisted of an issue
framing workshop, where experts indicated which ques-
tions the citizens needed to answer. This was followed by
the citizen forum, where 32 citizens discussed these
questions over three weekends, while being informed by a
neutral information package and a wide range of resource
persons. Finally, the recommendations of the citizens
formed the basis for a stakeholder workshop, where
experts and policy makers discussed the potential imple-
mentation of these recommendations into practice. The
entire process was supported by an expert committee and
audited by two independent researchers. The qualitative
analysis of the citizen forum showed that the citizen panel
talked about the genome as their property because it is the
most intimate part of an individual. Based on this state-
ment, citizens require autonomy in decision-making
related to the use of their genomic information and con-
sider that it is society’s responsibility to provide citizens
with the rights of individual control, transparency, and
traceability in the uses of this information. Citizens must
use these rights responsibly to protect their privacy. The
citizen panel strongly believes that “Individuals are more
than their genome and should not be prisoners of it”. To
this end, protection against any form of discrimination,
categorization, and rejection of individuals based on their
genetic makeup must be established. The citizens assert
that there are many societal responsibilities to protect
citizens from downsides and promote upsides from the
use of genomic information: the precautionary principle
should guide the way in the development of a framework
for genomics. Within a well-developed framework that
inspires trust around the use of genomic data, solidarity
and reciprocity are core values that citizens support in the
context of genomic data sharing. Citizens identify a range
of individual responsibilities in decision making in
genomics and accept that societal nudges might be
required to balance personal interests and the common
good. This citizen forum shows that citizens can make
meaningful contributions to a complex field like ELSI in
genomics. Continued citizen involvement of the public in
the governance of genomic information in society is vital.
It ensures that societal norms and values guide the tech-
nology and not the other way around.
W. Van Hoof: None. C. Mayeur: None.
S05 Development and Disease at Single Cell Resolution
S05.1
Embryo-scale, single-cell spatial transcriptomics
S. Srivatsan1, M. Regier1, E. Barkan1, J. Packer1, P.
Grosjean1, S. Saxton1, J. Ladd2, M. Spielmann3, P. Lampe2,
J. Shendure1,4,5, K. Stevens1, C. Trapnell4,6*
1University of Washington, Seattle, WA, United States,
2Fred Hutch Cancer Research Center, Seattle, WA, United
States, 3Max Planck Institute for Molecular Genetics,
Berlin, Germany, 4Brotman Baty Institute for Precision
Medicine, Seattle, WA, United States, 5Howard Hughes
Medical Institute, Seattle, WA, United States, 6Seattle, WA,
United States
Spatial patterns of gene expression span many scales, and are
shaped by both local (e.g. cell-cell interactions) and global
(e.g. tissue, organ) context. However, most in situ methods for
profiling gene expression either average local contexts or are
restricted to limited fields of view. Here we introduce sci-
Space, a scale-flexible method for spatial transcriptomics that
retains single cell resolution while simultaneously capturing
heterogeneity at larger scales. As a proof-of-concept, we
apply sci-Space to the developing mouse embryo, capturing
the approximate spatial coordinates of profiled cells from
whole embryo serial sections. We identify genes including
Hox-family transcription factors expressed in an anatomically
patterned manner across excitatory neurons and other cell
types. We also show that sci-Space can resolve the differential
contribution of cell types to signalling molecules exhibiting
spatially heterogeneous expression. Finally, we develop and
apply a new statistical approach for quantifying the con-
tribution of spatial context to variation in gene expression
within cell types.
S. Srivatsan: None. M. Regier: None. E. Barkan: None. J.
Packer: None. P. Grosjean: None. S. Saxton: None. J. Ladd:
None. M. Spielmann: None. P. Lampe: None. J. Shendure:
None. K. Stevens: None.
S05.2
Cellular drivers of injury response and regeneration in
the zebrafish heart
J. P. Junker*
Berlin Institute for Medical Systems Biology (BIMSB),
Berlin, Germany
A key goal of developmental biology is to understand how a
single cell transforms into a full-grown organism consisting
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of many cells. Although impressive progress has
been made in lineage tracing using imaging approaches,
analysis of vertebrate lineage trees has mostly been lim-
ited to relatively small subsets of cells. Here we
present LINNAEUS, a strategy for massively parallel
lineage tracing on the single cell level. We exploit the
fact that Cas9-induced generation of double-strand
breaks leads to formation of short insertions or deletions
(“genetic scars”) that are variable in their length and
position. We demonstrate that these genetic scars have
very high complexity, making them ideal cellular bar-
codes for lineage analysis. Reading out scar sequences
by single-cell RNA-seq enables us to simultaneously
measure lineage relationships and transcriptome profiles
in thousands of single cells. We introduce novel compu-
tational methods that address the major challenges of
CRISPR/Cas9-based lineage tracing, such as preferential
creation of specific scar sequences and stochastic
dropout events. LINNAEUS allows scaling up lineage
analysis to the level of the whole organism, which
makes it an ideal approach for studying processes
like organ regeneration after injury. Here, we use LIN-
NAEUS to identify the origin and function of transient
cell types that are generated upon heart injury, and
we identify novel cellular drivers of the regeneration
process.
J. P. Junker: None.
S05.3
Transcriptome-Scale Super-Resolved Imaging in Tis-
sues by RNA SeqFISH
L. Cai*
Caltech, Pasadena, CA, United States
Imaging the transcriptome in situ with high accuracy has
been a major challenge in single cell biology, particularly
hindered by the limits of optical resolution and the density
of transcripts in single cells. We developed seqFISH+, that
can image the mRNAs for 10,000 genes in single cells with
high accuracy and sub-diffraction-limit resolution, in the
mouse brain cortex, subventricular zone, and the olfactory
bulb, using a standard confocal microscope. The tran-
scriptome level profiling of seqFISH+ allows unbiased
identification of cell classes and their spatial organization
in tissues. In addition, seqFISH+ reveals subcellular
mRNA localization patterns in cells and ligand-receptor
pairs across neighboring cells. This technology demon-
strates the ability to generate spatial cell atlases and to
perform discovery-driven studies of biological processes
in situ.
L. Cai: None.
S06 Making Sense out of Nonsense
S06.1
Nonsense Mediated Decay in Neuronal Development
and Disease
M. Wilkinson*
Univerity of California, San Diego, CA, United States
Nonsense-mediated RNA decay (NMD) is a highly selective
and conserved RNA turnover pathway that promotes the decay
of specific subsets of RNAs. A critical factor in the NMD
pathway is UPF3B, an adapter protein that binds with other
NMD proteins to form a molecular complex that drives rapid
RNA decay. In humans, mutations in UPF3B cause intellectual
disability (ID) and are strongly associated with autism, atten-
tion-deficit hyperactivity disorder, and schizophrenia (SCZ).
To understand UPF3B’s role in vivo, we generated a mouse
model with a null mutation in the Upf3b gene. These Upf3b-
null mice are viable but exhibit a profound defect in pre-pusle
inhibition (PPI), a measure of sensomotor gating commonly
deficient in individuals with SCZ and other brain disorders.
These NMD-deficient mice also have deficits in specific forms
of learning and memory. Consistent with both their PPI and
learning defects, specific neuronal cell subsets in Upf3b-null
mice display deficient dendritic spine maturation in vivo.
Neural stem cells from Upf3b-null mice have impaired ability
to undergo differentiation and require prolonged culture to give
rise to functional neurons with electrical activity. During the
course of our analysis, we discovered that Upf3b-null mice
also have a phenotype consistent with a partial olfactory defect.
This provided an opportunity to examine the role of Upf3b in
olfactory neurogenesis, a simple and easily tractable neural
developmental system. Single-cell RNA sequencing (scRNA-
seq) analysis revealed that Upf3b-null mice have specific
defects in olfactory neurogenesis, including in olfactory stem
cells. These NMD-deficient mice also had deficits in the
olfactory receptor (OR) repertoire in olfactory sensory neuro-
nal subsets at different stages of development. The nature of
these defects strongly suggested that NMD has a key role in
the OR selection process. We suggest that NMD-deficient
Upf3b-null mice will be a useful model system to decipher the
roles of NMD in neural development and function in vivo.
M. Wilkinson: None.
S06.3
Unproductive splicing and ultraconserved nonsense
L. Lareau*
University of California, Berkeley, Berkeley, CA, United
States
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The most conserved regions of any human genes are found
within alternative exons that act as switches to turn off
expression of SR splicing factors. When these ‘poison’
exons are spliced into SR gene transcripts, they trigger
mRNA degradation by nonsense-mediated decay (Lareau
et al, 2007; Ni et al, 2007). This shifts the mRNA output of
the gene away from the productive, protein-coding form,
allowing post-transcriptional downregulation of SR protein
expression. However, despite the intense conservation, the
functional impact of this regulation is unknown. We set out
to identify developmental processes showing changes in the
splicing of poison exons in SR genes. Using bulk and single-
cell RNA-seq data, we found that the inclusion of poison
exons changes dramatically during neurogenesis, and that
the splicing patterns of different SR poison exons follow
distinct temporal profiles. To identify trans-acting regulators
of poison exon inclusion, we used publicly available CLIP-
seq data from 157 RNA-binding proteins to train motif-
based classifiers and predict binding in and near the poison
exons whose splicing changes during neurogenesis. We
found that SR splicing factors form a highly interconnected
network by binding both to their own poison exons and to
the poison exons of other SR splicing factors. During neu-
rogenesis, the expression of these splicing factors is tightly
coordinated with the splicing of several groups of exons to
which they bind. We identified specific regions within SR
poison exons that are bound by one or several splicing
regulators which may act in concert or in opposition. We are
removing these regions, as well as full poison exons, to
measure their impact on neuronal differentiation. Our results
indicate that poison exons function as an auto- and cross-
regulatory mechanism that tightly regulates the levels of
splicing factors during neurogenesis, and that this regulation





Challenges in Diagnostic Sequencing for Inherited
Cardiac Conditions
R. Walsh*
Amsterdam UMC, Amsterdam, Netherlands
Diagnostic genetic sequencing has become an integral part of
clinical management for most inherited cardiac diseases.
Although identifying the Mendelian variants underlying dis-
ease will inform treatment in only a minority of cases, it can be
used to confirm diagnosis and enable cascade screening in
patients’ families. However there are a number of challenges
associated with cardiovascular diagnostic sequencing that have
limited its effectiveness. The era of candidate gene studies led
to a plethora of weak and false gene-disease associations, and
subsequently a large increase in uncertain (and even false
positive) findings when incorporated into diagnostic panels.
Recent efforts through community curation initiatives such as
ClinGen and large-scale rare variant association studies have
clarified many of these associations, enabling more focused
and accurate diagnostic testing panels. Variant interpretation
remains a critical and often rate-limiting step - although
widespread adoption of the ACMG/AMP guidelines have
brought standardisation and stringency to variant classification,
they require customisation for specific diseases and genes and
can lead to the under-calling of pathogenic variants. A number
of approaches are being developed to address this issue,
including efforts to enhance data and knowledge sharing, high
throughput functional assays and quantitative and machine
learning variant classification methods. Finally, the more
complex and comprehensive genetic basis of inherited cardiac
diseases is now being investigated in greater depth, in parti-
cular though genome-wide association studies utilising multi-
centre studies and population biobanks. This research offers the
promise in the near future of more comprehensive diagnostic
sequencing that may more accurately predict the risk of disease
onset, severity and outcomes in patients and family members.
R. Walsh: None.
S08.3
Identification and Characterization of Novel Micropro-
teins in the Human Heart
S. van Heesch*
Max-Delbrück-Centrum for Molecular Medicine in the
Helmholtz Association (MDC), Berlin, Germany
RNA translation is widespread outside of the canonical
protein-coding complement of the human transcriptome,
vastly expanding its coding potential. In a cohort of 80
human hearts, we have recently identified hundreds of
previously undiscovered microproteins translated from
upstream open reading frames (uORFs) in mRNAs and
short ORFs (sORFs) in presumed long noncoding RNAs
(lncRNAs) (van Heesch et al., Cell 2019). Although these
included translated lncRNAs with known functional roles in
the heart (e.g. UPPERHAND, Myheart, Chaer, TRDN-AS
and GATA6-AS1), the biological activity of the micro-
proteins produced from these genes remained uncertain.
To address this, we characterized the subcellular
localization, cell type-specific expression, and protein
interactomes of hundreds of cardiac microproteins in a
high-throughput manner. Many of the investigated
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microproteins (57 out of 153 tested) localized to the
mitochondria, suggesting underappreciated functionality in
cardiac energy metabolism. Using a PRISMA screen, for
which tiled 15-aa segments of 271 novel microproteins
were spotted on a membrane and incubated with cell lysate,
we catalogued microprotein interaction partners and fine-
mapped precise interaction motifs, allowing us to categorize
functional microprotein classes. Among the identified
microproteins, 18 were specifically produced in the human
heart, most of which were cardiomyocyte-specific in a
single nucleus expression atlas with >500k sequenced
nuclei. Genetic perturbation of one of these human heart
specific microproteins primarily affected expression of
genes involved in oxidative phosphorylation and calcium
handling in hiPSC-derived cardiomyocytes. Preliminary
live-cell imaging of TTN-GFP labeled microprotein−/− cells
revealed a likely repressive function of this microprotein on
sarcomere contraction and relaxation times.
We have identified and characterized hundreds of novel
microproteins that are produced in the human heart, though
prevalent in other tissues. Despite the mostly evolutionary
young age of these microproteins, we discovered dedicated
subcellular localizations, highly specific interaction part-
ners, cell-type specificity, and functional involvement in
processes central to cardiac functioning.
S. van Heesch: None.
S09 Beyond Mendelian Inheritance
S09.1
From digenic combinations to oligogenic networks via a
new predictive approach
T. Lenaerts*
Université Libre de Bruxelles, Brussels, Belgium
The wide-spread use of high throughput-sequencing in the
last decades has helped immensely in unravelling the genetic
architecture of many rare diseases as wells as identifying the
causative variant in Mendelian ones. Notwithstanding the
many successes, different issues remain unsolved: Certain
cases exhibit incomplete penetrance, phenotypic variability,
locus heterogeneity, as well as non-Mendelian patterns of
inheritance. Novel technological advancements are thus
required to move beyond this current state of the art. Our
team pushes the envelope on new pathogenicity prediction
and ranking tools for the identification of the oligogenic
causes of diseases. We aim to identify more complex
inheritance models, where variants in a small number of
genes cause or modulate the development of disease. In this
presentation I discuss two advancements we recently pub-
lished: a new pathogenicity predictor, developed using
published medical data on digenic diseases, and an online,
publicly available platform that takes the results of this
predictor, aggregates this into oligogenic networks, which
combine highly affected gene pairs, and contextualises these
results with molecular knowledge. This platform, called the
Oligogenic resource for variant analysis (or ORVAL),
allows researchers to perform predictions on gene panels as
well as full exomes, receiving a full report on the potentially
relevant combinations, integrated into gene-pairs and net-
works, and annotated with known protein relationships as
well as functional information for all candidate pathogenic
combinations that can be found. These two advancements
provide researchers with a novel way to explore patient
exome data while also adding molecular knowledge and
other pieces of information. The predictor, which is called
the variant combination pathogenicity predictor (or Var-
CoPP) assigns pathogenicity scores to variant combinations
in gene pairs, similarly to well-known monogenic patho-
genicity predictors currently used in prioritisation pipelines.
Yet, as VarCoPP is trained on digenic diseases data, it
identifies other culprits than those that would be identified in
a monogenic way, opening new routes for exploration when
the classical approaches fail. In this way, we hope to assist in
providing more accurate insights into the reasons for phe-
notypic heterogeneity in diagnosed patients as well as to
raise the diagnosis level for many rare diseases.
T. Lenaerts: None.
S09.3
Resolution of Disease Phenotypes Resulting from Multi-
locus Genomic Variation
J. E. Posey*
BCM225, Baylor College of Medicine, Houston, TX, United
States
Elucidation of the genetic mechanisms underlying disease is a
critical step toward Genomic Medicine. As our understanding
of the role and frequency of multilocus genomic variation has
grown, it is increasingly clear that the relationships between
an individual’s genotype and phenotypic expression are
complex, and that such cases of multilocus variation are
challenging to ascertain clinically. We now know that least
5% of individuals for whom clinical exome sequencing (cES)
is diagnostic are identified to have more than one molecular
diagnosis, and the rate of multiple molecular diagnoses is
increasing with continued novel disease gene discovery.
Population substructure - identity-by-descent - can drive an
even higher frequency of multilocus genomic variation:
22.0% (18/82) of cases compared to a control cohort with a
4.9% (101/2076) frequency of multilocus variation. We find
that the observed rate of multiple molecular diagnoses is
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lower than that predicted, suggesting that such cases may be
under-ascertained. In seeking approaches to improve ascer-
tainment of multilocus variation, we find that the observation
of apparent phenotypic expansion in association with a pre-
viously-described gene may actually represent unrecognized
multilocus variation. ES analysis of cases with apparent
phenotypic expansion reveals a higher frequency of multiple
molecular diagnoses (31.6% [6/19]) compared to a cohort of
cases without apparent phenotypic expansion (2.3% [2/87, p
= 0.0004]), providing potential molecular mechanisms for the
observed clinical phenotypes in such cases. Applying a
computational approach to model genotype-phenotype rela-
tionships in the setting of multilocus variation, we demon-
strate that phenotypic similarity analyses can be used to model
pairs of Mendelian conditions having distinct or overlapping
phenotypic features (p= 1.77 × 10−7). Preliminary data sug-
gest that a ‘goodness-of-fit’ approach to modeling of patient
phenotypes and identified molecular diagnoses may support
identification of cases likely to have additional molecular
diagnoses. Computational modeling of observed and expected
clinical phenotypes will play an increasing role in human
genomics as our understanding of the combinatorial effects of
variation at more than one locus increases in complexity.
J. E. Posey: None.
S10 Single Cell Cancer Genetics
S10.1
Heterogeneity
B. Thienpont*, M. De Borre, P. Van Minsel, Q. Yu, E. Galle
KU Leuven, Laboratory for Functional Epigenetics,
Leuven, Belgium
Lung tumours are heterogeneous, being composed of a
number of stromal cell types as well as cancer cells. In this
talk, I will describe our recent efforts to unravel the het-
erogeneity of stromal cells within the lung tumour micro-
environment, and describe the ongoing studies in my lab
aimed at understanding how epigenetic enzymes can drive
transcriptional heterogeneity within cancer cell populations.
B. Thienpont: None. M. De Borre: None. P. Van Minsel:
None. Q. Yu: None. E. Galle: None.
S10.3
Single cell to understand AML progression
A. Perl*
Philadelphia, PA, United States
Acute myeloid leukemia (AML) is a highly studied cancer
in which tumor cells have a small number of recurrent, well-
described somatic mutations in a limited number of func-
tional classes of genes. Whole genomic sequencing of AML
tumor cells confirmed these tumors to be relatively simple
genetically in individual cells, yet patients treated with
molecularly-targeted therapy often relapse with highly
polyclonal disease, including genotypes rarely if ever seen
outside of this context.
We sought to study and characterize this polyclonality
using single cell techniques in order to better understand
molecular underpinnings of drug resistance and perhaps
identify clinical approaches that would circumvent these.
This talk will describe the genetics of AML and describe
how single cell analysis for the majority of recurrent
mutations seen in AML uncovered unexpected genetic
diversity and provided insight into intratumor heterogeneity
with implications for targeted therapy of other malignancies.
S11 Embryo and Placenta: Equal Partners
S11.1
The unsung hero: The essential role of the placenta for
development and lifelong health
M. Hemberger1,2,3*
1Calgary, AB, Canada, 2University of Calgary, Calgary,
AB, Canada, 3Alberta Children’s Hospital Research
Institute, Calgary, AB, Canada
The unsung hero: The essential role of the placenta for
development and lifelong health
Despite significant progress over the past decades in
gaining a better understanding of placental development
and the contribution of the placenta to fetal and postnatal
health, the placenta still remains a much too often
overlooked organ. Here, we present data from a recent
high-throughput phenotyping screen in which we system-
atically analysed the placental morphology of mouse
mutants that cause embryonic lethality. Much in contrast
to the known ~10% of extra-embryonic defects reported for
gene deletions that lead to intra-uterine demise, our
systematic analysis shows that indeed 60-70% of these
mutants are associated with a placental phenotype. This
discrepancy results from the fact that the placenta is
frequently ignored in the analysis of gene mutations, and
demonstrates a great gap in knowledge as to the cohort of
genes required for normal placentation. Linking the
placental phenotype data with embryonic phenotypes
obtained from the very same mouse lines, we observe a
strong correlation between defects in placental development
and abnormalities in heart, brain and vascular development.
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These unbiased correlations underpin the importance of the
placenta not just merely for fetal nutrition, but for
embryonic development on the whole which has long-
lasting consequences for postnatal health. In addition to
genetic mutations, pregnancy complications that are
unrelated to karyotypic abnormalities but often have their
roots in a defective placenta are well known to become
more prevalent with advanced maternal age. Here, we also
present data on the impact of maternal age on placentation,
and how changes to the uterine epigenome that accumulate
with age contribute to these defects.
S11.2
Genetics of Recurrent Hydatidiform Moles: Novel
Findings and Patient Counselling
R. Slim*
McGill University Health Centre Research Institute,
Montreal, QC, Canada
Hydatidiform mole (HM) is a human conception with
abnormal embryonic development and excessive tropho-
blastic proliferation. The common form of this condition is
sporadic, not recurrent and affects one in every 600 preg-
nancies in western countries. HM are classified according to
their morphological features (complete and partial) and
genotypes (Diploid androgenetic, monospermic and dis-
permic; triploid dispermic, and diploid biparental). Recur-
rent HM affect for 1 to 9% of women with a prior HM and
may have any of the three genotypes. Biallelic mutations in
two genes, NLRP7 and KHDC3L, underlie most cases of
recurrent diploid biparental moles. Recently, we identified
three novel genes, MEI, TOP6BL and REC114, responsible
for androgenetic HM associated with recurrent miscarriages
and with female and male infertility. We demonstrated that
HM tissues from two patients with recessive MEI1 muta-
tions are diploid androgenetic monospermic. Androgenetic
HM were first described in 1977, but how they occur have
remained open questions. We next investigated the occur-
rence of androgenesis in Mei1-deficient female mice and
discovered that 8% of their oocytes lose all their chromo-
somes by extruding them with the spindles into the first
polar body. We demonstrated that Mei1−/− oocytes are
capable of fertilization and 5% of them produce androge-
netic zygotes. We therefore uncovered a novel meiotic
abnormality in mammals and a mechanism for the genesis
of androgenetic zygotes. Our findings will advance our
understanding of the genetic causes of reproductive failure




Organoids to understand pregnancy disorders
G. J. Burton*
University of Cambridge, Cambridge, United Kingdom
Human early pregnancy is a difficult period to research, yet
mounting evidence indicates that many complications of
pregnancy, ranging from miscarriage to growth restriction, are
the result of poor placental development from implantation
onwards. It is now appreciated that development of the placenta
is supported predominantly by histotrophic secretions from the
uterine glands during the first trimester. These secretions are
well recognised in domestic species, where they are generically
referred to as ‘uterine milk’ due to their high lipid content.
Research in the sheep and horse has shown how lactogenic
hormones secreted by the placenta signal to the glands and
upregulate the secretion of ‘uterine milk’ proteins and growth
factors. These in turn feedback on the placenta to stimulate
proliferation and differentiation, in what has been referred to as
a servo-mechanism.
We have proposed an equivalent mechanism operates in the
human, but gaining evidence in vivo is difficult for ethical
reasons. We have therefore adopted the organoid approach,
generating organoid cultures of both the endometrial glands
and the placental trophoblast. These are genetically stable in
culture and hormonally responsive, and can be passaged for
over one year or frozen for biobanking. The transcript profile of
the organoids closely resembles that of the starting material.
Exposing our endometrial organoids to various combinations
of pregnancy hormones, such as human chorionic gonado-
tropin and prolactin, upregulates the transcription and secretion
of known ‘uterine milk’ proteins and growth factors that have a
mitogenic effect on the placenta.
The organoid approach therefore opens new possibilities for
researching the critical events during early placental develop-
ment in a systematic fashion. Our findings also reinforce the
concept that endometrial function and correct decidualisation
during the first trimester are critical to pregnancy outcome.
G. J. Burton: None.
S12 Where Science and Ethics Meet
S12.1
The state of the science of heritable human genome
editing and ethical concerns
M. Ramsay*
Sydney Brenner Institute for Molecular Bioscience, Faculty
of Health Sciences, University of the Witwatersrand,
Johannesburg, South Africa
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Scientific advances in DNA editing technologies are
approaching levels of accuracy and efficiency that bring us
closer to imagining a responsible clinical translational path-
way toward heritable human genome editing (HHGE). This
profound step would signal the acceptance of wilful manip-
ulation of human genomes, such that the changes are passed
on to future generations. It has triggered the formation of two
international panels to debate a responsible way forward. The
WHO has convened an Expert Advisory Committee on
Human Genome Editing to make recommendations on
appropriate governance standards and mechanisms for over-
sight of somatic and germline human genome editing. The
UK Royal Society and US National Academies of Medicine
and Sciences convened an International Commission on the
Clinical use of Human Germline Genome Editing. The
Commission has been tasked with developing a framework to
inform the development guidelines for a responsible pathway
from research to potential clinical application. This should be
done in the context of international discussions of societal
implications and include considerations of access, equity and
ethical norms and practices. The specific tasks include:
Identifying scientific issues that should be evaluated for var-
ious classes of HHGE; identifying appropriate protocols to
guide pre-clinical validation of potential adverse effects such
as unintended on- and off-target events, mosaicism and long
term effects; considering how to assess the balance between
potential benefits and harms to the child and future genera-
tions; providing guidelines for ethics approval and consent, as
well as long-term monitoring of children born with edited
genomes; and considering potential oversight structures
including the scientific criteria for establishing and monitoring
HHGE. The Commission’s recommendations should be
applicable to the global community and guide national policy
development and processes. * Ramsay is a member of the




Crack down on genomic surveillance
Y. Moreau*
University of Leuven, Leuven, Belgium
Biometric surveillance is rapidly reshaping life in societies
across the world. Genome sequencing is revolutionizing
medicine. At the confluence of these two trends lies forensic
DNA profiling, which is touted by law enforcement and
governments as a silver bullet against crime. Serious con-
cerns emerge however when this technology becomes a
cornerstone of human rights abuse, from Xinjiang in China
to the US-Mexico border. Moreover, consumer genomic
databases are now putting the privacy of the entire popu-
lation in jeopardy, and clinical genomic databases might
soon as well. Even where legal frameworks protect funda-
mental rights and privacy, major failures are seen in prac-
tice. Furthermore, legal instruments are lacking to hold
corporations accountable when they recklessly supply
technology to abusive authorities. The academic community
and scientific publishers have also failed to uphold their
professed ethical standards, and hundreds of ethically
questionable papers have been published in mainstream
scientific journals. Urgent action is needed to shore up
social norms, ethical standards, and legal frameworks to
regulate biometric surveillance technology, including DNA
profiling.
Y. Moreau: None.
S13 Lysosomes in Health and Disease
S13.1
The lysosome in the control of cell metabolism
A. Ballabio1,2,3*
1Telethon Institute of Genetics and Medicine (TIGEM),
Pozzuoli, Italy, 2Neurological Research Institute, Baylor
college of Medicine, Hoston, TX, United States, 3Casma
Therapeutics, Boston, MA, United States
The lysosome is the main mediator of cellular degradation
and recycling processes. Several diseases are due to lyso-
somal malfunction. We have identified a lysosomal gene
network and a master gene, TFEB, that controls lysosomal
biogenesis and autophagy. The activity of TFEB is regu-
lated by the mTORC1 kinase complex through a lysosomal
signaling pathway that enables lysosomal function to adapt
to environmental cues, such as nutrient availability. Thus,
the lysosome acts as a signaling hub to control cell home-
ostasis and the switch between anabolism and catabolism.
Targeting lysosome-mediated signaling pathways is an
attractive therapeutic strategy for a variety of disease
conditions.
A. Ballabio: Other; Significant; CASMA THERAPEUTICS.
S14 ESHG-ASHG Building Bridges Session on
Polygenic Risk Scores: Risky or Useful in the Clinic?
S14.2
Improving Polygenic Risk Scores,but also improving
our knowledge about them
K. Fischer*, K. Läll, M. Mändul
Tartu University, Tartu, Estonia
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In this presentation, the following aspects of implementa-
tion of the polygenic risk score (PGRS) will be discussed.
First, we consider one of the main problems in the PGRS
development - in many studies, there is some overlap
between samples used in the different steps: discovery
GWAS, score development and selection of the best PGRS,
and finally, validation of the final PGRS. Next, we will
highlight that there is no unique solution for choosing the
optinal PGRS. Depending on the phenotype, different
methodologies may lead to the best solution (simple PGRS
that uses clumping of the SNPs in the discovery study and a
p-value threshold, a PGRS with modified weights,
MetaGRS, LDPRED and other Bayesian approaches,
machine-learning methods, etc) A thirg range of problems is
connected to the effect size estimation of the PGRS. We
will show that incorrect time scale as well as the presence of
competing risks may lead to biased and misleading esti-
mates of the effect size. Finally, we address the question on
how to assess the added value of the PGRS to the existing
risk-prediction algorithms. We show that some results that
have been presented with some scepticism may actually
deserve another look.
K. Fischer: None. K. Läll: None. M. Mändul: None.
S15 Detection of Structural Variation
S15.1
Detection of Structural Variation and Haplotype-Aware
Genome Assembly
T. Marschall*
Heinrich Heine University, Düsseldorf, Germany
Recent breakthroughs in long-read sequencing technology
and assembly methodology enable the de novo assembly of
human genome to a quality approaching the quality of the
reference genome GRCh38. My talk will center around
creating such assemblies and how they facilitate the dis-
covery of structural variation. My talk comes in three parts:
In the first part, I will describe work done by the Human
Genome Structural Variation Consortium (HGSVC) and
summarize how we performed (reference-based) haplotype
phasing followed by local assembly to define the sequences of
SV alleles (Chaisson et al., Nature Communications, 2019).
In the second part, I introduce a workflow for fully phased
de novo genome assembly, overcoming the prevailing
genome assembly paradigm to produce sequences that
"collapse" parental haplotypes into a consensus sequence.
To achieve this, we leverage the chromosome-wide phasing
and scaffolding capabilities of single-cell strand sequencing
(Strand-seq) and combine them with either high-fidelity
(HiFi) long sequencing reads, PacBio CLR reads, or Oxford
Nanopore Technology reads. Employing this strategy, we
produce completely phased de novo genome assemblies
separately for each haplotype of a single individual of
Puerto Rican origin (HG00733) in the absence of parental
data. The assemblies are accurate (QV > 40), highly
contiguous (contig N50 > 25 Mbp) with low switch error
rates (0.17%) providing fully phased single-nucleotide
variants (SNVs), indels, and structural variants (SVs).
In the third part, I sketch a way forward to leverage such
haplotype-resolved genome assemblies to build a human
pangenome. I present preliminary result on a new tool,
PanGenie, able to genotype variation, and particularly SVs,
inherent to such a pangenome given a short read data set of
a study sample. This process is very scalable, going from
input Fastq to final call set in around 20 single core CPU
hours, and provides accurate genotypes for many SVs that
used to be inaccessible by short reads.
T. Marschall: None.
S15.2
Improving the detection and genotyping of structural
variation
B. Kehr1,2*
1Berlin Institute of Health (BIH), Berlin, Germany, 2Charité
- Universitätsmedizin Berlin, Berlin, Germany
Structural variants (SVs) can lead to a variety of diseases,
contribute significantly to human genetic diversity, and are
important marks of genome evolution. Therefore, incom-
plete detection and unreliable genotyping of SVs limit a
wide range of human genetic studies. As recent studies have
demonstrated that the number of SVs per human genome is
at least an order of magnitude greater than the number of
SVs we routinely detect in short read data, we need to
explore opportunities to improve the detection and geno-
typing of SVs. One such opportunity is the use of data from
novel technologies, e.g. long read data. Another opportunity
is joint detection of SVs in many genomes together, which
strengthens the detection of variants shared by different
genomes. In this presentation, I will introduce computa-
tional methods for detecting and genotyping SVs in many
short-read sequenced genomes jointly and demonstrate how
the joint approach leads to more complete and more reliable
SV call sets. Specifically, I will give an overview of the
tools PopDel and PopIns we developed for identifying
deletions and non-reference sequence variants in up to tens
of thousands of human genomes. Finally, I will show how
even the current SV callers for long read data are limited in
detecting certain types of SVs.
B. Kehr: None.
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S15.3
Annotation and Curation of High-Confidence Structural
Variants
A. Quinlan*
University of Utah, Salt Lake City, UT, United States
A typical human genome contains >4,000 structural variants
(SVs) larger than 300bp, ranging in size from hundreds to
millions of nucleotides. SVs cause diverse phenotypes, and
their size increases the potential to alter gene dosage, alter
chromatin structure, affect expression, remove regulatory
elements, and create gene fusions. However, detecting
structural variants in a human genome via whole-genome
sequencing is fraught is notoriously inaccurate. I will pre-
sent recently developed methods for isolating high-con-
fidence structural variants, recent advances in prioritizing
SVs that may have phenotypic consequences, and chal-
lenges that remain in interpreting this important, yet com-
plex form of genetic variation.
A. Quinlan: None.




Queen Mary University of London, London, United Kingdom
Inherited haematological malignancy syndromes are typi-
cally characterised by acute myeloid leukaemia/myelodys-
plasia (AML/MDS) occurring in two or more genetically
related family members. While these syndromes are con-
sidered relatively rare, accounting for <5% of all AML/
MDS cases, it is likely that many patients with germline
mutations are not readily identified, families may display
marked variations in disease phenotype, latency and pene-
trance across mutation carriers and these features, coupled
with an absence of comprehensive diagnostic assays and
paucity of clinical guidelines, give rise to an apparent
under-representation of familial leukaemia. Importantly,
lack of awareness regarding familial involvement may lead
to the unsuspecting selection of asymptomatic family
members as stem cell donors, with several reports describ-
ing donor-derived episodes of AML. Fortunately, we are
now making significant progress in recognising and
understanding the molecular pathogenesis of these syn-
dromes, as highlighted by the introduction of a provisional
diagnostic category in the World Health Organisation
(WHO) 2016 (Myeloid neoplasms with germ line
predisposition). To date mutations in >20 discrete loci have
been described but notably, investigators still report that
perhaps as many as 40-50% of families with an appropriate
clinical history have no readily identifiable genetic lesion
from interrogation of the coding genome. Unsurprisingly,
there is a significant overlap between genes mutated in both
sporadic and inherited forms of leukaemia. Each gene has a
distinct clinical, biological and molecular profile; for
example, familial CEBPA-mutated AML is a recognized
leukaemia predisposition entity where the pathological
features and long-term survival of individuals mirrors
sporadic CEBPAdm AML. We are lately beginning to
decipher the genetic evolution of leukaemia across family
members, with evidence suggesting that secondary muta-
tions may cluster within pedigrees, for example GATA2
mutations in families with germline CEBPA mutations and
JAK-STAT pathway mutations in RUNX1 pedigrees
potentially pointing to the host genotype impacting on the
acquisition of somatic mutations. In the absence of stan-
dardised testing, much of our new knowledge is emerging
from individual research groups and collaborations and will
require validation and collective evaluation across the leu-
kaemia research community. It is widely accepted that we
need to develop a network of international advisors who
may provide accessible guidance for clinicians worldwide,
particularly when rare and insightful clinical observations
may aid both clinical management and promote the detec-
tion of novel syndromes. Moving forward, it would be
sensible to have an unified approach to analyse sporadic and
familial leukaemia is now required.
J. Fitzgibbon: None.
S16.2
Genetics and Mechanisms of Acute Lymphoblastic
Leukemia
A. Ferrando*
Columbia University, New York, NY, United States
Relapse acute lymphoblastic leukemia (ALL) is associated
with chemotherapy resistance and poor prognosis. Persis-
tent leukemia initiating cells with increased self-renewal
capacity, clonal heterogeneity and selection of resistance-
driving genetic alterations have been proposed as drivers of
leukemia relapse. Gain of function mutations in the 5′-
Nucleotidase, Cytosolic II (NT5C2) gene are selectively
present in relapsed ALL and confer resistance to che-
motherapy with 6-mercaptopurine (6-MP). Yet, the specific
mechanisms mediating constitutive activation of NT5C2
and the role of these mutations as drivers of clonal evolution
during leukemia initiation and disease progression remain
unknown. Our structure function and crystallographic
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analyses have uncovered new intra-molecular mechanisms of
NT5C2 regulation specifically targeted by relapsed leukemia-
associated mutations. In addition, using an in vivo leukemia
model we demonstrate a dual role for NT5C2 R367Q, the
most frequent relapse-associated NT5C2 allele, as a loss of
fitness mutation impairing cell growth in the absence of
chemotherapy, and a gain of fitness mutation resulting in
disease progression and relapse in the context of 6-MP ther-
apy. These results have important implications for monitoring
of leukemia relapse driving clones and for the development of
targeted therapies for the treatment of relapsed disease.
A. Ferrando: None.
S17 Cornelia de Lange Syndrome and Cohesinopathies
S17.1
Cornelia de Lange Spectrum: does deep phenotyping help?
F. Ramos1*, A. Latorre-Pellicer1, L. Trujillano2,
M. Gil-Salvador1, M. Arnedo1, C. Lucía-Campos1,
R. Antoñanzas-Pérez1, B. Puisac1, P. Gómez-Puertas3,
J. Pié1
1University of Zaragoza, Zaragoza, Spain, 2University
Hospital "Lozano Blesa", Zaragoza, Spain, 3Molecular
Biology Center "Severo Ochoa", Madrid, Spain
Cornelia de Lange Syndrome (CdLS, OMIM #122470,
#300590, #610759 614701, #300882) is a multisystemic
condition characterized by a recognizable craniofacial
phenotype, characteristic limb malformations and wide
spectrum of symptoms from different organs and systems.
Two main clinical subgroups are currently recognized based
on the severity of manifestations: the classic (severe) CdLS
and the non-classic CdLS. The first subgroup, the most
common (≈60% of CdLS cases), includes the patients who
have a pathogenic variant in the gene NIPBL. These indi-
viduals have a characteristic facial appearance, distal limb
reduction defects (oligodactyly in the hands), hirsutism, and
moderate to severe growth and psychomotor retardation/
intellectual disability. The non-classic CdLS includes the
patients with milder craniofacial phenotypes and clinical
manifestations and bearing pathogenic variants in the other
four genes associated with the syndrome (SMC1A, SMC3,
HDAC8, and RAD21). Clinical diagnosis of many of these
individuals is often challenging and sometimes very diffi-
cult due to the overlapping with several syndromes that
share clinical manifestations with CdLS but are caused by
other genes that may not be related to the cohesin complex.
Deep phenotyping can be defined as the precise and com-
prehensive analysis of phenotypic anomalies in which the
individual components of the phenotype are observed and
described in detail. The generalized use of the Human
Phenotype Ontology (HPO) system to annotate clinical
manifestations has contributed to standardize the terminol-
ogy and improve the accuracy of the genotype-phenotype
correlations in many dysmorphic síndromes, including
CdLS. There are a number of tools currently available to
perform quick and efficient deep phenotyping processes and
algorithms that are able to accurately identify facial patterns
(gestalt) that match with specific dysmorphic known sín-
dromes. These new tools, rather than substitute the clinical
skills of the clinician, are intended to help them to diagnose
patients who do not fit a recognizable dysmorphic pattern.
We have used one of those deep phenotyping tools
(Face2Gene®) to check its diagnostic accuracy in 49 CdLS
patients whose clinical diagnosis was confirmed by mole-
cular testing. Thirty-three of them had pathogenic variants
in NIPBL, and the remaining in three of the other CdLS
genes (SMC1A, HDAC8, and RAD21). Average accuracy
was 83.7%, meaning that CdLS was listed as the first
choice. In 97.9% of the cases analyzed, CdLS was included
in the top-five suggestions. In the subgroup of patients with
the classic phenotype, 88.8% of the patients were diagnosed
as CdLS as the first choice. Overall, KBG was the second
most suggested diagnosis. No differences were found in the
top-one sensitivity when the phenotypes were compared by
age. Finally, we check the accuracy of the process com-
paring the facial phenotypes of the patients depending on
the genes involved. We found, as expected, a top-one sen-
sitivity of 97% for patients with variants in NIPBL, 66,6%
for RAD21, 60% for HDAC8, and 50% for SMC1A. We can
conclude that, in general, deep phenotyping tools are useful
for clinical geneticists and may help them in the diagnostic
process of patients with non-recognizable dysmorphic pat-
terns or in syndromes with overlapping phenotypes.
F. Ramos: None. A. Latorre-Pellicer: None. L. Trujillano:
None. M. Gil-Salvador: None. M. Arnedo: None. C. Lucía-
Campos: None. R. Antoñanzas-Pérez: None. B. Puisac:
None. P. Gómez-Puertas: None. J. Pié: None.
S17.3
Post-Zygotic Mutation as a Cause of Typical Cornelia
De Lange Syndrome
D. FitzPatrick*
MRC Human Genetics Unit, University of Edinburgh,
Edinburgh, United Kingdom
Typical Cornelia de Lange syndrome (CdLS, MIM #122470)
is a very severe, clinically distinct multisystem disorder
characterised by intellectual disability, prenatal onset growth
retardation, limb malformations, multiple chronic medical
problems and distinctive facial features. 60-70% of affected
individuals have de novo heterozygous, loss-of-function
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mutations in NIPBL which are detectable in blood DNA.
Many of the remaining typical cases have mosaic mutations in
NIPBL usually absent in DNA derived from peripheral leu-
cocytes but detectable in saliva samples at low levels and in
uncultured skin with variant allele frequencies approaching
50%. Strikingly most of the children with mosaicism have a
clinical disorder at least as severe as those with constitutional
mutations. Mosaicism may be the result of post zygotic
mutation (PZM) or rescue of a constitutional mutations via
mitotic homologous recombination in blood cell progenitors.
NIPBL performs fundamental functions critical for cell sur-
vival such as mitotic segregation of chromosomes, DNA
repair and developmental gene regulation. As such rescue
seemed the most plausible mechanism a priori. However
using data from whole genome sequence and tissue specific
genetic analysis we can find no evidence for rescue and, in a
number of cases, definitive evidence for PZM. Given the
severity of the phenotype in mosaic cases both at a cellular
and organismal level it seems likely that the mutant cells have
an advantage over wild-type cells in populating ectodermal -
neuroectodermal, in particular - lineages. This hypothesis can
be tested using in vitro differentiation cell competition assays.
D. FitzPatrick: None.
S18 Clonal Fitness of Somatic Mutations
S18.1
Somatic Evolution in Human Tissues
I. Martincorena*
Wellcome Sanger Institute, Cambridge, United Kingdom
Cancers develop by somatic mutation and clonal selection
within our tissues. Over the past decade, the ability to
sequence cancer genomes has transformed our understanding
of the genetics and evolution of a wide range of cancers.
However, owing to technical limitations, little is known about
the earliest steps of cancer and how cells in our tissues
accumulate mutations during normal ageing and in their
progression towards cancer. In this talk, I will present our
work unveiling a hidden and unexpected world of cellular
competition and somatic evolution in human healthy tissues,
with implications for our understanding of cancer and ageing.
I. Martincorena: None.
S18.2
Somatic Genetic Rescue in Mendelian Haematopoietic
Diseases
P. Revy*
Imagine Institute, Paris, France
Somatic mutations occur spontaneously in normal indivi-
duals and accumulate throughout life. These genetic mod-
ifications contribute to progressive ageing phenotypes and
are directly involved in cancer development. However, a
growing number of studies of Mendelian haematopoietic
disorders indicate that somatic genetic events called
"somatic genetic rescue" can offset the pathogenic effect of
germline mutations at the cellular level, leading to genetic
mosaicism and, in some cases, resulting in a milder disease
phenotype. I will present two examples of somatic genetic
rescue that we observed in our lab.
P. Revy: None.
S18.3
Somatic Mutations and Regeneration in Chronic Liver
Disease
H. Zhu*
University of Texas Southwestern, Dallas, TX, United States
Normal tissues accumulate genetic changes with age, but it is
unknown if somatic mutations promote clonal expansion of
non-malignant cells in the setting of chronic degenerative
diseases. Exome sequencing of diseased liver samples from
82 patients revealed a complex mutational landscape in cir-
rhosis. Additional ultra-deep sequencing identified recurrent
mutations in PKD1, PPARGC1B, KMT2D, and ARID1A.
The number and size of mutant clones increased as a function
of fibrosis stage and tissue damage. To interrogate the func-
tional impact of mutated genes, a pooled in vivo CRISPR
screening approach was established. In agreement with
sequencing results, examination of 147 genes again revealed
that loss of Pkd1, Kmt2d, and Arid1a promoted clonal
expansion. Conditional heterozygous deletion of these genes
in mice was also hepatoprotective in injury assays. Pre-
malignant somatic alterations are often viewed through the
lens of cancer, but we show that mutations can promote
regeneration, likely independent of carcinogenesis.
H. Zhu: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Ionis. F.
Consultant/Advisory Board; Modest; 28-7 Therapeutics.
S19 Data-driven Genomic Care and its Implementation
in the Clinic: A Paradigm Shift
S19.2
Empirical evidence in preventive genomics: MedSeq,
BabySeq and beyond
C. Blout*
Brigham and Women’s Hospital, Boston, MA, United States
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As genomic technologies advance and costs decline, the
ability to implement preventive genomics into everyday
medicine becomes possible. The Genomes2People (G2P)
research program is exploring the impact of implementing
genomic sequencing into routine medical care. This pre-
sentation will summarize G2P studies as well as the
development of the new Brigham Preventive Genomics
Clinic. The MedSeq Project, which was the first rando-
mized control trial of genome sequencing (GS), enrolled
not only a disease cohort (cardiomyopathy), but also a
healthy cohort. We enrolled 200 patients and 20 of their
health care providers. In the separate but similarly
designed BabySeq Project, we enrolled 309 newborns
recruited from the well-baby nursery and neonatal inten-
sive care unit. Both of these NIH-funded studies explored
the medical, behavioral and economic outcomes of GS
following disclosure.
Comprehensive sequencing and interpretation revealed
that 20% of MedSeq, and 11% of BabySeq, participants
had a non-indication-based, unanticipated variant in a
gene associated with a monogenic condition. Upon re-
phenotyping, after the variant was identified, 6/20
MedSeq participants and 11/18 BabySeq participants
were identified to have a personal and/or family history
of the disease. Carrier variants were identified in 94% of
MedSeq and 88% of BabySeq participants. In MedSeq
there were no significant cost differences between
sequenced cases and controls by 6 months, and in
BabySeq there was a small but significant increase in
downstream health care costs over 3 months among the
sequenced infants when compared to the controls. Both
studies revealed no increases in anxiety and depression
related to genomic information. Lessons learned from this
research prompted the creation of the Brigham and
Women’s Hospital Preventive Genomics clinic. This first
of its kind service has seen over 40 clinical patients to date
for preventive genomic consultations and testing. Our
research outlines the many benefits of population genomic
screening and our experiences provide important informa-
tion regarding clinical implementation as well as identify-
ing areas where further study is needed.
C. Blout: None.
S20 Integrating Large-scale Functional Data Into
Genome-Wide Association Studies
S20.1
Combining omics data with GWAS results
A. Gusev1,2*
1Dana-Farber Cancer Institute, Boston, MA, United States,
2Harvard Medical School, Boston, MA, United States
Genome-wide association studies (GWAS) have identified
thousands of variants associated with disease, but the
underlying mechanisms through which these variants
operate remain elusive. This talk focuses on three topics
related to overcoming this challenge: First, I will discuss
some insights into disease architecture that we have gained
from GWAS so far. Second, I will describe a statistical
framework we have developed called MESC, which aims to
quantify the total fraction of disease heritability that can be
explained by all observed expression QTLs. Applying
MESC to large-scale eQTL and GWAS data we find that
only ~11% of GWAS heritability appears to be mediated by
measurable eQTLs, most of which resides in eQTLs with
very weak effects that are difficult to detect. Finally, I will
describe a computational tool - PLASMA - that leverages
allele-specific expression to fine map such weak effect
QTLs and colocalize them with disease. In application to
real RNA-seq studies from hundreds of individuals,
PLASMA increased power over conventional QTL map-
ping and colocalization by an order of magnitude.
A. Gusev: None.
S20.2
A Bayesian Framework for Joint Fine-Mapping with
Applications to Immune-Mediated Diseases
J. Asimit*
MRC Biostatistics Unit, University of Cambridge, Cam-
bridge, United Kingdom
Hundreds of genetic variants have been identified as asso-
ciated with a spectrum of diseases and related traits but
pinpointing likely causal variants (fine-mapping) has been
complicated by extended linkage disequilibrium (LD) and
finite sample sizes. In the fine-mapping of single outcomes,
inaccuracies often occur when there are two or more distinct
causal variants that are both correlated with a single non-
causal variant. This motivates the development of MFM
(Multinomial Fine-Mapping) for multiple diseases with
shared controls; joint fine-mapping that leverages informa-
tion between outcomes in a Bayesian framework, where
prior model probabilities are formulated to favour combi-
nations of models with a degree of sharing of causal var-
iants between outcomes. Our simulation studies
demonstrate that MFM has greater accuracy than single
disease fine-mapping when there are shared causal genetic
variants between diseases, yet no precision loss if there is no
sharing. In addition, MFM analysis of six immune-mediated
diseases identifies novel genetic associations that are missed
by marginal analyses. We jointly fine-map association sig-
nals for six diseases and of particular interest is IL2RA,
which is known to be associated with several autoimmune
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diseases, including multiple sclerosis (MS), type 1 diabetes
(T1D), autoimmune thyroid disease (AITD) and coeliac
disease. MFM has the potential to increase fine-mapping
resolution in related diseases/traits without collecting larger





Manifold destiny: exploring genetic interactions in high
dimensions through massively parallel single cell RNA-
seq
J. Weissman*
UCSF/HHMI, San Francisco, CA, United States
A major principle that has emerged from modern genomic
and gene expression studies is that the complexity of cell
types in multicellular organisms is driven not by a large
increase in gene number but instead by the combinatorial
expression of a surprisingly small number of components.
This is possible because specific combinations of genes
exhibit emergent properties when functioning together,
enabling the generation of many diverse cell types and
behaviors. Understanding such genetic interactions has
important practical and theoretical applications. For exam-
ple, they can reveal synthetic lethal vulnerabilities in
tumors, identify suppressors of inherited and acquired dis-
orders, guide the design of cocktails of genes to drive trans-
differentiation between cell types, inform the search for
missing inheritance in genetic studies of complex traits, and
enable systematic approaches to define gene function in an
objective and principled manner. Defining how genes
interact is thus a central challenge of the post-genomic era.
The combinatorial explosion of possible genetic interac-
tions (GIs), however, has necessitated the use of scalar
interaction readouts (e.g. growth) that conflate diverse
outcomes. I will present our work developing an analytical
framework for interpreting manifolds constructed from
high-dimensional interaction phenotypes. We applied this
framework to rich phenotypes obtained by Perturb-seq
(single-cell RNA-seq pooled CRISPR screens) profiling of
strong GIs mined from a growth-based, gain-of-function GI
map. Exploration of this manifold enabled ordering of
regulatory pathways, classification of GIs in a principled
manner (e.g. identifying true suppressors), and mechanistic
elucidation of synthetic lethal GIs, including an unexpected
synergy between CBL and CNN1 driving erythroid
differentiation. Finally, we applied recommender system
machine learning to predict interactions, facilitating
exploration of vastly larger GI manifolds. We expect the
conceptual and computational frameworks presented here
will be broadly applicable to genetic interactions obtained
via other rich phenotyping approaches (e.g. proteomics,




Nanopore Sequencing of Human Genomes: the long and
short of it.
M. Loose*
School of Life Sciences, University of Nottingham, Notting-
ham, United Kingdom
The utility of long read sequencing has dramatically
increased in the last few years whilst costs have lowered.
We have exploited Nanopore sequencing to sequence
human genomes (and others) on MinION, GridION and
PromethION. To do this we have been involved in devel-
oping methods to sequencing ever longer molecules, cur-
rently up to 2.3 Mb in length. Alongside we have been
developing methods for targeted sequencing of specific
regions of genomes using CAS-9 library preparation
methods and, more recently, computational methods
including adaptive sampling allowing us to direct the
sequencer to specific regions of the genome as required. We
will present our work including sequencing over 700 cancer
gene targets and the MHC domain to 30x coverage on a
single MinION flowcell.
M. Loose: D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Oxford
Nanopore Technologies. F. Consultant/Advisory Board;
Modest; UK BioBank.
E01.4
Optical mapping for clinical structural variants
detection
A. Hoischen1,2,3*
1Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands, 2Radboud Institute
of Molecular Life Sciences, Radboud University Medical
Center, Nijmegen, Netherlands, 3Department of Internal
Medicine and Radboud Center for Infectious Diseases
(RCI), Radboud University Medical Center, Nijmegen,
Netherlands
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Oral Presentations 21
Structural variants (SVs) are an important source of genetic
variation in the human genome and they are involved in a
multitude of human diseases. SVs are enriched in repeat-
rich regions of the human genome, and several remain
undetected by conventional short-read sequencing technol-
ogies. Here I will introduce the basics of high-resolution
optical mapping that allow the sensitive genome-wide
identification of SVs. I shall demonstrate its utility for
molecular cytogenetics for constitutional SVs in cases with
e.g. germline micro-deletion/-duplication syndromes,
inversions and translocations. Recent advances also allow
for the sensitive identification of acquired i.e. somatic SVs
e.g. in leukemia samples. Finally I will showcase first
examples of how optical mapping enables unravelling of
hidden SVs in rare disease cases that remained undetected
by classical methods, including MLPA, Sanger sequencing,
exome and/or genome sequencing. In summary, I will show
how the complementary use of mapping rather than
sequencing approaches allow for comprehensive detection
of all cytogenetic abnormalities and how this can unmask
hidden SVs. I predict that ultra-long read mapping may
enable a revolution in ‘next generation cytogenetics’.
A. Hoischen: None.
E02 Abstracts Withdrawn
E03 Pharmacogenomics in the Clinic
E03.1
Pharmacogenetics - from bench to drug label
J. Stingl*
Institute of Clinical Pharmacology, UniversityHospital of
the RWTH Aachen, Aachen, Germany
The role of pharmacogenetic diagnostics has changed during
the past decades with a more explorative role in the beginning
explaining differences in drug metabolism and elimination,
further looking at differences in individual drug response and
safety, and nowadays developing to a therapy companion
diagnostic for indications of drug therapies. With the knowl-
edge on our pharmacogenome, also new methods for genetic
diagnostics arose, and large genome analyses now became
convenient, easy to handle, and relatively cheap. While in
centralized countries like the United States, the development of
guidelines and pharmacogenetic information in drug labels is
already advanced, in Europe, the diversity of national health
systems affects regulation for pharmacogenetic diagnostics. We
have now different sorts of pharmacogenetic information in the
drug label which could be informative, actionable, or obliga-
tory. The action consequence of this information depends on
the section in the label that contains the information. For
example, the section on indication would most probably con-
tain information on mandatory pharmacogenetic diagnostics
prior to onset of therapy, whereas in the section on adverse
drug reactions, mostly informative pharmacogenetic aspects are
mentioned about variability in the risk of side effects. Recently,
a European referral was opened that should clear the question
of a pretherapeutic testing of DPYD variants in therapy with
fluoropyrimidines. The outcome of the referral (expected in
2020) could mean that for the first time in Europe, a pharma-
cogenetic test is mandatory before onset of a common drug
therapy (so far, only genetic testing in rare disease therapy is
mandatory). Pharmacogenetics is now in the implication phase
with the use of pharmacogenetic tests for drug therapy indi-
cation, for individualized dosing and for the avoidance of side
effects. Depending also on national health systems, genetic
tests for therapy decisions are/and will become more and more
in use in realworld clinical practice.
J. Stingl: None.
E04 Hypermobility and the Ehlers Danlos Syndromes
E04.2
Vascular Presentation of the Ehlers Danlos Syndromes
P. Byers*
University of Washington, Seattle, WA, United States
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Given that many of the types of Ehlers Danlos syndrome
(EDS) result from mutations in genes that encode proteins
that are components of blood vessels, it should come as no
surprise that arterial dissection and rupture can complicate
the lives of people with these conditions. The flagship of
these conditions is vascular EDS (vEDS), which results
from pathogenic variants in COL3A1 that encodes type III
procollagen—a major component of arterial walls. These
events are uncommon in children but prove to the related to
the cause of death in most individuals, except for those with
haploinsufficiency. One contribution to premature death
(median survival of about 50 years) is that vessel wall is
friable and, so, difficult to suture; in addition, it is difficult
to anticipate dissection and rupture. Aortic and large arterial
vessel dissection appears to be an uncommon event in
people with classical EDS the most common kinds of
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mutations (COL5A1 haploinsufficiency) as well as those
with missense and splicing alterations. The recessively
inherited kyphoscoliotic EDS results from pathogenetic
variants in PLOD1 that encodes lysyl hydroxylase 1 (LH1),
and in FKBP14. These affect the hydroxylation of lysyl
residues in collagens that are critical for the formation of
tissue stabilizing intermolecular cross links. In both, dis-
section may occur in late childhood and early adolescence.
Surveillance protocols are not yet standardized among
groups and there is not yet consensus recommendations for
any of these conditions. Surgical intervention can be life-
saving and should not be ignored, and the effectiveness of
medical therapies have yet to be clearly demonstrated. The
pathway from nucleotide change to pathogenesis remains to
be explored but there are hopes that unexpected therapeutic
tools may be identified from ongoing studies.
P. Byers: None.
E05 Interpreting Variation Outside of Protein-Coding
Sequence
E05.1
Functional Characterization and Therapeutic Targeting
of Gene Regulatory Elements
N. Ahituv*
UCSF, San Francisco, CA, United States
Nucleotide variation in gene regulatory elements is a major
determinant of phenotypes including morphological diversity
between species, human variation and human disease. Despite
continual progress in the cataloging of these elements, little is
known about the code and grammatical rules that govern their
function. Deciphering the code and their grammatical rules will
enable high-resolution mapping of regulatory elements, accu-
rate interpretation of nucleotide variation within them and the
design of sequences that can deliver molecules for therapeutic
purposes. To this end, we are using massively parallel reporter
assays (MPRAs) to simultaneously test the activity of thou-
sands of gene regulatory elements in parallel. By designing
MPRAs to learn regulatory grammar or to carry out saturation
mutagenesis of every possible nucleotide change in disease
causing gene regulatory elements, we are increasing our
understanding of the phenotypic consequences of gene reg-
ulatory mutations. Regulatory elements can also serve as
therapeutic targets. To highlight this role, we used CRISPR/
Cas9 activation (CRISPRa) of regulatory elements to rescue
haploinsufficient diseases (having ~50% dosage reduction due
to having only one functional allele) in vivo. By targeting the
Sim1 promoter or its 270kb distant hypothalamic enhancer, we
were able to rescue the haploinsufficient obesity phenotype in
Sim1 heterozygous mice, both using a transgenic and adeno-
associated virus (AAV) approach. Using a similar AAV
CRISPRa approach, we also show that we can rescue the
obesity phenotype in Mc4r heterozygous mice. Our results
highlight how regulatory elements could be used as therapeutic
targets to treat numerous altered gene dosage diseases.
N. Ahituv: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Encoded
Therapeutics. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Enhancer
Therapeutics.
E05.2
Dissecting Non-Coding Sequences in Gene Regulation
A. Stark*
Research Institute of Molecular Pathology (IMP), Vienna,
Austria, Vienna, Austria
The vast majority of disease-associated SNPs in the human
genome is located in the non-protein-coding part, which
makes it difficult to assess the functional impact of the
sequence variants. Non-coding sequences, which make up
the largest part of the human genome, contain gene-reg-
ulatory elements - promoters and enhancers - that direct the
dynamic expression of genes in complex spatial and tem-
poral patterns. The promoter and enhancer sequences con-
tain this gene regulatory information, which in the cells is
realized by transcription factor and cofactor proteins.
Today, I will first introduce how reporter systems can be
used to understand the sequence-encoding of gene-regula-
tory information and how sequence changes alter regulatory
function. I will then present our recent work towards
understanding how cells utilize this information with
transcription factor and cofactor proteins. Using an inter-
disciplinary approach in Drosophila, we study how
enhancers and the cofactor proteins they recruit activate
different types of core promoters, enabling distinct sets of
genes and alternative promoters of the same genes to be
regulated differently. The distinct compatibilities between
cofactors and core promoters forms the basis of specificity
within and between gene regulatory programs.
A. Stark: None.
E06 Brain Size Matters!
E06.1
Microcephaly: genetics and disease mechanisms
G. M. S. Mancini*
ErasmusMC, Department of Clinical Genetics, Rotterdam,
Netherlands
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Microcephaly is defined by a head circumference (HC)
below 2 SD standard deviations for age and sex. A dis-
tinction is generally made between congenital or primary
microcephaly, i.e. a small HC for gestational age at birth,
and progressive or post-natal microcephaly, i.e. normal HC
at birth followed by insufficient growth during infancy and
childhood. When small head circumference reflects an
insufficient brain growth, microcephaly is associated with
neurodevelopmental disorders (NDD), such as intellectual
disability, epilepsy, autism. The most common structural
abnormality in primary microcephaly is a simplified gyral
pattern of the cortex. Association with other malformations,
e.g. lissencephaly or polymicrogyria, implies neurological
sequelae and influences disease course. Nevertheless,
prognostic evaluation in a newborn with microcephaly
remains difficult. Compatibly with a very high mitotic rate
and scheduled cell death of neural progenitors of the
developing human cortex, the most relevant genes and
processes affected in primary microcephaly relate to reg-
ulation of the cell cycle (e.g. mitotic spindle formation and
orientation, centrosome biology, mitotic chromosome
structure, double strand DNA repair and chromosome sta-
bility) or of scheduled apoptosis. There is partial etiologic
overlap with the pathogenesis of progressive microcephaly,
which mostly affect control of DNA repair, or regulation of
intermediate metabolism. However, novel paradigms are
emerging in the pathogenesis of microcephaly, which are
related to regulation of the balance between ER-controlled
proteostasis and cell cycle. This subtle balance might reveal
to be one of the factors determining the difference between
a stable microcephaly phenotype (as observed in many
types of primary microcephaly) to a progressive, hence
severe course as observed in many types of progressive
microcephaly.
G. M. S. Mancini: None.
E06.2
Macrocephaly
G. Mirzaa1*, F. Pirozzi2, A. Timms2, M. Berkseth2, R.
Shear2, G. Ruggeri2, E. Novotny3, W. Dobyns2, R. Kapur3,
J. Hauptman2, J. Ojemann2
1Seattle, WA, United States, 2Seattle Children’s Research
Institute, Seattle, WA, United States, 3Seattle Children’s
Hospital, Seattle, WA, United States
Megalencephaly: advances from genomic discoveries to
precision-based medicine
Megalencephaly disorders (MEG) constitute a growing
spectrum of developmental disorders associated with early
brain overgrowth, brain malformations including cortical
dysplasia, and neurodevelopmental co-morbidities such as
intractable epilepsy, autism and intellectual disability.
Constitutional and mosaic mutations of multiple cell growth
pathways, including the PI3K-AKT-MTOR and RAS
pathways, have been identified in this spectrum; with
promising therapeutic avenues on the horizon to ameliorate
the associated neurological deficits (e.g. MTOR pathway
inhibitors). However, significant molecular and clinical
challenges remain. Widely used molecular diagnostic
methods, such as standard-depth exome sequencing, lack
the sensitivity to detect low-level mosaic mutations
common in MEG. These methods are also not suitable for
screening limited amounts of surgically resected brain
tissues due to their high DNA input requirements.
Ultimately, more optimal molecular diagnostic methods
and high throughput pre-clinical models are necessary to
identify and study the effects of MEG-related mutations on
brain development. To address these challenges, we utilize a
combination of ultra-deep targeted sequencing employing
digital droplet PCR (ddPCR) as a new and sensitive tool for
screening common mutations in the PI3K-AKT-MTOR
pathway, and a quad based exome approach, sequencing
lesional (affected) tissues at a higher depth (200-250X). To
date, we performed genetic testing on a large cohort of
MEG families and have identified both known and novel
candidate genetic variants, including ultra-low-level mosaic
mutations in the PI3K-AKT-MTOR pathway. Our data
describe a gradient of mosaicism seen within the brain in
hemimegalencephaly samples; with mutation-positive
regions ranging in alternate allele frequencies (AAF) from
0.3% to 25.6% across several brain tissues. We subse-
quently aimed to model disease pathogenesis in vitro,
selecting patient-derived fibroblast lines with mutations in
key upstream (PIK3CA) and downstream (MTOR) nodes in
the pathway. We generated induced pluripotent stem cells
(iPSCs) carrying the common PIK3CAH1047R and
MTORT1977I mutations to characterize these nodes. Our
results suggest that targeted molecular analysis for the
common PI3K-AKT-MTOR pathway mutations by ddPCR
is an effective molecular diagnostic approach for MEG.
Given the high sensitivity and low DNA input requirements
for this assay, ddPCR may also be an effective molecular
tool for other mosaic disorders with a narrow mutational
spectrum. Our iPSC-derived lines provide a valuable model
for dissecting the functional consequences of these muta-
tions and future drug screens using PI3K-AKT-MTOR
pathway inhibitors.
F. Pirozzi: None. A. Timms: None. M. Berkseth: None.
R. Shear: None. G. Ruggeri: None. E. Novotny: None. W.
Dobyns: None. R. Kapur: None. J. Hauptman: None. J.
Ojemann: None.
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E07 Genome Editing: Multiple Tools and their
Applications
E07.1
Editing the Mammalian Genome: Targets and Tools
H. O’Neill*
University College London, London, United Kingdom
Genome editing comprises a powerful set of tools which
have enabled discovery in every model organism. CRISPR
genome editing has propelled research from bench to clinic
and shows promise for both the treatment and prevention of
genetic disorders. Ongoing research into the components of
this technology highlight where improvements can be made
to sharpen editing efficiencies. This lecture explains what
CRISPR is, how it works, and dissects the CRISPR
machinery to illuminate aspects of experimental design
which are essential for any genome editing experiment.
H. O’Neill: None.
E07.2
Genome-Wide CRISPR-Cas9 Screening in Immune
Cells
P. Tolar*
Francis Crick Institute, London, United Kingdom
The advent of CRISPR/Cas9-mediated genome editing has
revolutionised genetics. One of the new experimental
approaches afforded by the high efficiency of CRISPR/Cas9
gene editing are high-throughput gene targeting experi-
ments, such as genome-wide functional screens. Pooled-
library genome-wide screens are a particularly powerful and
efficient method to identify non-redundant genes regulating
a variety of cell intrinsic functions. For the first time this
allows comprehensive molecular characterisation of cellular
processes in cells from higher organisms in which previous
approaches failed, such as in primary immune cells from
mice and humans. I will discuss examples of CRISPR
screening strategies that my lab has developed for screening
of immune functions in B cells. The results of these screens
shed new light on molecular pathways that control antigen-
mediated B cell activation, proliferation, cell death and dif-
ferentiation into antibody-secreting cells under healthy and
pathological situations. The encouraging results of these
approaches hold promise for future advances in studies of
gene interactions, pathway mapping and molecular bases of
pathology inferred directly from diseased human cells.
P. Tolar: None.
E08 Does Genetic Counselling Work?
E08.1
What Was, What Is, What If - Trends and Predictions
In Assessing Genetic Counseling
R. G. Resta*
Swedish Medical Center, Seattle, WA, United States
Genetic counselling as a formalized clinical practice is
about 75 years old and as a profession is about 50 years old.
Initially (What Was) the criteria for assessing the effec-
tiveness of genetic counselling focused on reproductive
outcomes, cost-savings, and avoiding disability. As genetic
technologies have advanced, social values have changed,
and research sophistication has increased, (What Is) the
effectiveness of genetic counselling has been assessed by
patient focused outcomes such as empowerment, adapta-
tion, and personal disease risk reduction and avoidance.
Nonetheless, recurring themes of cost-savings and disability
avoidance continue to be proposed and used as measures of
genetic counselling success. Ultimately, the measures of the
"success" of genetic counselling reflect social, ethical, cul-
tural, geographic, and historical factors, as well as who is
measuring genetic counselling outcomes and for what pur-
poses. As genetic technologies and ethical values evolve
(What If), different measures of effective genetic counsel-
ling will likely emerge.
This presentation reviews the different measures of the
effectiveness of genetic counselling and their relationship to
sociocultural and historical influences and speculates on
emerging, potential, and speculative ways of assessing the
effectiveness of genetic counselling. Ultimately, the "effec-
tiveness" of genetic counselling depends upon how
effectiveness is defined, who is defining effectiveness, and
why they are defining effectiveness. The effectiveness of
genetic counselling is defined not so much by its
practitioners as it is by the sociocultural, medical, and
historical context in which genetic counselling takes place.
R. G. Resta: None.
E08.2
How to help society interact with genomic technology
A. Middleton*
Wellcome Genome Campus, Cambridge, United Kingdom
The ‘Your DNA, Your Say’ project is a global online survey
gathering public attitudes towards genomic data sharing.
This project explores how society is responding to genomic
technology and articulates the hopes and concerns that
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individuals have. I will share results from 37,000 members
of the public, from 22 countries (survey gathered data 15
languages) and offer insight into awareness of genomics,
interest in donating one’s data for research and clinical use
and fears around what would happen if a person is identified
from their data. I will also explore what trust looks like to
members of the public. I was also share details of another
study, ‘Music of Life’ that explores how to explain genetics
using metaphor in film. Films are being trialled at Adden-
brookes Hospital in Cambridge and I will share some of
these. All of my work focusses on how to build a bridge to
society so that we can help society interact with genomics.
Twitter: @genomethics, website: genomethics.org
A. Middleton: F. Consultant/Advisory Board; Modest;
RareMark, Congenica.
E10 Therapy for Rare Disorders
E10.1
Gene therapy in genetic disorders
M. Cavazzana1,2,3,4,5*
1Assistance Publique - Hôpitaux de Paris, Paris, France,
2Biotherapy Department, Hôpital Necker-Enfants malades,
Paris, France, 3Biotherapy Clinical Investigation Center,
Groupe Hospitalier Universitaire Ouest, Paris, France,
4Paris Descartes–Sorbonne Paris Cité University, Imagine
Institute, Paris, France, 5INSERM UMR 1163, Laboratory
of Human Lymphohematopoiesis, Paris, France
Over the last fifteen years, gene therapy has shown its
powerful outcome to successfully treat genetic diseases
such as X-SCID. Moreover the results of several other trials
have confirmed the clinical potential of gene therapy
approaches in other settings such as ADA deficiency and b-
hemoglobinopathies where the bone marrow content of the
different stem and precursor cells and the cells’ relationship
with the stroma have very specific characteristics. The
optimization of gene therapy requires better characterization
or identification of bone marrow homeostasis features in
disease settings. Recent progress has been achieved in the
harvesting and expansion of healthy hematopoietic stem
and progenitor cells (HSPCs) but also in identifying the
appropriate tools. The use of SIN retroviral vectors has
significantly reduced the risk of insertional mutagenesis and
has been the best choice for the introduction of a therapeutic
gene into autologous HSPCs than first-generation gamma
retroviral vectors. The use of autologous gene-corrected
HSPCs reduced the risk of alloreactive immune responses
and decreases the risk of infectious complications. Although
this progress is of great value, caution is required when
translating these findings into a diseased HSPC setting: (i)
in order to allow an engraftment of the corrected cells, gene-
modified autologous HSPCs need a conditioning regimen
that could be responsible for acute and chronic toxicity, (ii)
HSPCs derived from children under the age of 10 behave
differently in culture. Lastly, genome editing and homo-
logous recombination technologies have undergone spec-
tacular developments over the last couple of decades. In
view of the impressive progress reported for the gene
addition strategy, offering gene-editing approaches to
patients affected by inherited disorders would move gene




Trial readiness, trial endpoints and stakeholder
collaboration
V. Straub*
Institute of Genetic Medicine, Newcastle University, New-
castle, United Kingdom
Neuromuscular diseases (NMD) are rare diseases caused by
abnormalities in four anatomical structures: 1) the anterior
horn cell, 2) the axon of the 2nd motor neuron, 3) the neu-
romuscular junction and 4) the skeletal muscle cell itself.
Mutations in more than 600 genes causing 1000 different
diseases have so far been identified to cause genetic NMD.
The spectrum of phenotypes reaches from floppy babies to
late onset degenerative diseases. Most NMD are associated
with profound disability and many have a reduced life
expectancy. The clinical approach to NMD has changed
quite dramatically over the past 30 years from a rather
nihilistic and paternalistic to a research active and forward
looking approach. Life changing treatments have now been
approved for a number of genetic NMD, including gene
replacement therapy for spinal muscular atrophy type 1, and
many interventional trials and registration studies are ongo-
ing. This change in attitude was helped by improvements in
diagnostics, a better understanding of pathomechanisms and
joint international collaborations on trial readiness. Within
the past 15 years, a field with a profound lack in clinical trial
culture has changed into a specialty that is at the forefront of
advanced therapy activities. This change was amongst other
things made possible by TREAT-NMD, a patient centred
collaborative infrastructure programme supported by patient
advocacy groups and the European Commission. The project
started as a network of excellence within the EU Framework
Program 6 with the aim to accelerate the elaboration of
clinical trials for rare genetic NMD. Over the past 13 years
the network has established standardised operating proce-
dures for the assessment of various animal models, standard
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of care guidelines for a number of NMD, patient registries, a
care and clinical trial site inventory, a registry for outcome
measures, the TREAT-NMD advisory committee for ther-
apeutics (TACT), a global communication programme,
training and education activities, a consortium of biobanks
and close interactions with the regulatory authorities. The
successful translational infrastructure has helped to overcome
the fragmentation that existed in the field and shaped the way
all stakeholders are working together. The presentation





Heritability estimation and gene-environment
correlation
A. Young*
University of Southern California, Los Angeles, CA, United
States
Heritability measures the fraction of trait variation in a popu-
lation due to genetic inheritance. However, when genetic var-
iants and environment are correlated, heritability becomes
harder to measure. Sources of gene-environment correlation
include population stratification and indirect genetic effects
from relatives. indirect genetic effects are effects of genetic
variants in one individual on another individual’s trait through
the environment. indirect genetic effects have been shown to be
substantial for educational attainment, and likely affect other
human traits. In this talk, I discuss how to use genetic data on
families to separate out the direct causal effects of inherited
genetic variants from indirect genetic effects and population
stratification. The particular genetic variant that an individual
inherits is the outcome of random segregation in the parent of
that individual during meiosis. This randomisation, indepen-
dent of environment, enables unbiased estimation of direct
effects of SNPs and heritability by using genetic data on par-
ents and offspring. We discuss results of applying such meth-
ods and compare them to results from methods that do not
account for gene environment correlation.
A. Young: None.
E11.2
Flexible Heritability Estimation from Summary
Statistics
D. Speed*
Aarhus Institute of Advanced Studies, Aarhus, Denmark
The field of SNP-based heritability analysis began in 2010,
when Yang et al showed it was possible to estimate SNP
heritability, the total proportion of phenotypic variation
explained by single nuclotide polymorphisms, from gen-
ome-wide association study (GWAS) data. Since then,
many related methods have been proposed (e.g, methods for
estimating heritability enrichments, genetic correlations and
confounding bias), that allow us to further interrogate the
genetic architecture of complex traits.
I will begin by providing an introduction to the field, and
describing methods that use individual-level data. Then I
will discuss the second-generation methods, that require
only GWAS summary-statistics (and thus allow us to
analyze ever-increasing amounts of data). I will explain
how a crucial feature of all methods is the choice of
heritability model, which reflects our prior information
about the relative contributions of different SNPs. I will
finish by providing examples not only of how these
methods have improved our understanding of complex
traits (e.g., allowed us to determine which types of SNPs are
most important, and to infer the impact of selection), but
how this information can be utilized in other areas of
statistical genetics (e.g., to enable us to produce more
accurate polygenic risk scores).
D. Speed: None.
E12 Abstracts Withdrawn
E13 Mainstreaming Mitochondrial Replacement
Techniques?
E13.1
Mitochondrial replacement techniques: Exploring the
biological consequences
M. Herbert*, G. Hudson, Y. Takeda
Newcastle University, Newcastle upon Tyne, United
Kingdom
Mutations in mitochondrial DNA (mtDNA) are maternally
inherited and can cause a broad range of debilitating and
fatal diseases. Reproductive technologies, commonly
known as “mitochondrial replacement” (MR) have been
developed to enable women who carry pathogenic muta-
tions to have a genetically related child with a greatly
reduced risk of transmitting mtDNA disease. Such tech-
nologies involve transplantation of the nuclear DNA from
the egg of an affected woman to an enucleated egg from an
unaffected donor, effectively rescuing the nuclear genome
from its defective mitochondrial environment. The nuclear
DNA is transferred in a karyoplast containing a minimal
amount of cytoplasm, which can contain mitochondria.
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Oral Presentations 27
Under optimal conditions, the fraction of mtDNA co-
transferred with the nuclear genome typically accounts for
0-2% of the mtDNA content of MR embryos. Despite this, a
minority of embryonic stem (ES) cell lines derived from
MR embryos revert to the nuclear donor’s mitochondrial
genome. While the relevance to development in vivo is
unclear, reversion in ES cell lines remains a consideration in
the therapeutic application of MR. Our ongoing research,
focussed on understanding the drivers of reversion and on
developing techniques to prevent it, has revealed new
insights into mitochondrial homeostasis during pre-
implantation development.
M. Herbert: None. G. Hudson: None. Y. Takeda: None.
E14 Repeat Expansions: From Detection to Treatment
E14.2
Therapeutic advances in Huntington’s disease with
relevance to other repeat expansion disorders
S. J. Tabrizi*
University College London, London, United Kingdom
Huntington’s disease (HD) is one of the CAG repeat
expansion disorders, it is a devastating autosomal dom-
inantly inherited neurodegenerative disease for which there
is currently no effective disease modifying therapy. The
genetic predictability of HD provides an opportunity for
early therapeutic intervention many years before overt
symptom onset and at a time when reversal or prevention of
neural dysfunction may still be possible. As HD is mono-
genic, fully penetrant, and characterised by a long pre-
manifest phase, it is emerging as a potential model for
studying therapeutic intervention in other neurodegenera-
tive conditions such as Alzheimer’s or Parkinson’s disease
where no preclinical diagnostic tests exist. In addition, HD
manifests with a broad range of clinical symptoms and
signs, many of them common to these other diseases, and
involves widespread pathology throughout most of the
brain. Understanding of HD pathogenesis is evolving, and I
will present recent findings on identifying novel genetic
modifiers of age of onset and disease progression, and their
relevance for designing new therapeutics. In the main body
of my lecture, I will give an overview of important
approaches in development for targeting mutant HTT DNA
and RNA, and in particular I will focus on the recent suc-
cessful phase 1b/2a clinical trial testing the effects of
RG6042 (formerly known as IONIS HTT Rx) in patients
with early Huntington’s Disease and present the results of
the first successful HTT-lowering drug trial.
S. J. Tabrizi: F. Consultant/Advisory Board; Modest; F.
Hoffmann-La Roche Ltd, Takeda Pharmaceuticals Ltd. F.
Consultant/Advisory Board; Significant; Genentech.
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C01 From Carrier Screening to Infertility and Fetal
Diagnostics
C01.1
Consistency of carrier screening guidelines across seven
populations and 408,00 individuals
A. Arjunan*, R. Ben-Shachar, R. Torres, K. Johansen
Taber, K. E. Kaseniit, D. Muzzey
Myriad Women’s Health, South San Francisco, CA, United
States
Introduction: Current American College of Obstetricians
and Gynecologists (ACOG) guidelines recommend pan-
ethnic carrier screening for two conditions: cystic fibrosis
and spinal muscular atrophy. In addition, ACOG recom-
mends screening for approximately a dozen conditions in
certain ethnicities. Here we analyzed carrier rates of
176 serious conditions to determine whether current
guidelines support consistent care across all ethnicities.
Methods: Population-specific carrier rates of 176 Men-
delian conditions were estimated using self-reported
ethnicity in a cohort of over 408,000 individuals undergoing
expanded carrier screening. Carrier screening guidelines
were then analyzed to determine consistency across
ethnicities.
Results: We analyzed 44 population-condition combina-
tions, and found that the least frequent was cystic fibrosis
(CF) in the Southeast Asian population (population-
condition carrier rate 0.6%, 1 in 161). We then posited
the question: how many disorders not recommended for
screening are as frequent or more frequent than the least
frequent disorder currently recommended by carrier-screen-
ing guidelines? Searching across other permutations
revealed 191 additional population-condition carrier rates
in excess of 0.6%, suggesting that current guidelines are not
consistently capturing reproductive risk across populations
or conditions.
Conclusions: Many conditions have population-specific
incidence comparable to CF in the Southeast Asian
population—the rarest population-condition pair currently
recommended for carrier screening by ACOG. Expanding
guidelines to include pan-ethnic screening of additional
conditions with comparable or higher incidence in select
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populations would improve equitability of medical care
across all populations.
This study was funded by Myriad Genetics, Inc.
A. Arjunan: None. R. Ben-Shachar: A. Employment (full
or part-time); Significant; Myriad Genetics, Inc. E. Own-
ership Interest (stock, stock options, patent or other
intellectual property); Significant; Myriad Genetics, Inc.
R. Torres: A. Employment (full or part-time); Significant;
Myriad Genetics, Inc. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Significant;
Myriad Genetics, Inc. K. Johansen Taber: A. Employment
(full or part-time); Significant; Myriad Women’s Health. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Myriad Genetics, Inc. K.
E. Kaseniit: A. Employment (full or part-time); Significant;
Myriad Women’s Health. F. Consultant/Advisory Board;
Significant; Myriad Women’s Health. D. Muzzey: A.
Employment (full or part-time); Significant; Myriad
Women’s Health. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Significant;
Myriad Genetics, Inc.
C01.2
Expanded carrier screening of recessive disorders
(CarrierTest) in clinical practice
J. Diblík*, M. Bittóová, F. Lhota, F. Zembol, L. Dohnalová,
Z. Vilímová, I. Soldátová, M. Hrabíková, I. Pavlechová, M.
Koudová, D. Stejskal
GENNET s.r.o., Praha, Czech Republic
Introduction: Screening for carrier status of recessive dis-
orders is a standard part of preconception care. Expanded
screening is based on simultaneous detection of variants in
multiple genes that covers mutations prevalent in different
human populations.
Methods: CarrierTest is a custom designed test based on
amplicon sequencing of target regions in 77 genes for
detection of 835 pathogenic mutations causing more than 61
inherited disorders.
Results: We have examined 10752 individuals from
couples with infertility or recurrent pregnancy loss between
April 2017 and October 2019. In total we have detected
3899 pathogenic variants, most often in following genes:
GJB2 (in 4.9 % of individuals), CFTR (3.6 %), SERPINA1
(2.6 %), DHCR7 (2.6 %), SMN1 (2.5 %), PAH (2.3 %),
NBN (1.8 %), CYP21A2 (3.3 %), ATP7B (1.2 %), PMM2
(1.1 %), ACADVL (1.1 %) and ACADM (1 %). We have
found a high risk of autosomal recessive disorder in 67
couples (1.25 %), most often both partners were carriers of
mutations in GJB2 (18×), CFTR (13×), SMN1 (6×),
CYP21A2 (6×), SERPINA1 (3×), PAH (3×), MEFV (3×),
DHCR7 (2×), PMM2 (2×), ACADVL (2×), ACADM (2×),
HEXA (2×) and ARSA (2×).
Conclusion: Results of CarrierTest provide the couples
with information about the risk for their offspring. The
severity depends on the gene and exact mutations. The
findings thus must be assessed and communicated by a
clinical geneticist so that couples can make informed
decisions. The available preventive measures include
preimplantation genetic testing, prenatal diagnosis as well
as postnatal diagnosis for early treatment.
J. Diblík: None. M. Bittóová: None. F. Lhota: None. F.
Zembol: None. L. Dohnalová: None. Z. Vilímová: None. I.
Soldátová: None. M. Hrabíková: None. I. Pavlechová:
None. M. Koudová: None. D. Stejskal: None.
C01.3
Exome sequencing reveals variants in known and novel
candidate genes for severe sperm motility disorders
M. S. Oud1*, B. J. Houston2, L. Volozonoka3,4, F. K.
Mastrorosa4, B. Alobaidi4, P. F. de Vries1, G. Astuti1,
L. Ramos5, R. Burke2, R. I. McLachlan6, M. K. O’Bryan2,
J. A. Veltman1,4, H. E. Chemes7, H. Sheth4,8
1Department of Human Genetics, Radboudumc, Nijmegen,
Netherlands, 2Monash School of Biological Sciences,
Clayton, Australia, 3Riga Stradins University, Riga, Latvia,
4Biosciences Institute Newcastle University, Newcastle,
United Kingdom, 5Department of Gynaecology and Obste-
trics, Radboudumc, Nijmegen, Netherlands, 66Hudson
Institute of Medical Research, Clayton, Australia, 7Center
for Research in Endocrinology, Buenos Aires Children’s
Hospital, Buenos Aires, Argentina, 8Foundation for
Research in Genetics and Endocrinology, Ahmedabad,
India
Severe sperm motility disorders are a form of male inferti-
lity characterized by immotile sperm, often in combination
with a spectrum of structural abnormalities of the sperm
flagellum. Depending on the sub-categorization, genetic
factors explain up to 50% of these patients. We performed
exome sequencing on 21 patients with severe sperm moti-
lity disorders to identify the underlying genetic defects. A
diagnosis was reached in 9/21 patients (42.9%) due to
variants in previously described genes CFAP43 (3 patients),
CFAP44 (2 patients), QRICH2 (2 patients), DNAH1 (1
patient) and DNAH6 (1 patient). Furthermore, we identified
seven patients with variants in novel spermatogenesis-rela-
ted candidate genes: CFAP58, DNAH12, DRC1, MDC1,
PACRG, SSPL2C and TPTE2. One other patient carried
variants in four candidate genes. Electron microscopy
imaging was available to further characterize the sperm
flagellum phenotype in 4/9 diagnosed patients and 5/8
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patients with variants in candidate genes. This revealed
short, irregular tails with thickening of the fibrous sheath (9/
9 patients), abnormal outer dense fibers (5/9) and absence of
dynein arms (2/9 patients), central microtubule pairs (6/9
patients) or mitochondrial sheath (9/9). RNA interference
study in Drosophila melanogaster confirmed that loss of
DNAH6, DNAH12 and QRICH2 expression resulted in male
infertility, thus suggesting an evolutionary conserved role
for these genes. Our results confirm an important role for
five known genes and demonstrate that exome sequencing is
an effective method to diagnose patients with severe moti-
lity disorders. Sequencing of additional patient cohorts is
needed to further strengthen the role of the novel candidate
genes in motility disorders.
M. S. Oud: None. B. J. Houston: None. L. Volozonoka:
None. F. K. Mastrorosa: None. B. Alobaidi: None. P. F. de
Vries: None. G. Astuti: None. L. Ramos: None. R. Burke:
None. R. I. McLachlan: None. M. K. O’Bryan: None. J. A.
Veltman: None. H. E. Chemes: None. H. Sheth: None.
C01.4
Identification of novel causes for male infertility: loss-of-
function variants in MSH4 and MSH5
M. J. Wyrwoll1,2*, C. Friedrich1, E. Kaminsky3,
C. Krallmann2, S. Kliesch2, F. Tüttelmann1
1Institute of Human Genetics, University of Münster,
Münster, Germany, 2Centre of Reproductive Medicine and
Andrology, Department of Clinical and Surgical Androl-
ogy, University Hospital, Münster, Germany, 3Praxis für
Humangenetik Kaminsky, Hamburg, Germany
Infertility affects around 7% of all men and is in part due to
azoospermia. Testicular sperm extraction (TESE) from
biopsies in azoospermic patients offers the possibility to
recover sperm that can be used for assisted reproduction.
However, 2-10% of azoospermic patients have meiotic
arrest (MeiA). If MeiA is complete, TESE will not succeed.
We performed whole exome sequencing (WES) in 68
patients with MeiA and negative TESE procedures. Alter-
native causes for infertility were excluded in advance. WES
data was screened with focus on rare, biallelic variants
[maximum allele frequency (MAF) < 1% in all databases],
which are likely pathogenic (stop-, frameshift-, and splice
site-mutations). We detected two novel genes, MSH4 and
MSH5, as possible causes for MeiA in men. Both genes are
expressed predominantly in germ cells in humans and are
associated with premature ovarian insufficiency in women.
One of our MeiA patients carries biallelic loss of function
variants in MSH4, while three azoospermic patients have
homozygous variants in MSH5. MSH4 and MSH5 form a
heterodimer, which binds DNA strands during prophase 1,
stabilising the interaction between homologous chromo-
somes. Based on our data we propose that pathogenic var-
iants in MSH4 and MSH5 cause autosomal recessive MeiA.
If validated, screening of MSH4 and MSH5 in azoospermic
patients before testicular biopsy may prevent unnecessary
surgical procedures, if there is no chance of finding mature
spermatozoa in the testis. This work was carried out within
the frame of the DFG Clinical Research Unit ‘Male Germ
Cells: from Genes to Function‘(CRU 326).
M. J. Wyrwoll: None. C. Friedrich: None. E. Kaminsky:
None. C. Krallmann: None. S. Kliesch: None. F.
Tüttelmann: None.
C01.5
Non-invasive prenatal diagnosis by genome-wide haplo-
typing of cell-free plasma DNA
H. Che1*, D. Villela1,2, E. Dimitriadou1, C. Melotte1, N.
Brison1, M. Neofytou1, K. Van Den Bogaert1, O. Tsuiko1, K.
Devriendt1, E. Legius1, M. Zamani Esteki1,3,4, T. Voet1, J. R.
Vermeesch1
1Center of Human Genetics, KU Leuven, Leuven, Belgium,
2Department of Genetics and Evolutionary Biology, Insti-
tute of Biosciences, University of Sao Paulo, Sao Paulo,
Brazil, 3Department of Clinical Genetics, Maastricht
University Medical Center, Maastricht, Netherlands,
4Department of Genetics and Cell Biology, GROW School
for Oncology and Developmental Biology, Maastricht
University, Maastricht, Netherlands
Introduction: While non-invasive prenatal testing for
aneuploidies (NIPT-A) is widely implemented, there is an
increasing need for universal approaches for noninvasive
prenatal testing for monogenic diseases (NIPT-M). Here,
we present a cost-effective, generic cell-free fetal DNA
(cffDNA) haplotyping approach to scan the fetal genome
for the presence of inherited monogenic diseases.
Methods: Families participating in the preimplantation
genetic testing for monogenic disorders (PGT-M) program
were recruited for this study. 250000 SNPs captured from
maternal plasma DNA along with genomic DNAs from
family members were massively parallel sequenced.
Parental genotypes were phased via an available genotype
from a close relative, and the fetal genome-wide haplotype
and copy number were determined using cffDNA haplotyp-
ing analysis based on estimation and segmentation of fetal
allele presence in the maternal plasma.
Results: In all families tested, mutational profiles from
cffDNA haplotyping are consistent with embryo biopsy
profiles. Genome-wide fetal haplotypes are on average 97%
concordant with the newborn haplotypes and embryo
haplotypes.
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Conclusion: We demonstrate that genome-wide targeted
capture and sequencing of polymorphic SNPs from
maternal plasma cell free DNA (cfDNA) allows haplotyp-
ing and copy number profiling of the fetal genome during
pregnancy. The method enables the accurate reconstruction
of the fetal haplotypes and can be easily implemented in
clinical practice.
Grants: This work was funded by KULeuven funding
(C1/018), the Horizon 2020 WIDENLIFE: 692065 to J. R.
V. and T.V and by the Fonds voor Wetenschappelijk
Onderzoek (FWO-Vlaanderen: G080217N) to J. V. D. V.
was supported by FAPESP (2017/23448-8).
H. Che: None. D. Villela: None. E. Dimitriadou: None. C.
Melotte: None. N. Brison: None. M. Neofytou: None. K.
Van Den Bogaert: None. O. Tsuiko: None. K. Devriendt:
None. E. Legius: None. M. Zamani Esteki: None. T. Voet:
None. J. R. Vermeesch: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Agilent.
C01.6
Trio exome/whole exome sequencing in prenatal diag-
nosis: Experiences from >400 cases shows a high
diagnostic yield and a great benefit for pregnancy
management and genetic counselling.
H. Gabriel1*, C. Wilhelm2, F. Battke1, E. Goldmann2,
C. Bus2, S. Biskup1
1CeGaT, Tuebingen, Germany, 2Praxis für Humangenetik,
Tuebingen, Germany
Whole exome sequencing (WES) and trio exome sequen-
cing is becoming the first-tier diagnostic test for many
unclear genetic conditions. However, in prenatal testing,
several challenges have to be addressed: turn-around-time,
patient acceptability, additional findings, interpretation of
unclear variants, and ethical dilemmas. A cohort of >400
unselected fetuses with varying structural anomalies seen
during routine ultrasonography were analysed after amnio-
centesis or chorionic villus sampling. In 326 samples, trio
exome sequencing was performed. Only likely pathogenic
and pathogenic (according to the current ACMG guideline;
Richards et al., 2015), in genes to be potential involved in
the observed fetal phenotype were considered. 30% of the
cases were clearly solved by trio exome sequencing,
meaning that class 4 or 5 variants consistent with the fetal
phenotype were found. An additional 12% cases with var-
iants very likely causative for the phenotype were detected.
In most of these cases only limited clinical information was
available or only soft markers (e.g. increased nuchal trans-
lucency) were present. The mean turn-around-time (TAT)
was 18 days with a shortest TAT of 5 days. In this study, we
have shown the value of trio exome sequencing for the
prenatal genetic diagnosis of fetuses with varying structural
anomalies. A fast, stable, and reliable process including
sample processing, data analysis, and comprehensive
reporting is required to provide patients with the maximal
benefit. In summary, prenatal exome sequencing offers a
feasible diagnostic approach for fetuses with anomalies, but
a multidisciplinary team to cover all ethical, psychological,
social and medical aspects is required.
H. Gabriel: None. C. Wilhelm: None. F. Battke: None. E.
Goldmann: None. C. Bus: None. S. Biskup: None.
C02 Intellectual Disability
C02.1
SCAF4 loss of function in humans and Drosophila
implicates mRNA transcriptional termination in neuro-
developmental disorders
A. Fliedner1*, P. Kirchner1, K. E. Agre2, I. de Graaf-van de
Laar3, M. Dutra Clarke4, L. Davis-Keppen5, A. B. Ekici1, A.
Gregor1, N. Lippa6, K. McWalter7, G. Mirzaa8, G. Noh9, L.
Ohden5, D. A. Scott10, S. Lalani10, R. Straussberg11,12, R.
Cohen13,12, A. Wiesener1, C. Zweier1
1Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg, Erlangen, Germany, 2Clinical
Genomics, Mayo Clinic, Rochester, MN, United States,
3Department of Clinical Genetics, Erasmus MC, University
Medical Center Rotterdam, Rotterdam, Netherlands, 4Divi-
sion of Genetics and Genomic Medicine, Department of
Pediatrics, University of California-Irvine, School of
Medicine, Irvine, CA, United States, 5University of South
Dakota, Sanford School of Medicine, Sioux Falls, SD,
United States, 6Institute for Genomic Medicine, Columbia
University Medical Center, New York, NY, United States,
7Clinical Genomics, GeneDx, Gaithersburg, MD, United
States, 8Department of Pediatrics, University of Washing-
ton, Seattle, WA, United States, 9Department of Genetics,
Southern California Permanente Medical Group, Fontana,
CA, United States, 10Department of Molecular and Human
Genetics, Baylor College of Medicine, Houston, TX, United
States, 11INeurogenetics Clinic, Neurology Unit, Schneider
Children Medical Center, Petah Tikvah, Israel, 12Sackler
School of Medicine Tel Aviv University, Ramat Aviv, Israel,
13Neurology Institute and Epilepsy Center, Schneider
Children Medical Center, Petah Tikvah, Israel
Regulation of gene expression is highly complex and
involves a large number of different processes including
mRNA termination at polyA sites. This is mediated by
RNA polymerase II and requires binding of SR-related and
CTD-associated factor 4 (SCAF4). SCAF4 represses the
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usage of early polyA sites and thus prevents usage of
alternative last exons (ALEs) and formation of truncated,
non-functional proteins. SCAF4 is expressed in all adult and
fetal tissues, with high expression in brain, and has not been
associated with disease, yet. By exome sequencing and
international matchmaking we assembled six truncating,
two splice-site and one missense variant in SCAF4, all but
one de novo. All individuals presented with a variable
neurodevelopmental disorder with developmental delay,
mild to severe intellectual disability and various other
aspects such as epilepsy (6/9), behavioral anomalies (6/9)
and skeletal (3/9) or renal (3/9) anomalies. Knockdown of
the SCAF4 orthologue CG4266 in the model organism
Drosophila melanogaster resulted in impaired locomotor
function in the climbing assay and impaired learning and
short-term memory tested by the courtship conditioning
paradigm. Furthermore, we observed an increased number
of active zones in larval neuromuscular junctions, repre-
senting large glutamatergic synapses. These observations
indicate a role of CG4266 in nervous system development
and function and support a role of its human orthologue
SCAF4 in neurodevelopmental disorders. We establish
likely gene-disruptive variants in SCAF4 as causative for a
variable neurodevelopmental disorder and thus implicate
disturbed mRNA termination in impairment of neurodeve-
lopment and cognition.
A. Fliedner: None. P. Kirchner: None. K. E. Agre: None.
I. de Graaf-van de Laar: None. M. Dutra Clarke: None. L.
Davis-Keppen: None. A. B. Ekici: None. A. Gregor: None.
N. Lippa: None. K. McWalter: A. Employment (full or part-
time); Significant; GeneDx. G. Mirzaa: None. G. Noh:
None. L. Ohden: None. D. A. Scott: None. S. Lalani: None.
R. Straussberg: None. R. Cohen: None. A. Wiesener: None.
C. Zweier: None.
C02.2
Mutation-specific pathophysiological mechanisms in a
new SATB1-associated neurodevelopmental disorder
J. den Hoed1*, E. de Boer2,3, N. Voisin4, N. Guex4, L.
Snijders Blok1,2,3, J. Chrast4, The DDD study, L.
Manwaring5, M. Willing5, A. Waheeb6,7, M. Osmond7, K.
McWalter8, A. Vitobello9,10, F. Demurger11, A.
Lavillaureix12, S. Odent12, B. Mazel10, L. Faivre10, I.
Thiffault13,14, C. Schwager13,14, S. M. Amudhavalli13,14, J. A.
Rosenfeld15, K. Radtke16, E. Preiksaitiene17,18, E.
Ranza19,20, C. Depienne21, A. Kuechler21, S. Mohammed22,
Y. Hamzavi Abedi23,24, V. R. Bonagura25,24, B. Zuccarelli26,
B. Horist27, V. Krishnamurthy27, A. A. Kattentidt-
Mouravieva28, L. Granger29, A. Petersen29, K. L. Jones30,31,
M. Sinnema32, A. P. A. Stegmann2,32, R. Newbury-Ecob33,
U. Kini34, D. F. Newbury35, C. Gilissen2,36, H. Brunner2,3,32,
T. Kleefstra2,3, A. Reymond4, L. E. L. M. Vissers2,3, S. E.
Fisher1,3
1Max Planck Institute for Psycholinguistics, Nijmegen,
Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Don-
ders Institute for Brain, Cognition and Behaviour, Nijme-
gen, Netherlands, 4University of Lausanne, Lausanne,
Switzerland, 5Washington University School of Medicine,
St. Louis, MO, United States, 6Children’s Hospital of
Eastern Ontario, Ottawa, ON, Canada, 7Children’s Hospi-
tal of Eastern Ontario Research Institute, Ottawa, ON,
Canada, 8GeneDx, Gaithersburg, MD, United States, 9Uni-
versité de Bourgogne Franche-Comté, Dijon, France,
10Centre Hospitalier Universitaire de Dijon, Dijon, France,
11Vannes hospital, Vannes, France, 12Rennes University,
Institute of Genetics and Development of Rennes (IGDR),
Rennes, France, 13University of Missouri-Kansas City
School of Medicine, Kansas City, MO, United States,
14Children’s Mercy Hospital, Kansas City, MO, United
States, 15Baylor College of Medicine, Houston, TX, United
States, 16Ambry Genetics, Aliso Viejo, CA, United States,
17Vilnius University, Vilnius, Lithuania, 18Vilnius University
Hospital Santaros Klinikos, Vilnius, Lithuania, 19University
of Geneva, Geneva, Switzerland, 20University Hospitals of
Geneva, Geneva, Switzerland, 21University Hospital Essen,
University of Duisburg-Essen, Essen, Germany, 22Guy’s
Hospital, London, United Kingdom, 23Northwell Health,
Great Neck, NY, United States, 24Donald and Barbara
Zucker School of Medicine at Hofstra/Northwell, Hemp-
stead, NY, United States, 25Feinstein Institutes for Medical
Research, Manhasset, NY, United States, 26The University
of Kansas School of Medicine Salina Campus, Salina, KS,
United States, 27Pediatrics & Genetics Alpharetta, Alphar-
etta, GA, United States, 28Zuidwester, Middelharnis,
Netherlands, 29Randall Children’s Hospital at Legacy
Emanuel, Portland, OR, United States, 30Children’s
Hospital of the King’s Daughters, Norfolk, VA, United
States, 31Eastern Virginia Medical School, Norfolk, VA,
United States, 32Maastricht University Medical Center+,
Maastricht, Netherlands, 33St Michael’s Hospital Bristol,
University Hospitals Bristol NHS Foundation Trust, Bristol,
United Kingdom, 34Oxford University Hospitals NHS
Foundation Trust, Oxford, United Kingdom, 35Oxford
Brookes University, Oxford, United Kingdom, 36Radboud
Institute for Molecular Life Sciences, Nijmegen,
Netherlands
Introduction: Special AT-rich sequence-binding protein-1
(SATB1) is a transcription factor that has not been impli-
cated in neurodevelopmental disorders, but was recently
identified as a dominant candidate gene in two large-scale
meta-analyses, together comprising >65,000 patients with
32 J. del Picchia
neurodevelopmental disorders, including intellectual dis-
ability (ID) and/or autism spectrum disorders. A homo-
zygous knockout of the orthologous Satb1 leads to mice
lethality, demonstrating its importance in early
development.
Methods and results: Here, we report on 26 individuals
with SATB1 variants. Seventeen patients have missense
variants predicted to be deleterious, and nine have
truncating variants, three of which predicted to escape
nonsense-mediated decay. 21 of 26 variants (80%) were
confirmed to be de novo in origin. Patients showed a broad
phenotypic spectrum, including ID and/or neurodevelop-
mental delay, epilepsy, dental abnormalities and aspecific
brain MRI findings. Additionally, patients with missense
variants are more severely affected than those with
truncating variants. We characterized the effects of eight
different missense mutations, including two recurrent
variants, in cell-based assays. Compatible with a gain-of-
function effect of missense variants, mutated SATB1
proteins showed altered nuclear localization and increased
transcriptional repression on two characterized targets (IgH-
MAR site and the IL2 promoter). Consistent with this
hypothesis, fluorescent recovery after photobleaching
(FRAP) experiments demonstrated a decrease in mobility
of mutant SATB1, suggesting stabilization of DNA binding
underlying the increased transcriptional activity. Transcrip-
tome analysis is currently ongoing to further substantiate
these findings.
Conclusions: In summary, through multi-center colla-
borations, we show that SATB1 is associated with an
autosomal dominant neurodevelopmental disorder, resulting
from distinct mutation-specific pathophysiological
mechanisms.
J. den Hoed: None. E. de Boer: None. N. Voisin: None.
N. Guex: None. L. Snijders Blok: None. J. Chrast: None. L.
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C02.3
De novo frameshift variants in the neuronal splicing
factor NOVA2 result in a common C-terminal part and
cause a severe form of neurodevelopmental disorder
F. Mattioli1*, G. Hayot1, N. Drouot1, B. Isidor2, J.
Courraud1, M. Hinckelmann1, F. Tran Mau-Them3,4, C.
Sellier1, A. Goldman5, A. Telegrafi6, A. Boughton7, C.
Gamble7, S. Moutton3,4, A. Quartier1, N. Jean3,4, P. Van
Ness5, S. Grotto8, S. Nambot3,4, G. Douglas6, Y. Si6, J.
Chelly1,9, Z. Shad10, E. Kaplan10, R. Dineen10, C. Golzio1,
N. Charlet1, J. Mandel1, A. Piton1,9
1IGBMC, Illkirch, France, 2CHU de Nantes, Nantes,
France, 3CHU de Dijon, Dijon, France, 4Burgundy
University, Dijon, France, 5Baylor College of Medicine,
Houston, TX, United States, 6GeneDx, Gaithersburg, MD,
United States, 7Cook Children’s Genetics, Fort Worth, TX,
United States, 8AP-HP Robert-Debré, Paris, France,
9Hôpitaux Universitaires de Strasbourg, Strasbourg,
France, 10University of Illinois College of Medicine,
Chicago, IL, United States
Monogenic forms of intellectual disability (ID) are char-
acterized by an extreme heterogeneity, with more than 700
genes now implicated. The most frequent cause of mono-
genic ID - the fragile X-syndrome- is due to the absence of
the RNA-binding protein (RBP) FMRP. Many other ID
genes have been implicated in the RNA metabolism.
NOVA2 is a RBP known to regulate neuron specific
alternative splicing (AS). We identified 6 individuals with
de novo frameshift variants in NOVA2 affected with a
neurodevelopmental disorder characterized by ID, motor
and speech delay, autistic features, spasticity or ataxic gait
and abnormal brain MRI. All variants cluster in a small GC-
repeat rich region, located in the last exon, indicating that
the mutated transcript might escape to nonsense mediated
decay. All 6 frameshift variants lead to the addition of a
novel common C-terminal part instead of the last KH RNA-
binding domain, suggesting a dominant negative mechan-
ism. We detected 41 genes differentially spliced after
downregulation of NOVA2 in human neuronal cells. The
NOVA2 variant protein shows decreased ability to bind
target RNA sequences and to regulate target AS events. It
also fails to complement the effect on neurite outgrowth
induced by NOVA2 downregulation in vitro and to rescue
alterations of retinotectal axonal pathfinding induced by loss
of NOVA2 ortholog in zebrafish. Our results showed that
truncating mutations in NOVA2 cause a syndromic form of
ID, suggesting a hypomorphic mechanism rather than a full
heterozygous loss of function, although a specific con-
tribution of the novel C-terminal extension cannot be
excluded.
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C02.4
Location, location, location: protein truncating variants
in different loci of SRCAP cause three distinct neurode-
velopmental disorders, associated with distinctive DNA
methylation signatures
D. Rots1*, E. Chater-Diehl2, A. J. M. Dingemans1, M. Siu2,
C. Cytrynbaum2, N. Hoang2, S. Walker2, S. Scherer2, R.
Pfundt1, T. Rinne1, T. Gardeitchik1, B. B. A. de Vries1, C. T.
R. M. Stumpel3, S. J. C. Stevens4, J. van Harssel5, D. G. M.
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Rogers11, E. Morava11, E. W. Klee11, I. R. Berry12, J.
Campbell13, K. Lindstrom14, A. M. Neumeyer15, J. A.
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of Medicine, New Haven, CT, United States, 21Leiden
University Medical Center, Leiden, Netherlands, 22Depart-
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SRCAP functions in a chromatin remodeling complex,
involved in epigenetic regulation of gene expression. Pro-
tein-truncating variants (PTVs) in the last two exons of
SRCAP cause Floating-Harbor syndrome (FLHS), which is
characterized by typical facial features, short stature with
delayed bone age and expressive speech delay. We report
on novel genotype-phenotype correlations, associated with
SRCAP PTVs outside the FLHS locus.
We identified 21 probands with PTVs upstream, and 5
with PTVs downstream of the reported FLHS locus. Most
patients presented with speech delay and intellectual
disability. In contrast to FLHS, they have normal height
and bone age. Moreover, facial-recognition algorithms on
2D-photos showed that patients with upstream and down-
stream PTVs do not cluster with the FLHS-facial gestalt.
The upstream PTVs result in subtle facial dysmorphism,
autism spectrum disorder, severe behavioral problems and
joint issues, such as hypermobility and premature degen-
eration. In contrast, patients with downstream PTVs have
neurodevelopmental delay and Marfanoid habitus.
At the molecular level, FLHS is characterized by a unique
DNA methylation (DNAm) signature consisting of ~570
differentially methylated CpGs. The DNAm profiles of the
upstream and downstream PTVs yielded different signa-
tures from FLHS.
In summary, we delineate the phenotype of patients with
SRCAP PTVs outside the FLHS locus. None of the patients
show clinical features typical for FLHS. Analysis at the
molecular level suggests that each clinical entity is
associated with its own molecular mechanism. We propose
that the upstream PTVs result in haploinsufficiency,
whereas the downstream PTVs and FLHS-causing variants
result in distinct dominant-negative or gain-of-function
effect.
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C02.5
Mechanistic dissection of chromatin topology disruption
in the 5q14.3 MEF2C locus as an indirect driver of
neurodevelopmental disorders
K. Mohajeri1,2, E. D’haene3*, R. Yadav1,2, H. Gu4,5, B.
Menten3, A. Presser Aiden4,5, C. Lowther1,2, S. Erdin1,2, E.
Lieberman Aiden4, J. Gusella1,2, S. Vergult3, M.
Talkowski1,2
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Structural variants have the potential to create long-range
positional effects, uncouple genes from regulatory elements,
and facilitate aberrant 3D chromatin folding. In an inde-
pendent study, we revealed a significant enrichment of
intergenic balanced chromosomal abnormality (BCA)
breakpoints from congenital anomaly cases at chromosome
5q14. 3. All 11 5q14.3 BCA carriers had breakpoints dis-
rupting the topologically associated domain (TAD) housing
MEF2C, a known driver of neurodevelopmental disorders.
In a second study, we showed, using 4C-seq, that MEF2C
forms proximal and distal interaction loops within this
TAD, contacting multiple neuronal enhancers.
To understand the functional impact of these BCAs, we
performed a mechanistic dissection of the 3D regulatory
network at the 5q14.3 locus and its constituent functional
elements using Cas9-based genome editing. We generated
>200 cell lines, representing deletions of MEF2C alongside
five MEF2C TAD boundary and interaction loop targets in
iPS-derived neural stem cells (NSCs) and cortical induced
neurons (iNs). We profiled changes in expression and 3D
chromatin interactions within these models using RNA-seq
and 4C-seq. MEF2C was variably differentially expressed
upon deletion of proximal and distal MEF2C loop regions,
with effects depending on cell type and variant class.
Underlying chromatin interaction patterns revealed evi-
dence of loop maintenance in these models, possibly via
CTCF buffering, highlighting compensatory mechanisms
against 3D chromatin disruption. In contrast, deletion of the
proximal TAD boundary facilitated increased contacts with
predicted enhancers in the adjacent TAD.
Our results suggest novel regulatory mechanisms driving
phenotypic outcomes for the 5q14.3 region, with significant
implications for interpretation of pathogenic structural
variation.
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Crispr-Cas9-engineered Pigv341E mouse model mirrors
the human phenotype, reveals a hippocampal synaptic
defect and suggests a major role of impaired Abl1/
Ephrin signaling pathway in GPI anchor deficiency
M. Rodríguez de los Santos1,2,3*, M. Rivalan4, F. S.
David3,5, A. Knaus3, A. Stumpf6, L. Moreno Velasquez6, A.
Voigt6, D. Mattei7, M. Long4, L. Wittler8, B. Timmermann9,
D. Horn1, S. Mundlos1,2,10, U. Kornak1,10, D. Schmitz6, Y.
Winter4, P. M. Krawitz3
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Genetics, University of Bonn, Faculty of Medicine &
University Hospital Bonn, Bonn, Germany, 6Neuroscience
Research Center, Charité - Universitätsmedizin Berlin,
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Pathogenic germline mutations in PIGV result in a glyco-
sylphosphatidylinositol biosynthesis deficiency (GPIBD).
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Patients with biallelic mutations in genes of this molecular
pathway show cognitive impairments, a psychomotor delay
and often suffer from epilepsies. Thus far, the pathophy-
siology underlying the disease remains unclear and suitable
rodent models were lacking. Hence, we generated a mouse
model using CRISPR-Cas9 to introduce the most prevalent
hypomorphic mutation observed in European patients, that
is also conserved in mice Pigv:c.1022 C>A (p.Ala341Glu).
At the behavioral level, Pigv341E mice mutants showed
deficits in motor coordination and cognitive impairments in
long-term spatial memory. Furthermore, Pigv341E mice
displayed alterations in social behavior and sleep patterns
reflecting the human phenotype. Immunohistochemistry
showed a decreased synaptophysin immunoreactivity in
hippocampal CA1 and electrophysiology recordings
demonstrated a reduced hippocampal synaptic transmission
in Pigv341E mice that may explain impaired memory for-
mation. In addition, we performed single cell RNA
sequencing of hippocampal cells of adult Pigv341E mice that
exhibit changes of gene expression, most prominently in a
microglia subtype, subicular neurons and CA3 pyramidal
neurons. A significant reduction of Abl1 transcripts in
several cell clusters suggests a link to the signaling pathway
of GPI-anchored ephrins, which are known to play a major
role in synapse formation and plasticity. In summary, we
present here the first mouse model with a patient-specific
hypomorphic mutation that mirrors the human phenotype
and will allow us to explore the pathophysiology in
GPIBDs in future studies.
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C03 Novel Bioinformatic and Machine-Learning
Methods
C03.1
Reconciling GWAS and Mendelian genetics through
core-gene identification
O. B. Bakker1*, A. Claringbould1, H. Westra1, S. Mulcahy
Symmons1, M. Swertz1, I. H. Jonkers1, L. Franke1, P.
Deelen1,2
1University Medical Center Groningen, Groningen, Nether-
lands, 2University Medical Center Utrecht, Utrecht,
Netherlands
Genome-wide association studies (GWAS) have identified
thousands of disease susceptibility loci, however the
omnigenic model suggests that many of the genes in these
loci might not directly be involved in core disease pathways.
The omnigenic model postulates that most genes in the
GWAS loci are peripheral genes that exert smaller down-
stream effects on genes that directly affect the phenotype
(core genes). These core genes are expected to overlap with
genes that result in rare Mendelian diseases when mutated.
In order to map the relationships between peripheral and
core genes, we re-analysed 31,499 publicly available RNA-
seq samples from various tissues and cell-types to calculate
a gene-gene co-regulation network. We then integrated the
co-regulation network with GWAS summary statistics to
identify genes that are co-regulated with a large number of
GWAS genes. We hypothesise that these genes are more
likely to be core disease genes.
As a proof of concept, we applied this gene prioritization
strategy to a height GWAS and show that prioritized core
genes are strongly enriched for Mendelian disease genes for
both disproportionate short and tall stature (AUC 0.69 and
0.86 respectively) as expected under the omnigenic model.
The enrichment of Mendelian disease genes among the
predicted core genes suggest that complex disease and rare
disease genetics are on two ends of the same spectrum. We
therefore expect that our method can ultimately be used to
better understand common diseases and we hope to predict
new rare disease genes.
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Improved de novo mutation detection through deep
learning
K. Šablauskas*, W. Steyaert, D. Rots, R. Pfundt, H. G.
Yntema, H. G. Brunner, A. Hoischen, L. E. L. M. Vissers, C.
Gilissen
Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands
De novo mutations (DNMs) are an important cause of
genetic disorders. The accurate identification of DNMs is
therefore fundamental to rare disease research and diag-
nostics. Unfortunately, identifying reliable DNMs remains a
major challenge due to sequence errors, uneven coverage
and mapping artifacts.
Here, we developed a deep convolutional neural network
(CNN) DNM caller: deNovoCNN. We trained deNovoCNN
by encoding the sequence alignment reads for a trio as
164x160 resolution images. We trained our model (80/20%
training/validation split) on 4,868 high-quality DNMs from
whole exome sequencing (WES) data of 2,018 trios with
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intellectual disability (ID). We then compared the DNM
calls in 20 separate trios to those of three other de novo
callers: GATK, DeNovoGear (DNG), and Radboudumc in-
house tool (IH). The identified variants were manually
inspected though IGV.
deNovoCNN outperformed other calling approaches with
an accuracy of 99.38% (GATK 75.69%, DNG 30.97%, IH
97.54%). Additional Sanger validation for a subset of
mutations is ongoing. When applying deNovoCNN to 278
unresolved trios, we identified 5 previously missed DNMs
in monoallelic ID genes (CDK13, PAFAH1B1, TCF20,
SMC1A and PRKAR1A), that provide a likely diagnosis
based on ACMG criteria. All of these mutations were
confirmed to be de novo events by Sanger sequencing.
Overall, deep convolutional neural networks are a
powerful tool for DNM discovery, and have the potential
to call clinically relevant DNMs missed by existing
approaches.
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GestaltMatch: breaking the limits of rare Mendelian
disorder diagnosis by matching patients with next-
generation phenotyping
T. Hsieh1*, A. Bar-Haim2, G. Nadav2, T. J. Pantel3, N.
Fleischer2, P. Krawitz1
1Institute for Genomic Statistics and Bioinformatics, Bonn,
Germany, 2FDNA, Boston, MA, United States, 3Charité
Universitätsmedizin Berlin, Berlin, Germany
Introduction: Recent advances in next-generation pheno-
typing (NGP) for syndromology such as DeepGestalt have
learned phenotype representations of multiple disorders by
training on thousands of patient photos. However, many
Mendelian syndromes are still not represented by existing
NGP tools as only handful of patients were diagnosed. We
therefore propose “GestaltMatch” which utilizes the simi-
larity among patients to identify syndromic patients by their
facial gestalt in order to extend the coverage of NGP tools.
Methods: We compiled a dataset consisting of 23,000
patients with 1,500 different rare disorders. For each
individual a frontal photo and the molecularly confirmed
diagnosis were available. We utilized deep convolutional
neural networks to train a model on patient’s frontal photos,
and facial embeddings were further extracted to construct a
Clinical Face Phenotype Space (CFPS). Joint Bayesian was
used to quantify the similarity among patients and correct
the confounding effects of age and ethnicity in CFPS.
Results: The patients with similar phenotype were
located in close proximity in the CFPS. Ranking syndromes
by distance in CFPS, we achieved 80% top-10 accuracy in
identifying super rare Mendelian diseases that are not yet
represented in DeepGestalt. Moveover, as a tool for
matching patients of unknown cause, more than 100 pairs
of unrelated patients were identified that show a similarity
comparable to patients with the aforementioned super rare
disorders, suggesting novel phenotypes of shared molecular
etiology.
Conclusions: GestaltMatch opens the door to extend the
coverage of syndromes recognized by NGP tools and to
enable further exploration of the unknown phenotype-
genotype associations.
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Untranslated region (UTR) variant analysis across
71,702 genomes to build a framework for variant
interpretation
S. Pajusalu1,2,3*, N. J. Lake1,4, M. Lek1
1Department of Genetics, Yale University School of
Medicine, New Haven, CT, United States, 2Department of
Clinical Genetics, Institute of Clinical Medicine, University
of Tartu, Tartu, Estonia, 3Department of Clinical Genetics,
United Laboratories, Tartu University Hospital, Tartu,
Estonia, 4Murdoch Children’s Research Institute, Royal
Children’s Hospital, Melbourne, Australia
The importance of UTRs in the regulation of gene expression
has been widely appreciated. However, UTR variants asso-
ciated with Mendelian disorders have been understudied. This
is due to our inability to interpret the functional impact of
UTR variants and a lack of clear interpretation guidelines.
To investigate human UTR variants, we gathered
1,049,754 single nucleotide substitutions in canonical 5′
UTRs and 5,289,132 in canonical 3′UTRs from gnomAD
v3 database. Notably, this is more than a 2-fold increase of
UTR variants from the previous gnomAD release. We
assessed the effects of variants affecting upstream open
reading frames (uORFs), Kozak sequences, polyadenylation
signals, and miRNA-binding sites. These data were used to
build a publicly available variant annotation tool which is
the basis of our UTR variant interpretation framework.
Using a genome-wide heptamer model of constraint
enabled us to identify that UTRs show less variation than
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expected; this is even more pronounced across 5′UTRs and
functional elements like uORFs. By assessing UTR
constraint and the absence of variants with strong regulatory
effects, we were able to prioritize novel candidate disease
genes. For example, MDGA1, a regulatory synaptic protein,
is under strong constraint for 5′UTR and none of its 55
putative uORF-creating variants exist in gnomAD indicat-
ing strong negative selection.
We demonstrate the utility of the framework by
classifying variants reported in the literature and databases,
as well as present results from large neuromuscular disease
cohorts where we have applied this framework to improve
the interpretation of UTR variants.
Grant: PUTJD827
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Hotspot detection in homologous protein domains using
de novo mutations from 31,058 patients identify
candidate developmental disorder genes
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Vriend2, J. A. Veltman3,4, C. Gilissen1
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Identification of disease-causing variants is an ongoing
effort, and requires integration of various biologically
relevant prioritization strategies. We have previously shown
that genetic variation can be aggregated through homo-
logous protein domains and used to interpret variants of
unknown significance. Here, we show that we can use this
concept to robustly identify critical hotspots of de novo
mutations (DNMs) that suggest novel disease gene candi-
dates. We used a dataset of 45,221 DNMs from 31,058
patients with developmental disorders (DD). Of these,
15,392 DNMs locate to protein domain regions, belonging
to 2,311 protein domain families across 6,910 genes. We
curated this list for unique genomic positions and mapped
these onto aggregated domain families. We subsequently
used a binomial test to identify significantly enriched
positions as domain-based hotspots. From 12,389 aggre-
gated domain positions, we found three hotspots
significantly enriched for missense DNMs, all in the “ion
transport protein” (PF00520) domain family (position 96,
p= 3.6 × 10−2; 102, p= 7.1 × 10−5; and 231, p= 8.0 × 10−6),
and no hotspots enriched for protein truncating or synon-
ymous DNMs. The 57 missense variants driving enrichment
are located in 25 genes. So far, 20 of these genes (with 52
DNMs) have been previously associated with DD (p= 6.3 ×
10−15), suggesting that our approach is able to identify true
disease genes. In the remaining 5 genes, genetic intolerance
and molecular gene function suggest KCNH5, KCNG1, and
TPCN1 as putative novel candidate genes for DD. Thus, we
show a novel approach based on hotspot identification in
homologous protein domains that may be used to identify
candidate disease genes.
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Cell type specific genetic regulation of gene expression
across human tissues
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Department of Pharmacology, Northwestern University,
Feinberg School of Medicine, Chicago, IL, United States,
7Department of Systems Biology, Columbia University, New
York, NY, United States
Introduction: The Genotype-Tissue Expression (GTEx)
project has identified expression and splicing quantitative
trait loci (eQTLs and sQTLs) in cis for the majority of genes
across a range of human tissues. However, the interpretation
of these e/sQTLs has been limited by the heterogeneity of
cell type abundances in bulk tissue.
Materials and Methods: Here, we applied cell type
deconvolution to characterize the cell type specificity of
eQTLs and sQTLs for 43 cell type-tissue combinations,
using seven cell types across 35 tissues from up to 838
individuals.
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Results: Across cell types and tissues, we detected 3,347
genes with a cell type interacting eQTL (ieQTL) and 987
genes with a cell type interacting sQTL (isQTL) at 5%
FDR. Furthermore, ieQTL-genes (ieGenes) had a larger
number of independent eQTLs in standard eQTL mapping
and were enriched among tissue-specific eGenes, indicating
that cell type-specific regulatory activity drives cell type-
specific eQTL effects that contribute to allelic heterogeneity
and tissue-specificity of eQTLs. Cell type ieQTLs were also
enriched in sex-biased eQTLs suggesting that these higher
order G x E interactions are driven by cell composition
changes. Finally, colocalization analysis of cell type ieQTLs
and isQTLs with 87 complex traits not only pinpointed the
cellular specificity of known eQTLs but identified novel
colocalized loci that were masked in bulk tissue.
Conclusions: Our results emphasize the importance of
identifying genetic effects on gene expression at the cellular
level and demonstrate that cell type-specific effects can be
uncovered in bulk tissues by integrating increasingly
available single-cell and cell type-specific
transcriptomic data.
S. Kim-Hellmuth: None. F. Aguet: None. M. Oliva:
None. S. Kasela: None. M. Muñoz-Aguirre: None. V.
Wucher: None. R. Guigó: None. B. E. Stranger: None. K.
G. Ardlie: None. T. Lappalainen: None.
C04 Cancer Genetics I: Basic Research in Cancer
C04.1
Unique somatic mutation lanscape enhances tumor
predisposition in the kidney proximal tubule
I. Franco1*, H. T. Helgadottir1, A. Moggio1, M. Larsson2,
P. Vrtacnik1, A. Johansson3, N. Norgren4, P. Lundin5, D.
Mas-Ponte6, J. Nordström7, T. Lundgren7, P. Stenvinkel7, L.
Wennberg7, F. Supek6, M. Eriksson1
1Karolinska Institutet, HUDDINGE, Sweden, 2Science for
Life Laboratories, LINKÖPING, Sweden, 3Science for Life
Laboratories, UPPSALA, Sweden, 4Science for Life
Laboratories, UMEÅ, Sweden, 5Science for Life Labora-
tories, STOCKHOLM, Sweden, 6Institute for Research in
Biomedicine (IRB Barcelona), BARCELONA, Spain, 7Kar-
olinska University Hospital, HUDDINGE, Sweden
Introduction: Somatic mutations accumulating in the
genome of human cells can be used to track mutagen
exposure and to identify cancer-prone cell types.
Materials and methods: To detect somatic mutations in
single genomes from healthy, human cells, biopsies were
obtained from six healthy donors undergoing kidney
explant for donation. Donors´ age spanned from 30 to 69.
Single cells from kidney, skin, blood, subcutaneous and
visceral fat were clonally expanded and subjected to both
whole genome sequencing and gene expression analyses.
Multi-organ biopsies from each donor allowed well-
controlled comparison of somatic mutation landscapes in
different tissues.
Results: Somatic mutation and gene expression data
identified a population of kidney tubule progenitors that
showed a mutation profile similar to progenitor cells from
other tissues (fat, skeletal muscle and blood) and low
amount of mutations, indicating protection from mutagen
exposure. Conversely, de-differentiated cells derived from
damaged proximal tubules showed a mutation profile
similar to the most common cancer tumor subtypes (clear
cell renal cell- and papillary-carcinoma). High mutation
burden and a unique mutation landscape, characterized by
mutation enrichment in active chromatin, regulatory and
transcribed regions, caused 6-fold faster accumulation of
potential, cancer-driver mutations.
Conclusions: Our somatic mutation data support the
existence of a stem cell-like population protected from
mutations in the kidney tubules. Conversely, the proximal
tubule of healthy, human kidneys is exposed to unique
mutagenic processes that increase tumor predisposition.
Fundings from Swedish Research Council, Center for
Innovative Medicine, Engkvist, Hagelen, Österman and
Jeanssons Foundations, Svenska Läkaresällskapet and
Riksbankens Jubileumsfond
I. Franco: None. H. T. Helgadottir: None. A. Moggio:
None. M. Larsson: None. P. Vrtacnik: None. A. Johansson:
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C04.2
TFEB constitutive activation underlies polycystic kidney
and renal carcinoma in Birt-Hogg-Dube’ syndrome
C. Di Malta*, G. Napolitano, A. Esposito, M. Matarese, V.
Benedetti, A. Zampelli, D. Siciliano, A. Venuta, M. Cesana,
C. Vilardo, E. Nusco, J. Monfregola, A. Ballabio
Telethon Institute of Genetics and Medicine (TIGEM),
Pozzuoli (NA), Italy
Loss of function mutations in the Folliculin (FLCN) gene
are responsible for the autosomal dominant inherited Birt-
Hogg-Dube’ (BHD) syndrome, a genetic disorder char-
acterized by benign skin tumors, lung and kidney cysts and
kidney cancers. Renal tumors represent the most severe
manifestation of the disease and develop following a
somatic second-hit mutation leading to the inactivation of
the remaining FLCN allele. To date, the pathogenetic
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mechanisms downstream FLCN depletion are still
unknown. FLCN acts a GTPase-activating protein (GAP)
for the Rag family GTPase, in particular RagC/D, con-
verting them to their active forms, which signal amino acid
sufficiency to the mechanistic Target Of Rapamycin Com-
plex 1 (mTORC1), a key regulator of cell metabolism,
highly implicated in cancer. Previous studies indicated that
kidney-specific Flcn deletion in mice recapitulates kidney
phenotype observed in BHD patients. Here we show that
loss of FLCN induces a constitutive activation of the
Transcription Factor EB (TFEB), the master regulator of
lysosomal biogenesis and autophagy, which drives upre-
gulation of several target genes relevant for disease phe-
notype, in particular Rag C/D, thus leading to
hyperactivation of mTORC1 signaling. Remarkably,
depletion of Tfeb in Flcn-KO mice, which was achieved by
generating Flcn/Tfeb double KO mice, fully rescued kidney
phenotype and associated lethality, thus pointing to TFEB
as the major driver of BHD syndrome. Interestingly,
increased TFEB nuclear localization is also observed in
renal tumors from BHD patients, hence suggesting that
targeting this transcription factor could be a valuable ther-
apeutic strategy for the treatment of this genetic disorder.
C. Di Malta: None. G. Napolitano: None. A. Esposito:
None. M. Matarese: None. V. Benedetti: None. A.
Zampelli: None. D. Siciliano: None. A. Venuta: None. M.
Cesana: None. C. Vilardo: None. E. Nusco: None. J.
Monfregola: None. A. Ballabio: F. Consultant/Advisory
Board; Modest; CASMA Therapeutics, Inc, Cambridge,
MA 02139.
C04.3
Oncogenic transcription factors are over-represented in
mutated active DNA binding sites in neuroblastoma and
Wilms tumor
V. A. Lasorsa1,2*, F. Cimmino1,2, M. Avitabile1,2, S.
Cantalupo1,2, A. Montella1,2, B. De Angelis3, M. Morini4, C.
de Torres5, A. Castellano3, F. Locatelli3,6, A. Iolascon1,2, M.
Capasso1,2,7
1CEINGE - Biotecnologie Avanzate, Napoli, Italy, 2Depart-
ment of Molecular Medicine and Medical Biotechnology,
Università degli Studi di Napoli Federico II, Napoli, Italy,
3Department of Pediatric Haematology and Oncology,
IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy,
4Laboratory of Molecular Biology, IRCCS Istituto Giannina
Gaslini, Genova, Italy, 5Hospital Sant Joan de Déu,
Developmental Tumor Biology Laboratory and Department
of Oncology, Barcelona, Spain, 6Department of Paedia-
trics, Sapienza University of Rome, Roma, Italy, 7IRCCS
SDN, Napoli, Italy
Introduction: The contribution of coding mutations to
oncogenesis has been largely clarified whereas little is
known about somatic mutations in noncoding DNA and
their role in driving tumors remains controversial. Here, we
used an alternative approach to interpret the functional
significance of noncoding somatic mutations in promoting
tumorigenesis.
Methods: Noncoding somatic mutations of 151 neuro-
blastomas (NB) and of 81 Wilms tumours (WT) were, in
parallel, integrated with ENCODE data to locate somatic
mutations in regulatory elements specifically active in
tumor cells (of NB and WT), non-specifically active in
tumor cells (of NB and WT), and non-active. Within these
types of elements, we identified transcription factors (TFs)
whose binding sites (BS) were enriched or depleted in
mutations. For these TFs, a gene expression signature was
built to assess their implication in NB and WT.
Results: For both tumor types, the pathogenicity of
mutations was significantly higher in TFBS of regulatory
elements specifically active in tumor cells, as compared to
the others. Here, we found over-represented TFs mainly
involved in cell cycle phase transitions (n=18 and n=35 for
NB and WT, respectively), and under-represented TFs
primarily regulating cell differentiation (n=15 and n=21 for
NB and WT, respectively). A gene expression signature
based on over-represented TFs correlated with poor survival
and unfavourable prognostic markers.
Conclusions: We propose a novel approach to study the
involvement of regulatory variants in NB and WT that
could be extended to other cancers and provide further
evidence that alterations of gene expression may have
relevant effects in tumour development.
V. A. Lasorsa: None. F. Cimmino: None. M. Avitabile:
None. S. Cantalupo: None. A. Montella: None. B. De
Angelis: None. M. Morini: None. C. de Torres: None. A.
Castellano: None. F. Locatelli: None. A. Iolascon: None. M.
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C04.4
Characterization of circRNA profiles in childhood acute
lymphoblastic leukemia
A. Gutierrez-Camino1,2*, M. Caron2, C. Richer2, E. Lopez-
Lopez1, I. Martin-Guerrero1, B. Frutos1, P. St-Onge2, A.
Bataille2, D. Sinnett2,3
1University of the Basque Country, Leioa, Spain, 2Division
of Hematology-Oncology, Sainte-Justine University Health
Center, Montreal, QC, Canada, 3Department of Pediatrics,
Montreal University, Montreal, QC, Canada
Childhood acute lymphoblastic leukemia (cALL) represents
one of the most frequent causes of death by disease in
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children. Accurate patient diagnosis is fundamental to obtain
higher cure rates. In recent years, a new type of non-coding
RNAs, circRNA, has emerged as a promising biomarker for
cancer diagnosis, however little is known about their roles in
cALL development and treatment response. We propose to
investigate and characterize a circRNAs in cALL, which
might allow a more precise diagnosis and prognosis assess-
ment, thus opening the door to better outcomes. Towards this
goal we have performed a transcriptome analysis (RNA-Seq)
of 156 cALL patients (124 B-ALL and 26 T-ALL) from two
independent cohorts. CircExplorer was used to quantify,
annotate and characterize circRNAs. A total of 187,504 cir-
cRNAs were identified in the discovery cohort. The size of
the circRNAs was on average 820 bp, with a mean of 5 exons
per circRNA. The overall expression of circRNA variants was
between 1 and 452 per gene with a mean of 14,6. Unsu-
pervised clustering analysis showed that circRNAs could
properly stratify cALL subtypes. Differential circRNA
expression between ALL and controls showed a total of 726
deregulated in the whole cohort (390 upregulated and 336
downregulated). The 50% of circRNAs were unique for
specific subtypes. These results were validated in an inde-
pendent cohort. In conclusion, we have defined circRNA
characteristics in cALL and identified subtype-specific cir-
cRNAs. In addition to protein-coding genes and other non-
coding RNAs, we have shown that circRNA expression
profiles can accurately classify cALL subtypes.
A. Gutierrez-Camino: None. M. Caron: None. C. Richer:
None. E. Lopez-Lopez: None. I. Martin-Guerrero: None. B.
Frutos: None. P. St-Onge: None. A. Bataille: None. D.
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C04.5
Patient-derived PDAC organoids recapitulate tumor cell
state heterogeneity and functional hierarchy in vitro
T. G. Krieger1*, J. Jabs2, S. LeBlanc3, A. Giri1, O. Strobel3,
R. Eils1, C. Conrad1
1Digital Health Center, Berlin Institute of Health (BIH)/
Charité-Universitätsmedizin, Berlin, Germany, 2Division of
Theoretical Bioinformatics, German Cancer Research
Center (DKFZ), Heidelberg, Germany, 3European Pan-
creas Center, Department of Surgery, Heidelberg Uni-
versity Hospital, Heidelberg, Germany
Pancreatic ductal adenocarcinoma (PDAC) is projected to
be the second leading cause of cancer mortality by 2030,
and responses to current therapy differ markedly between
patients. Transcriptomic analyses have established two
subtypes of PDAC: ‘classical’ tumors characterised by a
higher level of differentiation, and ‘basal-like’ tumors
showing aggressive clinical behaviour. Recent single-cell
sequencing studies have demonstrated that PDAC tumors
comprise diverse cell populations, but the functional inter-
play and evolutionary hierarchy of PDAC cells remains
elusive.
We derived PDAC organoids from primary tumors of 18
patients, together with two matched samples from liver
metastases. By scRNA-seq, we determined that PDAC
organoids consist of ductal cells with patient-specific
expression of several gene groups. Organoids derived from
higher-grade tumors tend to show more ‘basal-like’ gene
expression, consistent with previous data. However,
‘classical’ and ‘basal-like’ cells may coexist within the
same tumor, and the level of subtype heterogeneity within
tumors is independently linked to poor prognosis.
Despite intertumor heterogeneity, we identified several
tumor cell states shared across patients, including a cycling
progenitor cell state and a differentiated secretory state,
which are connected by a differentiation hierarchy. By
integrating scRNA-seq data from PDAC organoids and
primary tumors, we show that these cell states and hierarchy
are mirrored within the ductal cell compartment in
primary PDAC.
Our results uncover a hierarchy of functional PDAC cell
states in organoids and primary tumors, supporting the use
of PDAC organoids as a clinically relevant model for
in vitro studies of tumor heterogeneity.
T. G. Krieger: None. J. Jabs: None. S. LeBlanc: None. A.
Giri: None. O. Strobel: None. R. Eils: None. C.
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C04.6
Integrative analyses of 100 genomes of Basal Cell
Carcinoma in the context of transcription and methyla-
tion profiles
S. I. Nikolaev1*, A. Yurchenko1, A. Sartori2, I. Padioleau1,
F. Rajabi1, L. Parmentier3, D. Salomon4, E. Dermitzakis2,
H. Ongen5
1Gustave Roussy, VILLEJUIF, France, 2Univeristy of
Geneva, Geneva, Switzerland, 3Hospital of Sierre, Sierre,
Switzerland, 4Seujet Dermatological Clinics, Geneva,
Switzerland, 5University of Geneva, Geneva, Switzerland
Basal Cell Carcinoma (BCC) of skin is the commonest
human malignancy with the lifetime risk of 30% and
increasing incidence. BCC is characterized by constitutive
activation of the Sonic hedgehog pathway and by hyper-
mutator phenotype due to UV. In this study we present
Whole Genome Sequences (WGS) of 96 and Whole Exome
Sequences of 259 BCC. These data are complemented by
RNA-Seq and Methylation profiling of BCC and adjacent
skin. Over 20 million point mutations allowed
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unprecedentedly detailed analysis of UV-induced muta-
genesis in skin cancer and revealed differences between
BCC and melanoma. Variation in spectrums and cluster-
ization of mutations across genomic regions with different
sets of genomic covariates including tumor-derived tran-
scriptomes and methylomes was used for decomposition
into separate biological processes. Driver discovery, per-
formed with multiple methods, validated known genes
including PTCH1, SMO, MYCN, PTPN14 and others as
well as rendered a handful of novel drivers in other cancer
pathways. RNA-Seq analysis uncovered the most important
pathways involved in BCC pathogenesis and histological
heterogeneity. Numerous structural variants and gene
fusions were retrieved using both WGS and RNA-Seq.
These events as well as a list of 23 focal deletions suggested
novel putative tumor suppressor genes in BCC. Functional
non-coding genomic variation was assessed with somatic
cis-eQTL analyses which revealed consequences of somatic
mutations in promoters at the allelic expression of nearby
genes including putative cancer drivers. This work repre-
sents a first large scale genomic study of BCC dissecting
mutational mechanisms and functional consequences of
coding and non-coding somatic mutations.
S. I. Nikolaev: None. A. Yurchenko: None. A. Sartori:
None. I. Padioleau: None. F. Rajabi: None. L. Parmentier:
None. D. Salomon: None. E. Dermitzakis: None. H.
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C05 Elucidating the Function of Cardiac Genes
C05.1
Investigating the role of KMT2C in heart development
S. C. Borland*, G. Tenin, R. Monaghan, S. Williams, M. Zi,
C. Wilson, S. Prehar, E. Cartwright, S. Abraham, B.
Keavney
Division of Cardiovascular Sciences, University of Man-
chester, Manchester, United Kingdom
Histone modifiers have been implicated as candidate genes
in congenital heart disease indicating they are important in
heart development. Previously, our lab performed exome
sequencing of 829 tetralogy of Fallot patients which iden-
tified 18 mutations in KMT2C that are absent in gnomAD
and have a combined annotation dependent depletion
(CADD) score of more than 20. KMT2C is a H3K4
methyltransferase active predominantly at enhancers. Using
in situ hybridisation we have shown Kmt2c expression
during key stages of mouse heart development. Human
embryonic hearts also show KMT2C expression during
equivalent stages. We have studied a mouse model where
the SET domain of KMT2C is deleted making the protein
catalytically inactive. Homozygous deletion results in neo-
natal lethality. Homozygous embryos and pups with the
deletion have an incompletely penetrant congenital heart
defect phenotype. They have ventricular septal defects with
or without an overriding aorta (as in tetralogy of Fallot). In
homozygous pups and embryos the ventricular myocardium
is abnormal resembling non-compaction. At day 16.5 of
development the compact myocardium of the left ventricle
is significantly thinner (p<0.05) in homozygous embryos
compared to wild-type. Adult heterozygous mice have a
significantly prolonged PR interval (p=0.01) compared to
wild-type (measured by unconscious ECG). All other
electrocardiography and echocardiography parameters
measured were not significantly different compared to wild-
type. Our data for the first time shows that KMT2C plays a
role in cardiac development and congenital heart disease.
We have also identified a novel role for KMT2C in myo-
cardium formation and cardiac function. Grant reference:
BHF FS/16/58/32734
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C05.2
Mutations in KDR, encoding for vascular endothelial
growth factor receptor 2, contribute to Tetralogy
of Fallot
D. Skoric-Milosavljevic1*, N. Lahrouchi1, F. Bosada1, G.
Dombrowsky2, F. Tjong1, I. El Bouchikhi3, M. Hababa1, S.
Williams4, R. Walsh1, L. Beekman1, A. Ilgun1, R. Lesurf5, E.
Audain2, J. Breckpot6, B. J. Mulder1, S. Clur1, S. Mital5, B.
Keavney4, M. Hitz2, V. Christoffels1, E. M. Lodder1, A. V.
Postma1, C. R. Bezzina1
1Amsterdam University Medical Center, Amsterdam, Neth-
erlands, 2University Medical Center Schleswig-Holstein,
Kiel, Germany, 3University of Sidi Mohammed Ben
Abdellah, Fez, Morocco, 4The University of Manchester,
Manchester, United Kingdom, 5The Hospital for Sick
Children, Toronto, ON, Canada, 6Center for Human
Genetics, Catholic University Leuven, Leuven, Belgium
Introduction: Congenital heart defects (CHD) are the most
common birth defects. Although there is a clear genetic
component, a substantial proportion of CHD cases remain
genetically unexplained. Family based studies are suitable
to identify rare, highly penetrant variants in novel
candidate genes.
Material and Methods: We conducted whole-exome
sequencing in a family with two children affected with
tetralogy of fallot (TOF). We generated and studied knock-
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in mice carrying variants homologues to two missense
variants in the gene KDR, which likely underlie the TOF
phenotype in the family. Furthermore, we screened a cohort
of TOF probands of European descent for likely disease-
causing variants in KDR and performed a burden test for
rare genetic variants in this gene in an ancestry-matched
case-control dataset.
Results: Both affected children are compound hetero-
zygous for two missense variants in KDR (p.Gly345Trp/p.
Gly537Arg), encoding vascular endothelial growth factor
receptor 2. While mice that were compound heterozygous
for these variants displayed no CHD, mice homozygous for
the p.Gly537Arg variant displayed embryonic lethality with
defective vasculogenesis and pericardial edema, mimicking
the phenotype of Kdr knock-out mice. Compared to the
gnomAD database there seems to be an enrichment of
protein-truncating variants (PTVs) among a set of 1,226
TOF probands of European descent (P=5x10−7). Further-
more, we identified a significant burden of rare
(MAF<0.1%) missense variants and PTVs in KDR in
European TOF patients versus controls (P=9x10−4).
Conclusions: Based on a family study and case-control
analysis, we highlight the importance of KDR in the
pathogenesis of CHD in humans.
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C05.3
Bi-allelic loss-of-function mutations in PLD1 cause
congenital right-sided cardiac valve defects and neonatal
cardiomyopathy
N. Lahrouchi1*, A. Postma2, C. M. Salazar3, D. De
Laughter4, F. Tjong1, L. Piherová5, F. Z. Bowling6, D.
Zimmerman1, E. M. Lodder1, A. Ta-Shma7, Z. Perles7, L.
Beekman1, A. Ilgun8, Q. Gunst8, M. Hababa1, D. Škorić‐
Milosavljević1, P. de Knijff9, R. de Leeuw9, J. Y. Robinson10,
S. C. Burn11, H. Mustafa11, M. Ambrose12, T. Moss13, J.
Jacober14, D. M. Niyazov14, A. Rousounides15, A. Aristidou-
Kallika16, G. Tanteles17, M. Magliozzi18, F. C. Radio19, G.
W. E. van Santen20, J. C. Herkert21, O. Elpeleg22, M. van
den Hoff8, B. Mulder1, M. V. Airola6, S. Kmoch5, J. V.
Barnett10, S. Clur23, M. A. Frohman3, C. R. Bezzina1
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Nicosia, Cyprus, 18Genetic and Rare Disease Research
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Bambino Gesù Children’s Hospital IRCC, Rome, Italy,
20Department of Human Genetics, Leiden University
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Groningen, University Medical Center Groningen, Depart-
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sah, Hebrew University Medical Center, Jerusalem, Israel,
23Department of Pediatric Cardiology, Emma Children’s
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Introduction: Mutations in PLD1, which encodes phos-
pholipase D1, were recently associated with severe con-
genital cardiac valve defects in two families. However, the
consequences of the mutations on PLD1 protein function
and the mechanism by which PLD1 dysfunction leads to
congenital valve abnormalities remained unknown.
Methods: We established an international cohort of
patients with autosomal-recessive mutations in PLD1. We
assessed the location of the disease-causing missense
mutations on the 3-dimensional structure of PLD1 and tested
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their effect on PLD1 enzymatic activity in a cellular assay. To
investigate the involvement of PLD1 in endocardial-
mesenchymal transition (EndoMT) we used an in vitro assay
to asses EndoMT in atrioventricular cushion explants.
Results: We identified 26 patients with bi-allelic PLD1
mutations. While most patients presented with right-sided
congenital cardiac valve defects (24/26), two patients
displayed isolated severe fetal/neonatal cardiomyopathy.
Using haplotype analyses, we established that p.I668F is a
founder mutation among the Ashkenazi-Jews (AJS, minor-
allele frequency in gnomAD-ASJ=2%). We found that
disease-causing PLD1 missense mutations cluster in regions
of the protein critical for catalytic activity. Correspondingly,
a drastic reduction in enzymatic activity was observed for
the mutant proteins. We demonstrate that PLD1 inhibition
decreases EndoMT, an established pivotal early step in
valvulogenesis.
Conclusion: We here provide the genetic and phenotypic
characterization of the largest cohort of PLD1 patients.
Genotyping of the p.I668F founder mutation using popula-
tion-based carrier screening may be justified to assess risk
of cardiac defects among ASJ-descendants. Finally, our
results demonstrate that functional testing is useful for
clinical interpretation of variants in PLD1.
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C05.4
Pathogenic variants in THSD4, encoding the ADAMTS-
Like 6 protein, predispose to inherited thoracic aortic
aneurysm
S. Elbitar1,2*, M. Renard3, P. Arnaud1,4,5, N. Hanna1,4,5, M.
Jacob1, D. Guo6, K. Tsutsui7, M. Gross1, K. Kessler8, L.
Tosolini1, V. Dattilo9, S. Dupont1, J. Jonquet1, M.
Langeois5, L. Benarroch1,10, M. Aubart1,11, Y. Ghaleb1,2, Y.
Abou Khalil1,2, M. Varret1, P. El Khoury1,2, B. Ho-Tin-
Noé1, Y. Alembik12, S. Gaertner13, B. Isidor14, L. Gouya5, O.
Milleron5, K. Sekiguchi7, D. Milewicz6, J. De Backer3, C. Le
Goff1, J. Michel1, G. Jondeau1,5, L. Y. Sakai15, C.
Boileau1,4,5, M. Abifadel1,2
1Laboratory for Vascular Translational Science, INSERM
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Xavier Bichat, Paris, France, 2Laboratory of Biochemistry
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Joseph University, Beirut, Lebanon, 3Center for Medical
Genetics, Ghent University, Ghent, Belgium, 4Département
de Génétique, Centre Hospitalo-Universitaire Xavier
Bichat, Paris, France, 5Hôpital Bichat, Centre de Référence
Maladies Rares, Syndrome de Marfan et pathologies
apparentées, Assistance Publique-Hôpitaux de Paris, Paris,
France, 6Department of Internal Medicine, McGovern
Medical School, University of Texas Health Science Center,
Houston, TX, United States, 7Institute for Protein Research,
Osaka University, Suita, Osaka, Japan, 8Centre for
Evolution and Cancer, Division of Molecular Pathology,
Division of Cancer Therapeutics, The Institute of Cancer
Research, London, United Kingdom, 9IRCCS Istituto
Centro San Giovanni di Dio Fatebenefratelli, Brescia,
Italy, 10Inserm UMRS_974, Centre de recherche en
myologie, G. H. Pitié-Salpétrière, 47 boulevard de
l’Hôpital, Paris, France, 11Service de Neuropédiatrie,
Hôpital Necker-Enfants-Malades, 149 rue de Sèvres, Paris,
France, 12Department of Clinical Genetic, Hôpitaux
Universitaires de Strasbourg, 67091, Strasbourg, France,
13Department of Hypertension, Vascular Diseases and
Pharmacology, University of Strasbourg, Strasbourg,
France, 14Service de Génétique Médicale, Hôpital Hôtel-
Dieu, Centre Hospitalier Universitaire de Nantes, 44093,
Nantes, France, 15Shriners Hospital for Children, Mole-
cular & Medical Genetics and Biochemistry & Molecular
Biology, Oregon Health & Science University, Portland,
OR, United States
Thoracic aortic aneurysm and dissection (TAAD) is a life-
threatening disease with often unrecognized inherited forms
(hTAAD). Although pathogenic variants have been found
in several genes, the majority of hTAAD cases are of
unknown etiology. We identified in probands and families
with TAAD, five functional variants in THSD4 of which
two heterozygous variants leading to a premature termina-
tion codon. THSD4 encodes ADAMTSL6 (member of the
ADAMTS/L superfamily), a microfibril-associated protein
that promotes fibrillin-1 matrix assembly. The THSD4
variants studied lead to haplo-insufficiency or impaired
assembly of fibrillin-1 microfibrils. Thsd4+/- mice showed
progressive dilatation of the thoracic aorta. Histologic
examination of aortic samples from a patient carrying a
THSD4 variant and from Thsd4+/- mice, revealed typical
medial degeneration and diffuse disruption of extracellular
matrix. These findings highlight the role of ADAMTSL6 in
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aortic physiology and TAAD pathogenesis. They will
improve genetic screening for hTAAD and could help
develop new targeted therapies.
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C05.5
Functional characterization of rare SHOX2 variants
identified in sinus node dysfunction and atrial
fibrillation
S. Hoffmann1,2*, C. Paone3, S. A. Sumer1,2, S. Diebold3, B.
Weiss1, R. Roeth1, S. Clauss4,5, I. Klier4,5, S. Kääb4,5, A.
Schulz6, P. S. Wild6, A. Ghrib7,8, T. Zeller7,8, R. B.
Schnabel7,8, S. Just3, G. A. Rappold1,2
1Department of Human Molecular Genetics, Institute of
Human Genetics, University of Heidelberg, Heidelberg,
Germany, 2DZHK (German Centre for Cardiovascular
Research), Partner site Heidelberg/Mannheim, Heidelberg,
Germany, 3Department of Internal Medicine II, University
of Ulm, Ulm, Germany, 4Department of Medicine I,
Klinikum Grosshadern, University of Munich (LMU),
Munich, Germany, 5DZHK (German Centre for Cardiovas-
cular Research), Partner site Munich, Munich, Germany,
6Preventive Cardiology and Preventive Medicine, Center
for Cardiology, University Medical Center of the Johannes
Gutenberg-University Mainz, Mainz, Germany, 7Depart-
ment of General and Interventional Cardiology, University
Heart Center Hamburg (UHZ), University Hospital Ham-
burg/Eppendorf, Hamburg, Germany, 8DZHK (German
Centre for Cardiovascular Research), Partner site Ham-
burg/Kiel/Luebeck, Hamburg, Germany
Sinus node dysfunction (SND) and atrial fibrillation (AF)
often coexist; however, the molecular mechanisms linking
both conditions remain elusive. Mutations in the homeo-
box-containing SHOX2 gene have been recently associated
with early-onset and familial AF. Shox2 is a key regulator
of sinus node development, and its deficiency leads to
bradycardia, as demonstrated in animal models. We inves-
tigated SHOX2 as a susceptibility gene for SND and AF by
screening 98 SND patients and 450 individuals with AF.
The functional relevance of the novel mutations was
investigated in vivo and in vitro. A heterozygous missense
mutation (p.P33R) was identified in the SND cohort and
four heterozygous variants (p.G77D, p.L129=, p.L130F, p.
A293=) in the AF cohort. Overexpression of the pathogenic
predicted mutations in zebrafish revealed pericardial edema
for p.G77D, whereas the p.P33R and p.A293= variants
showed no effect. In addition, a dominant-negative effect with
reduced heart rates was detected for p.G77D. In vitro reporter
assays demonstrated for both missense variants p.P33R and p.
G77D significantly impaired transactivation activity. Also, a
reduced Bmp4 target gene expression was revealed in zebra-
fish hearts upon overexpression of the p.P33R mutant. This
study associates rare variants in the SHOX2 gene implicated
in the susceptibility to arrhythmias and allows frequency
estimations in an AF cohort (3/990). We also demonstrate for
the first time a genetic link between SND and AF involving
SHOX2. This work was supported by grants from the DFG
(RA 380/14-4) and DZHK (81X2500107).
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C06 Sensory Disorders
C06.2
Whole Exome Sequencing, Molecular Assays, Immu-
nohistology and Animal Models associate USP48 to
Hereditary Hearing Loss
S. Bassani1*, A. Morgan2, M. Cocca3, N. Voisin4, J.
Chrast4, S. Pradervand4, N. Guex4, B. Delprat5, M. Rossel5,
H. Locher6, E. Van Beelen6, M. Tangui5, P. Gasparini2,3, G.
Girotto2,3, A. Reymond4
1University of Lausanne, Laussane, Switzerland, 2Depart-
ment of Medicine, Surgery and Health Sciences, University
of Trieste, Trieste, Italy, 3IRCCS Materno Infantile Burlo
Garofolo, Trieste, Italy, 4Centre for Integrative Genomics,
University of Lausanne, Lausanne, Switzerland, 5MMDN,
University of Montpellier, EPHE-INSERM U1198, Mon-
tpellier, France, 6Department of ORL-HNS, Leiden Uni-
versity Medical Center, Leiden, Netherlands
Non-Syndromic Hearing Loss (NSHL) is a sensorineural
disorder with high genetic heterogeneity and 115 genes
already associated. We identified through exome sequencing
and data aggregation an Italian family with six affected
individuals and two unrelated NSHL Dutch patients with
predicted-to-be deleterious missense variants in USP48. We
uncovered a ninth patient presenting unilateral cochlear nerve
aplasia and a de novo splice variant in the same gene. USP48
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encodes a ubiquitin carboxyl-terminal hydrolase under evo-
lutionary constraints according to GnomAD (pLI=1; Zmis-
sense=4.37). Pathogenicity of the patients’ missense variants
is supported by the three-dimensional representation of the
encoded peptide. For example, the Italian missense variant
affects a flexible loop that controls binding to ubiquitin thus
leading to an incapacity to hydrolyze tetra-ubiquitin in our
in vitro assays. Consistent with a contribution of USP48 to
auditory function, immunohistology showed that the encoded
protein is expressed in human hair cells/stereocilia of the
utricle, the dark cell area, the Reissner’s membrane, the stria
vascularis and the developing organ of Corti. Engineered
zebrafishes knocked-out for the USP48 paralog presented
with delayed primary motoneurons development, decreased
swimming velocity and circling swimming behavior indica-
tive of vestibular dysfunction and hearing impairment. Cor-
roboratingly, acoustic startle response assays revealed a
reduced auditory response of zebrafish lacking usp48 with a
significant decrease at 600Hz and 800Hz frequencies, high-
lighting the role of this gene in auditory function. In con-
clusion, we describe a novel NSHL gene through a
multipronged approach combining Exome Sequencing, Ani-
mal Modelization, Immunohistology and Molecular Assays.
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Voisin: None. J. Chrast: None. S. Pradervand: None. N.
Guex: None. B. Delprat: None. M. Rossel: None. H.
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C06.3
Ablation of the congenital microcoria (MCOR) critical
region on 13q32.1 activates common-type glaucoma
signaling pathways challenging a developmental etiology
of MCOR-associated glaucoma.
C. Angee1*, B. Nedelec1, P. David2, S. Gerber1, S. Crippa3,
B. Passet4, J. Vilotte4, N. Chassaing5, J. Kaplan1, C.
Costic3, P. Calvas5, J. Rozet1, L. Fares-Taie1
1Imagine Institute - Laboratory of Genetics in Ophtalmol-
ogy (LGO), Paris, France, 2Imagine Institute - Transgen-
esis Platform, Paris, France, 3Jules Gonin Eye Hospital,
Lausanne, Switzerland, 4INRA - Animal Models for the
Differentiation of Tissue (MoDiT), Jouy-en-Josas, France,
5Purpan Hospital, Toulouse, France
The iris is essential to controlling the intraocular pressure,
the elevation of which leads to glaucoma. Accordingly,
glaucoma is frequent in individuals with irido-dysgenesis,
including congenital microcoria (MCOR), a rare dominant
disease of dilator muscle (DM) development (>30%).
MCOR is due to deletions within a 1Mb TAD on 13q32. 1.
We generated deletions at/or around the 35-Kb critical
deletion (CD) in the mouse to investigate the regulatory
architecture of the region and its role in iris development
and glaucoma. Heterozygous mice carrying the CD devel-
oped normally, except for moderate reduction in pupil
diameter (p<0.01). RNAseq revealed ectopic expression of
Sox21, downstream of the CD. Other genes within the TAD
were unaffected. Smaller deletions encompassing CTCF-
insulators within the CD did not alter Sox21 regulation,
suggesting adoption of a nearby enhancer by Sox21 pro-
motor in CD mice. ChIPseq-H3K27Ac identified two
enhancers of Dct involved in melanin synthesis, at the 5′
boundary of the TAD. Consistent with a role of Dct
enhancer(s), immunohistology detected Sox21 in the pig-
mented epithelium (PE). It was undetectable in the anterior
layer where the DM develops, but ChIPseq identified a
trophic factor among Sox21 targets, the mRNA and product
of which were elevated in the iris and aqueous humor (AH)
of CD mice as determined by RNAseq (p<0.01) and ELISA
(p<0.01), respectively. Knowing that AH elevation of this
factor is associated with primary open-angle glaucoma
(POAG), we suggest that both DM malformation and
glaucoma in MCOR are secondary to Sox21-mediated
activation of a POAG paracrine signaling in the PE.
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C06.4
Mouse and human studies support a role for CAPN15
variants in cataract and microphthalmia
C. Zha1, C. A. Farah1, R. J. Holt2*, F. Ceroni2, L. AlAbdi3,4,
A. O. Khan4,5,6, R. Helaby4, F. S. Alkuray4,7, A. Kraus8, N.
K. Ragge2,9, W. S. Sossin1
1McGill University, Montreal, QC, Canada, 2Oxford
Brookes University, Oxford, United Kingdom, 3King Saud
University, Riyadh, Saudi Arabia, 4King Faisal Specialist
Hospital and Research Center, Riyadh, Saudi Arabia, 5Eye
Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United
Arab Emirates, 6Cleveland Clinic Lerner College of
Medicine at Case Western University, Cleveland, OH,
United States, 7Alfaisal University, Riyadh, Saudi Arabia,
8Leeds General Infirmary, Leeds, United Kingdom, 9West
Midlands Regional Clinical Genetics Service and Birming-
ham Health Partners, Birmingham Women’s and Chil-
dren’s NHS Foundation Trust, Birmingham, United
Kingdom
Introduction: Anophthalmia, microphthalmia and colo-
boma (AMC) are genetically heterogeneous developmental
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eye anomalies, with variants in over 100 genes implicated.
However, only 25-60% of affected individuals are geneti-
cally diagnosed, depending on the phenotype. Calpains are
a group of intracellular cysteine proteases important in
development. Calpain 15 (CAPN15) is located at chromo-
some 16p13.3, a region previously implicated in an indi-
vidual with cataracts and microphthalmia. We describe a
Capn15 mouse knockout with cataract and microphthalmia,
and three human families with developmental eye anoma-
lies and CAPN15 recessive variants.
Materials and Methods: A mouse Capn15 knockout
was generated using embryonic stem cells from the
International Mouse Phenotyping Consortium. Variants in
human AMC cases were identified through whole exome
sequencing of 55 individuals from a UK patient cohort,
examination of the Deciphering Developmental Disorders
Study cohort, and from a clinical diagnostic laboratory.
Results: During mouse development Capn15 was widely
expressed throughout the central nervous system, including
in the brain and eyes. Capn15 knockout mice presented
with a significant growth deficit and a range of structural
eye disorders, including cataract (31%), microphthalmia
(26%) and anophthalmia (18%). Three human cases with
phenotypes including growth delay (2/3), cataracts (1/3),
coloboma (2/3) and microphthalmia (2/3) were identified
with homozygous or compound heterozygous likely
pathogenic variants in CAPN15.
Conclusions: We present evidence that variants in
CAPN15 are associated with AMC. Testing for variants in
this gene can be used to enhance AMC patient diagnosis,
and meets criteria for clinical diagnostic testing, including
those of Clinical Genome Resource (ClinGen) and
Genomics England.
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C06.5
DYNC2H1 hypomorphic or retina-predominant variants
cause non-syndromic retinal degeneration
A. V. Vig1,2*, J. A. Poulter3, D. Ottaviani4, E. Tavares1, K.
Toropova5, A. M. Tracewska6,7, A. Mollica1, J. Kang1, O.
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G. Arno4,10, K. N. Khan3, M. McKibbin3, C. Toomes3, M.
Ali3, M. Di Scipio1, S. Li1, J. Ellingford11, G. Black11,12, A.
Webster4,10, M. Rydzanicz7, P. Stawiński7, R. Płoski7, A.
Vincent1,2, M. E. Cheetham4, C. F. Inglehearn3, A. Roberts5,
E. Heon1,2
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law, Poland, 7Medical University of Warsaw, Warsaw,
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Introduction: The cytoplasmic dynein-2, heavy chain 1
gene (DYNC2H1) encodes a motor protein important for
retrograde ciliary intraflagellar transport. DYNC2H1 var-
iants have been associated with severe syndromic condi-
tions such as Jeune asphyxiating thoracic dystrophy
(JATD), with rare retinal involvement.
Material and Methods: Genome and exome sequencing
were performed for 5 unrelated cases of IRD with no
identified variant. In vitro assays were developed to validate
the variants identified; fibroblast ciliation assay, iPSC-
derived retinal organoids, and an in vitro dynein
motility assay.
Results: Four novel DYNC2H1 variants (V1,
g.103327020_103327021dup; V2, g.103055779 A>T; V3,
g.103112272 C>G; V4, g.103070104 A>C) and one
previously reported (V5, g.103339363 T>G) were identi-
fied. V1 introduced a premature termination codon (PTC),
whereas V2 disrupted the exon 41 splice donor site causing
incomplete skipping of exon 41. V1 and V2 impaired
dynein-2 motility in vitro and perturbed IFT88 distribution
within cilia. V3 is predicted to cause a PTC in a retina-
predominant transcript. Analysis of retinal organoids
showed that expression of this transcript increased with
organoid differentiation.
Conclusions: The DYNC2H1 variants discussed were
either hypomorphic or affect a retina-predominant tran-
script. This is the first report of dynein variants, specifically
DYNC2H1 variants, causing non-syndromic IRD.
Funding: Foundation Fighting Blindness Canada and
USA, University of Toronto McLaughlin Centre WGS
Initiative, Henry Brent Chair in Innovative Pediatric
Ophthalmology Research, Brenda Eye Research Fund, Fight
For Sight UK, NIH Research, Moorfields Eye Charity,
Wellcome Trust, Cancer Research UK, Medical Research
Council, Retina UK, IRDC Leeds and Manchester, National
Science Center Poland, Royal Society, BBSRC.
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C06.6
Proteasome subunit PSMC3 variants cause neurosen-
sory syndrome combining deafness and cataract due to
proteotoxic stress
A. Kröll-Hermi1, F. Ebstein2, C. Stoetzel1, V. Geoffroy1, E.
Schaefer1, S. Scheidecker1, S. Bär3, M. Takamiya4, K.
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Patients with a very rare association of early-onset cataracts
and severe deafness as part of a neurological, sensorial and
cutaneous novel syndrome were explored by Whole Gen-
ome Sequencing in a very large family. A unique deep
intronic homozygous variant was identified in the PSMC3
gene (encoding the proteasome ATPase subunit Rpt5)
leading to the transcription of a cryptic exon. The ubiquitin-
proteasome system represents the most important non-
lysosomal cellular protein degradation machinery. By way
of the 26S proteasome as the degradative enzyme complex,
it is tightly connected with the ubiquitin-dependent timely
degradation of regulatory proteins involved in signalling
cascades and the elimination of mis-folded proteins. The
proteasome content and activity in patient’s fibroblasts was
however unaffected. Nevertheless, patient’s cells exhibited
impaired protein homeostasis characterized by accumula-
tion of ubiquitinated proteins suggesting severe proteotoxic
stress. Indeed, the TCF11/Nrf1 transcriptional pathway
allowing proteasome recovery after proteasome inhibition is
permanently activated in the patient’s fibroblasts. Upon
chemical proteasome inhibition this pathway was impaired
in patient’s cells, which were unable to compensate for
proteotoxic stress although a higher proteasome content and
activity was observed. PSMC3 knock-out in zebrafish
remarkably reproduced the human phenotype with inner ear
development anomalies as well as cataracts suggesting that
Rpt5 plays a major role in inner ear, lens and central ner-
vous system development. This report is the first description
of a recessive pathogenic variant in a proteasomal ATPase.
19S subunits are highly expressed in the central nervous
system and appear to be of utmost importance for neuronal
/sensorial protein homeostasis and development.
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C07 Impact of Genomic Medicine on Public and Patients
C07.1
Implementing a hybrid clinical/research model in
genomic medicine: post 100,000 Genomes Project
C. Patch1,2,3*, E. Thomas1, F. Maleady Crowe1, R. Wier1, T.
Fowler1, M. Bishop4, A. Pichini4
1Genomics England, London, United Kingdom, 2Wellcome
Genome Campus, Cambridge, United Kingdom, 3Sheffield
Hallam University, Sheffield, United Kingdom, 4Genomics
Education Programme, Health Education England, Bir-
mingham, United Kingdom
Building on the UK 100,000 Genomes Project and existing
NHS genomic infrastructure, the creation of the NHS
Genomics Medicine service by NHS England together with
Genomics England has established the principle of patient
choice to both have a diagnostic test and agree to use of
their data for the research. Through the national test direc-
tory whole genome sequencing (WGS) has been commis-
sioned for clinical diagnostic use for 21 rare disease clinical
indications and 4 cancer indications (https://www.england.
nhs.uk/publication/national-genomic-test-directories/). All
persons agreeing to the WGS testing will be offered the
opportunity to agree to the use of their data and available
samples within the National Genomic Research Library.
This will be part of the clinical pathway. The development
of the model and the development of the necessary complex
implementation processes was underpinned by collabora-
tion and informal co-design. This included ensuring the
choice model was compliant with current understandings of
governance across the clinical and research interface,
development of the Genomics England research environ-
ment, development of materials to support patients and the
clinical workforce and formalising processes for clinical
implementation. Implementation was informed by a series
of multi-agency task and finish groups and by consultation
with health care professionals, educationalists, participants
of the 100,000 genomes project and other stakeholders.
Here we present the finalised products for the first stage of
the Genomics Medicine Service. The long-term aim being
to create an ethically robust and trusted research ecosystem
as a routine part of clinical care.
C. Patch: A. Employment (full or part-time); Significant;
Genomics England. E. Thomas: A. Employment (full or
part-time); Significant; Genomics England. F. Maleady
Crowe: A. Employment (full or part-time); Significant;
Genomics England. R. Wier: A. Employment (full or part-
time); Significant; Genomics England. T. Fowler: A.
Employment (full or part-time); Significant; Genomics
England. M. Bishop: None. A. Pichini: None.
C07.2
A tailored approach towards informing relatives at risk
of inherited cardiac diseases: preliminary results of a
randomized controlled trial
L. M. Van den Heuvel1*, Y. M. Hoedemaekers2, A. F.
Baas3, M. J. H. Baars1, E. M. A. Smets1, J. P. van Tintelen3,
I. Christiaans4
1Amsterdam UMC, location AMC, Amsterdam, Nether-
lands, 2Radboud University Medical Centre, Nijmegen,
Netherlands, 3University Medical Centre Utrecht, Utrecht,
Netherlands, 4University Medical Centre Groningen, Gro-
ningen, Netherlands
Introduction: If undetected, inherited cardiac diseases can
lead to sudden cardiac death, while preventive and treat-
ment options are available. Predictive DNA testing is
advised for at-risk relatives. Currently, probands are asked
to inform relatives with a family letter. However, only half
of relatives attends genetic counselling.
Methods: Current practice was compared to a tailored
approach, in which probands were asked to decide to
(initially) inform relatives themselves or by the counsellor,
and family letters were sent directly 1 month after
disclosure of the probands’ test result with consent of the
proband. Outcomes were uptake of counselling in the first
year (using pedigrees), and impact on psychological/family
functioning, and evaluation of the approach (measured with
surveys at 3 (T1) and 9 (T2) months after disclosure).
Results: 96 probands were included; 549 relatives were
eligible for counselling. Preliminary findings showed no
significant difference in uptake of genetic counselling
between the control (34.5%) and the intervention (36.7%)
group. At T1, 92% of probands in the intervention group
reported that all relatives were informed, compared to 73%
in the control group. In both the intervention and control
group, probands were satisfied with the approach (resp.
95% vs. 88%) and reported no impact on family functioning
(resp. 94.6% vs. 92.3%).
Conclusions: Preliminary findings of this trial show no
differences in uptake, impact on family functioning and
satisfaction between the tailored and current approach,
despite more relatives being informed using the tailored
approach. Data collection of uptake and T2 surveys will be
finished in November 2020.
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C07.3
Measuring the burden of direct-to-consumer genetic
testing on clinical genetics services
J. M. Tiller1*, M. Millward2, M. Bogwitz3, H. Kincaid4, S.
Taylor3, A. Trainer3,2, P. Lacaze1
1Public Health Genomics, Monash University, Melbourne,
Australia, 2University of Melbourne, Melbourne, Australia,
3Genomic Medicine & Parkville Familial Cancer Centre,
Melbourne, Australia, 4Monash Health, Melbourne,
Australia
Introduction: Direct-to-consumer genetic testing
(DTCGT) is increasing in popularity, as is the practice of
consumers interrogating their resultant genotype data with
third-party software tools to generate unvalidated imputed
disease risk estimates. This is suspected to be creating a
burden on clinical genetic health services, as consumers
seek assistance with interpretation. However, few studies
have collected recent evidence regarding the extent of this
burden.
Methods and results: We administered an online survey
to Australian clinical genetic services, asking questions
related to DTCGT-related referrals over the past 10 years.
Eleven publicly-funded clinical genetic services completed
the survey, reporting over 100 DTCGT-related referrals.
Most referrals (83%) were made by general practitioners to
aid interpretation of DTCGT results. Over 30% of referrals
were related to imputed disease risk estimates generated
from third-party web-based software tools. Services
reported low validation rates for DTCGT results (<10%).
Procedures for managing DTCGT referrals and granting
appointments were variable between services, with most
services (8/11) lacking specific procedures.
Conclusions: Our study provides evidence that the
increasing popularity of DTCGT is causing a material
burden on publicly-funded Australian clinical genetics
services. We also report a sizeable portion of that burden
resulting from the use of third-party genetic risk-imputation
software tools. The impact of DTCGT is likely to increase
in coming years, if the use of DTCGT continues to grow.
Our findings are relevant for other countries with publicly-
funded or single-payer clinical genetics services, which will
have to contend with the growing popularity of DTCGT in
the near future.
J. M. Tiller: None. M. Millward: None. M. Bogwitz:
None. H. Kincaid: None. S. Taylor: None. A. Trainer:
None. P. Lacaze: None.
C07.4
Critical components of informed consent for genetic
testing: Results of a Delphi Consensus process
K. E. Ormond1*, M. Borensztein1, A. H. Buchanan2, W.
Faucett2, M. L. G. Hallquist2, H. L. Peay3, M. E. Smith4, E.
Tricou1, W. R. Uhlmann5, K. E. Wain2, C. R. Coughlin II6
1Stanford University, Stanford, CA, United States, 2Gei-
singer Health Care, Danville, PA, United States, 3RTI,
Research Triangle Park, NC, United States, 4Northwestern
University, Chciago, IL, United States, 5University of
Michigan, Ann Arbor, MI, United States, 6University of
Colorado, Denver, CO, United States
Background: Genetic testing has historically been tied to
pre-test genetic counseling to facilitate informed consent.
While core concepts exist for general informed consent,
there is not specific guidance defining them around the
clinical use of genetic testing.
Method: We conducted a scoping literature review that
identified 77 concepts, and used a modified Delphi
methodology to survey experts. Participants used 5 point
likert scales to determine how “critical” each concept was
for a “typical patient” to make an informed decision, and
ranked the top choices within each subcategory of concepts
over 2 rounds.
Findings: There were 25 respondents (9 medical
geneticists, 8 genetic counselors, 9 bioethicists), 60% of
whom regularly consent for genetic testing. The most highly
endorsed concepts for inclusion were: (1) condition(s)
tested; (2) management implications; (3) primary and (4)
secondary results to be returned, and options for choice; (5)
To whom results will be reported; (6) voluntariness of
testing; (7) test limitations (8) potential to learn unexpected
information about family relationships; (9) potential impact
on personal health, (10) on treatment/screening, and (11) on
the family (health, emotions, relationships); (12) risks for
discrimination and/or stigma. A larger survey, meant to
validate whether medical geneticists and genetic counselors
more broadly agree with the Delphi results, will be
conducted in spring 2020 and included in the presentation.
Discussion: Defining the minimal critical concepts to
allow clients to reach informed decisions about genetic
testing is important as genetic testing increases exponen-
tially and the consent process is increasingly done by non-
genetics healthcare providers.
K. E. Ormond: None. M. Borensztein: None. A. H.
Buchanan: None. W. Faucett: None. M. L. G. Hallquist:
None. H. L. Peay: None. M. E. Smith: None. E. Tricou:
None. W. R. Uhlmann: None. K. E. Wain: None. C. R.
Coughlin II: None.
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C07.5
Public attitudes towards human germline gene editing: a
baseline survey in the Netherlands
D. Houtman1*, M. Polak2, B. Vijlbrief1, P. Verheggen3, R.
Hofstra1, S. Riedijk1
1Erasmus Medical Center, Rotterdam, Netherlands, 2Eras-
mus University Rotterdam, Rotterdam, Netherlands, 3Moti-
vaction International B. V., Rotterdam, Netherlands
Introduction: A multidisciplinary consortium is organizing
a public dialogue about human germline gene editing
(GLGE) in the Netherlands. Challenges of public dialogue
include ensuring inclusivity, designing appropriate content
for engagement, and evaluating the impact of the dialogue
on opinion formation. The current study provides a baseline
measurement, which will later be used to evaluate the
impact of the dialogue. For now, we aim to use this mea-
surement to identify subgroups of society based on their
attitudes towards human GLGE and their willingness to
engage in science and technology.
Materials and Methods: A representative sample of
1185 adults filled out an online survey, measuring their
acceptance of different applications of human GLGE and
their willingness to discuss new technologies and how to
deal with them.
Results: By means of exploratory analyses we found that
in our sample 68.9% agreed with application to prevent a
severe muscle disease, 37.0% agreed with application to
prevent an infection disease, and 7.8% agreed with
application to increase intelligence. Willingness to discuss
new technologies and how to deal with them was associated
with income (χ²(3)= 15.577, p < 0.01), educational level
(χ²(2)= 25.830, p < 0.01), and personal values (χ²(7)=
68.930, p < 0.01). Comparatively, people who did not want
to discuss new technologies and how to deal with them
(36.5%) showed lower educational-level, lower income, and
more traditional and consumption-oriented values.
Conclusions: Our data provide insights into attitudes of
the Dutch population towards different applications of
human GLGE and into the identification of subgroups of
society for whom participation is not self-evident.
D. Houtman: None. M. Polak: None. B. Vijlbrief: None.
P. Verheggen: A. Employment (full or part-time); Modest;
Motivaction International B. V. R. Hofstra: None. S.
Riedijk: None.
C07.6
Does Genetic Counseling lead to effective coping with
genetic risk information?
B. B. Biesecker1*, M. T. Cho2
1RTI, International, Bethesda, MD, United States, 2NHGRI,
National Institutes of Health, Bethesda, MD, United States
Patient coping has been intermittently studied as a practice
outcome of genetics services. Yet, assessments have been
inconsistent and coping strategies have been reported
without evidence of their effectiveness. Discrepant theore-
tical and methodological approaches may have distracted
attention from compelling evidence that genetic counseling
can enhance effective patient coping and, with time, adap-
tation to genetic information. We report key findings from a
systematic literature review of 68 abstracts that met our
inclusion criteria for studies of coping with genetic risk or a
condition. The studies represent 12,006 patients. Study
designs included: cross-sectional (31), longitudinal (10),
randomized (5), and observational (1). Among qualitative
studies were semi-structured interviews (16) and focus
groups (3). The majority were studies conducted in cancer
genetics, yet most specialty settings were represented. A
synthesis of outcomes generated five hypotheses: H1: The
effectiveness of coping strategies depends on their congruence
with the stress source and its actionability. H2: In the face of
genetic risk, avoidant coping is most likely to result in psy-
chological distress, unless used to avoid learning unwanted
genetic information. H3: Family history, risk perception and
personality traits mediate effective use of coping strategies to
manage illness-related stress. H4: Identifying unhelpful cop-
ing strategies and offering useful ones reduces risk-related
distress and promotes adaptation. H5: Enhancing patient
coping self-efficacy improves coping effectiveness. Overall,
the evidence that generated these hypotheses suggests that
genetics providers have important clinical opportunities to
enhance coping effectiveness as a valuable outcome in help-
ing patients adapt to genetic risk or a condition.
B. B. Biesecker: None. M. T. Cho: None.
C08 Impact of Diagnostics Improvements in Healthcare
C08.1
Project Baby Bear: The first state-funded quality
improvement project of rapid Whole Genome Sequen-
cing in neonatal and pediatric intensive care units in
the USA
K. A. Ellsworth1*, S. Caylor1, W. Benson1, C. Ashburner2,
J. Carmichael2, E. Cham3, S. Chowdhury1, J. Cleary4, A.
D’Harlingue3, L. Farnaes1, J. Hunt4, C. Hobbs1, K.
Houtchens3, P. Joe3, J. Knight4, A. Kochhar2, M. Joseph2, J.
Limon2, M. Martin5, S. Nahas1, K. A. Rauen5, A. Schwarz4,
S. P. Shankar5, R. Spicer2, M. Rojas2, O. Vargas-Shiraishi4,
K. Wigby1, N. Zadeh4, S. Kingsmore1, D. Dimmock1
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1Rady Children’s Institute for Genomic Medicine, San
Diego, CA, United States, 2Valley Children’s Healthcare,
Madera, CA, United States, 3University of California – San
Francisco, Benioff Children’s Hospital Oakland, Oakland,
CA, United States, 4Children’s Hospital of Orange County,
Orange, CA, United States, 5University of California Davis
Children’s Hospital, Sacramento, CA, United States
Previous studies showed that rapid Whole Genome
Sequencing (rWGS) results in improved outcomes and
reduced costs for acutely ill infants in the intensive care unit
(ICU) when compared to standard of care. Currently, rWGS
is not a reimbursed test under California Medicaid (Medi-
Cal), private insurers or federal Medicare programs. Cali-
fornia’s State Department of Health Care Services appro-
priated $2,000,000 for rWGS Quality Improvement Pilot
Program, known as Project Baby Bear (PBB) with a goal to
identify the clinical and economic benefits of rWGS for
critically ill pediatric patients enrolled in Medi-Cal. rWGS
was performed on 116 babies admitted to five medical
centers in California. Data was collected on the outcomes of
patients and costs to evaluate the clinical and economic
benefits of rWGS. The clinical utility of diagnoses and
changes in outcome were determined by patients’ medical
teams. To date, 43% of those sequenced received a mole-
cular diagnosis, with turnaround time for provisional results
in <72 hrs. In >35% of cases, rWGS altered the clinical
management. Collectively, patients avoided >225 hospital
days, numerous invasive procedures and diagnostic tests. In
the preliminary analysis of PBB cases, it was estimated a
charge expenditure saving of up to $2.4M across all epi-
sodes of care. In conclusion, the preliminary data from PBB
demonstrated the clinical utility and cost effectiveness of
utilization of rWGS in the pediatric ICU setting. PBB
provided evidence that rWGS should become a Medi-Cal
covered benefit, and presented the framework for future
studies in other states to show the utility of rWGS.
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C08.2
Integration of genome sequencing into health care -
experiences from 3211 rare disease patients show high
diagnostic rates across multiple clinical entities
A. Lindstrand1,2*, H. Stranneheim1,3,4, K. Lagerstedt-
Robinson1,2, M. Kvarnung1,2, N. Lesko1,3, D. Nilsson1,2, B.
Anderlid1,2, H. Arnell5, C. Backman Johansson3, M.
Barbaro3, E. Björck1,2, H. Bruhn3, J. Eisfeldt1,2,4, M.
Engvall3, C. Freyer3, G. Grigelioniene1,2, P. Gustavsson1,2,
A. Hammarsjö1,2, M. Hellström-Pigg1,2, A. Jemt6, M.
Laaksonen7, S. Lind Enoksson8, M. Magnusson1,7, H.
Malmgren1,2, K. Naess3, M. Nordenskjöld1,2, M. Oscarson3,
M. Pettersson1,2, C. Rasi4, A. Rosenbaum7, E. Sahlin1,2, T.
Stödberg3,5, B. Tesi1,2, E. Tham1,2, H. Thonberg1,2, U. von
Döbeln3, S. Vonlanthen8, A. Wikström8, J. Wincent1,2, O.
Winqvist8, A. Wredenberg3, S. Ygberg3,5, R. H. Zetterström3,
P. Marits8, M. Johansson-Soller1, M. Johansson Soller1,2,
A. Nordgren1,2, V. Wirta4,6,7, A. Wedell1,3
1Department of Molecular Medicine and Surgery, Karo-
linska Institutet, Stockholm, Sweden, 2Department of
Clinical Genetics, Karolinska University Hospital, Stock-
holm, Sweden, 3Centre for Inherited Metabolic Diseases,
Karolinska University Hospital, Stockholm, Sweden,
4Science for Life Laboratory, Department of Microbiology,
Tumour and Cell Biology, Karolinska Institutet, Stockholm,
Sweden, 5Department of Women’s and Children’s Health,
Karolinska Institutet, Stockholm, Sweden, 6Genomic Med-
icine Center Karolinska, Karolinska University Hospital,
Stockholm, Sweden, 7Science for Life Laboratory, School of
engineering sciences in Chemistry, Biotechnology and
Health, KTH Royal Institutet of Technology, Stockholm,
Sweden, 8Department of Clinical Immunology and Transfu-
sion Medicine, Karolinska University Hospital, Stockholm,
Sweden., Stockholm, Sweden
We report the findings from 4553 samples (3211 cases) that
have been analyzed by genome sequencing at the Genomic
Medicine Center Karolinska-Rare Diseases (GMCK-RD).
GMCK-RD represents a long-term collaborative initiative
between Karolinska University Hospital and SciLifeLab to
establish advanced, genomics-based diagnostics in the
Stockholm healthcare setting. Our bioinformatic analysis
pipeline includes SNVs, Indels, CNVs (including SMN),
balanced structural variants and short tandem repeat
expansions. Visualization of results for clinical interpreta-
tion is carried out in Scout - a custom-developed decision
support system. Both singleton (84%) and trio/family (16%)
analysis is performed. The variant interpretation is done by
15 expert teams at the hospital involving staff from three
clinics and for patients with complex phenotypes data is
shared between the teams. Overall 33% of the patients
receive a molecular diagnosis (1208 positive findings)
ranging from 30% to 60% for specific disease groups. There
is extreme heterogeneity regarding causative genes (n=701)
with some of the most common being SCN1A (n=13; epi-
lepsy), TNFRSF13B (n=5; inborn errors of immunity) and
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ARID1B (n=8; intellectual disability). Some of the causa-
tive variants were recurrent; including both previously
known founder mutations, known recurrent de novo muta-
tions and novel recurrent variants. Overall, GMCK-RD has
had dramatic results as a large number of patients have
received specific molecular diagnoses. Furthermore, nega-
tive cases are systematically included in research studies
that have led to the discovery of 21 novel disease-causing
genes. To facilitate discovery of new disease genes,
GMCK-RD has joined international data sharing initiatives,
including ClinVar, UDNI, Beacon and MatchMaker
Exchange.
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C08.3
Genomic loci susceptible to systematic sequencing bias
in clinical whole genomes
T. M. Freeman1*, Genomics England Research
Consortium, D. Wang1, J. Harris2
1The University of Sheffield, Sheffield, United Kingdom,
2Personalis Inc., Menlo Park, CA, United States
Introduction: Accurate massively parallel sequencing
(MPS) of genetic variants is key to many areas of science
and medicine, including diagnosing genetic diseases. Cer-
tain genomic positions can be prone to higher rates of
systematic sequencing and alignment bias that limit accu-
racy, resulting in false positive variant calls. Current stan-
dard practices to differentiate between loci that can and
cannot be sequenced with high confidence utilise consensus
between different sequencing methods as a proxy for
sequencing confidence. These practices have significant
limitations and alternative methods are required to
overcome these.
Materials and Methods: We have developed a novel
statistical method based on summarising sequenced reads
from whole genome clinical samples and cataloguing them
in “Incremental Databases” that maintain individual con-
fidentiality. Allele statistics were catalogued for each
genomic position that consistently showed systematic biases
with the corresponding MPS pipeline.
Results: We found systematic biases present at ~1-3% of
the human autosomal genome across five patient cohorts.
We identified how susceptible different genomic regions
were to systematic biases, including large homopolymer
flanks (odds ratio=23.29-33.69) and the NIST high
confidence genomic regions (odds ratio=0.154-0.191). We
confirmed our predictions on a gold-standard reference
genome and showed that these systematic biases can lead to
suspect variant calls within clinical panels.
Conclusion: Our results recommend increased caution to
address systematic sequencing biases. This study imple-
ments a novel statistical approach to enhance quality control
of clinically sequenced samples by flagging variants at
suspect loci for further analysis or exclusion.
This work has recently been accepted for publication in
Genome Research.
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C08.4
Systematic analysis of short tandem repeats in 38,256
exomes provides additional diagnostic yield
B. P. G. H. van der Sanden1,2*, M. de Groot1, J.
Corominas1, M. Pennings1, R. P. P. Meijer1, L. E. L. M.
Vissers1,2, E. Kamsteeg1, C. Gilissen1,3
1Department of Human Genetics, Radboudumc, Nijmegen,
Netherlands, 2Donders Institute for Brain, Cognition and
Behaviour, Nijmegen, Netherlands, 3Radboud Institute for
Molecular Life Sciences, Nijmegen, Netherlands
Short tandem repeats (STRs) are defined as tandemly
repeated nucleotide motifs of 2-12 base pairs in length and
occur across the genome. Extreme expansion of specific
STRs can lead to approximately 30 different human genetic
disorders. Despite the extensive application of whole exome
sequencing (WES) in routine diagnostic genetic testing,
STRs are not routinely identified from these data. Here, we
present our results of a systematic analysis for STR
expansion disorders in our cohort of 38,256 clinical
exomes.
We evaluated four different tools, exSTRa, STRetch,
ExpansionHunter, and GangSTR, on a validation cohort of
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11 patients with known pathogenic repeat expansion allele
(s). ExpansionHunter demonstrated highest sensitivity
(91%) and specificity (100%), after which we applied it to
2,900 exomes from movement and muscle disorder patients.
We identified 49 patients with a likely aberrant STR
length. Validation by GeneScan® and/or triplet repeat-
primed PCR technologies confirmed the presence of
aberrant expansion allele(s) for 18 (0.6%). Importantly, 10
STR expansions had not previously been identified using
conventional genetic testing, and may result in novel
diagnoses. Three expansions were detected in ATXN7,
known to cause spinocerebellar ataxia type 7, for which
increase in repeat size between generations may cause
extreme anticipation. We subsequently tested the remainder
of our diagnostic WES cohort, including over 30 clinically
and genetically heterogeneous disorders, and currently
1,187 aberrant expansion alleles are being validated.
Our results show that systematic STR evaluation may
increase diagnostic WES yield by 0.6%, and should become
a routine part of WES data analysis in genetic testing
laboratories.
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C08.5
A cost-effectiveness and utility analysis of genomic
sequencing in a prospective versus historical cohort of
complex pediatric patients
A. Yeung1,2*, N. B. Tan1, T. Y. Tan1,2,3, Z. Stark1,2,3, N.
Brown1,3, M. J. Hunter4,5, M. Delatycki1,3, C. Stutterd1,3, R.
Savarirayan1,3, G. McGillivray1, R. Stapleton1, S. Kumble1,
L. Downie1, M. Regan4,5, S. Lunke1, B. Chong1, D. Phelan1,
G. Brett1, A. Jarmolowicz1, Y. Prawer4, G. Valente6, Y.
Samarinsky1, M. Martin7,2,3, C. McEwan2, I. Goranitis7,8, C.
Gaff7,2,3, S. M. White1,2,3
1Victorian Clinical Genetics Services, Murdoch Children’s
Research Institute, Parkville, Australia, 2Melbourne Geno-
mics Health Alliance, Parkville, Australia, 3Department of
Paediatrics, University of Melbourne, Parkville, Australia,
4Monash Genetics, Monash Health, Melbourne, Australia,
5Department of Paediatrics, Monash University, Mel-
bourne, Australia, 6Genetics in the North East, Austin
Health, Melbourne, Australia, 7Murdoch Children’s
Research Institute, Parkville, Australia, 8Centre for Health
Policy, Melbourne School of Population and Global
Health, University of Melbourne, Parkville, Australia
The diagnosis of children with genetic conditions places a
significant economic burden on health care services. The
lack of well-defined comparative cohorts has been a lim-
itation of health economic studies comparing first-line
genomic sequencing (GS) against traditional approaches.
Aim: To evaluate utility and cost effectiveness of early
GS in pediatric patients with complex monogenic condi-
tions compared to a matched historical cohort.
Method: Data, including diagnosis rate and investigation
costs, were collected in a prospective cohort of 92 pediatric
patients who underwent singleton GS over an 18-month
period (2016-2017). Inclusion required patients to have two
of the following: a condition with high morbidity or
mortality, a multi-system disease involving three or more
organ systems, or severe limitation of daily function. For
comparison, data were collected in a historical patient
cohort fulfilling the inclusion criteria who underwent
traditional investigations in the two years (2012-2013) prior
to the availability of clinical genomic sequencing.
Results: Genomic sequencing yielded a diagnosis in 42%
while traditional investigations yielded a diagnosis in 23%
(p= 0.003). 75% of diagnosed patients experienced a
change in management, compared to 33% of diagnosed
patients who underwent traditional investigations. In the GS
cohort, four times fewer invasive investigations were
observed. Compared to traditional investigations, singleton
genomic sequencing at a cost of $3100 AUD resulted in a
mean saving per person of $2780 AUD (95%CI $1585 -
$3974).
Conclusion: Early genomic sequencing is highly cost-
effective while doubling the diagnostic yield of traditional
approaches and improving the care of patients with complex
genetic conditions.
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C08.6
The impact of the 100,000 Genomes Project on rare
disease in national healthcare
D. Smedley1,2*, S. Abbs3, G. Arno4, E. Baple5, M. Barnes1,
P. Beales6, M. Bitner-Glindzicz6, G. Black7, P. Brennan8, G.
Chan2, P. Chinnery3,9, V. Cipriani1, S. Ellard5, J.
Ellingford7, P. Elliott6, H. Firth3, F. Flintner10, K. Ibanez
Garikano1,2, H. Houlden6, M. Irving10, J. Jacobsen1, E.
McDonagh2, D. McMullan11, L. Moutsianas1,2, W.
Newman7, W. H. Ouwehand3,9,12, T. Ratnaike3, A. Rueda
Martin2, C. Penkett3,12, F. Raymond3,9, J. Sayer8, R. Scott2,6,
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K. Smith2, H. Stark9,12, K. Stirrups9,12, J. Taylor13, E.
Thomas2, A. Tucci2,1,6, J. Vandrovcova6, L. Vestito6, A.
Webster4, W. Wei9, M. Wielscher2, H. Williams6, A.
Wilkie13, C. Wright5, A. Rendon2,9, M. Caulfield2,1,. NIHR
BioResource3, . Genomics England Research Consortium2
1Queen Mary University of London, London, United
Kingdom, 2Genomics England, London, United Kingdom,
3Cambridge University Hospitals, Cambridge, United
Kingdom, 4Moorfields Eye Hospital, London, United King-
dom, 5University of Exeter, Exeter, United Kingdom, 6Uni-
versity College London, London, United Kingdom,
7University of Manchester, Manchester, United Kingdom,
8The Newcastle upon Tyne NHS Foundation Trust, New-
castle, United Kingdom, 9University of Cambridge, Cam-
bridge, United Kingdom, 10Guys and St Thomas’ NHS
Foundation Trust, London, United Kingdom, 11Birmingham
Women’s and Children’s NHS Trust, Birmingham, United
Kingdom, 12NHS Blood and Transplant, Cambridge, United
Kingdom, 13University of Oxford, Oxford, United Kingdom
Introduction: The UK 100,000 Genomes Project was cre-
ated to define the role of whole genome sequencing (WGS)
in rare disease, cancer and infection. For rare disease a
diagnostic pipeline and research environment was built to
address the needs of patients who remained undiagnosed
following standard testing in the National Health Service
(NHS) in England.
Methods: Detailed clinical features on enrolled partici-
pants were captured, WGS performed and automated
variant interpretation run based on gene panels (PanelApp)
as well as phenotype-based prioritisation (Exomiser).
Prioritised variants were returned to the NHS for laboratory
review and clinical reporting.
Results: We report on the first 4660 participants across a
broad spectrum of rare disease. Diagnostic yields varied by
family structure (highest in trios and larger pedigrees) and
disease. Likely Mendelian disorders had higher yields
(37%) with intellectual disability, hearing and eye disorders
achieving 40-50%. Those with more complex causes (e.g.
familial cancer) had lower yields (11%), particularly where
known loci had been excluded by standard tests. The overall
diagnostic yield was 26%, involving 470 unique diagnoses.
Clinical phenotypes (Human Phenotype Ontology terms)
were critical to performance of the automated pipeline in
detecting 90% of SNV/indel diagnoses. WGS enabled
diagnoses that would be missed by other technologies: 4%
involved non-coding variation, 9% with structural variants,
and 8% in coding regions with no/low coverage by whole
exome sequencing. Finally, cohort-wide analysis detected
numerous novel disease-gene associations.
Conclusions: Our findings will inform healthcare
uptake and utilisation of WGS world-wide, identifying
and enabling prioritization of clinical indications for
adoption.
D. Smedley: F. Consultant/Advisory Board; Modest;
Congenica Ltd. S. Abbs: None. G. Arno: None. E. Baple:
None. M. Barnes: None. P. Beales: None. M. Bitner-
Glindzicz: None. G. Black: None. P. Brennan: None. G.
Chan: None. P. Chinnery: None. V. Cipriani: None. S.
Ellard: None. J. Ellingford: None. P. Elliott: None. H. Firth:
None. F. Flintner: None. K. Ibanez Garikano: None. H.
Houlden: None. M. Irving: None. J. Jacobsen: None. E.
McDonagh: None. D. McMullan: None. L. Moutsianas:
None. W. Newman: None. W. H. Ouwehand: None. T.
Ratnaike: None. A. Rueda Martin: None. C. Penkett: None.
F. Raymond: None. J. Sayer: None. R. Scott: None. K.
Smith: None. H. Stark: None. K. Stirrups: None. J. Taylor:
None. E. Thomas: None. A. Tucci: None. J. Vandrovcova:
None. L. Vestito: None. A. Webster: None. W. Wei: None.
M. Wielscher: None. H. Williams: None. A. Wilkie:
None. C. Wright: None. A. Rendon: None. M. Caulfield:
None. NIHR BioResource: None. Genomics England
Research Consortium: None.
C09 Metabolic and Mitochondrial Disorders
C09.1
The Australian Genomic Health Alliance Mitochondrial
Flagship - A national approach to genomic diagnostics
D. Thorburn1,2,3*, N. Baker3, S. Balasubramaniam4, D.
Bratkovic5, D. Coman6, A. Compton1, M. Delatycki3, C.
Ellaway4, M. Fahey7, J. Fletcher8, A. Frazier1, R. Ghaoui8,
H. Goel9, D. Hock10, M. Kava11, N. Lake12, P. Lamont13, J.
Lee14, J. Panetta7, L. Phillips8, R. Rius1, M. Ryan15, N.
Smith5, D. Stroud10, M. Tchan16, M. Walsh7, M. Wallis17, A.
Welch1, C. Wools7, J. Christodoulou1,2,3
1Murdoch Children’s Res Inst, Melbourne, Australia, 2Uni-
versity of Melbourne, Melbourne, Australia, 3Victorian
Clinical Genetics Services, Melbourne, Australia, 4Sydney
Children’s Hospitals Network, Sydney, Australia,
5Women’s and Children’s Hospital, Adelaide, Australia,
6Queensland Children’s Hospital and Wesley Hospital,
Brisbane, Australia, 7Royal Melbourne Hospital, Mel-
bourne, Australia, 8Royal Adelaide Hospital, Adelaide,
Australia, 9Hunter Genetics, John Hunter Hospital, New-
castle, Australia, 10Bio21 Molecular Science and Biotech-
nology Institute, Melbourne, Australia, 11Perth Children’s
Hospital, Perth, Australia, 12Yale School of Medicine, New
Haven, CT, United States, 13Royal Perth Hospital, Perth,
Australia, 14Royal Children’s Hospital, Melbourne, Aus-
tralia, 15Monash Biomedicine Discovery Institute, Monash
University, Melbourne, Australia, 16Westmead Hospital,
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Sydney, Australia, 17Tasmanian Clinical Genetics Service,
Hobart, Australia
Introduction: The Australian Genomics Health Alliance is
a nationally funded health services research project focused
on bringing genomic technologies to the clinic. The Mito-
chondrial Disease (MD) Flagship brings together expert
clinicians from around Australia, specialist diagnostic
laboratories and researchers expert in functional character-
ization of MD to examine the clinical utility of genomic
sequencing for efficient diagnosis of MD.
Methods: We recruited 134 paediatric and adult
individuals with a probable or definite MD diagnosis, based
on modified Nijmegen criteria. Their blood DNA was
randomized to either whole genome sequencing or whole
exome plus mitochondrial DNA sequencing.
Results: Our definitive diagnostic yield is currently
~36% for both whole genome and whole exome/
mitochondrial DNA approaches, with most diagnosed
cases having a primary defect in the nuclear genome. Not
surprisingly, 14% of individuals with confirmed molecu-
lar diagnoses had mutations in non-MD genes, reflecting
phenotypic overlap. Unsolved patients have been triaged
to one or more targeted functional tests, quantitative
proteomics, RNAseq or long-read genome sequencing.
This enabled re-categorising of numerous class 3 variants
and identification of novel disease genes and mechanisms,
including a de novo duplication within the ATAD3 locus
resulting in a presumably toxic fusion protein (see Frazier
et al. abstract).
Conclusions: Our collaborative effort has demonstrated
that using a consistent national approach for clinically
triaging cases for genomic sequencing is both effective and
efficient, usually obviates the need for invasive biopsies and
in some cases enables targeted therapies. Supported by
grants from an NHMRC Targeted Call for Research
(GNT1113531) and the Mito Foundation.
D. Thorburn: None. N. Baker: None. S. Balasubrama-
niam: None. D. Bratkovic: None. D. Coman: None. A.
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C09.2
High resolution respirometric analysis of a Barth
Syndrome disease model
G. Oemer1*, K. Lackner1, J. Koch1, E. R. Werner1, C.
Doerrier2, G. Krumschnabel2, G. Leman1, S. Dubrac1, R.
Houtkooper3, J. Zschocke1, M. A. Keller1
1Medical University of Innsbruck, Innsbruck, Austria,
2Oroboros Instruments, Innsbruck, Austria, 3Amsterdam
Medical Center, Amsterdam, Netherlands
Barth Syndrome is a rare X-linked disorder that is char-
acterized by mitochondrial dysfunction leading to severe
cardiomyopathy, growth delay, muscle weakness and neu-
tropenia. The affected TAZ gene encodes the CoA-indepen-
dent transacylase tafazzin that remodels the acyl chains of
cardiolipins. This phospholipid, which is synthesized and
localized in mitochondrial membranes, is functionally
involved in cristae formation, protein anchoring, super-
complex assembly, ROS scavenging and apoptotic signaling.
Cardiolipin has a unique structure with four fatty acyls ren-
dering cardiolipins the most diverse phospholipid class. We
generated a Barth Syndrome disease model by CRISPR/Cas9-
mediated HEK TAZ-knockout cell lines and have thoroughly
characterized the induced alterations on cardiolipin home-
ostasis and mitochondrial functions. Furthermore we applied a
recently developed LC-MS/MS lipidomics method to quali-
tatively, quantitatively and structurally characterize changes in
the cardiolipin composition. In combination with systematic
alteration of the lipid environment by BSA-mediated fatty
acid supplementation, we obtained new insights in the com-
plex mitochondrial - and partially rescuable - phenotypes of
Barth Syndrome. As such, we observed fatty acid dependent
mitochondrial fission and oxidative stress in TAZ-knockouts.
Most strikingly, high-resolution respirometry revealed a shift
in the OXPHOS flux control from NADH-depended to suc-
cinate-linked pathways without affecting the mitochondrial
central carbon metabolic network or ß-oxidation. This indi-
cates a compensatory adaptation caused by the altered mito-
chondrial lipid homeostasis in TAZ-deficient cells.
G. Oemer: None. K. Lackner: None. J. Koch: None. E. R.
Werner: None. C. Doerrier: None. G. Krumschnabel: None.
G. Leman: None. S. Dubrac: None. R. Houtkooper: None.
J. Zschocke: None. M. A. Keller: None.
C09.3
Recurrent de novo ATAD3 duplications cause fatal
perinatal mitochondrial cardiomyopathy, persistent
hyperlactacidemia, encephalopathy and heart-specific
mitochondrial oxidative phosphorylation complex I
deficiency.
A. E. Frazier1,2, A. G. Compton1,2*, Y. Kishita3, D. H.
Hock4, A. E. Welch1, S. S. C. Amarasekera1,2, R. Rius1,2, L.
E. Formosa5, A. Imai-Okazaki3,6, D. Francis7, M. Wang1, N.
J. Lake1,2,8, S. Tregoning1,7, J. S. Jabbari9, A. Lucattini9, K.
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R. Nitta3, A. Ohtake10, K. Murayama11, D. J. Amor1,2, G.
McGillivray7, F. Y. Wong12, M. S. van der Knaap13,14, R. J.
Vermeulen15, E. J. Wiltshire16, J. M. Fletcher17, B. Lewis18,
G. Baynam19,20, C. Ellaway21,22, S. Balasubramaniam21, K.
Bhattacharya21,22, M. L. Freckmann23, R. J. Taft24, S.
Sadedin1,7, M. J. Cowley25,26, A. E. Minoche26, S. E.
Calvo27, V. K. Mootha27, M. T. Ryan5, Y. Okazaki3, D. A.
Stroud4, C. Simons1,28, J. Christodoulou1,2,7, D. R.
Thorburn1,2,7
1Murdoch Children’s Research Institute, Melbourne, Aus-
tralia, 2Department of Paediatrics, University of Mel-
bourne, Melbourne, Australia, 3Diagnostics and
Therapeutics of Intractable Diseases, Intractable Disease
Research Center, Juntendo University, Graduate School of
Medicine, Tokyo, Japan, 4Department of Biochemistry and
Molecular Biology and Bio21 Molecular Science and
Biotechnology Institute, University of Melbourne, Mel-
bourne, Australia, 5Department of Biochemistry and
Molecular Biology, Monash Biomedicine Discovery Insti-
tute, Monash University, Melbourne, Australia, 6Division of
Genomic Medicine Research, Medical Genomics Center,
National Center for Global Health and Medicine, Tokyo,
Japan, 7Victorian Clinical Genetics Services, Murdoch
Children’s Research Institute, Royal Children’s Hospital,
Melbourne, Australia, 8Department of Genetics, Yale
School of Medicine, New Haven, CT, United States,
9Australian Genome Research Facility Ltd, Victorian
Comprehensive Cancer Centre, Melbourne, Australia,
10Department of Pediatrics & Clinical Genomics, Saitama
Medical University Hospital, Saitama, Japan, 11Department
of Metabolism, Chiba Children’s Hospital, Chiba, Japan,
12Ritchie Centre, Hudson Institute of Medical Research;
Department of Paediatrics, Monash University; and
Monash Newborn, Monash Children’s Hospital, Mel-
bourne, Australia, 13Child Neurology, Emma Children’s
Hospital, Amsterdam University Medical Centers, Vrije
Universiteit and Amsterdam Neuroscience, Amsterdam,
Netherlands, 14Functional Genomics, Center for Neuroge-
nomics and Cognitive Research, Vrije Universiteit and
Amsterdam Neuroscience, Amsterdam, Netherlands,
15Department of Neurology, Maastricht University Medical
Center, Maastricht, Netherlands, 16Department of Paedia-
trics and Child Health, University of Otago Wellington and
Capital and Coast District Health Board, Wellington, New
Zealand, 17Department of Genetics and Molecular Pathol-
ogy, SA Pathology, Adelaide, Australia, 18Department of
Clinical Biochemistry, PathWest Laboratory Medicine
Western Australia, Perth, Australia, 19Western Australian
Register of Developmental Anomalies and Genetic Services
of Western Australia and King Edward Memorial Hospital
for Women Perth, Perth, Australia, 20Telethon Kids Institute
and School of Paediatrics and Child Health, The University
of Western Australia, Perth, Australia, 21Genetic Metabolic
Disorders Service, Sydney Children’s Hospital Network,
The Children’s Hospital at Westmead, Sydney, Australia,
22Disciplines of Genomic Medicine and Child and Adoles-
cent Health, Sydney Medical School, University of Sydney,
Sydney, Australia, 23Clinical Genetics, The Canberra
Hospital, Canberra, Australia, 24Illumina, Inc., San Diego,
CA, United States, 25Children’s Cancer Institute, and St
Vincent’s Clinical School, UNSW Sydney, Sydney, Austra-
lia, 26Kinghorn Centre for Clinical Genomics, Garvan
Institute of Medical Research, Sydney, Australia, 27Broad
Institute; Howard Hughes Medical Institute and Depart-
ment of Molecular Biology, Massachusetts General Hospi-
tal; and Harvard Medical School, Boston, MA, United
States, 28Institute for Molecular Bioscience, The University
of Queensland, Brisbane, Australia
Mitochondrial disorders are clinically heterogeneous and
comprise over 350 different genetic conditions. However,
the molecular diagnosis is unknown in ~50% of cases,
partly due to some genomic regions being refractory to
standard genomic analysis. One such region is the ATAD3
locus consisting of 3 highly homologous tandemly arrayed
genes (ATAD3C, ATAD3B and ATAD3A) encoding mito-
chondrial proteins implicated in processes including cho-
lesterol metabolism, and mitochondrial replication,
dynamics and morphology. Recessive deletions and domi-
nant duplications in this locus have recently been reported
to cause rare, lethal perinatal mitochondrial disorders
characterised by pontocerebellar hypoplasia or cardiomyo-
pathy, respectively. We report 17 subjects from 16 unrelated
families with cardiomyopathy, persistent hyperlactacidemia,
encephalopathy and frequently corneal clouding or cataracts
due to de novo ATAD3 duplications. The six different 68 Kb
duplications were consistently identifiable from whole
genome and exome sequencing, but usually missed on
microarray. The duplications all resulted in the formation of
an identical chimeric ATAD3A/ATAD3C fusion protein,
which appears to act in a dominant manner causing altered
ATAD3 complexes and a striking reduction in mitochon-
drial oxidative phosphorylation complex I and its activity in
heart tissue. In our experience, the ATAD3 locus is one of
the five most common causes of nuclear-encoded paediatric
mitochondrial disease but the repetitive nature of the locus
means ATAD3 diagnoses may be frequently missed by
current genomic strategies. Supported by grants from the
Australian NHMRC 1164479 and 1113531, US DoD
CDMRP PR170396; the Japanese AMED 19ek0109273,
18ek0109177, 19kk0205014 and 18kk0205002; Japanese
JSPS 19H03624 and the Australian Mito Foundation.
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C09.4
Hyperuricemia and gout caused by missense mutation in
D-lactate dehydrogenase, revealing novel enzymatic
activity
M. Drabkin1*, Y. Yogev1, L. Zeller2, R. Zarivach1, R. Zalk1,
D. Halperin1, O. Wormser1, E. Gurevich3, D. Landau4, R.
Kadir1, Y. Perez1, O. S. Birk1
1Ben-Gurion University, Beer-Sheva, Israel, 2Soroka Med-
ical Center, Beer-Sheva, Israel, 3"Clalit" Health Services,
Beer-Sheva, Israel, 4Tel-Aviv University, Tel-Aviv, Israel
Introduction: Gout is caused by deposition of monosodium
urate crystals in joints when plasma uric acid levels are
elevated beyond saturation threshold, mostly due to renal
under-excretion of uric acid. While molecular pathways of
this under-excretion have been elucidated, its etiology
remains mostly unknown. We studied a consanguineous
Bedouin kindred affected with gout and hyperuricemia.
Materials and Methods: Whole-exome sequencing,
linkage analysis, protein structure modeling, mass-spectro-
metry, metabolomics, confocal microscopy, in-vivo meta-
bolic studies, co-immunoprecipitation, proteomics,
knockout mouse model.
Results: We demonstrate that gout can be caused by a
mutation in LDHD within the putative catalytic site of the
encoded D-lactate dehydrogenase, resulting in augmented
blood and urine levels of D-lactate, a stereoisomer of L-
lactate, normally present in human blood in miniscule
amounts. Consequent excessive renal secretion of D-lactate
in exchange for uric acid reabsorption culminated in
hyperuricemia and gout. Metabolome analysis of patient’s
blood and urine using mass-spectrometry revealed elevated
levels of intermediate metabolites of purine degradation,
which ultimately lead to uric acid production. Further
metabolome analyses performed on LDHD knockout mice
generated using CRISPR-Cas9 recapitulated the human
phenotype. We showed that LDHD expression is enriched
in tissues with high metabolic rate and abundant mitochon-
dria, and that D-lactate dehydrogenase resides in the
mitochondria of cells overexpressing the human LDHD
gene. In line with the human phenotype, injection of D-
lactate to naïve mice resulted in hyperuricemia.
Conclusion: Hyperuricemia and gout can result from
accumulation of D-lactate and possibly additional metabo-
lites whose renal excretion is coupled to uric acid
reabsorption.
M. Drabkin: None. Y. Yogev: None. L. Zeller: None. R.
Zarivach: None. R. Zalk: None. D. Halperin: None. O.
Wormser: None. E. Gurevich: None. D. Landau: None. R.
Kadir: None. Y. Perez: None. O. S. Birk: None.
C09.5
Metabolite set enrichment improves biomarker identifi-
cation and detection in untargeted metabolic profiling
(UMP) data for patients with inborn errors of
metabolism
B. Hoegen1*, U. F. H. Engelke2, K. L. M. Coene2, J. E.
Hampstead1, P. Kulkarni2, R. A. Wevers2, H. G. Brunner3,
C. Gilissen1
1Department of Human Genetics, Radboud Institute for
Molecular Life Sciences, Radboud University Medical
Center, Nijmegen, Netherlands, 2Department of Laboratory
Medicine, Translational Metabolic Laboratory (TML),
Radboud University Medical Center, Nijmegen, Nether-
lands, 3Department of Human Genetics, Donders Center for
Neuroscience, Radboud University Medical Center, Nijme-
gen, Netherlands
Inborn errors of metabolism (IEMs) are a large, pre-
dominantly recessive class of genetic disorders associated
with the congenital disruption of one or more metabolic
pathways. Untargeted metabolomic profiling (UMP) allows
the simultaneous measurement of hundreds of metabolites,
including diagnostic biomarker metabolites for IEM dis-
orders, in a single test and can aid in the interpretation of
variants of uncertain significance (VUS) in genes with a
known or suspected metabolic phenotype. However, the
large amount of data generated in a single UMP run limits
its diagnostic utility. Here, we present a metabolite set
enrichment method (MSEA) that leverages biological
pathway information to prioritise clinically relevant meta-
bolites and their associated pathways in UMP data. We
further cluster enriched pathways into pathway sets to
eliminate redundancy. We ran MSEA across 43 diagnosed
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patient plasma samples with pathway information available
in databases (KEGG=317, SMPDB=901) spanning 21
distinct IEMs, and show that MSEA prioritises known
diagnostic biomarkers better than a naive filtering approach
in 18 samples across 10 IEMs without a genetic prior
(p= 0.00015). This has particular relevance for patients
with unresolved IEMs, or novel IEMs not included on
standard gene panels. Additionally, our method identifies
putative novel biomarkers for at least one IEM. MSEA
improves the analysis of UMP data for patient diagnostics,
and provides a first approach to opening the metabolome.
These approaches will be crucial for the interpretation of
variants of unknown significance from WES data, and for
the integration of WES and WGS results with untargeted
metabolomics data.
B. Hoegen: None. U. F. H. Engelke: None. K. L. M.
Coene: None. J. E. Hampstead: None. P. Kulkarni: None. R.
A. Wevers: None. H. G. Brunner: None. C. Gilissen: None.
C09.6
A genome-wide association study for a proxy non-
alcoholic fatty liver phenotype identifies novel loci and
trait-relevant candidate genes
M. Vujkovic1,2, S. Ramdas3, K. Gawronski4, K. Lorenz1,3,5,
M. Serper1,2,6, D. E. Kaplan1,2, R. Carr1,2, K. M. Lee7, S.
Saiju Pyarajan8,9, T. Edwards10,11, D. Klarin8,12,13, Y. V.
Sun14,15, D. R. Miller16,17, P. D. Reaven18,19, L. S.
Phillips14,20, C. J. O’Donnell8,9, J. B. Meigs21,22,23, P. W. F.
Wilson24,25, R. Vickers-Smith1,26, H. R. Kranzler1,27, A. C.
Justice28,29, M. Gaziano9,30, S. Muralidhar31, S. L. DuVall32,
T. L. Assimes33,34, J. S. Lee33,34, P. S. Tsao33,34, D. J.
Rader2,3,35, C. D. Brown3, S. M. Damrauer1,36, J. A.
Lynch32,37, D. Saleheen38,39, B. F. Voight1,3,5*, K. M.
Chang1,2, on behalf of the VA Million Veteran Program
1Corporal Michael J. Crescenz VA Medical Center,
Philadelphia, PA, United States, 2Department of Medicine,
University of Pennsylvania, Philadelphia, PA, United
States, 3Department of Genetics, University of Pennsylva-
nia, Philadelphia, PA, United States, 4Cellular and
Molecular Biology Graduate Group, University of Penn-
sylvania, Philadelphia, PA, United States, 5Department of
Systems Pharmacology and Translational Therapeutics,
University of Pennsylvania, Philadelphia, PA, United
States, 6Leonard Davis Institute of Health Economics,
Philadelphia, PA, United States, 7VA Salt Lake City Health
Care System, Salt Lake City, UT, United States, 8VA Boston
Healthcare System, Boston, MA, United States, 9Depart-
ment of Medicine, Brigham Women’s Hospital, Boston, MA,
United States, 10Nashville VA Medical Center, Philadel-
phia, PA, United States, 11Vanderbilt Genetics Institute,
Vanderbilt University Medical Center, Nashville, TN,
United States, 12Center for Genomic Medicine, Massachu-
setts General Hospital, Boston, MA, United States, 13Divi-
sion of Vascular Surgery and Endovascular Therapy,
University of Florida School of Medicine, Gainesville, FL,
United States, 14Atlanta VA Health Care System, Atlanta,
GA, United States, 15Department of Epidemiology, Emory
University Rollins School of Public Health, Atlanta, GA,
United States, 16Edith Nourse Rogers Memorial VA
Hospital, Bedford, MA, United States, 17Department of
Health Law, Policy and Management, Boston University
School of Public Health, Boston, MA, United States,
18Phoenix VA Health Care System, Pheonix, AZ, United
States, 19College of Medicine, University of Arizona,
Tuscon, AZ, United States, 20Division of Endocrinology,
Emory University School of Medicine, Atlanta, GA, United
States, 21Division of General Internal Medicine, Massachu-
setts General Hospital, Boston, MA, United States,
22Department of Medicine, Harvard Medical School,
Boston, MA, United States, 23Broad Institute of MIT and
Harvard, Boston, MA, United States, 24Atlanta VA Medical
Center, Atlanta, GA, United States, 25Division of Cardiol-
ogy, Emory University School of Medicine, Atlanta, GA,
United States, 26University of Louisville, Louisville, KY,
United States, 27Department of Psychiatry, University of
Pennsylvania, Philadelphia, PA, United States, 28Veterans
Affairs Connecticut Healthcare System, West Haven, CT,
United States, 29Yale School of Medicine and Yale School of
Public Health, New Haven, CT, United States, 30Massa-
chusetts Veterans Epidemiology Research and Information
Center, Veterans Affairs Boston Healthcare System, Boston,
MA, United States, 31Office of Research and Development,
Veterans Health Administration, Washington, DC, United
States, 32VA Informatics and Computing Infrastructure, VA
Salt Lake City Health Care System, Salt Lake City, UT,
United States, 33VA Palo Alto Health Care System, Palo
Alto, CA, United States, 34Department of Medicine,
Stanford University, Stanford, CA, United States, 35Depart-
ment of Pediatrics, University of Pennsylvania, Philadel-
phia, PA, United States, 36Department of Surgery,
University of Pennsylvania, Philadelphia, PA, United
States, 37University of Massachusetts College of Nursing
and Health Sciences, Boston, MA, United States, 38Depart-
ment of Medicine and Cardiology, Columbia University
Irving Medical Center, New York, NY, United States,
39Center for Non-Communicable Diseases, Karachi,
Pakistan
Introduction: Non-alcoholic fatty liver disease (NAFLD) is
a prevalent, heritable trait that can progress to cirrhosis,
liver failure, and cancer. Elucidation of its etiology has been
stymied by the lack of human genomics data at scale. We
previously reported a proxy phenotype for NAFLD: elevated
serum alanine aminotransferase levels across multiple time
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points without alternate causes of liver disease, recovering all
previously associated variants. Using this definition, we per-
formed genome-wide association in a cohort of United States
Veteran participants in the Million Veteran Program.
Methods: Trans-ethnic meta-analysis included 95,940
cases and 145,858 controls of European, African, Asian,
and Latinx ancestries. Gene prioritization was based on
linkage with coding variants or co-localization (COLOC
P4 > 0.8) with quantitative trait loci (QTL) from GTEx.
Enrichment analyses were performed via GREGOR and
DEPICT; heritability analyses via LD-score regression.
Results: 75 loci exceeded genome-wide significance,
with 3 additional loci identified in an African-American
specific scan. Candidate genes at 34 loci were prioritized
based on coding or QTL variation tightly linked with lead
variants, with 9 variants predicted damaging or had reduced
expression associated with lower incidence of our proxy
trait. Total liability scale h2 was estimated at 16% (95% CI:
12-19%). Functional genomic annotations and gene-sets
demonstrated enrichment of liver biology at associated sites.
Causal inference analyses indicated that body mass index
(BMI) and waist-hip ratio adjusted for BMI were associated
with our proxy trait (P < 10−10).
Conclusion: We identified novel loci with 34 candidate
genes plausibly associated with non-alcoholic fatty liver
disease.
M. Vujkovic: None. S. Ramdas: None. K. Gawronski:
None. K. Lorenz: None. M. Serper: None. D. E. Kaplan:
None. R. Carr: None. K. M. Lee: None. S. Saiju Pyarajan:
None. T. Edwards: None. D. Klarin: None. Y. V. Sun: None.
D. R. Miller: None. P. D. Reaven: None. L. S. Phillips: None.
C. J. O’Donnell: None. J. B. Meigs: None. P. W. F. Wilson:
None. R. Vickers-Smith: None. H. R. Kranzler: None. A. C.
Justice: None. M. Gaziano: None. S. Muralidhar: None. S. L.
DuVall: None. T. L. Assimes: None. J. S. Lee: None. P. S.
Tsao: None. D. J. Rader: None. C. D. Brown: None. S. M.
Damrauer: None. J. A. Lynch: None. D. Saleheen: None. B.
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C10 Rare and Common Variants in Personalized
Medicine
C10.1
Recessive vs dominant GWAS of 82,516 coding variants
on electronic health records in a population-wide ana-
lysis of 176,899 Finns
H. O. Heyne1,2,3*, J. Karjalainen1,2,3, S. M. Lemmelä1,4,
FinnGen, A. S. Havulinna1,4, M. Kurki1,2,3, A. Palotie1,2,3,
M. J. Daly1,2,3
1Institute for Molecular Medicine Finnland: FIMM, Hel-
sinki, Finland, 2Analytic and Translational Genetics Unit,
Massachusetts General Hospital, Boston, MA, United
States, 3Broad Institute of MIT and Harvard, Cambridge,
MA, United States, 4Finnish Institute for Health and
Welfare, Helsinki, Finland
Rare genetic variants influencing diseases often have large
effect sizes with potential direct treatment implications;
studying their effects comprehensively requires however large
cohort sizes. The population-wide cohort of FinnGen offers an
unprecedented opportunity to investigate phenotype associa-
tions of rare variants because the founding bottleneck of
Finland concentrates them to higher population frequencies.
This ‘Finnish disease heritage’ applies particularly to recessive
variants. Here, we studied recessive, dominant and additive
effects of 82,516 coding variants on 2,264 disease endpoints
using nation wide electronic health record data of 176,899
Finns. Globally, variant effects in different GWAS models
were in agreement with inheritance modes of the respective
genes in OMIM (recessive, dominant or “both”). However,
there were many exceptions e.g. 33 genes listed only as
recessive in OMIM had coding variants with dominant asso-
ciations (p < 10−7). One example was XPA (recessive disease:
Xeroderma pigmentosa), where a heterozygous truncating
variant was associated with skin cancer (p= 8 × 10−11, beta=
1.24). Another example was a variant in SCN5A associated
with sick sinus syndrome in recessive state. Interestingly, in
heterozygous form it had a protective effect for cardiac
arrhythmia phenotypes (p= 2 × 10−8, beta=−0.48, repli-
cated in UK Biobank with p= 0.04, beta=−0.39). Our data
also included 6794 coding variants listed in ClinVar. We
found significantly more phenotype associations than for
random intergenic variants in 498 (likely) pathogenic/con-
flicting, but also 4019 “benign” variants in dominant and
recessive genes. We report new findings from associations of
coding variants with population wide electronic health record
data in FinnGen.
H. O. Heyne: None. J. Karjalainen: None. S. M.
Lemmelä: None. A. S. Havulinna: None. M. Kurki: None.
A. Palotie: None. M. J. Daly: E. Ownership Interest (stock,
stock options, patent or other intellectual property); Modest;
Maze Therapeutics.
C10.2
Germline genetic testing following tumor sequencing in
cancer patients has a remarkably high yield of clinically
important findings that inform patient care
S. Lincoln*, K. Das, N. Ngo, S. Michalski, S. Yang, D.
Pineda, E. Esplin, S. Aradaya, R. Nussbaum
Invitae, San Francisco, CA, United States
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Introduction: Recent ESMO guidelines recommend
germline genetic testing following tumor sequencing, but
only for certain genes in specific patients (PMID
31050713). We examined the utility of germline findings in
patients receiving both test types.
Methods:1849 consecutive patients were analyzed, who:
(a) received germline testing, and (b) previously had
received tumor sequencing. Indications for germline testing
were diverse and included: tumor findings of potential
germline origin, treatment/surgical planning, personal/
family history, and patient concern. 238 patients had
colorectal cancer, 227 breast, 208 prostate, 189 lung, 173
pancreas, and the remainder had other cancers. 12% had
multiple primary diagnoses.
Results: 31% of patients harbored a high or moderate
penetrance pathogenic germline variant (PGV) in a known
cancer predisposition gene. Mutations in certain genes
were more likely to be germline compared to others
(Table) and PGVs were prevalent among most cancer
types studied. Most PGVs were potentially actionable, but
25% of PGVs failed to meet ESMO criteria for germline
testing. 8.6% of PGVs were not reported by tumor
sequencing as either somatic or germline findings, often
because of test limitations. 9.3% of patients had PGVs
identified only after presenting with a second, possibly
preventable, cancer.
Conclusions: Germline testing following tumor sequen-
cing often produces clinically important findings. Our
results suggest that such testing may however be under-
utilized and that guidelines for reflex testing appear
effective although conservative.
Germline and Somatic Findings in 1849 Patients (Genes with no









BRCA1/2 765 295 (39%) Yes MG, PT, CT
ATM 136 58 (43%) No MG, CT
MLH1, MSH2,
MSH6, PMS2
182 55 (30%) Yes MG, PT, CT
CHEK2 68 49 (72%) No MG, CT
PALB2 60 44 (73%) Yes MG, CT
BRIP1 24 10 (42%) Yes MG, CT
TP53 357 14 (4%) 10/14 No* MG, CT
RET 23 8 (35%) Yes MG, CT
BAP1 33 7 (21%) 3/7 No* MG, CT
CDKN2A 105 6 (6%) No MG
NF1 41 6 (15%) Yes MG
SDHA 13 5 (39%) Yes MG
FH 6 5 (83%) 3/5 No* MG
(continued)
Germline and Somatic Findings in 1849 Patients (Genes with no









NBN 11 5 (46%) No MG, CT
CDH1 67 4 (6%) No MG
RAD51C 4 4 (100%) Yes MG, CT
Others 312 28 (9%) varies varies
*ESMO criteria for this gene specify patient age and/or tumor types
**MG: Management Guidelines, PT: Precision Therapy (FDA), CT:
Clinical Trials
S. Lincoln: A. Employment (full or part-time); Signifi-
cant; Invitae. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Illumina,
Thermo Fisher. K. Das: A. Employment (full or part-time);
Significant; Invitae. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Amarin Dx. F. Consultant/Advisory Board; Modest;
Amarin Dx. N. Ngo: A. Employment (full or part-time);
Significant; Invitae. S. Michalski: A. Employment (full or
part-time); Significant; Invitae. S. Yang: A. Employment
(full or part-time); Significant; Invitae. D. Pineda: A.
Employment (full or part-time); Significant; Invitae. E.
Esplin: A. Employment (full or part-time); Significant;
Invitae. S. Aradaya: A. Employment (full or part-time);
Significant; Invitae. R. Nussbaum: A. Employment (full or
part-time); Significant; Invitae.
C10.3
The first genotype-phenotype study on European
carriers of CDH1 germline mutations
J. García-Peláez1*, R. Monteiro1, L. Sousa1, H. Pinheiro1,
S. Castedo1,2,3, L. Garrido2, M. Teixeira4,5, G. Michils6, V.
Bours7,8,5, R. de Putter9,5, L. Golmard & M. Blanluet10, C.
Colas10,5, P. Benusiglio11, S. Aretz & I. Spier12,13,5, R.
Hüneburg13,14, L. Gieldon15,16, E. Schröck15,16,5, E.
Holinski-Feder & V. Steinke17,18,5, D. Calistri & G.
Tedaldi19, G. Ranzani20, M. Genuardi21,22, C. Silveira & I.
Silva23, M. Krajc & A. Blatnik24,5, S. Novakovic24, A.
Patiño-García25, J. Soto26, C. Lázaro27,5, G. Capellá27,5, J.
Brunet-Vidal28,5, J. Balmaña29,5, E. Domínguez-Garrido30,
M. Ligtenberg31,5, E. Fewings32, R. Fitzgerald33, E.
Woodward34,35,5, G. Evans36,5, H. Hanson37, K. Lagerstedt-
Robinson38, S. Bajalica-Lagercrantz38,5, C. Egas39, C.
Martínez-Bouzas et al.40,41, K. Dahan & D. Feret42, N.
Hoogerbrugge31,5, M. Tischkowitz32,5, C. Oliveira43
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1IPATIMUP/i3S, Porto, Portugal, 2Centro Hospitalar
Universitário São João (CHSJ), Porto, Portugal, 3Faculty
of Medicine of the University of Porto (FMUP), Porto,
Portugal, 4IPO, Instituto Português de Oncologia do Porto,
Porto, Portugal, 5European Reference Network on Genetic
Tumour Risk Syndromes (ERN GENTURIS), Nijmegen,
Netherlands, 6Centre for Human Genetics, KU Leuven,
Leuven, Belgium, 7Laboratory of Human Genetics, GIGA-
Institute, University of Liège, Liège, Belgium, 8Center of
Genetics, University Hospital (CHU), Liège, Belgium,
9Clinical Genetics department, University Hospital of
Ghent, Ghent, Belgium, 10Genetic Department, Institut
Curie, Paris, France, 11Département de Génétique, GH
Pitié-Salpêtrière, Paris, France, 12Institute of Human
Genetics, University of Bonn, Bonn, Germany, 13National
Center for Hereditary Tumor Syndromes, University of
Bonn, Bonn, Germany, 14Department of Internal Medicine
I, University Hospital Bonn, Bonn, Germany, 15Institut für
Klinische Genetik, Medizinische Fakultät Carl Gustav
Carus, Dresden, Technische Universität Dresden, Dresden,
Germany, 16Core Unit for Molecular Tumordiagnostics
(CMTD), National Center for Tumor Diseases (NCT) site
Dresden, German Cancer Research Center (DKFZ)Heidel-
berg, German Cancer Consortium (DKTK), Dresden,
Germany, 17Medizinische Klinik und Poliklinik IV, Campus
Innenstadt, Klinikum der Universität München, Ziems-
senstr, Münich, Germany, 18MGZ - Medizinisch Genet-
isches Zentrum, Münich, Germany, 19Biosciences
Laboratory, Istituto Scientifico Romagnolo per lo Studio e
la Cura dei Tumori (IRST) IRCCS, Meldola, Italy,
20Department of Biology and Biotechnology “Lazzaro
Spallanzani”, University of Pavia, Pavia, Italy, 21Fonda-
zione Policlinico Universitario “A. Gemelli” IRCCS, UOC
di Genetica Medica, Rome, Italy, 22Istituto di Medicina
Genomica, Università Cattolica del Sacro Cuore, Rome,
Italy, 23Genomed Diagnósticos de Medicina Molecular, S.
A., Lisbon, Portugal, 24Institute of Oncology Ljubljana,
Department of Molecular Diagnostics, Ljubljana, Slovenia,
25Clinical Genetics Unit and CIMA LAB Diagnostics.
University Clinic of Navarra, Pamplona, Spain, 26Molecu-
lar Genetics Laboratory, Elche University Hospital, Elche,
Spain, 27Catalan Institute of Oncology, IDIBELL, CIBER-
ONC, Barcelona, Spain, 28Catalan Institute of Oncology,
IDIBELL, IDIBGI, Barcelona-Girona, Portugal, 29Hospital
Vall d’Hebron, Barcelona, Spain, 30Molecular Diagnostics
Laboratory, Fundación Rioja Salud, Logroño, Spain,
31Department of Human Genetics, Radboud University
Medical Center and Radboud Institute for Molecular Life
Sciences, Nijmegen, Netherlands, 32Academic Laboratory
of Medical Genetics. National Institute for Health Research
Cambridge Biomedical Research Centre, Cambridge, UK
University of Cambridge, Cambridge, United Kingdom,
33MRC Cancer Unit, Hutchison-MRC Research Centre,
University of Cambridge, Cambridge, United Kingdom,
34NW Genomic Laboratory hub, Manchester Centre for
Genomic Medicine, Manchester University Hospitals NHS
Foundation Trust, Manchester, United Kingdom, 35Division
of Evolution and Genomic Sciences, School of Biological
Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, Manchester Academic Health
Science Centre, Manchester, United Kingdom, 36Manche-
ster Centre for Genomic Medicine, Manchester Centre for
Genomic Medicine, Manchester, United Kingdom, 37St
Georges NHS Foundation Trust, London, United Kingdom,
38Department of Molecular Medicine and Surgery, Kar-
olinska Institutet and Department of Clinical Genetics,
Karolinska Univ Hospital, Stockholm, Sweden, 39Advanced
Services Unit, Biocant - Biotechnology Innovation Center,
Cantanhede, Portugal, 40Biocruces Health Research Insti-
tute, Barakaldo, Spain, 41Molecular Genetics Laboratory,
Genetics Service, Cruces University Hospital, Barakaldo,
Spain, 42Institut de Génétique et de Pathologie, IPG,
Gosselies, Belgium, 43i3S & Ipatimup & FMUP & ERN-
GENTURIS & CDH1-ClinGen working Group, Porto,
Portugal
Hereditary Diffuse Gastric Cancer-HDGC syndrome, pre-
disposing for diffuse gastric cancer-DGC and lobular breast
cancer-LBC, is caused by germline CDH1 Pathogenic-P
and Likely Pathogenic-LP variants. Surveillance/prophy-
lactic surgery is life-saving in asymptomatic carriers, but
clinical management remains challenging in carriers lacking
clinical criteria. Through genotype-phenotype analysis in P/
LP variant carrier-families, we studied CDH1-associated
spectrum and age-of-disease onset to optimize clinical
management. We collected/curated variant classification,
family phenotypes and clinical-criteria of 506 coding and
splice-site CDH1-variant’ carriers, registering 1361 pheno-
types of 1302 family members from 10 European ERN-
GENTURIS countries. From 506 families, 160 (31.6%)
fulfilled HDGC clinical-criteria and 87.5% of these carried
P/LP actionable variants (96.4% truncating). From 346
(68.3%) families lacking criteria, 13.3% carried such var-
iants (100% truncating). Among P/LP-variant bearing
families fulfilling criteria, 48% of family phenotypes was
DGC and 6% was LBC, both before 50 and without
enrichment of other cancer types. In families lacking cri-
teria, LBC increases to 24%, and DGC drops to 8%, still in
the 40-50 age-range. CDH1 missense variant carrier-
families were almost completely excluded after clinical
classification. Still, the ones remaining as P/LP revealed an
enrichment in non-specified breast cancer and other cancer
types, rarely presenting DGC and LBC. This is the first P/
LP CDH1 variant-driven genotype-phenotype analysis. It
demonstrates that clinically-actionable CDH1 variants are
mainly truncating, most carriers fulfill HDGC clinical-
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criteria, reinforcing use in clinical practice; supports 50 as
the upper age-limit for CDH1 testing; supports widening
criteria to accommodate family history of LBC, and; high-
light a likely irrelevant role of missense variants in HDGC.
J. García-Peláez: None. R. Monteiro: None. L. Sousa:
None. H. Pinheiro: None. S. Castedo: None. L. Garrido:
None. M. Teixeira: None. G. Michils: None. V. Bours:
None. R. de Putter: None. L. Golmard & M. Blanluet:
None. C. Colas: None. P. Benusiglio: None. S. Aretz & I.
Spier: None. R. Hüneburg: None. L. Gieldon: None. E.
Schröck: None. E. Holinski-Feder & V. Steinke: None. D.
Calistri & G. Tedaldi: None. G. Ranzani: None. M.
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None. J. Soto: None. C. Lázaro: None. G. Capellá: None. J.
Brunet-Vidal: None. J. Balmaña: None. E. Domínguez-
Garrido: None. M. Ligtenberg: None. E. Fewings: None. R.
Fitzgerald: None. E. Woodward: None. G. Evans: None. H.
Hanson: None. K. Lagerstedt-Robinson: None. S. Bajalica-
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et al.: None. K. Dahan & D. Feret: None. N. Hoogerbrugge:
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C10.4
Enhancing rare variant interpretation in inherited
arrhythmias through quantitative analysis of 5182 cases
from long QT syndrome and Brugada syndrome
consortia cohorts and gnomAD population controls
R. Walsh1*, N. Lahrouchi1, C. Glinge1,2, C. Krijger1, D.
Skoric-Milosavljevic1, N. Whiffin3, F. Mazzarotto4, J. S.
Ware3, R. Tadros5, International Brugada Syndrome
Genetics Consortium, International LQTS Genetics
Consortium, C. R. Bezzina1
1Amsterdam UMC, Amsterdam, Netherlands, 2Copenhagen
University Hospital, Copenhagen, Denmark, 3Imperial
College, London, United Kingdom, 4University of Florence,
Florence, Italy, 5Montreal Heart Institute, Montreal, QC,
Canada
Introduction: Guidelines for variant interpretation in
Mendelian disease set stringent criteria to report variants as
(likely) pathogenic, prioritising control of false positive rate
over test sensitivity and diagnostic yield, and require cus-
tomisation for the specific genetic characteristics of gene-
disease dyads. Inherited arrhythmias like long QT syndrome
(LQTS) and Brugada syndrome (BrS) are genetically het-
erogeneous, with missense variants constituting the pre-
ponderance of disease-causing variants. Evidence from
family segregation or functional assays to confirm patho-
genicity are often unavailable or impractical in clinical
genetic testing, leading to high rates of variants of uncertain
significance and false negative test results.
Materials and Methods: We compared rare variant
frequencies from 1847 LQTS (KCNQ1,KCNH2,SCN5A)
and 3335 BrS (SCN5A) cases from the International LQTS/
BrS Genetics Consortia to population-specific gnomAD
data. We propose disease-specific criteria for ACMG/AMP
evidence classes - rarity (PM2/BS1 rules) and enrichment of
individual (PS4) and domain-specific (PM1) variants in
cases over controls.
Results: Rare SCN5A variant prevalence differed between
BrS cases with spontaneous (28.7%) versus induced
(15.8%) type 1 Brugada ECG (p= 1.3 × 10−13) and
between European (20.8%) and Japanese (8.9%) patients
(p= 8.8 × 10−18). Transmembrane regions and specific N-
terminus (KCNH2) and C-terminus (KCNQ1/KCNH2)
domains were characterised by high enrichment of case
variants and >95% probability of pathogenicity. Applying
the customised rules, 17.5% of European BrS cases and
73.7% of European LQTS cases had variants classified as
(likely) pathogenic, compared to estimated diagnostic yields
(case excess over gnomAD) of 19.3%/82.6%.
Conclusions: Large case/control datasets enable quanti-
tative implementation of ACMG/AMP guidelines and
increased sensitivity for inherited arrhythmia genetic testing.
R. Walsh: None. N. Lahrouchi: None. C. Glinge: None.
C. Krijger: None. D. Skoric-Milosavljevic: None. N.
Whiffin: None. F. Mazzarotto: None. J. S. Ware: None.
R. Tadros: None. C. R. Bezzina: None.
C10.5
Genome wide association study based on cardiac magnetic
resonance imaging in 23,634 individuals identifies five new
loci associated with left atrial enlargement
G. Ahlberg1,2*, L. Andreasen1,2, J. Ghouse1,2, S. Haunsoe1,3,
J. H. Svendsen3,4, M. S. Olesen1,2
1Laboratory for Molecular Cardiology, Department of
Cardiology, Centre for Cardiac, Vascular, Pulmonary
and Infectious Diseases, Rigshospitalet, University Hospital
of Copenhagen, Copenhagen, Denmark, 2Department of
Biomedical Sciences, University of Copenhagen, Copenha-
gen, Denmark, 3Department of Clinical Medicine, Uni-
versity of Copenhagen, Copenhagen, Denmark,
4Department of Cardiology, Centre for Cardiac, Vascular,
Pulmonary and Infectious Diseases, Rigshospitalet, Uni-
versity Hospital of Copenhagen, Copenhagen, Denmark
Background: Left atrial enlargement is associated with
mortality due to cardiovascular disease. The pathology
behind and the association with cardiovascular outcomes
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are, however, poorly characterised. Compromised atrial
function predisposes for stroke.
Methods: We obtained data from the UK Biobank
cardiovascular magnetic resonance (CMR) protocol con-
taining CMR scans from ~31,000 individuals at the time of
study. Genome-wide association studies were carried out on
state-of-the-art imaging variables exposed to machine
learning algorithms to investigate the genetic basis of left
atrial volume and function.
Results: We tested 10.6 million variants for association
with left atrial (LA) minimum/maximum volumes and LA
emptying fraction in 23,624 European individuals without
prevalent myocardial infarction or heart failure. We
identified five genetic loci located in close proximity to
the genes EIF2D, C9orf3, ANKRD1, FGFR2, andMYO18B.
We observed a notable genetic correlation between both
maximum and minimum LA volumes and stroke and
cardioembolic stroke.
Conclusions: We report on five genetic loci and suggest
several plausible candidate genes important for atrial
structural pathology. Genetic correlation analyses indicate
that the genetic determinants of LA volumes could be
markers of stroke risk. These findings enhance our under-
standing of the importance of the LA and are potential novel
therapeutic targets for cardiovascular disease, including
stroke.
G. Ahlberg: None. L. Andreasen: None. J. Ghouse: None.
S. Haunsoe: None. J. H. Svendsen: None. M. S.
Olesen: None.
C10.6
Genetic interactions modulate lipid plasma levels and
cellular uptake
M. Zimon1*, Y. Huang2, A. Trasta1, J. Liu2, C. Chen2, A.
Halavatyi1, P. Blattmann1, B. Klaus1, C. Whelan2, D.
Sexton2, S. John2, E. Tsai2, W. Huber1, R. Pepperkok1, H.
Runz2
1EMBL, Heidelberg, Germany, 2Biogen Inc., Cambridge,
MA, United States
Introduction: Genetic Interactions (GIs), where variants in
two genes collectively cause non-additive phenotypes dif-
ferent from the sum of the variants’ individual effects, are
considered a foundational element in the genetic archi-
tecture of complex traits. In humans, however, GIs have
remained largely elusive. Here, we combined exome-
sequencing and genotyping in the UK Biobank with sys-
tematic cell-based RNA-interference (RNAi) to assess
whether GIs between lipid genes contribute to changes in
plasma lipid levels as risk factors for coronary artery
disease (CAD).
Materials and Methods: We systematically tested for
modifier effects between 30 lipid-regulatory genes derived
from GWAS loci associated with plasma LDL, HDL, TG,
TC or CAD using robust linear model fitting with three
complementary data types: protein-truncating variants
(PTVs) from whole-exome sequencing of 161,508 UK
Biobank participants; GWAS lead SNPs from 378,033
UK Biobank participants; and results from a combinator-
ial RNAi screen measuring cellular LDL-uptake.
Results: We show that additive effects between lipid
genes are pervasive, consistent with the use of summed
effect sizes in polygenic risk scores. Yet, all three
approaches also indicated existence of non-additive GIs,
with one GI identified from PTV-based, 26 from SNP-
based, and 20 from cell-based analyses, respectively.
Integrating genetic and functional data validated three
GIs as modulating both plasma lipid levels and cellular
uptake.
Conclusions: Our combined genetic and functional
analyses propose distinct gene pairs that modulate plasma
and cellular lipid levels via additive and non-additive
effects. Our results can help prioritize drug target pairs for
the development of lipid-lowering combination therapies.
M. Zimon: None. Y. Huang: A. Employment (full or part-
time); Significant; Biogen Inc. E. Ownership Interest (stock,
stock options, patent or other intellectual property);
Significant; Biogen Inc. A. Trasta: None. J. Liu: A.
Employment (full or part-time); Significant; Biogen Inc.
E. Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Biogen Inc. C. Chen: A.
Employment (full or part-time); Significant; Biogen Inc. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Biogen Inc. A. Halavatyi:
None. P. Blattmann: None. B. Klaus: None. C. Whelan: A.
Employment (full or part-time); Significant; Biogen Inc. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Biogen Inc. D. Sexton:
A. Employment (full or part-time); Significant; Biogen Inc.
E. Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Biogen Inc. S. John: A.
Employment (full or part-time); Significant; Biogen Inc. E.
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None. R. Pepperkok: None. H. Runz: A. Employment (full
or part-time); Significant; Biogen Inc. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
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C11 Multiple Malformation Syndromes I
C11.1
Biallelic variants in KYNU cause a multisystemic syn-
drome with hand hyperphalangism
N. Ehmke1*, K. Cusmano-Ozog2, R. Koenig3, M.
Holtgrewe4,5, B. Nur6, E. Mihci6, H. Babcock7, C. Gonzaga-
Jauregui8, J. D. Overton9, J. Xiao10, B. Fischer-Zirnsak1, C.
Huber11, U. Kornak1, S. H. Elsea12, V. Cormier-Daire13, C.
R. Ferreira14,15
1Institute of Medical Genetics and Human Genetics, Berlin,
Germany, 2Biochemical Genetics and Metabolism Labora-
tory, Children’s National Medical Center, Washington, DC,
United States, 3Department of Human Genetics, University
of Frankfurt, Frankfurt, Germany, 4Core Unit Bioinfor-
matics – CUBI, Berlin Institute of Health, Berlin, Germany,
5Charité - Universitätsmedizin Berlin, Berlin, Germany,
6Department of Pediatric Genetics, Akdeniz University
Medical School, Antalya, Turkey, 7Rare Disease Institute,
Children’s National Health System, Washington, DC,
United States, 8Regeneron Genetics Center, Regeneron
Pharmaceuticals Inc. Tarrytown, Tarrytown, NY, United
States, 9Regeneron Genetics Center, Regeneron Pharma-
ceuticals Inc. TarrytownInstitute of Medical Genetics and
Human Genetics, Tarrytown, NY, United States, 10Depart-
ment of Molecular and Human Genetics, Baylor College of
Medicine, Houston, TX, United States, 11Department of
Genetics, INSERM UMR 1163, Université Paris Descartes-
Sorbonne Paris Cité, Institut Imagine, AP-HP, Hôpital
Necker Enfants MaladesInstitute of Medical Genetics and
Human Genetics, Paris, France, 12Department of Molecu-
lar and Human Genetics, Baylor College of MedicineIn-
stitute of Medical Genetics and Human Genetics, Houston,
TX, United States, 13Department of Genetics, INSERM
UMR 1163, Université Paris Descartes-Sorbonne Paris
Cité, Institut Imagine, AP-HP, Hôpital Necker Enfants
Malades, Paris, France, 14Institute of Medical Genetics and
Human GeRare Disease Institute, Children’s National
Health Systemnetics, Washington, DC, United States,
15National Human Genome Research Institute, National
Institutes of Health, Bethesda, MD, United States
Catel-Manzke syndrome is characterized by the combina-
tion of Pierre Robin sequence and radial deviation, short-
ening as well as clinodactyly of the index fingers, due to an
accessory ossification center. Mutations in TGDS have been
identified as one cause of Catel-Manzke syndrome, but
cannot be found as causative in every patient with the
clinical diagnosis. We performed a chromosome microarray
and/or exome sequencing in three patients with hand
hyperphalangism, heart defect, short stature, and mild to
severe developmental delay, all of whom were initially
given a clinical diagnosis of Catel-Manzke syndrome. In all
patients, we detected biallelic variants in KYNU, mainly
missense variants. Plasma and urine metabolomic analysis
of two patients indicated a block along the tryptophan
catabolic pathway and urine organic acid analysis showed
excretion of xanthurenic acid. Biallelic loss-of-function
mutations in KYNU were recently described as a cause of
NAD deficiency with vertebral, cardiac, renal and limb
defects; however, no hand hyperphalangism and excretion
of xanthurenic acid were described in those patients, and
Catel-Manzke syndrome was not discussed as a differential
diagnosis. In conclusion, we present unrelated patients
identified with biallelic variants in KYNU leading to
kynureninase deficiency and xanthurenic aciduria as a very
likely cause of their hyperphalangism, heart defect, short
stature, and developmental delay. We found urine organic
acid analysis as a simple method that will facilitate differ-
ential diagnosis in patients with hyperphalangism and sus-
pected Catel-Manzke syndrome. Funding resources: Rahel-
Hirsch program (Charité); Intramural Research Program,
National Human Genome Research Institute, National
Institutes of Health.
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None. M. Holtgrewe: None. B. Nur: None. E. Mihci: None.
H. Babcock: None. C. Gonzaga-Jauregui: A. Employment
(full or part-time); Significant; Regeneron Genetics Center
from Regeneron Pharmaceuticals Inc. J. D. Overton: None.
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C11.2
Integrated genome and transcriptome analyses solves
about one third of the patients with rare developmental
disorders and negative first-line molecular investigations
A. Vitobello1,2*, F. Tran Mau-Them1,2, A. L. Bruel1,2, Y.
Duffourd1, E. Tisserant1, P. Callier1,2, S. Moutton1,3, S.
Nambot1,3, D. Lehalle1,3, N. Jean-Marçais3, J. Delanne1,3,
C. Racine1, J. Thevenon3, C. Poe1, T. Jouan1, M. Chevarin1,
M. Willems4, C. Coubes4, D. Geneviève4,5, N. Houcinat1,3,
A. Masurel-Paulet3, A. Mosca-Boidron1,2, A. Sorlin1,2,3, B.
Isidor6, S. Heide7, A. Afenjar8, D. Rodriguez9, C. Mignot7,
D. Heron7, M. Vincent6, P. Charles7, S. Odent10, C.
Dubourg11, A. Faudet7, B. Keren7, B. Cogné12, A. Boland13,
R. Olaso13, C. Philippe1,2, J. F. Deleuze13, L. Faivre1,3, C.
Thauvin-Robinet1,2,3
1Inserm UMR 1231 GAD team, Genetics of Developmental
disorders, Université de Bourgogne-Franche Comté, Dijon,
France, 2Unité Fonctionnelle d’Innovation diagnostique
des maladies rares, Pôle de Biologie, CHU Dijon
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Bourgogne, Dijon, France, 3Centre de Référence maladies
rares « Anomalies du Développement et syndrome mal-
formatifs » de l’Est, Hôpital d’Enfants, CHU Dijon
Bourgogne, Dijon, France, 4Département de Génétique
Médicale, Maladies Rares et Médecine Personnalisée,
Centre de Référence Maladies Rares Anomalies du
Développement et Syndromes Malformatifs ADSOOR,
CHU Montpellier, Montpellier, France, 5Université Mon-
tpellier, Unité Inserm U1183, Montpellier, France, 6CHU
de Nantes, Service de Génétique Médicale, Nantes, France,
7AP-HP, Département de Génétique, Hôpital de la Pitié-
Salpêtrière, 75013, Paris, France et Centre de Référence
"déficiences intellectuelles de causes rares", 75013, Paris,
France, 8APHP, Département de génétique et embryologie
médicale, Hôpital Armand Trousseau, F-75012, Paris,
France, 9Centre de Référence de Neurogénétique et Service
de Neurologie Pédiatrique, AP-HP, Hôpital Armand
Trousseau, GHUEP ; Sorbonne Université, GRC n°19,
pathologies Congénitales du Cervelet-LeucoDystrophies,
Paris, France, 10CHU de RENNES, Génétique; Univ
Rennes, CNRS, IGDR (Institut de Génétique et Développe-
ment de Rennes) UMR 6290, Rennes, France, 11Service de
Génétique Moléculaire et Génomique, BMT-HC « Jean
Dausset », CHU Pontchaillou, 2 rue Henri Le Guilloux,
35033, Rennes, France, 12L’institut du thorax, INSERM,
CNRS, UNIV Nantes, CHU de Nantes, Nantes, France.,
Nantes, France, 13Centre National de Recherche en
Génomique Humaine (CNRGH), Institut de Biologie
François Jacob, CEA, Université Paris-Saclay and LabEx
GENMED, F-91057, Evry, France
Exome sequencing (ES) represents the first-tier diagnostic
test in patients presenting with syndromic developmental
delay with suspected monogenic etiology. Yet, about 50%
of these patients remain unsolved, arguing the interest to
extend the genetic investigations beyond the protein-coding
genome and to integrate multi-omics approaches. We
launched a multi-centric pilot study gathering 53 unsolved
patients, after trio ES and array-CGH results, presenting
with heterogeneous mild to severe syndromic intellectual
disabilities. We performed genome sequencing (GS) com-
bined with transcriptome analysis, highlighting a molecular
cause in 32% of the cohort (18/53 patients). GS identified 7
causative structural variants, including 1 deletion, 2
balanced inversions, 1 balanced translocation and 3 com-
plex variants. The molecular readouts of such variants were
all validated and furtherly investigated by RNAseq. One
deep intronic SNV causing the activation of a cryptic exon,
changing the open reading frame of the transcript, was
detected by RNAseq. Two frameshift-causing indels were
identified in protein-coding regions not captured by ES.
Three variants were identified in genes not yet known as
disease-causing at the time of the ES analysis. Finally,
genotype-phenotype correlation could establish 3 additional
diagnoses not identified during the ES analysis. In addition,
we detected 2 complex structural variants of unknown
significance, not resolvable by short-read GS, as well as
new candidate genes identified through RNA-seq differ-
ential expression analysis. Overall, GS and RNAseq ana-
lyses allowed the identification of the molecular
mechanisms underlying 1/3 of previously unsolved patients,
and additional candidate variants requiring further investi-
gation (3rd-generation sequencing, 3C techniques) to
demonstrate their causality.
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D. Rodriguez: None. C. Mignot: None. D. Heron: None. M.
Vincent: None. P. Charles: None. S. Odent: None. C.
Dubourg: None. A. Faudet: None. B. Keren: None. B.
Cogné: None. A. Boland: None. R. Olaso: None. C.
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C11.3
Characterization and treatment of overactive KATP
channels associated with Cantú syndrome in zebrafish
H. I. Roessler1*, S. S. Singareddy2, C. McClenaghan2, S.
Savelberg1, F. Tessadori3, J. Bakkers3, R. Tyron2, C. G.
Nichols2, G. van Haaften1
1Department of Genetics, Center for Molecular Medicine,
University Medical Center Utrecht, Utrecht, Netherlands,
2Department of Cell Biology and Physiology, and Center
for the Investigation of Membrane Excitability Diseases
(CIMED), Washington University, St. Louis, MO, United
States, 3Hubrecht Institute-KNAW and University Medical
Centre Utrecht, Utrecht, Netherlands
Cantú Syndrome (CS) is a rare genetic disorder caused by
gain-of-function (GoF) mutations in genes encoding the
pore-forming (Kir6.1, KCNJ8) and regulatory (SUR2,
ABCC9) subunits of cardiovascular ATP-sensitive potas-
sium (KATP) channels. CS patients consistently present with
hypertrichosis and facial anomalies alongside a varying
range of cardiovascular abnormalities. CS is debilitating
with no targeted therapy available. To further elucidate the
complex pathophysiology of CS and to perform therapeutic
drug screening, we introduced patient-specific point
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mutations in the germline of zebrafish orthologues of
ABCC9 and KCNJ8. Applying RT-PCR and patch-clamp-
ing of isolated ventricular cardiomyocytes (VCMs) and
vascular smooth muscle cells (VSMCs) we confirm for the
first time that expression, composition and functional
properties of cardiovascular KATP channels are conserved
between zebrafish and mammals. CS-related GoF in mutant
fish was validated and is reflected by a shift in ATP sen-
sitivity in VCMs and a greater basal K conductance in
VSMCs. It is postulated that by directly targeting over-
active KATP channels repurposing channel blockers, it may
be possible to reverse consequences of GoF. Thus, we
tested the in vivo efficacy of glibenclamide and repaglinide,
clinically applied to block GoF KATP channels involved in
neonatal diabetes, and the Kir6.1 inhibitor PNU-37883.
Glibenclamide resulted in significant correction of CS car-
diac phenotypes in abcc9 knock-in (KI) larvae, whereas
repaglinide revealed similar effects in kcnj8 KI mutants.
These results indicate that zebrafish represent a suitable
model to study pathophysiology and therapy options for CS
and further disorders involving aberrant cardiovascular
KATP channels.
E-Rare 2014 ‘CantuTreat’ (I-2101-B26) to GvH.
H. I. Roessler: None. S. S. Singareddy: None. C.
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C11.4
Biallelic MADD variants cause a phenotypic spectrum
ranging from developmental delay to a multisystem
disorder
P. E. Schneeberger1*, F. Kortüm1, G. C. Korenke2, M.
Alawi3, R. Santer4, M. Woidy4, D. Buhas5, S. Fox5, D.
McKnight6, M. Alfadhel7, B. D. Webb8, E. G. Coci9, R.
Abou Jamra10, A. Finck10, M. Siekmeyer11, S. Biskup12, C.
Heller12, E. M. Maier13, P. Javaher-Haghighi14, M. F.
Bedeschi15, P. F. Ajmone16, M. Iascone17, H. Peeters18, K.
Ballon19, J. Jaeken20, A. Rodríguez Alonso21, M.
Palomares-Bralo22, F. Santos-Simarro22, M. E. C.
Meuwissen23, D. Beysen24, R. Kooy25, H. Houlden26, D.
Murphy26, M. Doosti27, E. G. Karimiani27, M. Mojarrad28,
R. Maroofian26, B. D. Gelb8, I. Kurth29, M. Hempel1, K.
Kutsche1
1Institute of Human Genetics, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, 2Klinik für
Neuropädiatrie und angeborene Stoffwechselerkrankungen,
Klinikum Oldenburg, Oldenburg, Germany, 3Bioinfor-
matics Core Unit, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany, 4Department of Pediatrics,
University Medical Center Hamburg-Eppendorf, Hamburg,
Germany, 5Division of Medical Genetics, Department of
Specialized Medicine, McGill University Health Centre,
Montreal, QC, Canada, 6GeneDx, Gaithersburg, MD,
United States, 7Division of Genetics, Department of
Pediatrics, King Abdullah specialized Children’s Hospital,
Riyadh, Saudi Arabia, 8Department of Genetics and
Genomic Sciences, Icahn School of Medicine at Mount
Sinai, New York, NY, United States, 9Department for
Neuropediatrics, University Children’s Hospital, Ruhr
University Bochum, Bochum, Germany, 10Institute of
Human Genetics, University Medical Center Leipzig,
Leipzig, Germany, 11Universitätsklinikum Leipzig - AöR,
University of Leipzig, Hospital for Children and Adoles-
cents, Leipzig, Germany, 12CeGaT GmbH and Praxis für
Humangenetik Tübingen, Tübingen, Germany, 13Dr. von
Hauner Children’s Hospital, University of Munich, Munich,
Germany, 14Medicover Humangenetik Hannover, Hanover,
Germany, 15Medical Genetic Unit, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milan, Italy,
16Child and Adolescent Neuropsychiatric Unit, Fondazione
IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan,
Italy, 17Laboratorio di Genetica Medica, ASST Papa
Giovanni XXIII, Bergamo, Italy, 18Center for Human
Genetics, KU Leuven, Leuven, Belgium, 19Centre for
Developmental Disabilities, Department of Development
and Regeneration, KU Leuven, Leuven, Belgium, 20Center
for Metabolic Diseases, KU Leuven, Leuven, Belgium,
21Unidad de Patología Compleja, Servicio de Pediatría,
Hospital Universitario La Paz, Madrid, Spain, 22Instituto
de Genética Médica y Molecular, Hospital Universitario La
Paz, IdiPAZ, CIBERER, ISCIII, Madrid, Spain, 23Center of
Medical Genetics, University Hospital Antwerp, Antwerp,
Belgium, 24Department of Pediatric Neurology, University
Hospital Antwerp, Antwerp, Belgium, 25Department of
Medical Genetics, University of Antwerp, Antwerp, Bel-
gium, 26Department of Neuromuscular Diseases, UCL
Queen Square Institute of Neurology and The National
Hospital for Neurology and Neurosurgery, London, United
Kingdom, 27Next Generation Genetic Polyclinic, Mashhad,
Iran, Islamic Republic of, 28Department of Medical
Genetics, Mashhad University of Medical Sciences, Mash-
had, Iran, Islamic Republic of, 29Institute of Human
Genetics, RWTH Aachen University, Aachen, Germany
We report a new pleiotropic disorder with a unique con-
stellation of neurological, endocrine, exocrine, and hema-
tological findings that is caused by biallelic MADD variants.
MADD, the mitogen-activated protein kinase (MAPK)
activating death domain protein, regulates various cellular
functions, such as vesicle trafficking, activity of the Rab3
and Rab27 small GTPases, tumor necrosis factor-α (TNF-
α)-induced signaling and prevention of cell death. Through
international collaboration, we collected 20 patients with 18
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different pathogenic MADD variants identified by next-
generation sequencing. We clinically evaluated the patients
and categorized the phenotypes in two groups. Eleven
patients in Group 1 had severe developmental delay,
endocrine and exocrine dysfunction, impairment of sensory
and autonomic nervous system, and hematological anoma-
lies. Nine patients in Group 2 presented with predominant
neurological phenotype comprising developmental delay,
hypotonia, speech impairment, and seizures. Relative
quantification of MADD mRNA and protein in patients’
fibroblasts showed drastic reduction or loss of MADD.
Treatment of patient-derived fibroblasts with TNF-α resul-
ted in reduced phosphorylation of ERK1/2, enhanced acti-
vation of the pro-apoptotic caspase-3 and -7 and increased
apoptosis compared to control cells. Internalization study of
epidermal growth factor (EGF) in patient cells revealed a
defect in endocytosis of EGF. We conclude that MADD
deficiency underlies multiple cellular defects that can be
attributed to alterations of TNF-α-dependent signaling
pathways and defects in vesicular trafficking. Our data
highlights the multifaceted role of MADD as signaling
molecule in different organs and reveals its physiological
role in regulating the function of the sensory and autonomic
nervous system and endocrine and exocrine glands.
P. E. Schneeberger: None. F. Kortüm: None. G. C.
Korenke: None. M. Alawi: None. R. Santer: None. M.
Woidy: None. D. Buhas: None. S. Fox: None. D.
McKnight: None. M. Alfadhel: None. B. D. Webb: None.
E. G. Coci: None. R. Abou Jamra: None. A. Finck: None.
M. Siekmeyer: None. S. Biskup: None. C. Heller: None. E.
M. Maier: None. P. Javaher-Haghighi: None. M. F.
Bedeschi: None. P. F. Ajmone: None. M. Iascone: None.
H. Peeters: None. K. Ballon: None. J. Jaeken: None. A.
Rodríguez Alonso: None. M. Palomares-Bralo: None. F.
Santos-Simarro: None. M. E. C. Meuwissen: None. D.
Beysen: None. R. Kooy: None. H. Houlden: None. D.
Murphy: None. M. Doosti: None. E. G. Karimiani: None.
M. Mojarrad: None. R. Maroofian: None. B. D. Gelb: None.
I. Kurth: None. M. Hempel: None. K. Kutsche: None.
C11.5
Modelling the developmental spliceosomal craniofacial
disorder Burn-McKeown Syndrome using induced
pluripotent stem cells
K. A. Wood*, C. Rowlands, H. Thomas, S. Woods, J.
O’Flaherty, S. Kimber, W. Newman, R. O’Keefe
University of Manchester, Manchester, United Kingdom
The developmental craniofacial disorder Burn-McKeown
Syndrome (BMKS) is caused by compound heterozygous
mutations in the pre-messenger RNA splicing factor
TXNL4A/DIB1. Patients with BMKS have a 34 base pair
deletion in the promoter region of one allele of TXNL4A
combined with a loss-of-function mutation in the other
allele, resulting in reduced TXNL4A expression. However, it
is unclear how reduced expression of this spliceosome
protein results in craniofacial defects during development.
Here we reprogramme BMKS patient and parent blood cells
into induced pluripotent stem cells (iPSCs) and differentiate
the iPSCs into induced neural crest cells (iNCCs). We find
that patient-derived iPSCs proliferate more slowly than
parent- and unrelated control-derived iPSCs. Patient iPSCs
show defective differentiation into iNCCs compared to
parent and unrelated control iPSCs, in particular undergoing
an epithelial-to-mesenchymal transition. RNA-seq analysis
of the iNCCs reveals considerable differential gene
expression and mis-splicing in genes relevant to craniofacial
development. The mis-spliced genes share common physi-
cal properties such as length and splice site strengths, sug-
gesting that splicing of certain subsets of genes is
particularly sensitive to changes in TXNL4A expression. We
are comparing mis-expressed and mis-spliced genes in
iPSCs and iNCCs from patients with parent and unrelated
control lines to delineate why neural crest cells are parti-
cularly affected by reduced TXNL4A expression. Using this
disease-relevant model, we will study properties such as
migration and the cell cycle in patient-specific iNCCs to
unravel how BMKS-specific mutations in TXNL4A result in
craniofacial defects.
Grant references: MRC (1916606; 1926882), BBSRC
(BB/N000358/1), NIHR Manchester Biomedical Research
Centre (IS-BRC-1215-20007).
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C11.6
A novel Bannayan-Riley-Ruvalcaba (BRRS)/CLOVES
syndrome model in Xenopus tropicalis, by CRISPR/
Cas9
D. Dimitrakopoulou*, S. Demuynck, K. Vleminckx
Ghent Univeristy, Ghent, Belgium
Introduction: Xenopus has been widely used in disciplines
of developmental biology and functional genomics and the
CRISPR/Cas9 breakthrough has significantly expanded its
use for human disease modeling. Activating mutations in
the PIK3CA gene and PTEN loss of function mutations
generate PIK3CA-related overgrowth syndromes (PROS/
CLOVES) and Bannayan-Riley-Ruvalcaba (BRRS) syn-
drome, respectively. Although the genetic mutations that
drive these syndromes are different, disease phenotypes
68 J. del Picchia
overlap. Here we describe a BRRS/CLOVES model by
CRISPR/Cas9 targeting of the pten gene in X. tropicalis.
Materials and methods: X.tropicalis 4-cell stage
embryos were injected with pten+myc+notch1* and pten
+notch1* sgRNA complexed with Cas9. After 5 weeks,
froglets’ limbs and main body demonstrated overgrowths
and at critical point, animals were sacrificed. Overgrowths
and internal organs were histologically processed. The
mutation pattern of overgrowths was evaluated by targeted
deep sequencing.
Results: The pten mutant animals, that presented over-
growths were dissected. These animals demonstrated
muscle hyperthrophy and abdominal haemorrhage. Histo-
logical analysis characterized the overgrowths as lipoma-
tous tumors. Furthermore, immunohistochemical analysis of
lipomas demonstrated highly activated PI3K/AKT pathway.
Internal organs displayed disorganized architecture and
highly activated PI3K/AKT pathway. Samples from over-
growths were sequenced, revealing that bi-allelic inactiva-
tion of the pten gene is sufficient for CLOVES
development. Pten mutants will be used for validating our
model by testing BYL719, a PIK3CA inhibitor with
efficacy in treating human CLOVES patients.
Conclusion: We generated the first amphibian model in
BRRS/CLOVES syndrome. We believe that a Xenopus
tropicalis BRRS/CLOVES model could become a valid
experimental platform for further compound testing or
identification of new drug targets.




Polygenic background of psychotic disorders and
genetic determinants of disease severity
A. V. Ahola-Olli1*, Z. Misiewicz2, N. Mars2, M.
Lähteenvuo3, B. Neale1, T. Männynsalo4, E. Isometsä5, A.
Wegelius5, J. Hietala6, W. Haaki6, O. Kampman7, J.
Veijola8, J. Tiihonen3, T. Kieseppä9, J. Suvisaari9, S.
Hyman1, M. Daly2, A. Palotie2
1Broad Institute of MIT and Harvard, Cambridge, MA,
United States, 2Institute for Molecular Medicine Finland
(FIMM), Helsinki, Finland, 3Department of Forensic
Psychiatry, University of Eastern Finland, Niuvanniemi
Hospital, Kuopio, Finland, 4Department of Psychiatry,
Helsinki City Health Centre, Helsinki, Finland, 5Depart-
ment of Psychiatry, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland, 6Department of
Psychiatry, Turku University Hospital, Turku, Finland,
7Faculty of Medicine and Life Sciences, Tampere
University, Tampere, Finland, 8Department of Psychiatry,
Research Unit of Clinical Neuroscience, University of Oulu,
Oulu, Finland, 9Department of Public Health Solutions,
Mental Health Unit, National Institute for Health and
Welfare, Helsinki, Finland
Introduction: SUPER-Finland is a nationwide study which
has recruited 10,075 patients with psychotic disorder across
the country. Because of comprehensive national registers,
longitudinal data on education, employment, hospitaliza-
tions, drug prescriptions and cause of death can be drawn
from registers and linked to information collected at study
visit using national social security number. Our aim is to
shed light to genetic basis of different psychotic disorders.
Materials and Methods: Illumina Global Screening
Array was used to genotype 10,075 subjects from SUPER-
Finland study. Genotypes were imputed using population-
specific Sequencing Initiative Suomi panel as reference.
Polygenic risk scores were calculated with LDpred software
using publicly available genome-wide association study
summary statistics. Data on hospitalizations, duration of
involuntary hospitalization and psychosocial functioning at
hospitalization and discharge was drawn from registers.
Results: When comparing PRSs for schizophrenia and
major depression jointly, subjects with schizoaffective
disorder have different polygenic background than those with
schizophrenia and bipolar disorder. Schizoaffective disorder is
also different from psychotic depression. Subjects with high
polygenic risk for schizophrenia have lower psychosocial
functioning at hospital discharge, possibly reflecting residual
disease. They also have more involuntary hospital days.
Conclusions: Schizoaffective disorder seems to have
different polygenic background from other forms of
psychotic illnesses. This supports the idea of maintaining
it as separate disorder in psychiatric disease classification.
High polygenic risk for psychotic illness predisposes to
more severe disease forms.
Funding: The Stanley Center for Psychiatric Research at
the Broad Institute of MIT and Harvard, Orion Research
Foundation, Finnish Cultural Foundation.
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C12.2
Autism-linked Cullin3 germline haploinsufficiency
impacts cytoskeletal dynamics and cortical neurogenesis
through RhoA signaling
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M. Amar1, A. Pramod1, V. Munive Herrera1, N. Yu2, L. R.
Qiu3, P. Moran-Losada1, P. Zhang1, C. A. Trujillo1, J.
Ellegood3, J. Urresti1, K. Chau1, J. Diedrich2, J. Chen1, J.
Gutierrez1, J. Sebat1, D. Ramanathan1, J. P. Lerch3, J. R.
Yates III2, A. R. Muotri1, L. M. Iakoucheva1*
1University of California San Diego, La Jolla, CA, United
States, 2The Scripps Research Institute, La Jolla, CA,
United States, 3Hospital for Sick Children, Toronto, ON,
Canada
Introduction: E3-ubiquitin ligase Cullin3 (Cul3) is a high
confidence risk gene for Neurodevelopmental Disorders
(NDD) including Autism Spectrum Disorder (ASD) and
Developmental Delay (DD). To better understand the
impact of ASD-associated Cul3 mutations on brain devel-
opment, we generated Cul3-haploinsufficient mouse model
using CRISPR/Cas9 genome editing technology.
Materials and Methods: We investigated brain anatomy,
behavior, molecular, cellular, and circuit-level mechanisms
dysregulated by Cul3 mutations. Brain MRI, transcriptomic
and quantitative proteomic profiling of cerebral cortex,
hippocampus, and cerebellum of Cul3-haploinsufficient
mice were carried out at three developmental periods
(embryonic, early postnatal and adult) to understand
spatiotemporal impact of Cul3 mutations.
Results: Brain MRI of Cul3 mutant animals found
profound abnormalities in half of brain regions, including
decreased volume of cortical regions and increased volume
of subcortical regions. Cul3 mutant mice exhibited social
and cognitive deficits, and hyperactive behavior. Spatio-
temporal transcriptomic and proteomic profiling of the brain
implicated neurogenesis and cytoskeletal defects as key
drivers of Cul3 functional impact. Cortical neurons from
mutant mice had reduced dendritic length and loss of
filamentous actin puncta, along with reduced spontaneous
network activity. Inhibition of small GTPase RhoA, a
molecular substrate of Cul3 ligase, rescued dendrite length
phenotype.
Conclusions: Novel CRISPR/Cas9 Cul3-haploinsuffi-
cient mouse model implicated dysregulation of RhoA
pathway and downstream cytoskeletal and neurogenesis
defects during early brain development in autism. This
study identified RhoA signaling as a potential mechanism,
through which Cul3 mutation impacts early brain
development.
Funding: NIH grants MH108528, MH109885,
MH105524, MH104766, and Simons Foundation for
Autism Research #345469.
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C12.3
Tissue-specific transcriptional and functional signatures
in reciprocal genomic disorders : Insights from inte-
grated mouse and human neuronal models
R. Yadav1,2,3*, D. JC Tai1,2,3, J. Wang4,5, T. Aneichyk1,2, S.
Erdin1,3, B. B Currall1,2,3, K. O’Keefe1,2, A. Stortchevoi1,2,
U. Rudolph6, R. H. Perlis4,5, J. F Gusella1,2,3,7, M. E
Talkowski1,2,3
1Center for Genomic Medicine and Department of Neurol-
ogy, Massachusetts General Hospital, Boston, MA, United
States, 2Department of Neurology, Harvard Medical
School, Boston, MA, United States, 3Program in Medical
and Population Genetics, Broad Institute of MIT and
Harvard, Cambridge, MA, United States, 4Center for
Quantitative Health, Center for Genomic Medicine, and
Department of Psychiatry, Massachusetts General Hospital,
Boston, MA, United States, 5Department of Psychiatry,
Harvard Medical School, Boston, MA, United States,
67Department of Comparative Biosciences, College of
Veterinary Medicine, University of Illinois at Urbana-
Champaign, Urbana, IL, United States, 7Department of
Genetics, Harvard Medical School, Boton, MA, United
States
Reciprocal genomic disorders (RGDs) involve large copy
number variation (CNV) mediated by flanking segmental
duplications. Though individually rare, the collective con-
tribution of RGDs to developmental disorders is substantial.
Here, we compared the tissue-specific functional and tran-
scriptional signatures associated with two RGDs: 16p11.2
(740 kb, 29 genes) and 15q13.3 (1.5 Mb, 7 genes). For
16p11.2 we generated 304 RNAseq libraries across three
tissues cerebellum, prefrontal cortex, and striatum from 101
total mice, and isogenic CRISPR-engineered human neural
stem cells (NSCs, n=27 lines) and NGN2-induced neurons
(iNs, n=19 lines), while 119 libraries were analyzed for
15q13.3 across NSCs (24 lines), iNs (23 lines), and brain
tissue from 48 mice. Transcriptome profiling of both the
RGDs revealed that the strongest and most consistent
effects occurred within the CNV segment while most sec-
ondary regulatory effects were tissue-specific. Co-expres-
sion analyses isolated modules that were enriched for RGD
genes, DEGs, and highly constrained and genes associated
with NDD and autism. Genes regulating actin filament and
cytoskeleton organization, neuron projection, calcium sig-
naling pathway, and ion channel activity were significantly
altered in 15q13.3 iNs. Using a weighted z-score meta-
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analysis, we discovered convergence on shared molecular
pathways across the RGDs, most prominently including
alterations to genes involved in myelin sheath formation,
dendritic function, and mitochondrial function. Intriguingly,
neuron phenotyping assays revealed significant antagonistic
effect of these RGDs on neurite length and number of
branchpoints in iNs. These results suggest the pathogenic
mechanisms associated with recurrent RGDs may converge
on common molecular signatures.
R. Yadav: None. D. JC Tai: None. J. Wang: None. T.
Aneichyk: None. S. Erdin: None. B. B Currall: None. K.
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C12.4
Autism Comorbidities: Role of CHD8 during the
Development of the Enteric Nervous System
G. L. Hayot*, C. Weber, C. Golzio
IGBMC, Illkirch-Graffenstaden, France
Introduction: CHD8 is mutated in 0.21% of total autism
spectrum disorders (ASD) cases. Recently, clinical reas-
sessment highlighted the high prevalence of gastrointestinal
(GI) defects in ASD. Transient suppression of chd8 in
zebrafish led to a reduced number of enteric neurons and a
decreased gut mobility which likely drive the GI problems
(Bernier et al. Cell, 2014).
Materials and Methods: To understand how the loss of
chd8 causes the loss of mature enteric neurons, we
generated and characterized a stable mutant zebrafish line:
Tg(chd8sa19827;phox2bb:GFP) in which the neuronal pro-
genitors (i.e. enteric neural crest cells, eNCCs) are labeled
with GFP.
Results: First, we observed a migration delay and
reduced proliferation of eNCCs during early development
and a decreased number of mature neurons and more
specifically serotonergic neurons at 5 days post-fertilization.
Second, transcriptomic analyses of eNCCs revealed the
upregulation of the serotonin receptor htr6 and the
dysregulation of several actors of the Wnt/Planar Cell
Polarity and RhoA pathways, extracellular matrix compo-
nents, and several genes from the human morbid genome.
Third, behavioral analyses showed i) hyperactivity of the
mutant chd8 larvae and ii) normal sociability and no
aggressive behavior in the adult mutants.
Conclusion: We showed that the decreased number of
enteric neurons in absence of chd8 is due to a combination
of proliferation, migration and differentiation defects of the
eNCCs. Moreover, our transcriptomic data identified
druggable targets in chd8-associated signaling pathways
and we are currently performing rescue experiments with
small molecules in the chd8 mutants.
Grants: ANR-10-IDEX-0002-02, ANR-10-LABX-0030-
INRT
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C12.5
A human single-cell atlas of the Substantia nigra reveals
novel cell-specific pathways associated with the genetic
risk of Parkinson’s disease and neuropsychiatric
disorders.
D. Agarwal1, C. Sandor2, V. Volpato2, T. Caffrey1, J.
Monzon-Sandoval2, R. Bowden1, J. Alegre-Abarrategui1, R.
Wade-Martins1, C. Webber2,1*
1Oxford University, Oxford, United Kingdom, 2UK Demen-
tia Research Institute, Cardiff, United Kingdom
We sequenced ~ 17,000 nuclei from both the Cortex and
Substantia Nigra (SN) of five human brains and generated
the first human single-nuclei transcriptomic atlas of the SN,
a region playing important roles in reward and movement.
By mapping genetic variants associated with different
human traits to SN cell-type-specific gene expression pat-
terns, we demonstrate for the first time that Parkinson’s
disease (PD) genetic risk, for which the symptoms are
caused by loss of SN dopaminergic neurons (DaNs), is
indeed associated with DaN-specific gene expression
affecting pathways such as mitochondrial organisation and
functioning, protein ubiquitination and vesicle transport.
However, we also identify a distinct cell type association
between PD risk and oligodendrocyte-specific gene
expression. Unlike Alzheimer’s disease (AD), we find no
association between PD risk and microglia or astrocytes,
suggesting that neuroinflammation plays a less causal role
in PD than AD. Beyond PD, we find other neuropsychiatric
disorders, particularly schizophrenia (SCZ), to be associated
to SN DaNs and GABAergic neurons. Nevertheless, we find
that each neuropsychiatric disorder is associated with a
distinct set of genes within those neuronal types. On the
contrary, we find an overlapping component of risk between
neuropsychiatric disorders in the association to glial cells,
particularly oligo-precursor cells (OPCs). This atlas pro-
vides the first objective associations between genetic risk of
multiple disorders and the midbrain cell types these risks
likely manifest through, thereby directing our aetiological
understanding.
D. Agarwal: None. C. Sandor: None. V. Volpato: None.
T. Caffrey: None. J. Monzon-Sandoval: None. R. Bowden:
None. J. Alegre-Abarrategui: None. R. Wade-Martins:
None. C. Webber: None.
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C12.6
Clinical and molecular complexity of X-linked clustering
epilepsy, a disorder of cellular mosaics
J. Gecz1*, K. Kolc1, L. Sadleir2, C. Depienne3, C. Marini4, I.
E. Scheffer5, R. S. Moller6, M. Trivisano7, N. Specchio7, R.
Kumar1, D. Pham1, R. Roberts1
1The University of Adelaide, Adelaide, Australia, 2Univer-
sity of Otago, Wellington, New Zealand, 3University
Hospital Essen, Essen, Germany, 4University of Florence,
Florence, Italy, 5University of Melbourne, Melbourne,
Australia, 6The Danish Epilepsy Centre, Dianalund, Den-
mark, 7Bambino Gesù Children’s Hospital, Rome, Italy
PCDH19 is a well-established neurodevelopmental dis-
ability (NDD) gene implicated in an early onset seizure
disorder, X-linked clustering epilepsy or XCE. XCE is
one of the most frequent epilepsies. It is a disorder of
cellular mosaics, i.e. heterozygous females (due to X-
inactivation mosaicism) or postzygotic somatic mosaic
males. Hemizygous males without functional PCDH19
are not affected. In the present study we investigated
the complexity of the XCE NDD phenotype as well as
the cellular and molecular determinants of its variable
(~80%) penetrance. Firstly, using standardized survey
tools we have assessed executive function (Behavior
Rating Inventory) and psychiatric comorbidities (Social
Responsiveness Scale, Social Communication Ques-
tionnaire, Strengths and Difficulties Questionnaire, and
Dimensional Obsessive Compulsive Scale) on 112 indi-
viduals with deleterious PCDH19 variant, males and
females. Genetic, seizure, and developmental information
were also collected. Developmental delay prior to seizure
onset occurred in 18%, executive dysfunction and ASD in
60% of individuals. 21% of individuals met criteria for
obsessive-compulsive disorder, distinct from ASD. There
were no phenotypic differences between heterozygous
females and somatic mosaic males attesting to the cellular
mosaicism as the disease driver. Secondly, we assessed
322 PCDH19 missense variants, 45 of which we tested
experimentally using in vitro assays to engineer a high
accuracy PCDH19 variant predictor toolbox. Thirdly,
using patient-derived skin fibroblast cell lines we identi-
fied genetic (mRNA, protein) and epigenetic (methyla-
tion) biomarkers of the penetrance of XCE even among
discordant monozygotic twins. Our research set founda-
tions of a Phase III international clinical trial of ganax-
olone in XCE.
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Depienne: None. C. Marini: None. I. E. Scheffer: None. R.
S. Moller: None. M. Trivisano: None. N. Specchio: None.
R. Kumar: None. D. Pham: None. R. Roberts: None.
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Landscape of cohesin-mediated chromatin loops in the
human genome
F. Grubert1*, R. Srivas1, D. Spacek1, M. Kasowski1, M.
Ruiz-Velasco2, N. Sinnott-Armstrong1, P. Greenside1, A.
Narasimha1, Q. Liu1, B. Geller1, A. Sanghi1, M. Kulik3, S.
Sa1, M. Rabinovitch1, A. Kundaje1, S. Dalton3, J. Zaugg2,
M. Snyder1
1Stanford University, Stanford, CA, United States, 2EMBL,
Heidelberg, Germany, 3University of Georgia, Athens, GA,
United States
Physical interactions between distal regulatory elements in the
genome play a key role in regulating gene expression, yet the
extent to which these interactions vary between cell types and
contribute to cell type-specific gene expression and how they
are related to overall gene function remains unclear. To address
these questions as part of ENCODE Phase III, we mapped
cohesin-mediated chromatin loops, using a high-resolution
ChIA-PET assay, and gene expression in 24 diverse human
cell types, including core ENCODE cell lines. We find that
28% of all chromatin loops vary across cell types, and these
changes are effective at grouping cell types based on their
tissue of origin, indicating commonalities in three-dimensional
(3D) genome architecture amongst related cell types. This also
applied to different cell types that were derived from the same
individual, demonstrating that the observed variation is mainly
due to epigenetic changes. Cell type-specific loops show dif-
ferent patterns of chromatin states, with stem cell loops being
depleted of active promoter states and transcription, and enri-
ched in bivalent states. We further find that the connectivity of
genes corresponds to different functional classes, with house-
keeping genes being connected by few loops, and dosage-
sensitive genes being highly connected to enhancer elements.
Finally, we demonstrate that genetic variants identified
in GWAS are enriched in variable loops in disease-relevant
cell types. Overall, our results provide important insights
on how variation in 3D chromatin organization corresponds
to cell type-specific functions and identity.
F. Grubert: None. R. Srivas: None. D. Spacek: None. M.
Kasowski: None. M. Ruiz-Velasco: None. N. Sinnott-
Armstrong: None. P. Greenside: None. A. Narasimha: None.
Q. Liu: None. B. Geller: None. A. Sanghi: None. M. Kulik:
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C13.2
Analysis of chromatin looping at joint endometrial-
ovarian cancer risk loci to identify candidate target genes
D. Glubb*, I. Jeong, A. Spurdle, T. O’Mara
QIMR Berghofer Medical Research Institute, Brisbane,
Australia
We have previously identified 11 joint risk endometrial-
ovarian cancer loci through analysis of genome-wide
association study (GWAS) data from the two largest studies
of these diseases. To find candidate target genes at joint risk
loci, we performed HiChIP chromatin looping analysis of
three endometrial and three ovarian cancer cell lines. To
enrich for enhancer-promoter interactions, a mechanism
through which GWAS-identified variation may target
genes, we captured loops associated with H3K27Ac histone
(characteristic of promoters and enhancers). We identified
60,208-182,001 replicated loops per cell line, 28-44% of
which contacted a promoter. Intersection of promoter-
associated loops with statistically credible risk variants
highlighted 59 genes, at eight joint risk loci, as candidate
targets in both endometrial and ovarian cancer cell lines.
These genes included those with well-established oncogenic
roles (e.g. TERT, MYC and CCND1). Among the candidate
target genes, there was a two-fold enrichment (p=0.01) for
genes differentially expressed in endometrial or ovarian
tumours. Network analysis prioritised a set of proteins that
interact with those encoded by candidate target genes. This
set was 16-fold enriched (p=2×10−15) for endometrial or
ovarian cancer drivers and included proteins encoded by
mismatch repair genes MLH1, MSH2 and MSH6, for which
variants are penetrant for endometrial cancer and ovarian
cancer. Lastly, candidate target genes and prioritised inter-
acting proteins were over-represented in pathways related to
endometrial and ovarian cancer development. In summary,
we have identified biologically relevant candidate genes and
pathways, providing insight into endometrial and ovarian
cancer aetiology.
Funded by NHMRC project grant #1158083 (DG
and TOM)
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C13.3
When the silent genome gets loud: transcription of
repeated genomic elements at the single-cell resolution in
K27M-mutated high-grade gliomas
M. Coutelier1,2*, V. Lisi2,3, S. Hébert1,2, D. Faury4,3, B.
Krug4,3, N. De Jay1,2, N. Jabado4,3, C. L. Kleinman1,2
1Department of Human Genetics, McGilll University,
Montreal, QC, Canada, 2Lady Davis Institute for Medical
Research, Jewish General Hospital, Montreal, QC,
Canada, 3The Research Institute of the McGill University
Health Center, Montreal, QC, Canada, 4Department of
Pediatrics, McGill University, Montreal, QC, Canada
Introduction: High-grade gliomas are a leading cause of
cancer-related death in children and young adults, and no
targeted treatments are currently available. A recurrent
lysine-to-methionine substitution at position 27 of histone 3
variants has been shown to induce alterations of repressive
and active chromatin landscapes, respectively a global loss
of H3K27 trimethylation, and a pervasive gain of H3K27
acetylation. Repeated genomic elements are particularly
targeted by this de-repression, leading to an exquisite
sensitivity of H3K27M cells to agents triggering viral
mimicry.
Materials and methods: In K27M-mutated gliomas, we
combine single-nuclei (sn)RNA-sequencing and snATAC-
sequencing to investigate the intra-tumoral heterogeneity of
genomic repeats expression.
Results: In several samples bearing K27M mutations in
all three variants of histone 3, we consistently identified
gradients of repeats expression. These gradients correlated
with gene signatures specific of K27M gliomas, a result
corroborated by snATAC-sequencing. Cells displaying high
repeats expression also showed a higher enrichment for
targets of the repressive methylation complex PRC2, as well
as a transcriptomic profile resembling less differentiated
oligodendrocyte progenitor cells.
Conclusions: We have implemented an approach to
detect expression of genomic repeats at the single cell level
and demonstrate gradients of expression in high-grade
gliomas. Our results corroborate the existence of tumor
compartments in K27M-tumors that consist of progenitor-
like, aggressive malignant cells, displaying higher expres-
sion of the silent genome. They advocate for the potential of
viral mimicry trigger as therapeutic option for these
untreatable tumors.
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C13.4
CDH1 regulatory noncoding elements: a hidden master
for tissue-specific E-cadherin expression
C. São José1,2,3*, A. R. Monteiro1, A. André1, A. Qamra4, R.
Acuna-Hidalgo3, P. Tan4, S. Mundlos3,5,6, C. Oliveira1,2
1Instituto de Investigação e Inovação em Saúde da
Universidade do Porto (i3S)/Institute of Molecular
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Oral Presentations 73
Pathology and Immunology of the University of Porto
(Ipatimup), Porto, Portugal, 2Faculty of Medicine of the
University of Porto, Porto, Portugal, 3Max Planck Institute
for Molecular Genetics, Berlin, Germany, 4Cancer Science
Institute of Singapore (NUS), Singapore, Singapore, 5Insti-
tute for Medical and Human Genetics, Charité Universi-
tätsmedizin, Berlin, Germany, 6Berlin-Brandenburg Center
for Regenerative Therapies (BCRT), Charité Universitäts-
medizin, Berlin, Germany
Introduction: Germline CDH1/E-cadherin loss of function
(LoF) causes inherited gastric and breast cancer; and
somatic LoF occurs during progression of most epithelial
cancers. Classical genetic/epigenetic/post-transcriptional
inactivation mechanisms fail to explain CDH1 LoF in most
inherited/somatic contexts. We hypothesized that CDH1
LoF occurs due to defects in the CDH1 regulatory network
and explored potential expression modifier sequences con-
trolling CDH1 expression.
Materials and Methods: Six gastric-cancer cell lines
were submitted to Capture Hi-C (cHi-C) and 4C-seq with a
CDH1 promoter viewpoint. Interactors’ expression patterns
in normal tissues were explored in GTex. Interactors’
regulatory function was assessed in mouse embryo LacZ-
reporter assays, followed by tissue-specific β-galactosidase
expression analysis in transgenic embryonic stomach,
esophagus, duodenum, liver (endoderm), heart (ectoderm)
and skin (mesoderm).
Results: We found simultaneous interactions between
CDH1 promotor and (1) a new lncRNA at chromosome#2
short-arm, and (2) a CDH1-intronic cis-regulatory element
(CDH1-iCRE). These were specific for CDH1 non-expres-
sing cells, and undetected in CDH1-expressing cells,
highlighting a potential negative regulatory network. GTEx
data revealed that lncRNA and CDH1 have mutually
exclusive expression patterns, with CDH1 being expressed
across epithelial tissues, and the lncRNA restricted to brain
and testis. CDH1 expression was 100-fold higher than
lncRNA expression. The interacting CDH1-iCRE showed
tissue-specificity in endodermal-derived tissues where E-
cadherin exerts a primordial function (stomach, esophagus
and duodenum).
Conclusion: We found a potential negative regulatory
network in gastric cancer cell lines through CDH1 promoter
cis and trans interactions, and evidence for tissue-specific
regulation. These findings suggest a novel mechanism
triggering CDH1/E-cadherin LoF.
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C13.5
Local gene co-expression: molecular characterisation,
tissue specificity and its genetic control
D. Ribeiro1,2*, A. Ramisch3,2, E. Dermitzakis3,2, O.
Delaneau1,2
1University of Lausanne, Lausanne, Switzerland, 2Swiss
Institute of Bioinformatics (SIB), Lausanne, Switzerland,
3University of Geneva, Geneva, Switzerland
Many Eukaryotic genes tend to be expressed together.
Recent studies highlight the existence of structural and
regulatory domains orchestrating the organised expression
of nearby genes (Delaneau et al. 2019 Science 364(6439)).
Yet, the molecular mechanisms, genetic control and tissue
specificity of local gene co-expression are far from being
understood. Here, we developed a novel method to identify
groups of nearby genes (within 1Mb) that are co-expressed,
using genome-wide RNA-seq datasets from large popula-
tions (e.g. >200 individuals). First, we identified 9548 high-
confidence co-expressed gene pairs (FDR 1%) from 358
human lymphoblastoid cell line (LCL) samples from the
Geuvadis dataset. These constitute 52.5% of the protein-
coding and lincRNA genes expressed in LCLs, demon-
strating that local gene co-expression is highly prevalent.
Next, by integrating various molecular assays (e.g. ChIP-
seq, Hi-C), we determined the relative contribution of
several molecular features towards local gene co-expres-
sion. For instance, we found that CTCF binding plays a role
in determining which gene pairs can be co-expressed,
whereas chromatin contacts between genes shown to be key
only when these are distant (>200kb) from each other.
Notably, developing novel QTL mapping approaches, we
found that the co-expression of more than 50% of the gene
pairs is controlled by nearby genetic variants (co-QTLs),
many of whom falling within shared regulatory elements,
such as enhancers. Finally, we applied our novel approaches
across 53 human GTEx tissues to study in-depth the tissue-
specificity and genetic control of local gene co-expression,
ultimately improving the functional interpretation of QTL
and GWAS findings.
D. Ribeiro: None. A. Ramisch: None. E. Dermitzakis:
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Structural variants in HDAC9 that disrupt TWIST1
transcriptional regulation but not HDAC9 protein
function are associated with craniofacial and limb
malformations
R. Y. Birnbaum1,2*, N. Hirsch3
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The Ben-Gurion University of the Negev, Israel., Beer-
Sheva, Israel, 2Center of Evolutionary Genomics and
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Sheva, Israel, 3Department of Life Sciences, Faculty of
Natural Sciences, The Ben-Gurion University of the Negev,
Beer-Sheva, Israel
Structural variants (indels, translocations and inversions) are
associated with human variations. SVs affecting protein
coding sequences and\or regulatory elements are associated
with human disorders. However, SVs disrupting protein
coding sequences that also function as transcriptional reg-
ulation are yet to be demonstrated. Here, we show that
patients with SVs involving HDAC9 protein coding
sequence are associated with craniosynostosis due to dis-
ruption of TWIST1 regulatory elements that reside in
HDAC9 sequence and not due to disruption of HDAC9
protein. By generating CRISPR\Cas9 mouse models, we
deleted Hdac9 protein coding sequence that also function as
Twist1 transcription enhancers (eTw5-7Δ/Δ) that altered
Twist1 expression and led to significant craniofacial phe-
notype and polydactyly, resemble Saethre-Chotzen syn-
drome. Furthermore, deletion of Hdac9 sequence
encompasses CTCF site (CTCFΔ/Δ) disrupted Twist1
enhancer-promoter interactions which led to craniofacial
phenotype and polydactyly. Using RNA-seq and 4C-seq,
we demonstrate that in both Hdac9 deletion models Twist1
expression, but not Hdac9, was reduced and the effect on
the downstream targets of Twist1 elucidated unexpected
pathways. Finally, we generated a large inversion of the
entire Hdac9 sequence (Hdac9INV/+) that does not disrupt
Hdac9 coding sequence but rather reposition Twist1 reg-
ulatory elements. We showed reduction of Twist1 expres-
sion, but not of Hdac9, that led to craniofacial phenotype
and polydactyly. Thus, we elucidated the TWIST1 tran-
scriptional machinery that reside in HDAC9 sequence,
suggesting that SVs encompass protein coding sequences
could lead to a phenotype that is not attributed to the protein
function but rather a disruption of the transcription regula-
tion of nearby gene, such as TWIST1.
R. Y. Birnbaum: None. N. Hirsch: None.
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Implication of FOXD2 in autosomal recessive
syndromic CAKUT
K. M. Riedhammer1,2*, M. Nguyen3, B. Alhaddad1, S. J.
Arnold4, G. J. Kim4, U. Heemann2, M. Schmidts5, J.
Hoefele1
1Institute of Human Genetics, Klinikum rechts der Isar,
Technical University of Munich, Munich, Germany,
2Department of Nephrology, Klinikum rechts der Isar,
Technical University of Munich, Munich, Germany,
3Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands, 4Institute of
Experimental and Clinical Pharmacology and Toxicology,
Faculty of Medicine, University of Freiburg, Freiburg,
Germany, 5Center for Pediatrics and Adolescent Medicine,
Freiburg University Hospital, University of Freiburg,
Freiburg, Germany
Introduction: 50% of chronic kidney disease up to age 30
can be attributed to congenital anomalies of the
kidney and urinary tract (CAKUT). CAKUT is genetically
complex: Although more than 40 genes have been
linked to monogenic CAKUT and familial clustering is
frequent, monogenic causes can only be identified in about
12% of cases. Exome sequencing (ES) has become a
valuable tool for the analysis of genetically heterogeneous
diseases both in diagnostics and research. We report a
multiplex consanguineous Arab family with several indi-
viduals segregating syndromic kidney hypoplasia in
which ES identified a homozygous frameshift variant in
FOXD2 and show functional characterization of Foxd2
knockout (KO).
Material & Methods: Analysis of the index patient by
ES, Sanger sequencing of relatives. CRISPR/Cas9-mediated
KO of Foxd2 (Foxd2−/−) in murine metanephric mesench-
yme cells (mk4). RNA sequencing of KO cells.
Results: ES identified a homozygous frameshift variant
in FOXD2 NM_004474.3:c.789dup, p.(Gly264Argfs*228)
in the index patient (bilateral hypoplastic kidneys, facial
dysmorphism, developmental delay). Sanger sequencing
confirmed segregation of the variant in the family. Pathway
analysis of RNA data from Foxd2−/− cells vs. WT revealed
significant enrichment of differential expression of renal
developmental genes. Pax2 and Wnt4 were notable
significantly downregulated genes.
Discussion: FOXD2 is a transcription factor with strong
expression in the developing kidney. Foxd2−/− mice can
show a CAKUT phenotype. Our data implicate FOXD2 in
autosomal recessive syndromic CAKUT. RNA sequencing
results suggest that KO of Foxd2 leads to impaired
transition from metanephric mesenchyme to epithelium in
the developing kidney via the Pax2-Wnt4 axis.
K. M. Riedhammer: None. M. Nguyen: None. B.
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Heterozygous DACT1 mutations in patients with renal
anomalies and features of Townes-Brocks syndrome
A. Christians1, E. Kesdiren1, I. Hennies2, A. D. Hofmann3,
M. Trowe4, F. Brand1, H. Martens1*, I. A. Kindem5, Z.
Gucev6, M. Zirngibl7, R. Geffers8, T. Seeman9, A. Kispert4,
H. Billing7, A. Bjerre5, V. Tasic6, D. Haffner2, J.
Dingemann3, R. G. Weber1
1Department of Human Genetics, Hannover Medical
School, Hannover, Germany, 2Department of Pediatric
Kidney, Liver and Metabolic Diseases, Hannover Medical
School, Hannover, Germany, 3Department of Pediatric
Surgery, Hannover Medical School, Hannover, Germany,
4Institute of Molecular Biology, Hannover Medical School,
Hannover, Germany, 5Division of Pediatric and Adolescent
Medicine, Oslo University Hospital, Oslo, Norway, 6Med-
ical Faculty Skopje, University Children’s Hospital, Skopje,
Macedonia, The Former Yugoslav Republic of, 7Depart-
ment of Pediatric Nephrology, University Children’s
Hospital Tübingen, Tübingen, Germany, 8Genome Analy-
tics Research Group, Helmholtz Centre for Infection
Research, Braunschweig, Germany, 9Department of Pedia-
trics, Second Faculty of Medicine, Charles University
Prague, Prague, Czech Republic
Less than 20% of patients with congenital anomalies of the
kidney and urinary tract (CAKUT) carry variants in the
approximately 50 known CAKUT genes, indicating that
this disorder is genetically highly heterogeneous. To iden-
tify novel genes associated with CAKUT, we applied
whole-exome sequencing to a patient with renal anomalies,
i.e. left-sided agenesis and right-sided duplex, who also had
extrarenal abnormalities, e.g. anorectal and sacral mal-
formation, thus detecting a rare heterozygous missense
variant in the dishevelled binding antagonist of beta catenin
1 (DACT1) gene. As combined renal, anorectal, and skeletal
defects, features overlapping Townes-Brocks syndrome,
were previously described in a family carrying a DACT1
nonsense variant and in Dact1-deficient mice, the identified
DACT1 variant was presumed causative in our patient.
Therefore, we aimed to determine the frequency of DACT1
variants in patients with renal anomalies. Taken together,
we identified seven maternally inherited, heterozygous,
likely pathogenic DACT1 missense variants in 8 of 209
families (3.8%) with renal agenesis/dysplasia/hypoplasia
and other features of Townes-Brocks syndrome. Immuno-
precipitation revealed reduced dishevelled segment polarity
protein 2 (DVL2) binding capacity of mutant DACT1. By
RNA in situ hybridization on murine embryo sections,
Dact1 expression was detected in different organs including
anal canal and kidney, whereby renal expression was
confined to the mesenchyme of ureter, kidney capsule,
cortical and medullary stroma. CRISPR/Cas9-derived
Dact1-deficient murine inner medullary collecting duct cells
showed impaired tubule formation. Altogether, we demon-
strate a statistically significant overrepresentation of rare
heterozygous hypomorphic DACT1 variants in patients with
renal anomalies versus controls. (DFG grant no. KO5614/2-
1)
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Loss of UNC45A causes microvillus inclusion disease-
like by impairing myosin-dependent epithelial
morphogenesis
R. Duclaux-Loras1, F. Charbit-Henrion1, C. Lebreton1, O.
Nicolle2, M. Rabant3, C. Guerrera4, A. Fabre5, L. Faivre6,
G. Michaux2, H. Uligh7, F. Ruemmele3, N. Cerf-
Bensussan1, M. Parlato1*
1Institut Imagine, Paris, France, 2CNRS, UMR6290, Institut
de Génétique et Développement de Rennes, Rennes, France,
3Assistance Publique-Hôpitaux de Paris, Hôpital Necker-
Enfants Malades, Department of Pediatric Gastroenterol-
ogy, Paris, France, 4Proteomics platform 3P5-Necker,
Université Paris Descartes-Structure Fédérative de
Recherche Necker, INSERM US24/CNRS UMS3633, Paris,
France, 5Service de pédiatrie multidisciplinaire, Hôpital de
la Timone Enfants, APHM, Marseille, France, 6Centre de
Génétique, Hôpital d’Enfants, CHU Dijon, Dijon, France,
7Department of Pediatrics, University of Oxford; Transla-
tional Gastroenterology Unit, University of Oxford, Oxford,
United Kingdom
Introduction: Congenital diarrhea disorders (CDDs) are
rare inherited diseases characterized by chronic enteropathy
starting early in life. Recently, mutations in UNC45A,
coding for a myosins- co-chaperone, have been associated
with a complex syndrome combining cholestasis, diarrhea,
deafness and bone fragility. We aimed to investigate the
pathomechanism underlying the intestinal defect in
UNC45A deficient patients.
Materials and Methods: We investigated 4 unrelated
patients with history of intestinal failure due to congenital
diarrhea. We used next generation sequencing to uncover
the underlying gene defect and immunohistochemistry/
electron microscopy to analyse intestinal tissue. UNC45A
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−/− CaCo2 cells were generated by CRISPR/Cas9 editing
and cultured in matrigel to form cysts. UNC45A inter-
actome was investigated by mass spectrometry. Organoids
were generated from controls and from patients using
blood-derived pluripotent stem cells.
Results: Exome analysis identified biallelic mutations in
UNC45A in all patients. Abnormal PAS and CD10
accumulation throughout the subapical cytoplasm was
found on patient duodenal biopsies. Microvesicles and
microvilli inclusions were associated with microvillous
atrophy. UNC45A−/−CaCo2 cells developed into multilu-
mens-cysts, indicating a defect in epithelial morphogenesis.
Mass spectrometry confirmed MYO5B as UNC45A-HSP90
client and expanded the number of non-muscle myosins-II,
dependent on UNC45A for proper folding and maturation.
Patient‘s organoids displayed features of microvillus
inclusion disease.
Conclusions: We identified 6 novel mutations in
UNC45A causative of a complex syndrome including
congenital diarrhea. EM on patient derived organoids
recapitulates the defects of morphology and polarization
observed in patient’s biopsies. Overall, our results under-
score the important role of UNC45A in shaping epithelial
morphogenesis in the gut.
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A comprehensive exome study of the genetic architec-
ture of asthma reveals a putative novel patient subgroup
defined by filaggrin truncating variants
S. R. Cameron-Christie1*, H. Olsson2, A. Mackay2, Q.
Wang3, M. Hühn2, D. Muthas2, G. Lassi1, J. Lindgren4, G.
Povysil5, D. B. Goldstein5, G. Belfield4, I. Dillmann4, Y.
Ohne6, S. Cohen7, S. Young8, A. Platt2, S. Petrovski1
1Centre for Genomics Research, Precision Medicine and
Genomics, IMED Biotech Unit, AstraZeneca, Cambridge,
United Kingdom, 2Translational Science and Experimental
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Inflammation and Autoimmune (RIA), R&D BioPharma-
ceuticals, AstraZeneca, Cambridge, UK, Gothenburg,
Sweden, 3Centre for Genomics Research, Precision Med-
icine and Genomics, IMED Biotech Unit, AstraZeneca,
Waltham, MA, United States, 4Translational Genomics,
Discovery Sciences, R&D BioPharmaceuticals, AstraZe-
neca, Gothenburg, Sweden, Gothenburg, Sweden, 5Institute
for Genomic Medicine, Columbia University Irving Medical
Center, New York, New York, New York, NY, United States,
6Bioscience Asthma, Research and Early Development,
Respiratory, Inflammation and Autoimmune (RIA), Bio-
Pharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden,
7Bioscience Asthma, Research and Early Development,
Respiratory, Inflammation and Autoimmune (RIA), Bio-
Pharmaceuticals R&D, AstraZeneca, Cambridge, United
Kingdom, 8Precision Medicine, Oncology R&D, AstraZe-
neca, Cambridge, UK, Cambridge, United Kingdom
Asthma is a highly heterogenous disease with considerable
unmet need. Understanding the genetic architecture may
enable a precision medicine approach. We studied exome data
from 24,584 asthma cases from the UKBiobank (UKB) and
SAGA, an AstraZeneca study. Controls were 120,557 UKB
participants with FEV/FVC ratio >70%, without respiratory
illness. In addition to all-comer asthma (n= 24,584), we stu-
died familial (n= 1,065) and early-onset (age<18yrs, n=
5,962) asthma subsets. Gene- and variant-level analyses iden-
tified statistically significant signals from moderate-to-common
protein-truncating variants (PTVs), including in FLG, which
has previously been associated with asthma. Asthma risk was
significantly increased not only by common FLG PTVs, but
also the collection of rare-to-private FLG PTVs. This signal
was driven by early onset asthma, with no measurable impact
on diagnoses >18 years old (p= 0.91, OR= 1.00). Risk was
strongest among atopic asthma (diagnoses<18 y.o., p=
1.13 × 10−37, OR= 2.32), but remained significant after cor-
recting for allergies and related phenotypes (p= 1.26 × 10−13,
OR= 1.4). Finally, we found FLG-associated asthma does not
correlate with eosinophil levels. In addition, a single splice
variant in IL33, rs146597587-C, previously proposed as a
protective, loss-of-function PTV (Smith D (2017) PLoS
Genet), was replicated as protective (p= 8.0 × 10−10, OR=
0.58). We further observed significantly lower carrier rates of
this splice-variant among early-onset asthmatics (0.36%)
compared to later onset (0.61%) (Mann-Whitney p= 0.001).
While we did not find evidence of novel asthma genes among
current samples, we did identify a putative novel patient sub-
group from the recognised FLG asthma loci, namely FLG
PTV carriers, whose prevalence in UKB is 12%.
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Random plasma glucose GWAS in 479,678 individuals:
genetic relationships with impaired lung function and
intestinal health
M. A. Kaakinen1,2*, L. Jiang2,3, A. Ulrich2, L. Zudina1,2, Z.
Balkhiyarova1,2, P. Todorov4, T. H. Pers4, V. Lagou5, I.
Prokopenko1,2, MAGIC Investigators
1University of Surrey, Guildford, United Kingdom, 2Imper-
ial College London, London, United Kingdom, 3The
University of Queensland, Brisbane, Australia, 4University
of Copenhagen, Copenhagen, Denmark, 5VIB Center for
Brain & Disease Research, Leuven, Belgium
Fasting glucose and 2-hour post-prandial glucose are used
as the gold standard tests for diagnosing type 2 diabetes
(T2D). High non-fasting i.e. random plasma glucose (RG)
levels may also indicate abnormal glucose homeostasis. We
sought to characterise the genetic architecture of RG and its
genetic relationships with other traits by performing a
genome-wide association study of 8.1M SNPs with
MAF>1% for RG in non-diabetic individuals from 17
European studies, including UK Biobank, adjusted for i)
age, sex, population structure (N= 479,678) and ii) addi-
tionally for time since last meal (N= 438,678). We eval-
uated the results from each model and their combination.
The LD score regression was used to evaluate the genetic
correlation between RG and other traits. We identified
156 signals at 117 loci associated with RG at genome-wide
significance (P < 5 × 10−8), including 38 novel signals for
glycaemic traits and T2D. These include five common
coding variants within GCKR, TET2, RREB1, NMT1 and
WIPI1, and three low-frequency nonsynonymous variants
within EDEM3, NEUROD1 and GLP1R genes. The LD
score regression revealed significant genetic correlations
between RG and glycaemic/obesity traits and T2D, as well
as a novel inverse genetic correlation with forced vital
capacity (rg=−0.088, SE= 0.022, P= 6.04 × 10−5). The
latter finding brings molecular clues to the observational
studies showing an impairment in lung function in indivi-
duals with T2D. DEPICT analysis of large-scale human
expression data showed significant enrichment of genes at
RG-associations in ileum and pancreas, indicating a role of
the digestive tract in RG level regulation.
Funding: H2020-SC1-HBC-28-2019-LONGITOOLS,
WCRF-2017/1641.
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A complementary study approach unravels novel
players in the pathoetiology of Hirschsprung‘s disease
T. Mederer1, S. Schmitteckert1*, J. Volz1, C. Martinez1,2, R.
Röth1,3, T. Thumberger4, V. Eckstein5, J. Scheuerer6, C.
Thöni6, F. Lasitschka6, L. Carstensen7, P. Günther7, S.
Holland-Cunz8, R. Hofstra9, E. Brosens9, D. Schriemer10, I.
Ceccherini11, M. Rusmini11, J. Tilghman12, B. Luzón-
Toro13,14, A. Torroglosa13,14, S. Borrego13,14, C. Szeman
Tang15, M. Garcia-Barcelo15, P. Tam15, N. Paramasivam16,
M. Bewerunge-Hudler17, C. de la Torre18, N. Gretz18, G.
Rappold1,19, P. Romero7, B. Niesler1,3,19
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berg University, Heidelberg, Germany, 5FACS Core
Facility, Campus Heidelberg, Heidelberg, Germany, 6Insti-
tute of Pathology, Heidelberg University Hospital, Heidel-
berg, Germany, 7Pediatric Surgery Division, Heidelberg
University Hospital, Heidelberg, Germany, 8Pediatric
Surgery, University Children’s Hospital, Basel, Switzer-
land, 9Department of Clinical Genetics, Erasmus University
Medical Center, Rotterdam, Netherlands, 10Department of
Neuroscience, University Medical Center, Groningen,
Netherlands, 11UOSD Genetica e Genomica delle Malattie
Rare, IRCCS, Instituto Giannina Gaslini, Genova, Italy,
12Center for Human Genetics and Genomics, New York
University School of Medicine, New York, NY, United
States, 13Department of Maternofetal Medicine, Genetics
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University Hospital Virgen del Rocío/CSIC/University of
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Research on Rare Diseases (CIBERER), Seville, Spain,
15Department of Surgery, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong, China, 16Divi-
sion of Theoretical Bioinformatics, German Cancer
Research Center, Heidelberg, Germany, 17Genomics and
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Proteomic Core Facility, German Cancer Research Center,
Heidelberg, Germany, 18Center of Medical Research,
Medical Faculty Mannheim, Mannheim, Germany, 19Inter-
disciplinary Center for Neurosciences, University of
Heidelberg, Heidelberg, Germany
Introduction: Hirschsprung’s disease (HSCR, OMIM
142623) involves congenital intestinal obstruction caused
by dysfunction of neural crest cells and their progeny during
enteric nervous system (ENS) development. HSCR is a
multifactorial disorder and risk genes have only been
identified in a minority of cases. Due to its complex genetic
architecture, defining novel disease-relevant gene variants
remains challenging.
Material and Methods: To identify candidate genes,
whole exome sequencing (WES) of two HSCR patients and
their non-affected parents was performed. To examine their
disease-causing relevance, a complementary study approach
has been established. This included transcriptome analysis
of murine embryonic ENS-relevant tissues, in silico
network analyses, expression analyses as well as functional
assays assessing migration, differentiation, proliferation and
cell survival capability of genome-edited cell clones.
Results: WES data were nailed down to four novel
HSCR candidate genes: ATP7A, SREBF1, ABCD1 and
PIAS2. Further rare variants in these genes were identified
in additional HSCR patients, indicating disease relevance.
In addition, transcriptomics revealed that these genes are
expressed in embryonic and fetal gastrointestinal tissues.
Functional analyses using candidate gene-specific, neuro-
nal-like CRISPR/Cas9-edited knockout cell clones demon-
strated impaired differentiation, proliferation and/or cell
survival capacity.
Conclusions: Our approach identified and validated
candidate HSCR genes and provided further insight into
underlying pathomechanisms of HSCR.
Major Funding: This study was supported by the
Heidelberg Stiftung Chirurgie, the Heinz and Heide Dürr
Stiftung and the Dres. Majic/Majic Schlez Stiftung.
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START: The STudy of Assisted Reproductive
Technologies
R. Lyle1*, C. Page2, Y. Lee2, K. L. Haftorn2, A. Jugessur2, J.
Bohlin2, H. K. Gjessing2, P. Magnus2, S. Håberg2
1Oslo University Hospital, Oslo, Norway, 2Norwegian
Institute of Public Health, Oslo, Norway
In the last few decades there have been marked changes in
patterns of fertility and family structure in rich countries.
These include increasing age at childbirth, a lower number
of children born to each woman or man, greater use of
assisted reproductive technology (ART), higher frequency
of family disruptions and increasingly complex family
structures. The Centre for Fertility and Health (CeFH;
www.cefh.no) consists of a multidisciplinary research team
of epidemiologists, geneticists, demographers, sociologists
and economists with research themes including fertility
problems and intergenerational transmission of health. The
START project aims to understand the causes and health
consequences of subfertility and how genetic influences and
epigenetic differences are associated with subfertility and
Assisted Reproductive Technologies (ART). ART may
introduce epigenetic changes in the embryo since the pro-
cedures are during a period of extensive epigenetic repat-
terning. It is unknown which genes may be affected and the
potential health consequences for the children. START uses
data from the Norwegian Mother, Father and Child Cohort
Study (MoBa; https://www.fhi.no/en/studies/moba/), which
follows more than 110 000 children and their parents. We
have collected genetic and epigenetic data from 1000 trios
with children born after ART, and 1000 trios from naturally
conceived children analyzed with the Illumina EPIC array
and the Illumina HumanCoreExome chip. Investigations are
focussed on the effect of ART treatment on imprinted genes
and fertility genes, and how epigenetic age acceleration
interacts with fertility and ART treatment. Our results show
DNA methylation changes due to both parental subfertility
and ART procedures.
R. Lyle: None. C. Page: None. Y. Lee: None. K. L.
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Evaluating diagnostic challenges with ABCA4-related
retinal disease - experience with a 7500 IRD patient
cohort sent for genetic diagnostics
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J. Känsäkoski*, K. Kämpjärvi, S. Tuupanen, K. Wells, L.
Sarantaus, P. von Nandelstadh, K. Merkkiniemi, H.
Västinsalo, E. Mårtensson, R. Perez Carro, E. Sankila, J.
W. Koskenvuo, S. Myllykangas, T. Alastalo
Blueprint Genetics, Espoo, Finland
Introduction: ABCA4 variants cause autosomal recessive
Stargardt disease (STGD1), the most prevalent hereditary
macular disease. Major challenges in STGD1 molecular
diagnostics include (i) non-coding variants typically not
targeted by available genetic tests (ii) copy number variants
(CNV) missed by standard testing, and (iii) interpretation
challenges with common hypomorphic variants. We eval-
uated the significance of challenging ABCA4 variants and
their contribution to STGD1 diagnostic yield in a cohort of
inherited retinal disease (IRD) patients.
Materials and Methods: We included 7500 IRD patients
tested at a CLIA laboratory between 2017 and 2019.
Sequencing analysis, including established non-coding
ABCA4 variants and high resolution CNV detection, was
done by using in-house developed and validated NGS
platform.
Results: Two disease-causing ABCA4 variants were
identified in 663 patients, of which 20 (20/663; 3%) had an
established non-coding variant and 11 (11/663; 1.5%) a
CNV. In 192 patients with clinically diagnosed ABCA4-
related disease, only one disease-causing variant was
identified. Among those, the hypomorphic allele ABCA4
c.5603A>T, p.(Asn1868Ile) was identified in 109 patients
(109/192: 57%), with a significantly increased allele
frequency (126/384= 0.328) compared to controls in
gnomAD (AF 11928/282712= 0.042) (OR: 11.087, 95%
CI: 8.953-13.73, p < 0.001). The median age at genetic
testing among the 109 patients was 56 years, which was
significantly higher compared to 37 years among the 663
patients with two disease-causing variants.
Conclusions: Non-coding variants and CNVs contribute
significantly to diagnostic yield in ABCA4-related disease.
Our large dataset supports the important role of the
hypomorphic allele ABCA4 c.5603A>T, p.(Asn1868Ile)
in diagnostics of late-onset STGD1.
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Insights into the retinal function of ciliopathy proteins
gained through zebrafish models
M. Masek, R. Bachmann-Gagescu*
University of Zurich- Medical Genetics, Zürich, Switzerland
Ciliopathies are disorders caused by dysfunction of primary
cilia, ubiquitous organelles involved in signal transduction.
In retinal photoreceptors (PRs), light sensation occurs in the
outer segments (OSs), which represent highly specialized
ciliary compartments. Consequently, retinal disease is a
common manifestation in ciliopathy patients. Our efforts to
elucidate the molecular functions of ciliopathy proteins rely
on zebrafish mutants in genes associated with Joubert syn-
drome, an iconic ciliopathy associated with retinal disease
in 25% of patients. We focus on genes that encode proteins
participating in distinct ciliary complexes: Cc2d2a at the
transition zone, representing the gate to the cilium, or Tal-
pid3/KIAA0586 at the basal body (BB), anchoring the
cilium in the cell. While both mutants display decreased
visual function, we identify distinct ultra-structural pheno-
types indicating specific roles for each protein in primary
cilium function. We find that Cc2d2a organizes the vesicle
fusion machinery at the periciliary margin and provides a
docking point for incoming vesicles through a chain of
interactions linking CC2D2A to NINL-MICAL3-RAB8. In
contrast, Talpid3 is involved in BB docking and ciliogen-
esis upstream of Rab8a activation. Retina-specific tran-
scriptomics identifies both shared and distinct effects on
gene transcription: while transcription of phototransduction
genes is decreased in both mutants, likely as a secondary
effect, we observe downregulation of the BBSome, a multi-
protein complex associated with the ciliopathy Bardet-Biedl
syndrome, only in talpid3 mutants, while Nek8 is
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upregulated only in cc2d2a mutants. In conclusion, our
findings demonstrate how mutations in genes causing the
same human disorder result in similar phenotypes through
distinct mechanisms.
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Functional characterization of a Xenopus tropicalis
knockout and a human cellular model of RCBTB1-
associated inherited retinal disease shows involvement of
RCBTB1 in the cellular response to oxidative stress
M. Carron1,2*, T. Naert1, G. Ascari2, S. Demuynck1, T. Van
Nieuwenhuyzen1, T. Rosseel2, D. Priem3,4, A. Kremer4, H.
Van Landeghem1, S. Hoogstoel2, F. Coppieters2, C.
Guérin5, K. Vleminckx1, E. De Baere2
1Ghent University, Biomedical Molecular Biology, Ghent,
Belgium, 2Ghent University, Center for Medical Genetics
and Dept of Biomolecular Medicine, Ghent, Belgium,
3Ghent University, Ghent, Belgium, 4VIB-UGent Center
for Inflammation Research, Ghent, Belgium, 5VIB Bioima-
ging Core, Ghent, Belgium
Introduction: The function of RCBTB1, recently impli-
cated in syndromic and non-syndromic inherited retinal
disease (IRD), remains unknown so far. Patients with
biallelic missense variants in RCBTB1 display diverse IRD
phenotypes such as retinitis pigmentosa. Here, we tested the
hypothesis that RCBTB1 is involved in NRF2-regulated
protection against reactive oxygen species in the eye, more
specifically in the retinal pigment epithelium (RPE).
Materials and Methods: A Xenopus tropicalis rcbtb1-/-
knockout (KO) was generated using CRISPR/Cas9 editing.
Histology and three-dimensional electron microscopy was
performed on retinas of rcbtb1-/- frogs. RNA-seq analysis
was performed on RCBTB1-mutated patients’ lymphocytes,
treated with H2O2, as well as on embryos from the rcbtb1-/-
KOs treated with CdCl2. An RCBTB1 knockdown cell line
was generated in ARPE-19 cells and functional assays (flow
cytometry, MTT-assay, cell death kinetics) assessed the
consequences of RCBTB1 loss-of-function.
Results: Rcbtb1-/- animals showed changes in the RPE,
similar to observations in human cases, including loss of
apical-basal cell polarity, cuboidal cell morphology,
spreading of the pigment granules and vacuolisation.
NRF2 downstream targets and several metallothioneins
were found to be differentially expressed, both in the KO
and cellular models. Functional assays in ARPE-19 cells
revealed that RCBTB1 depletion affects cellular responses
to external insults of oxidative stress.
Conclusion: We showed that the Xenopus tropicalis
rcbtb1-/- KO recapitulates the human IRD phenotype. Both
in vivo and in vitro functional data show involvement of
RCBTB1 in the cellular response to oxidative stress. This
provides insight into the mechanism underlying RCBTB1-
associated IRD and uncovers potential therapeutic
opportunities.
Funding: FWO/1802220N; FWO/1S52818N; BOF15/
GOA/011; BOF20/GOA/023.
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Loss of function of RIMS2, a synaptic membrane
exocytosis gene, causes a new phenotype characterized
by congenital cone-rod synaptic disease associated with
neurodevelopmental and pancreatic involvement
S. Mechaussier1*, B. Almoallem2, C. Zeitz3, K. Van Schil2,
L. Jeddawi4, J. Van Dorpe5, C. Condroyer3, O. Pelle6, M.
Polak7, N. Boddaert8, N. Bahi-Buisson9, M. Cavallin10, J.
Bacquet11, A. Mouallem-Bézière11, O. Zambrowski11,12, J.
Sahel3,13,14, I. Audo3,14,15, J. Kaplan1,11, J. Rozet1, E. De
Baere2, I. Perrault1
1Laboratory of Genetics in Ophthalmology (LGO),
INSERM UMR1163, Institute of Genetic Diseases, Imagine
and Paris University, Paris, France, 2Center for Medical
Genetics, Ghent University and Ghent University Hospital,
Ghent, Belgium, 3Sorbonne Université, INSERM, CNRS,
Institut de la Vision, Paris, France, 4Pediatric Ophthalmol-
ogy Division, Dhahran Eye Specialist Hospital, Dharan,
Saudi Arabia, 5Department of Pathology, Ghent University
and Ghent University Hospital, Ghent, Belgium, 6Cell
Sorting Facility, INSERM UMR1163, Institute of Genetic
Diseases, Imagine and Paris University, Paris, France,
7Endocrinology, Gynecology and Pediatric Diabetology
Department, University Hospital Necker-Enfants Malades,
Paris, France, 8Department of Pediatric Radiology, Hôpital
Necker-Enfants Malades, Paris University, Paris, France,
9Pediatric Neurology Department, University Hospital
Necker-Enfants Malades, Paris, France, 10Laboratory of
Embryology and genetics of human malformation, INSERM
UMR1163, Institute of Genetic Diseases, Imagine and Paris
University, Paris, France, 11Service d’Ophtalmologie,
Centre Hospitalier Intercommunal de Créteil (CHIC),
Créteil, France, 12Ophthalmology Department, University
Hospital Necker-Enfants Malades, Paris, France,
13Department of Ophthalmology, The University of Pitts-
burgh School of Medicine, Pittsburgh, PA, United States,
14Centre Hospitalier National d’Ophtalmologie des Quinze-
Vingts, INSERM-DHOS CIC 1423, Paris, France,
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Introduction: Anomalies in pre- and post-synaptic trans-
mission of visual information from photoreceptors to
bipolar cells are responsible for stationary congenital night
blindness (CSNB). Pre-synaptic disorders, characterized by
congenital nystagmus and photophobia, night blindness, are
known as cone-rod synaptic disorder (CRSD) can be mis-
taken for Leber congenital amaurosis (LCA). Full-field
electroretinogram is crucial for the differential diagnosis,
but it can be difficult to perform in young children. Here, we
report (i) the identification of biallelic mutations in the
RIMS2 gene encoding a pre-synaptic protein not yet asso-
ciated with human diseases in 3/4 families initially referred
for LCA and (ii) the diagnostic adjustment to CRSD with
variable associated alteration including autistic behavior
and insulinopathy.
Methods: Exome sequencing combined with targeted
RIMS2 testing were performed in 46 prescreened patients
with CRSD and 94 with LCA. Biallelic RIMS2-mutated
cases underwent ophthalmologic, neurologic and metabolic
assessment. RIMS2 immunostaining was performed on
human retina, brain and pancreas. Nonsense variants were
functionally investigated in mammalian cells. Results.
Biallelic RIMS2 sequence variants were found in four
unrelated families. RIMS2, a protein regulating synaptic
membrane exocytosis localizes in the human retinal outer
plexiform layer, Purkinje cells and pancreatic islets. Apart
from CRSD, neurodevelopmental disease was observed in
all cases, and abnormal glucose homeostasis in the eldest
patient.?Nonsense variants lead to truncated RIMS2 and
decreased insulin secretion in mammalian cells.
Conclusion: This is the first report of syndromic CRSD
with neurodevelopmental or pancreatic involvement due to
RIMS2 loss-of-function. The disease presentation is con-
sistent with the localization and function of RIMS2.
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Genetic and molecular analysis of urinary magnesium
concentration in Scottish and Croatian populations
C. B. Joseph1*, C. M. Stanton1, C. Drake1, T. S. Boutin1, J.
F. Wilson2, O. Polasek3, O. Devuyst4, T. Hurd1, C.
Hayward1
1MRC Human Genetics Unit, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh,
United Kingdom, 2Centre for Global Health Research,
Usher Institute for Population Health Sciences and
Informatics, University of Edinburgh, Edinburgh, United
Kingdom, 3Split Medical School, Split, Croatia, 4Institute of
Physiology, University of Zurich, Zurich, Switzerland
Magnesium is the second most abundant bivalent cation in
the body and is essential for many cellular processes. Renal
magnesium handling plays an important role in maintaining
magnesium homeostasis, however the exact biological
mechanisms remain unclear. A recent genome-wide asso-
ciation study (GWAS) identified an association between
urinary magnesium concentration (uMg) and variants in the
ARL15 gene on chromosome 5. ARL15 encodes a GTP-
binding protein that regulates the magnesium transporter
channel TRPM6, and other proteins involved in magnesium
homeostasis in physiologically relevant cell lines. We
conducted meta-analyses for urinary magnesium in 11, 617
individuals from Scottish and Croatian populations to
determine possible genes involved in these traits. Mass
spectrometry analysis was conducted to determine inter-
actors of Arl15 and in-vitro knockout models of Arl15 was
established using CRISPR-Cas9. The top SNP associated
with uMg in our meta-analyses lies within a transcription
factor binding site in an enhancer region of ARL15. Indi-
viduals homozygous for the alternate allele of rs35931 has
lower urinary magnesium levels compared to individuals
with the homozygous reference allele. Arl15 interacts with
magnesium transporters within the distal convoluted tubule
segment of the kidneys. Furthermore, we find that homo-
zygous deletion of Arl15 is lethal at the organismal level.
We hypothesise that the variant found affects the expression
of ARL15, which, in turn modulates magnesium transport
by regulating magnesium transporters. We are performing
further functional studies to elucidate the role ARL15 plays
in magnesium homeostasis both in vitro and in vivo.
C. B. Joseph: None. C. M. Stanton: None. C. Drake:
None. T. S. Boutin: None. J. F. Wilson: None. O. Polasek:
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C15.08
RNA-seq approach to detect splicing alterations in
primary ciliary dyskinesia and non-CF bronchiectasis
J. Legebeke1*, G. Wheway1, H. Wai1, W. Walker1,2, J. S.
Lucas1,2, D. Baralle1,2
1University of Southampton, Southampton, United King-
dom, 2University Hospital Southampton, Southampton,
United Kingdom
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Mutations that cause PCD have been reported in >40 genes.
Most cases are recessive, caused by biallelic changes in
these genes. These account for around 70% of cases, sug-
gesting that additional genes, and non-coding or synon-
ymous changes in known genes, remain to be identified.
Non-CF bronchiectasis is a heterogeneous group of dis-
orders and adults may need to be investigated for PCD.
Here we present an optimised pipeline for RNA analysis
from nasal brushings taken from the inferior turbinate of
patients with suspected PCD or non-CF bronchiectasis. We
present analysis pipelines to investigate differences in gene
expression, alternative splicing and the identification of
deleterious splicing events. We developed gene-neutral and
gene-specific analysis protocols, from both nasal brushings
stored in RNA-later and cells from nasal brushings cultured
at the air-liquid interface (ALI). We present this RNA-seq
approach as a particularly useful diagnostic tool to inves-
tigate patients in whom a single pathogenic variant has been
identified in a known PCD gene and where we suspect an
alteration in splicing of the same gene due to a second
intronic or synonymous / non-synonymous exonic variant.
This represents a step towards using RNA analysis for
increasing diagnostic yield in rare recessive respiratory
disease. JL, DB and HT are supported by a NIHR Research
Professorship to DB (RP- 2016-07-011). JL is further sup-
ported by Southampton NIHR BRC. GW is funded by a
Wellcome Trust Seed Award in Science (Grant No. 204378/
Z/16/Z) and a University of Southampton Faculty of Med-
icine Research Management Committee research grant.
G. Wheway: None. H. Wai: None. W. Walker: None. J.
S. Lucas: None. D. Baralle: None.
C15.09
Combined exome/genome sequencing with in-house
variant data repository mining confirm USP53 as a
causal gene for intrahepatic cholestasis
S. Alawbathani1*, M. Rocha1, H. Arshad Cheema2, R.
Boustany3, S. Nampoothiri4, A. Alswaid5, N. El Koofy6, V.
Karageorgou1, I. Hövel1, S. Khan1, C. Beetz1, A. Rolfs1, P.
Bauer1, A. M. Bertoli-Avella1
1Centogene AG, Rostock, Germany, 2Children’s Hospital
and Institute of Child Health, Lahore, Pakistan, 3AUBMC
American University of Beirut Medical Center, Beirut,
Lebanon, 4Amrita Institute of Medical Sciences, Kerala,
India, 5King Abdulaziz Medical City, Riadh, Saudi Arabia,
6Abu El Reesh Children’s Hospital, Cairo, Egypt
Cholestatic liver disease is a significant cause of morbidity
and mortality in the paediatric population, starting in the
early postnatal life. Severity is variable, from benign idio-
pathic neonatal hepatitis to intrahepatic cholestasis leading
to liver failure and transplant. There are several genes
described for different genetic diseases that lead to choles-
tasis. USP53 has been recently suggested as a candidate
gene for paediatric intrahepatic cholestasis based on one
family with two affected siblings. Interestingly, USP53
interacts with tight junction protein 2 (TJP2) for which
pathogenic variants are known to cause progressive familial
intrahepatic cholestasis. To date, the USP53 gene has not
been linked to an OMIM phenotype. By combining exome/
genome sequencing and mining our in-house variant data-
base we identified five patients from unrelated families. All
affected individuals display a similar phenotype, mainly
including early onset intrahepatic cholestasis. Moreover,
one family showed hearing loss as an additional phenotype.
All patients were homozygotes for different loss-of-function
variants in the USP53 gene. USP53 (ubiquitin specific
peptidase 53) is a tight junction-associated protein that is
known to involve in the survival of auditory hair cells and
hearing. Our results confirm USP53 as a novel gene for
autosomal recessive intrahepatic cholestasis. Additionally,
we demonstrate that combined exome/genome sequencing
and variant database mining is an effective approach to
discover and confirm novel genes related to human diseases.
This accelerate the process of gene discovery and ultimately
shortens the diagnostic odyssey in rare genetic disorders.
S. Alawbathani: A. Employment (full or part-time);
Significant; Centogene AG, Rostock, Germany. M. Rocha:
A. Employment (full or part-time); Significant; Centogene
AG, Rostock, Germany. H. Arshad Cheema: None. R.
Boustany: None. S. Nampoothiri: None. A. Alswaid: None.
N. El Koofy: None. V. Karageorgou: A. Employment (full
or part-time); Significant; Centogene AG, Rostock, Ger-
many. I. Hövel: A. Employment (full or part-time);
Significant; Centogene AG, Rostock, Germany. S. Khan:
A. Employment (full or part-time); Significant; Centogene
AG, Rostock, Germany. C. Beetz: A. Employment (full or
part-time); Significant; Centogene AG, Rostock, Germany.
A. Rolfs: A. Employment (full or part-time); Significant;
Centogene AG, Rostock, Germany. P. Bauer: A. Employ-
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Rostock, Germany. A. M. Bertoli-Avella: A. Employment
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Elucidating the molecular mechanism underlying later-
ality defects
D. Antony1,2,3*, A. Maver4, M. A. Deardorff5,6, L. Slagter2,
K. Wu2, Z. Bakey1,2, E. Gulec7, A. Gezdirici7, H. Brunner2,3,
M. Schmidts1,2,3
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Introduction: Laterality defects are rare developmental
disorders, occurring isolated or as part of complex syn-
dromes. Underlying cause is frequently dysfunction of
motile cilia causing Primary Ciliary Dyskinesia (PCD) and
rarely, non-motile cilia defects or non-ciliary causes. In
addition to randomization of the left right body axis, PCD is
characterized by frequent respiratory infections and
infertility.
Methods: We used Whole Exome Sequencing (WES) to
delineate the underlying molecular cause in 37 mainly
consanguineous families with laterality defects.
Results: We identified causative variants in 32% with
majority of mutations detected in genes previously
associated with PCD, including 2 small homozygous
CNVs. Variants in non PCD genes, PKD1l1 and GJA1
were also detected. We further identified homozygous
null mutations in two genes not previously associated
with human disease, MNS1 and DNAH9, both in cases
with situs inversus but little or no respiratory symptoms.
Gene matcher database revealed two additional families
with biallelic DNAH9 mutation and immunofluorescence
analysis revealed complete absence of DNAH9 from
respiratory cilia of one affected while DNAH9 localises
to the distal half of cilia in controls. Further, we found
direct interaction of DNAH9 with the ODA docking
complex protein CCDC114 using Y2H screening
also interaction with DNAH5 and DNAI2 using co-
Immunoprecipitation.
Conclusion: We could only solve a third of the laterality
cases genetically using WES, pointing towards non coding
variations, genetic mosaicism or epigenetic effects while we
were able to identify two novel human disease causing
genes, MNS1 and DNAH9, both causing laterality defects
with no or little respiratory disease. ERC: TreatCilia
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Biallelic missense variant in SVBP causes impaired
detyrosination of tubulin leading to complex hereditary
spastic paraplegia without microcephaly
E. Verdura1,2*, N. Launay1,2, G. Fernandez Garcia de
Eulate3,4,5, J. Ondaro4,5, A. Schlüter1,2, M. Ruiz1,2, S.
Fourcade1,2, A. López de Munain3,4,5, A. Pujol1,2
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IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain,
2Center for Biomedical Research on Rare Diseases
(CIBERER U759), Ministry of Science, Innovation and
University, Madrid, Spain, 3Department of Neurology,
Hospital Universitario Donostia, San Sebastián, Spain,
4Department of Neurosciences, Instituto Biodonostia, San
Sebastián, Spain, 5Department of Neurosciences, School of
Medicine and Nursery, University of the Basque Country,
UPV-EHU, San Sebastián, Spain
Introduction: Reversible C-Terminal detyrosination of
alpha-tubulin is crucial for microtubule organization, and is
strongly linked to neuronal differentiation. VASH1 and
VASH2, in complex with SVBP, have recently been iden-
tified as responsible for intracellular tubulin detyrosination
activity. Biallelic loss-of-function mutations in SVBP have
much recently been described in patients showing intellec-
tual disability, microcephaly, ataxia and hypotonia.
Methods: All patients underwent accurate clinical
evaluation and provided informed consent. Whole-exome
sequencing (WES) was performed using patients’ DNA
samples, and segregation in relatives was confirmed by
Sanger sequencing. Primary fibroblasts were generated from
patients’ skin biopsies, and cultured cells were incubated
with paclitaxel to analyze detyrosinated tubulin levels by
immunofluorescence and western blot. cDNA of VASH1
and wild-type/mutated forms of SVBP were cloned into a
pCMV-Tag4A vector, and then cotransfected into HeLa
cells for Western Blot analysis.
Results: We report two families with multiple patients
harboring an homozygous missense variant in SVBP (p.
Leu49Pro). Affected individuals show spastic paraplegia,
peripheral neuropathy, verbal apraxia and intellectual
disability, in absence of microcephaly, broadening the
previously reported phenotype. In vitro experiments in
patients’ fibroblasts demonstrate a significant loss of
VASH1/2 detyrosination activity and decreased SVBP
levels. Cotransfection studies show that SVBP p.Leu49Pro
variant reduces both VASH1 and SVBP soluble quantities
or their stability.
Conclusions: Our results expand the phenotypic spec-
trum of SVBP mutations to complex spastic paraplegia
without microcephaly, and confirm for the first time that a
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detyrosination defect is observed in patients’ cell lines,
enabling functional testing of SVBP variants and extended
pathogenetic studies.
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Understanding the mechanism of RNF216-mediated
neurodegeneration: genetic, proteomic, neuropathologi-
cal and cellular approach
S. Roy1,2*, P. Ervilha Pereira1,2, N. Schuermans1,2, A.
Sieben3,4, F. Thery5,6, E. Mondragon Rezola7, E.
Debackere1,2, P. LeBlanc1,2, M. Galas8, P. Santens3,4, F.
Impens5,6, E. Bogaert1,2, B. Dermaut1,2
1Center for Medical Genetics, Ghent University Hospital,
Gent, Belgium, 2Department of Biomolecular Medicine,
Faculty of Medicine and Health Sciences, Ghent University,
Ghent, Belgium, 3Department of Neurology, Ghent Uni-
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Skin, Faculty of Medicine and Health Sciences, Ghent
University, Ghent, Belgium, 5Department of Biomolecular
Medicine, Faculty of Medicine and Health Sciences, Ghent
University, Gent, Belgium, 6Center for Medical Biotechnol-
ogy, VIB Ghent, Ghent, Belgium, 7Department of Neurol-
ogy, University Hospital Donostia, Basque Country
University, Donostia, Spain, 8Inserm, UMRS1172, JPARC,
Alzheimer & Tauopathies, Lille, France
Introduction: Neurodegenerative diseases frequently result
from mutations in ubiquitin-signaling genes. Our group was
among the first to report bi-allelic mutations in RNF216, an
E3 ubiquitin ligase, as the genetic cause of Gordon Holmes
syndrome (GHS), an adult-onset rare neurodegenerative
disorder characterized by ataxia, dementia and hypogona-
dotropic hypogonadism or Huntington-like disorder (HDL).
To date, >10 mutations in RNF216 have been reported not
only from the catalytic active site but also from N-terminal
part of the protein.
Objective: We intend to unravel the mechanisms by
which RNF216 mutations lead to GHS and HDL. We aim
to identify novel RNF216 mutations for genotype-
phenotype correlation studies, identify protein composi-
tion of the pathological intranuclear inclusions, and
understand the cellular and biochemical function of the
RNF216 protein.
Methods: Frozen and fixed brain material from patient
were used for generalized proteomics and neuropathological
studies and patient fibroblast and Hela cells were used for
cellular studies.
Results: We describe a Spanish patient with HDL having
2 novel compound heterozygous missense mutations in
RNF216. The study of brain material from one of the two
reported Belgian families demonstrated ubiquitin- and p62-
positive intranuclear inclusions, negative for Tau, ?-synu-
clein and TDP-43. Proteomics generated a list of candidate
genes whose histopathological examination is currently
ongoing. Hela cells transfected with wildtype and mutant
RNF216 constructs revealed RNF216 and ubiquitin positive
intranuclear speckle-like bodies.
Conclusion: The identity of intranuclear bodies should be
further analyzed hoping to reveal molecular intricacies
linked to this neurodegenerative disease. Odysseus Type-I
(G0H8318N) FWO grant, Starting grant (01N10319) Ghent
University
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The genotype-phenotype correlation of intragenic
RBFOX1 deletions.
M. A. Paczkowska*, M. Geremek, B. Nowakowska
Institute of Mother and Child, Warsaw, Poland
The RBFOX1 gene encodes a protein that regulates pre-
mRNA splicing in developmental genes expressed in
muscle, heart and neuronal cells. Intragenic deletions of
RBFOX1 gene have been identified as susceptibility loci
and reported in patients with aggressive behavior, conduct
disorder, epilepsy and autism spectrum disorder. Despite of
the documented correlation with neurodevelopmental dis-
orders, the deletions of RBFOX1 gene are often inherited
from the healthy parents, therefore the clinical interpretation
of CNVs within this gene is still unclear. We applied oli-
gonucleotide microarrays (OGT) in a cohort of 9430
patients with neurodevelopment disorders and their healthy
relatives. The analyses of genomes were performed using
genome-wide array to accurate detection of copy number
variation at the exon level in RBFOX1 gene. Chromosomal
analysis revealed intragenic RBFOX1 deletions in 36
patients. The differential distribution across the gene
between patients with neurodevelopmental disorders and
the control group allowed to distinguished evidently
pathogenic areas within the gene. Deletions of exones 1-2
and 13-14 have high penetrance, and are mainly associated
with conduct disorder and autism spectrum disorder. While
the middle part of the gene and all intronic CNVS were
observed with higher frequency in the control group,
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suggesting their benign impact on the phenotype. The work
was supported by MINDDS - CA COST Action CA16210 -
Maximising Impact of research in NeuroDevelopmental
DisorderS
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Mitochondrial dysfunction and oxidative stress contri-
bute to the phenotype of FOXP1 deficiency
J. Wang*, H. Fröhlich, G. A. Rappold
Institut für Humangenetik, Heidelberg, Germany
Patients with FOXP1 haploinsufficiency present intellectual
disability, autism spectrum disorder, severe speech and lan-
guage impairments as well as motor dysfunction. To unravel
the pathological mechanism underlying FOXP1 syndrome,
we analysed Foxp1+/- mice, which closely reflect FOXP1
haploinsufficiency. We can show that Foxp1+/- animals
exhibit behavioural deficits such as reduced neonatal ultra-
sonic vocalization, hyperactivity, anxiety and alterations in
spatial navigation and memory. Furthermore, they manifest
decreased exercise capacity and endurance. We also found
that Foxp1+/- animals display a reduced striatal expression of
proteins involved in mitochondrial biogenesis and dynamics
(Pgc-1?, Tfam, Opa1 and Drp1), suggesting that mitochon-
drial dysfunction may contribute to the symptoms. To address
this issue in more detail, we investigated mitochondria in WT
and Foxp1+/- animals. We demonstrate that Foxp1+/- striatal
neurons display a disrupted mitochondrial membrane poten-
tial. In addition, we detected an increased abundance of
reactive oxygen species, increased cytochrome C release as
well as lipid peroxidation in the Foxp1+/- striatum. In sum-
mary, our results indicate mitochondrial dysfunction in mur-
ine Foxp1 deficiency, suggesting that mitochondrial
dysfunction and increased oxidative stress may also con-
tribute to the deficits in FOXP1 Syndrome.
H. Fröhlich: None. G. A. Rappold: None.
C16 The Interplay of Law, Policy and Genomics
C16.1
Regulating Preimplantation Genetic Diagnosis: A com-
parison of international policy trends and perspectives
R. Isasi*, M. E. Ginoza
Miller School of Medicine, University of Miami, Miami, FL,
United States
Preimplantation genetic diagnosis (PGD) is a reproductive
technology which allows prospective parents to select their
future offspring based on genetic characteristics. During the
last decade, its regulation has followed mostly a linear path,
with incremental changes driven by scientific advances or
by court driven alterations. But also, shift has been
prompted by greater societal uptake. No longer considered
an experimental practice, stakeholders have challenged the
status quo, recognizing that both technological and policy
developments do not take place in a moral vacuum. They
have done so under the flag of reproductive freedom,
equitable access and welfare considerations, amongst other
ethical concerns. Despite the passage of time, the ubiquitous
presence of eugenics seems to constantly cast a shadow
over technologies that open the door for selecting the
genetic characteristics of a human offspring. For this reason,
we can predict that despite greater societal acceptance,
widening its permissibility criteria will remain contested
and a matter of continue social and policy debate. In this
presentation, we examine variations in policy approaches.
We draw on a representative sample of 19 countries (Aus-
tralia, Austria, Belgium, Brazil, Canada, China, France,
Germany, India, Israel, Italy, Japan, Mexico, Netherlands,
Singapore, South Korea, Switzerland, United Kingdom, and
the United States) to provide a global landscape of the
spectrum of policy and legislative approaches. We also
explore central socio-ethical and policy issues and con-
tentious applications as for instance, permissibility criteria
(e.g. medical necessity), non-medical sex selection and
reproductive tourism. Finally, we further outline genetic
counseling requirements across policy approaches.
R. Isasi: None. M. E. Ginoza: None.
C16.2
Regulation of international direct-to-participant (DTP)
genomic research: results and recommendations from a
31-country study
M. Zawati1*, M. Rothstein2, B. Knoppers1
1McGill University, Montreal, QC, Canada, 2University of
Louisville, Louisville, KY, United States
International direct-to-participant (DTP) research promises
to greatly increase the number and diversity of participants
for research on genetic disorders. This phenomenon, in
which participants recruited online supply biosamples or
provide access to electronic health records, may be thwarted
by prohibitions on research without ethics review in each
participating country. Though global recruitment is a pro-
mising research strategy, there is an urgent need to under-
stand the international regulatory landscape to foster a more
global DTP genomics research ecosystem. In this
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presentation, we set out to determine how DTP genomics
research is regulated in 31 countries. We engaged with local
experts in 31 countries, each of whom were asked to pre-
pare a report of 2,000 words in response to a 10-item
questionnaire on the regulation of DTP research. These
reports represent the first systematic effort to assess the legal
environment for international DTP genomic research. We
will describe the results of this work, including the state of
regulation of international genomic research practices. We
found, for example, that 17/31 experts reported it would be
unlawful for an international researcher to conduct DTP
research without local ethics approval. We will conclude by
outlining our team’s recommendations on international DTP
genomic research, elaborating on themes of ethics equiva-
lence and the importance of incorporating cultural con-
siderations in policy development. While there are
significant legal barriers to expanding DTP genomics
research internationally, sound policy will maximize its
potential.
Funding information: National Institute of Health (NIH),
National Human Genome Research Institute (NHGRI),
Grant No. 5R01HG009914-02.
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Genomic sequencing capacity, data retention and
personal access to raw data in Europe
S. Narayanasamy1*, V. Markina1, A. Thorogood2, A.
Blazkova1, M. Shabani3, B. M. Knoppers2, B. Prainsack4, R.
Koesters1
1Megeno S.A., Esch-sur-Alzette, Luxembourg, 2Centre of
Genomics and Policy, McGill University, Montreal, QC,
Canada, 3Metamedic, Faculty of Law and Criminology,
Ghent University, Ghent, Belgium, 4Department of Political
Science, University of Vienna, Vienna, Austria
Whole genome/exome sequencing (WGS/WES) has
become widely adopted in research and, more recently, in
clinical settings. Many hope that the information obtained
from interpretation of this data will have medical benefits
for patients and - in some cases - also their biological
relatives. Because of the manifold possibilities to reuse
genomic data, enabling sequenced individuals to access
their own raw (uninterpreted) genomic data is a highly
debated issue. This paper reports some of the first empirical
findings on personal genome access policies and practices.
We interviewed 39 respondents, working at 33 institutions
in 21 countries across Europe. These sequencing institutions
generate massive amounts of WGS/WES data and represent
varying organisational structures and operational models.
Taken together, in total, these institutions have sequenced
317,259 genomes and exomes to date. Most of the
sequencing institutions reported that they are able to store
raw genomic data in compliance with various national
regulations, although there was a lack of standardisation of
storage formats. Interviewees from 12 of the 33 institutions
included in our study reported that they had received
requests for personal access to raw genomic data from
sequenced individuals. In the absence of policies on how to
process such requests, these were decided on an ad hoc
basis; in the end, at least 28 requests were granted, while
there were no reports of requests being rejected. Given the
rights, interests, and liabilities at stake, it is essential that
sequencing institutions adopt clear policies and processes
for raw genomic data retention and personal access.
S. Narayanasamy: A. Employment (full or part-time);
Significant; Megeno S. A. V. Markina: A. Employment (full
or part-time); Significant; Megeno S. A. A. Thorogood: F.
Consultant/Advisory Board; Modest; Megeno S. A. A.
Blazkova: A. Employment (full or part-time); Significant;
Megeno S.A. M. Shabani: None. B. M. Knoppers: None. B.
Prainsack: None. R. Koesters: A. Employment (full or part-
time); Significant; Megeno S.A.
C16.4
The genome as individual property or common good.
Conceptualization of the genome within a citizen forum
C. Mayeur*, W. Van Hoof
Sciensano, Anderlecht, Belgium
In recent years, policymakers and experts showed particular
interest in public engagement in genomics. However, most
projects focus on expressed values, without exploring the
concepts behind them. To understand which uses of genomic
information citizens support, one should first examine their
conceptualization of the human genome and then explore the
values they assign to it. We organized a citizen forum on the
ethical, legal and societal issues surrounding the use of
genomic information in healthcare. During three weekends, a
panel of 32 citizens, informed by experts of different back-
grounds, debated and reflected with the final aim of producing
political recommendations for the ministry of public health.
An inductive thematic analysis of their discussions shows that
citizens view the genome as the most intimate part of indi-
viduals, that warrants protection to avoid breach of privacy.
Additionally, citizens claim that humans are more than their
genetic makeup: they are socially, culturally, emotionally, and
psychologically complex, and should be treated and con-
sidered accordingly. This is why citizens vehemently oppose
genetic categorization and discrimination. Finally, a funda-
mental tension remains between two conceptions of the
genome - the individual’s property versus common good -
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with consequences on sensitive issues such as commerciali-
zation, access to and sharing of data, individual responsibility
and autonomy. Citizens’ conceptions of the genome inform
such different norms and values that it is important for pol-
icymakers and experts to appreciate them to be able to inform
citizens and engage with them on genomics. Innovative
Partnership for Action Against Cancer funded this study.
C. Mayeur: None. W. Van Hoof: None.
C17 New Therapeutic Approaches
C17.1
An innovative dual-reporter cell line to identify protein
level modulators in drug-repositioning for rare genetic
diseases: a proof-of-principle in Autosomal Dominant
LeukoDystrophy (ADLD)
E. Giorgio1*, E. Pesce2, E. Pozzi1, E. Sondo2, M.
Lorenzati3, M. Ferrero1, G. Borrelli1, E. Della Sala1, A.
Buffo3, N. Pedemonte2, A. Brusco1,4
1University of Torino-Dep Medical Sciences, Torino, Italy,
2IRCCS Istituto Giannina Gaslini-UOC Genetica Medica,
Genova, Italy, 3University of Torino-Dep. Neuroscience
Rita Levi Montalcini and Neuroscience Institute Cavalieri
Ottolenghi, Torino, Italy, 4Città della Salute e della Scienza
University Hospital-Medical Genetics Unit, Torino, Italy
Rare genetic diseases affect a small number of patients each,
and thus are of limited interest to the biopharmaceutical
industry. Since the vast majority still have no treatment
options, a cost-effective strategy is the repurposing of existing
drugs as therapies for new disorders. The success of drug-
repositioning approaches is strongly related to the optimiza-
tion of an appropriate reporter cell line suitable for high
throughput screening (HTS). Here, we report the development
and optimization of a stable cell line constitutively expressing
an innovative dual-reporter IRES-containing bicistronic vec-
tor allowing the rapid and efficient identification of mod-
ulators acting at protein level. Drugs restoring physiological
protein levels represent a promising therapeutic strategy for
genetic disorders associated with genomic deletions/duplica-
tions. An instructive example is Autosomal Dominant Leu-
koDystrophy (ADLD), a rare disease caused by LMNB1
accumulation due to gene duplication or to a regulatory
alteration. We have screened by HTS ~ 400 FDA-approved
drugs and we have identified a positive hit. This drug (name
reserved) has been validated in 5 different cell lines con-
firming its ability to specifically reduce LMNB1 levels (30%-
80% of reduction). Finally, the treatment of ADLD fibroblasts
showed a decrease of about 50% of cytoplasmic LMNB1,
supporting the therapeutic value of our molecule. Our results
pave the way towards a clinical trial for ADLD following the
“compassionate use” practice. Finally, our strategy using a
stable dual-reporter cell line can be exploited for identifying
effective drugs for other genetic and multifactorial disorders
in which the modulation of a protein represents a promising
therapeutic option.
E. Giorgio: None. E. Pesce: None. E. Pozzi: None. E.
Sondo: None. M. Lorenzati: None. M. Ferrero: None. G.
Borrelli: None. E. Della Sala: None. A. Buffo: None. N.
Pedemonte: None. A. Brusco: None.
C17.2
Low-dose infigratinib, an oral selective fibroblast
growth factor receptor (FGFR) tyrosine kinase inhibitor
(TKI), demonstrates activity in preclinical models of
achondroplasia (ACH)
B. Demuynck1*, J. Flipo1, G. Li2, C. Dambkowski2, L.
Legeai-Mallet1
1Université de Paris, Institut Imagine, Laboratory of
Molecular and Physiopathological Bases of Osteochondro-
dysplasia, INSERM, Paris, France, 2QED Therapeutics
Inc., San Francisco, CA, United States
Background: FGFR3 gain-of-function mutations play a
crucial role in ACH, thanatophoric dysplasia (TD), and
hypochondroplasia. Therapies blocking the MAP kinase
(MAPK) pathway, such as C-type natriuretic peptide (CNP)
analogues, are in development; however, FGFR3 can also
promote chondrocyte proliferation via alternate pathways
(e.g. STAT1). We tested the hypothesis that the FGFR1-3
selective oral TKI infigratinib (BGJ398) is more efficacious
than a CNP analog due to inhibition of both MAPK and
STAT1 in preclinical models of ACH carrying FGFR3
gain-of-function mutations.
Methods: Human TD chondrocytes were incubated with/
without infigratinib or vosoritide, and total/phospho-ERK1/
2 levels were measured. A mouse model (Fgfr3Y367C/+)
mimicking ACH received subcutaneous injections of
infigratinib or vehicle control daily (0.2, 0.5 mg/kg/day)
or every 3 days (1 mg/kg) for 15 days.
Results: In vitro, 10−10M infigratinib led to significant
inhibition of ERK1/2 phosphorylation (p<0.05) in TD
chondrocytes, while vosoritide treatment had significant
activity only at concentrations >10−5M. In vivo,
significant improvement was observed in upper limbs
(humerus +7%, ulna +11%), lower limbs (femur +11%,
tibia +16%), foramen magnum length and organization
of growth plate structure in mice treated with infigratinib
(daily and intermittent injections). Infigratinib activity
was dose dependent with no apparent toxicities.
Conclusions: Infigratinib has superior activity over
vosoritide in vitro, suggesting that inhibition of multiple
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pathways downstream of FGFR3 may lead to better
efficacy. Results in vivo indicate that clinically relevant
doses of infigratinib significantly promote growth. Pre-
clinical data support development of infigratinib in ACH,
with a clinical study launching this year.
B. Demuynck: None. J. Flipo: None. G. Li: A. Employ-
ment (full or part-time); Significant; QED Therapeutics Inc.
E. Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; QED Therapeutics Inc.
C. Dambkowski: A. Employment (full or part-time);
Significant; QED Therapeutics Inc. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Significant; BridgeBio Pharma, Novonate, Origin Bios-
ciences. L. Legeai-Mallet: None.
C17.3
CRISPR/Cas9 gene editing approach completely
repaired the causative COL4A5 10bp deletion in a
naturally occurring dog model of Alport Syndrome.
S. Daga1*, K. Capitani2,3, F. Donati2, G. Beligni1, S. Croci1,
F. Valentino1, C. Fallerini1, R. Tita4, C. Rivera5, S. Clark5,
M. Mencarelli4, M. Baldassarri4, E. Benetti1, S. Furini3, E.
Frullanti1, M. Nabity5, A. Auricchio6,7, S. Conticello2, A.
Renieri1,4, A. Pinto4
1Medical Genetics, University of Siena, Siena, Italy, 2Core
Research Laboratory - ISPRO, Florence, Italy, 3Depart-
ment of Medical Biotechnologies, University of Siena,
Siena, Italy, 4Genetica Medica, Azienda Ospedaliera
Universitaria Senese, Siena, Italy, 5Department of Veter-
inary Pathobiology, Texas A&M University College of
Veterinary Medicine and Biomedical Sciences, College
Station, TX, United States, 6Telethon Institute of Genetics
and Medicine (TIGEM), Pozzuoli, Italy, 7Department of
Advanced Biomedicine, Federico II University, Naples,
Italy
Alport Syndrome (AS) is a genetic disorder characterized by
clinicopathologic alterations ranging from GBM abnormal-
ities up to ESRD. Extensively reported mutations in the
COL4A3/A4/A5 genes are causative of both the autosomal
and the X-linked forms. Although great pharmacological
advances have been achieved in the past years, unfortunately
no definitive therapy is currently available. Podocytes,
terminally differentiated cells, produce a unique collagen in
the GBM. We have previously demonstrated that podocyte-
lineage cells can be isolated from AS patients’ urine, and we
have proven the efficiency of a bi-plasmid (AAV)2-
CRISPR/Cas9 approach to restore the wild-type genotype
in-vitro. Two mutations, namely the COL4A5 p.G624D and
the COL4A3 p.G526E, mimicking XLAS and ADAS forms
respectively, were effectively corrected with an HDR
percentage greater than 44% and undesired in/dels lower
than 12%. Here we show that, moving to a preclinical
approach, it is possible to correct the causative COL4A5-
Ex9-10bp-deletion in a naturally occurring dog model, using
a macro-500bp-DNA-Donor. The target region, in 80% of
all treated cells, was corrected without in/dels in the neigh-
boring sites. A silent mutation, inserted as a tag on the PAM,
was used to monitor the correction and to protect the DNA
from a new spCas9 cut. Based on AAV2/GFP biodistribu-
tion, in-vivo infection with (AAV)2-CRISPR/Cas9 will be
performed at 2-3 months of age using single carotid artery
catheterization to target both renal arteries. This patented
approach, providing the proof-of-principle for a revolu-
tionary AS gene therapy, can open up the possibility to
novel clinical trials, based on personalized strategy.
Italian patent application n102018000020230
S. Daga: None. K. Capitani: None. F. Donati: None. G.
Beligni: None. S. Croci: None. F. Valentino: None. C.
Fallerini: None. R. Tita: None. C. Rivera: None. S. Clark:
None. M. Mencarelli: None. M. Baldassarri: None. E.
Benetti: None. S. Furini: None. E. Frullanti: None. M.
Nabity: None. A. Auricchio: None. S. Conticello: None. A.
Renieri: None. A. Pinto: None.
C17.4
Single-intrathecal delivery of a new AAV9-mediated
gene therapy vector provides long-term safe expression
of frataxin and prevents neurological and cardiac
deficits, neurodegeneration and iron deposition in a
Friedreich’s Ataxia mouse model
E. Balagué1*, D. Cota-González1, K. Adrián-Campbell1, B.
García-Lareu2, A. Bosch2, J. Coll-Cantí3, M. Chillón4, I.
Sánchez1,5, A. Matilla-Dueñas1,5
1Translational and Functional Neurogenetics Unit, Depart-
ment of Neuroscience, Germans Trias Research Institute
(IGTP), Universitat Autònoma de Barcelona-Campus Can
Ruti, Badalona, Spain, 2Institut de Neurociències (INc),
Department of Biochemistry and Molecular Biology,
Universitat Autònoma Barcelona 5th level, Edifici H,
Institut Neurociencies, Campus UAB, Bellaterra, Spain,
3Unitat de Neuromuscular, Hospital Universitari Germans
Trias i Pujol, Badalona, Spain, 4Institució Catalana de
Recerca i Estudis Avançats (ICREA), Vall d’Hebron Institut
de Recerca, Hospital Universitari Vall d’Hebron, Vector
Production Unit (UPV) and Universitat Autònoma Barce-
lona, Barcelona, Spain, 5Functional Biology and Experi-
mental Therapeutics lab, Translational and Functional
Neurogenetics Unit, Department of Neuroscience, Germans
Trias Research Institute (IGTP), Universitat Autònoma de
Barcelona-Campus Can Ruti, Badalona, Spain
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Introduction: Friedreich’s ataxia (FRDA) is a recessively
inherited neurodegenerative disease caused by frataxin
(FXN) deficiency. FRDA is characterised by progressive
ataxia, sensory loss and hypertrophic cardiomyopathy.
Neurodegeneration is identified in DRG neurons, peripheral
sensory nerves, the posterior column, and cerebellar dentate
nucleus. To date, proof-of-concept approaches have high-
lighted the therapeutic potential of AAV-gene therapy in
FRDA. However, these studies have used synthetic pro-
moters initially providing very high-yields of FXN levels
and known to shutdown over time. Recent data point to the
importance of maintaining frataxin levels within a range due
to potential toxicity.
Methods: We generated a new AAV9-gene therapy
vector encoding a DNA sequence for frataxin regulated by
the hPGK1 promoter, which provides constitutive, ubiqui-
tous, and long-term expression of frataxin in YG8R
FRDA mice.
Results: Here we show that a single intrathecal admin-
istration of this vector into 2-month-old FRDA mice results
in effective transduction of the recombinant frataxin gene
into DRG, spinal cord, cerebellar dentate, heart, and liver,
resulting in expression of recombinant frataxin protein at
levels within those in WT mice, for at least 12 months with
no apparent vector-induced toxicity. AAV9-FXN treated
FRDA mice show preservation of motor coordination, the
electrophysiological properties in sensory caudal nerve, the
clasping reflex, the neuronal structural preservation of the
DRG, spinal cord and dentate nucleus, along with
cardiomyopathy correction, reduction of iron deposits and
preservation of mitochondrial electron transport chain.
Conclusion: These data provide support for the clinical
therapeutic potential of this gene therapy vector for the
treatment of Friedreich’s ataxia.
E. Balagué: None. D. Cota-González: None. K. Adrián-
Campbell: None. B. García-Lareu: None. A. Bosch: None.
J. Coll-Cantí: None. M. Chillón: None. I. Sánchez: None.
A. Matilla-Dueñas: None.
C17.5
HDAC inhibitor CI-994 rescues phenotype in a mouse
model of Birk-Barel intellectual disability syndrome
A. Cooper1, T. Butto2*, N. Hammer3, S. Jagannath3, D.
Lucia Fend-Guella1, J. Akhtar2, K. Radyushkin4, F.
Lesage5, J. Winter1,6, S. Strand7, J. Roeper3, U. Zechner1,8,
S. Schweiger1,9
1Institute of Human Genetics, University Medical Center of
the Johannes Gutenberg University, Mainz, Germany,
2Institute for Developmental Biology and Neurobiology,
Johannes Gutenberg University, Mainz, Germany, 3Institute
of Neurophysiology, Goethe University Frankfurt, Ger-
many, Frankfurt, Germany, 4University Medical Center of
the Johannes Gutenberg University, Mainz, Germany,
Mainz, Germany, 5LabEx ICST, Institut de Pharmacologie
Moléculaire et Cellulaire, CNRS and Université de Nice-
Sophia Antipolis, Valbonne, France, 6University Medical
Center of the Johannes Gutenberg University, Mainz,
Germany, 7Department of Internal Medicine I, University
Medical Center of the Johannes Gutenberg University,
Mainz, Germany, 8Senckenberg Center of Human Genetics,
Frankfurt, Germany, 9Orphan Diseases of the Central
Nervous System, University Medical Center of the Johannes
Gutenberg University, Mainz, Germany
Epigenetic modulators provide a powerful tool for disease
treatment through alteration of the epigenomic regulative
system. In our study, we focused on the effect of epigenetic
modulators on the maternally imprinted Kcnk9 gene.
Mutations in the Kcnk9 gene were shown to affect the
modulation of the membrane potential and excitability of
neurons, causing Birk-Barel intellectual disability syndrome
(BBIDS). Using the BBIDS mouse model, we here present
evidence for a small yet evident non-canonical expression
of the parental Kcnk9 allele in Kcnk9KOmat animals, which
was sufficient to provide an intermediate phenotype in
nocturnal locomotor activity compared to Kcnk9KOhom. We
further identified the locus coeruleus (LC), a region
involved in regulation of arousal and nocturnal activity in
mice, as the main target region altered in Kcnk9KOmat
animals. Following screening of numerous epigenetic
modulators, we show that CI-994, a class I HDAC inhibitor,
could increase paternal Kcnk9 expression up to three-fold
and fully rescue the behavioral phenotype in Kcnk9KOmat
animals. We utilized ChIP-qPCR to further demonstrate that
CI-994 affects histone 3 lysine 27 acetylation (H3K27ac) at
the promoter and intronic region of Kcnk9 in the LC tissue
samples thereby promoting open accessible chromatin and
increasing expression of Kcnk9. Interestingly, using allele-
specific ChIP, we show that the effects on the inactive
paternal allele were significantly higher that on the maternal
allele. Taken all together, our findings provide further
characterization of the role of Kcnk9 in BBIDS pathology as
well as exciting evidence for a promising therapeutic effect
of CI-994 in mouse model for BBIDS.
A. Cooper: None. T. Butto: None. N. Hammer: None. S.
Jagannath: None. D. Lucia Fend-Guella: None. J. Akhtar:
None. K. Radyushkin: None. F. Lesage: None. J. Winter:
None. S. Strand: None. J. Roeper: None. U. Zechner: None.
S. Schweiger: None.
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C18 Cancer Genetics II: Clinical Cancer Research
C18.1
Development of a rapid functional assay on peripheral
blood for clinical interpretation of germline TP53 var-
iants and detection of non-coding functional variants
S. Raad1, M. Rolain1, S. Coutant1, C. Derambure1, R.
Lanos1, F. Charbonnier1, J. Bou1, E. Bouvignies1, G.
Lienard1, S. Vasseur1, M. Farrel2, O. Ingster3, S. Baert-
Desurmont1, E. Kasper1, G. Bougeard1, T. Frébourg1, I.
Tournier1*
1Inserm U1245, UNIROUEN, Normandie Univ, and
Genetics Department, Rouen University Hospital, Nor-
mandy Centre for Genomics and Personalized Medicine,
Rouen, France, 2Mater Private Hospital, Dublin, Ireland,
3Angers University Hospital, Department of Genetics,
Angers, France
Interpretation of germline TP53 variants remains complex
and is critical for an appropriate medical management of
patients. We developed a functional assay directly per-
formed on blood for the rapid interpretation, within a week,
of unclassified TP53 variants. In this assay, peripheral blood
mononuclear cells are cultured and activated for 48h hours,
exposed to doxorubicin and the p53-mediated transcrip-
tional response is quantified using RT-MLPA and RT-
QMPSF, including 10 p53 targets and 2 amplicons to
measure p53 mRNA levels. Functional assay and TP53
molecular screening were performed in 71 individuals, in
parallel and blind conditions. In 51 wild-type TP53 indi-
viduals, the mean p53 functionality score was 12. 7. Among
8 individuals harboring likely pathogenic or pathogenic
variants, the scores were reduced (mean 4.8) and p53
mRNA levels were reduced in patients harboring truncating
variants allowing to identify them unambiguously. The
assay applied to 11 rare unclassified variants [p.(Pro72His),
p.(Gly105Asp), p.(Arg110His), p.(Phe134Leu), p.
(Arg158Cys), p.(Pro191Arg), p.(Pro278Arg), p.(Arg283-
Cys), p.(Asp352Tyr), p.(Asn131del), c.-117G>T] led us to
consider them, except the p.(Pro72His), p.(Pro191Arg) and
c.-117G>T variants, as pathogenic. Remarkably, the assay
also revealed that the c.*1175A>C polymorphic TP53
variant located within the polyadenylation signal impacts,
when present on both alleles, p53 functionality with the
same magnitude as a germline pathogenic TP53 variant and
could act as a modifier factor in pathogenic variant carriers.
This assay should therefore be a useful tool for the rapid
interpretation of germline TP53 variants of unknown sig-
nificance and the indirect detection of cryptic alterations
within regulatory regions impacting p53 function. SR, MR:
equal contribution
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C18.2
Are pathogenic germline variants in metastatic mela-
noma associated with unfavorable survival?
S. Biskup1*, T. Amaral2, T. Sinnberg2, M. Nieser1, P.
Martus2, C. Garbe2, F. Battke1, A. Forschner2, M. Schulze1
1CeGaT, Tuebingen, Germany, 2University clinic, Tuebin-
gen, Germany
Immunotherapy has revolutionized the treatment landscape
of patients with advanced melanoma. Despite the survival
improvements there are still patients that do not benefit from
immunotherapy. For those patients early biomarkers that
indicate potential resistance are highly relevant and other
therapeutic alternatives should be considered. We compre-
hensively analyzed tumor and blood samples from 116
patients with advanced melanoma and scheduled for sys-
temic therapy between January and June 2018. Descriptive
and survival analysis were performed for all patients and for
those receiving combined immunotherapy (n=59). We
focused on tumor mutational burden, genome instability,
major driver and tumor suppressor genes. Interestingly, a
total of 20 germline variants were identified in our cohort.
Nine patients with germline variants received combined
immunotherapy. The 1-year melanoma specific survival
(mMSS) for the sub-group with a germline variant was 52.9
percent versus 71.9 percent for the sub-group without
germline variant. For patients receiving combined immu-
notherapy with ipilimumab and nivolumab, the 1y-MSS
was 33.3 percent and 67.2 percent respectively for patients
with and without a germline variant (p=0.019; 95 percent
CI: 2.5-64.1 and 54.1-80.3). The median progression-free
survival was 2.0 months for patients with a germline variant
and 4.0 months for those without a germline variant
(p=0.021; 95 percent CI: 1.5-2.5 and 0.6-7.4). Conclusion:
For the first time, we show in patients with advanced
melanoma that the presence of germline variants might be
associated with worse prognosis and failure in response to
combined immunotherapy. Other therapeutic options should
be considered early as alternative or in combination with
immunotherapy.
S. Biskup: None. T. Amaral: None. T. Sinnberg: None.
M. Nieser: None. P. Martus: None. C. Garbe: None. F.
Battke: None. A. Forschner: None. M. Schulze: None.
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C18.3
Germline, somatic and clinical associations with
response to Immune Checkpoint Inhibitors and adverse
events in a large patient cohort
S. Groha1*, S. Abou Alaiwi1, K. Taraszka2, E. Lepisto1, M.
Manos1, O. Rahma1, T. Choueiri1, M. L. Freedman1, D.
Schrag1, K. Kehl1, A. Gusev1
1Dana Farber Cancer Institute, Boston, MA, United States,
2UCLA, Los Angeles, CA, United States
Immune Checkpoint Inhibitors (ICIs) have led to an
unprecedented improvement in durable responses in cancer
therapy but only a fraction of patients derive lasting benefit,
with many patients developing auto-immune disease-like
adverse events (irAE), motivating research into ICI
response mechanisms and biomarkers.
Using a large cohort of ICI patients at DFCI in a clinical
setting (N=1800 pan-cancer), we probe the influence of
genetic and clinical factors on overall survival (OS) and
irAE incidence. We impute common germline features from
panel sequenced tumors and investigate clinical, somatic
and germline influences on OS and irAEs using multivariate
and multistage survival analysis.
We find significant associations between OS and common
germline HLA alleles (q<0.1), validating one association in
an external cohort. We furthermore find somatic copy
number alterations (CNAs) (q<0.1), with alterations of
AKT3, RSPO2 and MYC validating in at least two
independent cohorts. Moreover, we find general lab tests
taken at treatment initiation are associated with OS, specific
to patients on ICIs. We show that an integrated prognostic
model using somatic, germline and clinical data from EHR
records significantly outperforms the baseline model of
demographics and tumor mutational burden (a known
putative biomarker), increasing concordance from 0.63 to
0.70. We furthermore find significant predictors of future
irAEs from previous auto-immune disease diagnosis (p<1e-
5), individual cancer driver mutations, and common HLA
alleles (q<0.01).
Our study identifies novel mechanisms influencing OS
and irAEs in patients on ICIs and shows the benefit of
prognostic models utilizing clinical patient history.
NCI R01CA227237, Claudia Adams Barr Foundation
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None. A. Gusev: None.
C18.4
Rare germline variants in the tumor suppressor gene
CDH1 are associated with familial glioma
A. Förster1*, F. Brand1, R. Banan2, R. Hüneburg3,4, C. A.
M. Weber1, N. Elyan1, C. Previti5, J. Kronenberg6,7, U.
Beyer1, H. Martens1, B. Hong8, J. K. Krauss8, J. H.
Bräsen9, A. Zimpfer10, M. Stangel6,7, A. Samii11, S. Wolf5, S.
Aretz3,12, B. Wiese8,13, C. Hartmann2, R. G. Weber1
1Department of Human Genetics, Hannover Medical
School, Hannover, Germany, 2Division of Neuropathology,
Department of Pathology, Hannover Medical School,
Hannover, Germany, 3National Center for Hereditary
Tumor Syndromes, University Hospital Bonn, Bonn,
Germany, 4Department of Internal Medicine I, University
Hospital Bonn, Bonn, Germany, 5Genomics and Proteomics
Core Facility, German Cancer Research Center (DKFZ),
Heidelberg, Germany, 6Clinical Neuroimmunology and
Neurochemistry, Department of Neurology, Hannover
Medical School, Hannover, Germany, 7Center for Systems
Neuroscience, University of Veterinary Medicine Hannover,
Hannover, Germany, 8Department of Neurosurgery, Hann-
over Medical School, Hannover, Germany, 9Department of
Pathology, Hannover Medical School, Hannover, Germany,
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10Institute of Pathology, University of Rostock, Rostock,
Germany, 11Department of Neurosurgery, International
Neuroscience Institute, Hannover, Germany, 12Institute of
Human Genetics, University Hospital Bonn, Bonn, Ger-
many, 13Department of Neurology, Henriettenstift, Diako-
vere Krankenhaus gGmbH, Hannover, Germany
The genetic basis of familial gliomas, representing about
5% of all gliomas, is poorly understood. In search of rare
germline alterations predisposing to glioma, we applied
whole-genome, whole-exome and targeted sequencing to
germline-DNA of 21 glioma patients from 15 families with
at least two glioma cases each. Thereby, we identified two
families with rare variants in the tumor suppressor gene
CDH1 encoding E-cadherin that co-segregate with the
tumor phenotype, a significant overrepresentation of rare
CDH1 variants in glioma families versus controls. In a
separate cohort of 45 individuals from 25 gastric cancer
families carrying CDH1 germline mutations, brain tumors
were observed in two cases, a significantly higher pre-
valence than in the general population. As most rare CDH1
variant carriers in the two glioma families were affected by
oligodendroglioma, we performed mutational analysis in a
separate cohort of 101 oligodendroglioma-DNAs identify-
ing rare CDH1 alterations in about 6% of tumors. CDH1
expression was detected in oligodendroglial precursor cells
and differentiated oligodendrocytes isolated from rat brain.
Functional studies of CDH1 germline variants using
CRISPR/Cas9-mediated knock-in or stably transfected cell
models demonstrated their pathogenicity with respect to cell
surface expression, cell migration and aggregation com-
pared to control cells. One CDH1 variant showed reduced
binding to beta-catenin and increased nuclear levels of
active beta-catenin that were diminished by treatment with
the MAPK interacting serine/threonine kinase 1 inhibitor
CGP57380. Our data provide evidence for a role of rare
CDH1 variants in the risk and tumorigenesis of gliomas,
particularly of oligodendrogliomas (supported by Wilhelm
Sander-Stiftung grant 2018.097.1).
A. Förster: None. F. Brand: None. R. Banan: None. R.
Hüneburg: None. C. A. M. Weber: None. N. Elyan: None.
C. Previti: None. J. Kronenberg: None. U. Beyer: None. H.
Martens: None. B. Hong: None. J. K. Krauss: None. J. H.
Bräsen: None. A. Zimpfer: None. M. Stangel: None. A.
Samii: None. S. Wolf: None. S. Aretz: None. B. Wiese:
None. C. Hartmann: None. R. G. Weber: None.
C18.5
Prostate cancer risk and prognosis for carriers of
germline pathogenic variants in disease implicated genes
N. Camacho Ordonez*, L. Dong, A. Matakidou
AstraZeneca, Melbourn, Royston, Hertfordshire, United
Kingdom
Germline mutations in DNA Damage Response (DDR)
genes such as BRCA2 and ATM have been associated with
prostate cancer risk and agressiveness. These associations
are largely based on studies that ascertain for cancer diag-
nosis and family history and provide risk estimates with
limited population-level accuracy. Here we evaluate the
clinical significance of germline pathogenic variants in 20
DDR genes and four known susceptibility coding variants
in POUF51B, HOXB13 and KLK3 using whole exome
sequences from (1) the UK Biobank (UKBB), a population-
based cohort (200,000 participants) and (2) patients
recruited in AZ clinical trials. Whole exomes from 4,975
prostate cancer patients (3,954 UKBB and 1,021 AZ) and
59,438 cancer-free males were analysed. Known and novel
pathogenic variants were identified and population risk of
disease, metastasis and overall survival (UKBB only) were
estimated (multiplicity corrected P value <0.005). ATM
(1.15%), BRCA2 (1.11%) and HOXB13 G48E (1.29%) were
the largest contributors to prostate cancer risk, each con-
ferring an increase of ~4-fold; followed by CHEK2 with a
moderate contribution (0.4%). BRCA2 carriers were more
likely to metastasise (OR 3.32, 95% CI 1.74-6.45,
p=9.94E-05) and had poorer overall survival (Log-Rank
p=1.33E-08), with 85% dying from prostate cancer com-
pared to 53% of non-BRCA2 carriers. This is the largest
study to date providing population-based estimates of
prostate cancer risk, metastasis an survival. Analyses will be
updated with data from the full 500,000 UKBB participants
(11,000 prostate cancers).
N. Camacho Ordonez: A. Employment (full or part-
time); Significant; AstraZeneca. L. Dong: A. Employment
(full or part-time); Significant; AstraZeneca. A. Mataki-
dou: A. Employment (full or part-time); Significant;
AstraZeneca.
C18.6
Clinical and molecular characterization of 1253 carriers
of a deleterious CHEK2 mutation from the German
Consortium for Hereditary Breast and Ovarian Cancer
(GC-HBOC)
W. Habhab1*, U. Faust1, G. Günther1, U. Siebers-Renelt2,
M. Kiechle3, C. Ott4, N. Dikow5, K. Kast6, A. Vesper7, C.
Solbach8, N. Harbeck9, M. Stiller10, A. Gehrig11, C.
Thomssen12, H. Wallaschek13, N. Arnold14, I. Holzhauser15,
S. Kaulfuß16, A. Volk17, W. Janni18, C. Engel19, R.
Schmutzler20, O. Rieß1, C. Schroeder1, K. Bosse1
1Institute of Medical Genetics and Applied Genomics,
University of Tuebingen, Tuebingen, Germany, 2Institute
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of Human Genetics, University of Muenster, Muenster,
Germany, 3Department of Gynecology, University Hospital,
Technical University of Munich, Munich, Germany, 4Insti-
tute of Medical Genetics and Human Genetics, Charité
University medicine of Berlin, Berlin, Germany, 5Institute of
Human Genetics, University Hospital Heidelberg, Heidel-
berg, Germany, 6Department of Gynecology and Obstetrics,
Medical Faculty and University Hospital Carl Gustav
Carus, Technische University Dresden, Dresden, Germany,
7Department of Gynecology and Obstetrics, Medical
Faculty and University Hospital Duesseldorf, Heinrich-
Heine University Duesseldorf, Duesseldorf, Germany,
8Department of Obstetrics & Gynecology, University
Hospital, Frakfurt, Germany, 9Department of Obstetrics
& Gynecology, University of Munich (LMU), Munich,
Germany, 10Institute of Human Genetics, University of
Leipzig Hospitals and Clinics, Leipzig, Germany, 11Institute
of Human Genetics, University of Wuerzburg, Wuerzburg,
Germany, 12Department of Gynecology and Obstetrics,
Medical Faculty and University Hospital Halle, Halle,
Germany, 13Institute of Human Genetics, University
Hospital of Hannover, Hannover, Germany, 14Department
of Gynecology and Obstetrics, University Hospital Schles-
wig-Holstein, Campus Kiel, Christian Albrechts University
Kiel Institute of Clinical Molecular Biology, University
Hospital of Schleswig-Holstein, Campus Kiel, Christian-
Albrechts Universi, Kiel, Germany, 15Institute of Human
Genetics, University of Regensburg, Regensburg, Germany,
16Institute of Human Genetics, University Medical Center
Goettingen, Goettingen, Germany, 17Institute of Human
Genetics, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany, 18Department of Obstetrics and
Gynecology, University Clinic Ulm, Ulm, Germany, 19Insti-
tute of Medical Informatics, Statistics and Epidemiology,
University of Leipzig, Leipzig, Germany, 20Center of
Hereditary Breast and Ovarian Cancer, University of
Cologne, Cologne, Germany
Introduction: Published relative risk estimates for breast
cancer for CHEK2 mutation carriers vary between 1.5 and
3. The risk for contralateral breast cancer is elevated. An
association with ovarian cancer is still under debate. Here
we present the clinical and molecular characteristics of 1253
female and male CHEK2 mutation carriers recruited by the
German Consortium for Hereditary Breast and Ovarian
Cancer (GC-HBOC).
Materials and Methods: Deleterious mutations in
BRCA1 and BRCA2 had been excluded in the study group.
The information was gained from the central registry
database of the Consortium.
Results: A total of 1253 patients were tested positive for
a pathogenic germline CHEK2 variant (1176 females, 77
males). More than 60% of the female carriers had developed
breast- and/or ovarian cancer. Approximately 13% of the
females with breast cancer reported a contralateral cancer.
Ovarian cancer was diagnosed in 35 carriers (2.98%; 13 of
them <50yrs). About 6.5% of the males developed breast
cancer. Sixteen mutation carriers developed skin and 14
thyroid cancer, respectively. The most common observed
variant was c.1100delC followed by Del Ex9-10.
Conclusion: CHEK2-mutations are a substantial cause of
hereditary female breast cancer in the German population.
Female carriers face a relevant risk of developing
contralateral cancer. CHEK2 mutation carriers present with
a broad spectrum of additional cancers. Besides ovarian
cancer, thyroid and skin cancer are the most frequent
entities. A causal association with an increased risk of
ovarian cancer and male breast cancer remains to be proven
in larger study cohorts and matched to healthy controls.
W. Habhab: None. U. Faust: None. G. Günther: None. U.
Siebers-Renelt: None. M. Kiechle: None. C. Ott: None. N.
Dikow: None. K. Kast: None. A. Vesper: None. C. Solbach:
None. N. Harbeck: None. M. Stiller: None. A. Gehrig:
None. C. Thomssen: None. H. Wallaschek: None. N.
Arnold: None. I. Holzhauser: None. S. Kaulfuß: None. A.
Volk: None. W. Janni: None. C. Engel: None. R.
Schmutzler: None. O. Rieß: None. C. Schroeder: None.
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C19 Multiple Malformation Syndromes II
C19.1
One test for all: whole genome sequencing in 62 trios
with congenital limb malformation identifies structural
variants and new disease genes
J. Elsner1, M. A. Mensah1, M. Holtgrewe2, W. Hülsemann3,
S. Mundlos4,1, M. Spielmann4,1*
1Institute of Medical Genetics and Human Genetics,
Charité - Universitätsmedizin Berlin, Berlin, Germany,
2Core Unit Bioinformatics, Berlin Institute of Health,
Berlin, Germany, 3Handchirurgie, Katholisches Kinderk-
rankenhaus Wilhelmstift, Hamburg, Germany, 4Max Planck
Institute for Molecular Genetics, Berlin, Germany
Introduction: The extensive clinical and genetic hetero-
geneity of congenital limb malformation requires compre-
hensive analysis of genome-wide genetic variation. Whole
genome sequencing (WGS) has the potential to identify
both coding and non-coding as well as structural variants in
a single test. Thus, WGS may increase the diagnostic rate in
cases of congenital limb malformation.
Methods: We collected a cohort of 62 trios featuring
congenital limb malformations that were mutation negative
after standard clinical genetic testing. The cohort was
94 J. del Picchia
subjected to whole genome sequencing (Ilumina, 30x
coverage, paired-end, 150bp). Data were analyzed for both
coding and non-coding single nucleotide variants and
structural variants using the SODAR and VarFish pipelines.
Results: Overall we identified coding pathogenic single
nucleotide variants in 9 cases (14%). We found mutations in
7 known disease genes including one repeat expansion in
HOXD13. In two unrelated cases of ectrodactyly we
identified likely pathogenic variants in UBA2 establishing
it as a novel disease gene. In addition we found two
pathogenic structural variants (3%) : one inversion
segregating with the phenotype and one de novo deletion.
Furthermore, we identified variants in 3 novel high
confidence candidate genes. We also describe and perform
a framework to identify potential non-coding pathogenic
variants.
Conclusions: Whole genome sequencing is a powerful
strategy to identify all types of genomic variants associated
with congenital limb malformation. It also detects repeat
expansions and copy number neutral inversions that are
missed by most other approaches.
J. Elsner: None. M. A. Mensah: None. M. Holtgrewe:
None. W. Hülsemann: None. S. Mundlos: None. M.
Spielmann: None.
C19.2
Biallelic mutations in TOGARAM1 cause a novel
primary ciliopathy
V. Morbidoni1,2, E. Agolini3, K. C. Slept4, L. Pannone5, D.
Zuccarello1, E. Grosso6, G. Gai6, L. Salviati1,2, B.
Dallapiccola7, A. Novelli3, S. Martinelli5, E. Trevisson1,2*
1Clinical Genetics Unit, Dept of Women’s and Children’s
Health, University of Padova, Padova, Italy, 2Istituto di
Ricerca Pediatrica IRP, Padova, Italy, 3Laboratory of
Medical Genetics, IRCCS-Bambino Gesù Children’s Hos-
pital, Roma, Italy, 4Department of Biology, University of
North Carolina, Chapel Hill, NC, United States, 5Depart-
ment of Oncology and Molecular Medicine, Istituto Super-
iore di Sanità, Roma, Italy, 6Medical Genetics Unit, Città
della Salute e della Scienza University Hospital, Torino,
Italy, 7Scientific Directorate, Bambino Gesù Children’s
Hospital and Research Institute, Roma, Italy
Background: Dysfunction in non-motile cilia is associated
with a broad spectrum of developmental disorders char-
acterized by clinical heterogeneity. Despite over one hun-
dred genes have been associated with primary ciliopathies,
with wide phenotypic overlap, some patients still lack a
molecular diagnosis. The aim of this work was to investi-
gate and functionally characterize the molecular cause
underlying a Meckel-Gruber-like phenotype in two sibling
foetuses.
Methods: we used a trio-based whole exome sequencing
(WES) strategy to identify candidate variants in
TOGARAM1. In silico, in vitro and in vivo (C. elegans)
studies were carried out to explore the impact of mutations
on protein structure and function, and relevant biological
processes.
Results: TOGARAM1 encodes a member of the Cres-
cerin1 family of proteins regulating microtubule dynamics.
Its orthologue in C. elegans, che-12, is expressed in the
cilium of a subset of sensory neurons, where it is required
for chemosensation. Nematode lines harbouring the mis-
sense variant in TOGARAM1 were generated by CRISPR/
Cas9 technology. Although chemotaxis ability on a NaCl
gradient and lipophilic dye-uptake were not impaired, che-
12 knock-in mutants displayed a shorter cilium in sensory
neurons, and even shorter cilia in hemizygous worms,
which recapitulate the genotype observed in the affected
foetuses. Finally, in vitro analysis of microtubule polymer-
ization in the presence of the wild-type or mutant TOG2
domain revealed a faster polymerization associated with the
mutant protein, indicating aberrant tubulin binding.
Conclusions: Our data suggest a causative role of
TOGARAM1 variants in the pathogenesis of this novel
disorder, connecting this gene with primary ciliopathy.
V. Morbidoni: None. E. Agolini: None. K. C. Slept: None.
L. Pannone: None. D. Zuccarello: None. E. Grosso: None.
G. Gai: None. L. Salviati: None. B. Dallapiccola: None. A.
Novelli: None. S. Martinelli: None. E. Trevisson: None.
C19.3
Biallelic loss-of-function variations in SMO, encoding
the key transducer of the Sonic Hedgehog pathway,
cause a broad phenotypic spectrum of hedgehogopathies
T. L. LE1,2*, Y. Sribudiani3,4, X. Dong5,6, C. Huber1, C.
Kois7, G. Baujat1,8, C. T. Gordon1, V. Mayne5, L.
Galmiche8, V. Serre9,2, N. Goudin2, M. Zarhrate1, C. Bole-
Feysot2, C. Masson2, P. Nitschké2, F. W. Verheijen3, L.
Pais10, A. Pelet1, S. Sadedin5, J. A. Pugh7, N. Shur11, S. M.
White5, S. E. Chehadeh12, J. Christodoulou5,6, V. Cormier-
Daire1,8, R. M. W. Hofstra3, S. Lyonnet1,2,8, T. Y. Tan5,6, T.
Attié-Bitach1,2,8, W. S. Kerstjens-Frederikse13, J. Amiel1,2,8,
S. Thomas1
1Imagine Institute - INSERM U1163, Paris, France, 2Uni-
versité de Paris, Paris, France, 3Erasmus Medical Center,
Rotterdam, Netherlands, 4Universitas Padjadjaran, Ban-
dung, Indonesia, 5Royal Children’s Hospital, Melbourne,
Australia, 6University of Melbourne, Melbourne, Australia,
7Albany Medical Center, Albany, NY, United States,
8Hôpital Necker-Enfants Malades, Paris, France, 9Institut
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Jacques Monod - CNRS U7592, Paris, France, 10Broad
Institute, Cambridge, MA, United States, 11Children’s
National, Washington, WA, United States, 12Hôpital de
Hautepierre, Strasbourg, France, 13University Medical
Centre Groningen, Groningen, Netherlands
The evolutionarily conserved Hedgehog (Hh) pathway is
essential for organogenesis and plays critical roles in postnatal
tissue maintenance and renewal. A unique feature of verte-
brate Hh pathway is that signal transduction requires the
primary cilium (PC) where major pathway components are
dynamically enriched. These factors include Smoothened
(SMO) and Patched, that constitute the core reception system
for Sonic Hedgehog (SHH) as well as GLI transcription
factors, the key mediators of the pathway. Here, we report
biallelic loss-of-function variations in SMO in seven cases
from five independent families causing a wide phenotypic
spectrum of hedgehogopathies affecting development of the
brain (hypothalamic hamartoma, microcephaly), heart (atrio-
ventricular septal defect), skeleton (postaxial polydactyly,
narrow chest, shortening of long bones) and the enteric ner-
vous system (aganglionosis). Patient-derived cells showed
normal ciliogenesis but severely altered Hh signal transduc-
tion due to either altered PC trafficking or abnormal activation
of the pathway downstream of SMO. In addition, Hh-inde-
pendent GLI2 accumulation at the PC tip in patient cells
suggest a potential novel function of SMO in regulating basal
ciliary trafficking of GLI2 when the pathway is off. Thus, loss
of SMO function in humans results in abnormal PC dynamics
of key components of the Hh signaling pathway and leads to a
large continuum of malformations in humans.
T. L. Le: None. Y. Sribudiani: None. X. Dong: None. C.
Huber: None. C. Kois: None. G. Baujat: None. C. T.
Gordon: None. V. Mayne: None. L. Galmiche: None. V.
Serre: None. N. Goudin: None. M. Zarhrate: None. C.
Bole-Feysot: None. C. Masson: None. P. Nitschké: None.
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C19.4
Bi-allelic Variants in RALGAPA1 Cause Profound
Neurodevelopmental Disability, Muscular Hypotonia,
Infantile Spasms, and Feeding Abnormalities
M. Wagner1,2*, Y. Skorobogatko3, B. Pode-Shakked4, C. M.
Powell5, B. Alhaddad1, A. Seibt6, O. Barel7, G. Heimer7, C.
Hoffmann4, L. A. Demmer8, Y. Perilla-Young5, M. Remke9,
D. Wieczorek10, T. Navaratnarajah6, P. Lichtner11, D.
Klee12, H. E. Shamseldin13, F. A. Mutairi14, E. Mayatepek6,
T. M. Strom1, T. Meitinger1, F. S. Alkuraya13, Y. Anikster7,
A. R. Saltiel3, F. Distelmaier6
1Institute of Human Genetics, Munich, Germany, 2Institute
for Neurogenomics, Helmholtz Zentrum München, Neu,
Germany, 3San Diego School of Medicine, La Jolla, CA,
United States, 4Sheba Medical Center, Tel Aviv, Israel,
5Department of Pediatrics, Chapel Hill, NC, United States,
6University Children´s Hospital, Düsseldorf, Germany,
7Sheba Medical Center, Tel-Hashomer, Israel, 8Atrium
Health Levine Children’s Hospital, Charlotte, NC, United
States, 9Department of Pediatric Oncology, Düsseldorf,
Germany, 10Institute of Human Genetics, Düsseldorf,
Germany, 11Institute of Human Genetics, Neuherberg,
Germany, 12Department of Diagnostic and Interventional
Radiology, Düsseldorf, Germany, 13King Faisal Specialist
Hospital and Research Center, Riyadh, Saudi Arabia,
14King Abdulaziz Medical City, Riyadh, Saudi Arabia
Introduction: Ral (Ras-like) GTPases play an important
role in the control of cell migration and have been impli-
cated in Ras-mediated tumorigenicity. Recently, variants in
RALA were described as a cause of intellectual disability
and developmental delay, indicating the relevance of this
pathway to neuropediatric diseases.
Materials and Methods: Exome sequencing was per-
formed in four affected individuals. Immunoblotting, qRT-
PCR, immunofluorescence, flow cytometry and a drug
screen pipeline using cell viability were used to functionally
characterize patient derived fibroblasts.
Results: Biallelic variants in RALGAPA1 were identified
in four unrelated individuals with profound neurodevelop-
mental disability, muscular hypotonia, feeding abnormal-
ities, recurrent fever episodes, and infantile spasms.
RalGAPA1 was absent in the fibroblasts derived from two
affected individuals and levels of RalGAPB, a scaffolding
subunit of the RalGAP complex, were reduced. RalA
activity was increased in these cell lines, implying that
RalGAPA1 deficiency causes a dysfunctional RalGAP
complex and a constitutive activation of RalA. Addition-
ally, RalGAPA1 deficiency increased cell-surface levels of
lipid raft components in detached fibroblasts, indicating that
anchorage-dependence of cell growth signaling is disturbed.
The drug screen assay showed altered survival rates of cells
upon treatment with pathway specific compounds.
Conclusions: Our findings indicate that the dysregulation
of the RalA pathway has an important impact on neuronal
function and brain development. In light of the partially
overlapping phenotype between RALA and RALGAPA1-
associated diseases, it appears likely that dysregulation of
the RalA signaling pathway leads to a distinct group of
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genetic syndromes that we suggest could be named
RALopathies.
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C19.5
Functional genomics and extended analyses of unsolved
exome-negative cases through the Undiagnosed Diseases
Project in Victoria (UDP-Vic)
T. Y. Tan1*, T. Cloney1, N. B. Tan1, L. Gallacher1, J.
Elliott1, G. Helman2, C. Simons2, S. Sadedin1, L. Pais3, A.
O’Donnell-Luria3, J. Christodoulou2, S. M. White1
1Victorian Clinical Genetics Services, Parkville, Mel-
bourne, Australia, 2Murdoch Children’s Research Institute,
Parkville, Melbourne, Australia, 3Broad Center for Mende-
lian Genomics, Cambridge, MA, United States
Clinical exome sequencing (cES) achieves a diagnostic
yield of 40-50% in individuals with a suspected monogenic
disorder. Optimal strategies for solving cES-negative cases
are unclear. Aim: Develop a research program to identify
diagnoses in unsolved cES-negative individuals. Methods:
We established the Undiagnosed Diseases Project in Vic-
toria (UDP-Vic) in collaboration with the Broad Center for
Mendelian Genomics to undertake family-based sequencing
and multifaceted approaches including genomic re-analysis,
copy number variant identification, RNA-sequencing and
functional studies. Results: We recruited 288 cES-negative
families to UDP-Vic for family-based exome (ES; 263) or
genome sequencing (GS; 25). Probands are paediatric with
syndromic neurodevelopmental phenotypes. Analysis is
complete in 133 families, of which 56 (42.1%) are con-
sidered solved (comprising known, newly emerging, and
strong novel candidate genes). Family-based ES/GS was the
most useful strategy in identifying candidate variants, and
adjunctive analyses such as RNA-sequencing (4/18 cases
analysed; 22.2%), high-resolution microarray (2/32 cases
analysed; 6.3%); re-analysis of original data (2/12 cases
analysed; 16.7%) provided additional diagnoses. GS iden-
tified only one coding variant that was missed in the original
cES. We identified strong candidates in 20 novel disease
genes, of which data-sharing and functional analyses led to
publication of 6 (MSL3, THOC2, FIG4, HNRNPU, SYT1,
ZNF462). Cell-based and animal model functional analyses
are ongoing for other novel candidates. Conclusion: UDP-
Vic has been highly effective in extending the diagnostic
yield beyond that achieved by cES. Our multifaceted
strategy has enabled us to query clinically-driven hypoth-
eses and identify cryptic diagnoses. We plan to incorporate
additional ‘-omics’ approaches to our pipeline.
T. Y. Tan: None. T. Cloney: None. N. B. Tan: None. L.
Gallacher: None. J. Elliott: None. G. Helman: None. C.
Simons: None. S. Sadedin: None. L. Pais: None. A.
O’Donnell-Luria: None. J. Christodoulou: None. S. M.
White: None.
C19.6
Identification of DNA methylation episignatures for
PRC2-related overgrowth syndromes
M. A. Levy1,2*, E. Aref-Eshghi1, T. B. Balci1,2,3, J. Kerkhof1,
G. Merla4, C. Schwartz5, B. Sadikovic1,2
1London Health Sciences Centre, London, ON, Canada,
2Western University, London, ON, Canada, 3Lawson
Health Research Institute, London, ON, Canada, 4IRCCS-
Casa Sollievo della Sofferenza, San Giovanni Rotondo,
Italy, 5Greenwood Genetic Center, Greenwood, CT, United
States
Introduction: An expanding number of genetic syndromes
have been shown to have unique genomic DNA methyla-
tion patterns (episignatures). EZH2 and EED are core
components of the polycomb repressive complex 2 (PRC2)
chromatin remodeling complex which catalyzes methyla-
tion of lysine 27 on histone H3 (H3K27). Mutations in these
genes lead to the overgrowth/intellectual disability syn-
dromes Weaver syndrome (EZH2) or Cohen-Gibson
syndrome (EED).
Materials and Methods: We used DNA methylation
microarrays which interrogate 450,000-850,000 individual
CpGs, along with machine learning statistical techniques, to
identify EZH2- and EED-specific DNA methylation
signatures present in peripheral blood from affected
individuals.
Results: Using these signatures we differentiated between
individuals with EZH2 or EED mutations, controls, and
those with a wide range of other developmental disability/
intellectual disability (DD/ID) syndromes. In addition, we
were able to distinguish between pathogenic and benign
mutations in either gene, demonstrating the usefulness of
these DNA methylation signatures for classifying variants
of uncertain significance. Weaver and Cohen-Gibson
syndromes exhibit overlapping clinical characteristics and
their methylation signatures reflect this.
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Conclusions: These results contribute to the growing
catalogue of DNA methylation episignatures useful for the
clinical diagnosis of DD/ID and related syndromes.
M. A. Levy: None. E. Aref-Eshghi: None. T. B. Balci:
None. J. Kerkhof: None. G. Merla: None. C. Schwartz:
None. B. Sadikovic: None.
C20 Neurogenetics
C20.1
An ancestral 10bp repeat expansion in gene encoding
component of ECM causes a novel autosomal-recessive
peripheral neuropathy
A. T. Pagnamenta1*, Y. Zou2, S. Donkervoort2, S. B.
Neuhaus2, R. Maroofian3, N. Dominik3, H. Y. Yip3, A. H.
Nemeth4,5, M. O’Driscoll6, F. Norwood7, J. Rankin8, T.
Lavin9, C. Marini-Bettolo10,11, H. Jungbluth12,13,14, L.
Medne15, S. Y. Yum16, A. R. Foley2, A. Need17, M. Sedghi18,
B. Ansari19, K. Basiri19, A. R. Moslemi20, H. Tajsharghi21,
C. C. Muraresku22, Z. Zolkipli-Cunningham22, S. Lassche23,
C. Marcelis23, Genomics England Research Consortium, J.
C. Taylor1, C. G. Bönnemann2, H. Houlden3
1Wellcome Centre for Human Genetics, University of
Oxford, Oxford, United Kingdom, 2Neuromuscular and
Neurogenetic Disorders of Childhood Section, NINDS,
National Institutes of Health, Bethesda, MD, United States,
3Department of Neuromuscular Disorders, UCL Queen
Square Institute of Neurology, London, United Kingdom,
4Nuffield Department of Clinical Neurosciences, University
of Oxford, Oxford, United Kingdom, 5Oxford Centre for
Genomic Medicine, Oxford University Hospitals NHS
Trust, Oxford, United Kingdom, 6Birmingham Women’s
NHS Foundation Trust, Birmingham, United Kingdom,
7Department of Neurology, King’s College Hospital,
London, United Kingdom, 8Peninsula Clinical Genetics
Service, Royal Devon and Exeter NHS Trust, Exeter, United
Kingdom, 9Department of Neurology, Salford Royal NHS
Foundation Trust, Manchester, United Kingdom, 10The
John Walton Muscular Dystrophy Research Centre,
Institute of Genetic Medicine, Newcastle University, New-
castle, United Kingdom, 11Newcastle upon Tyne Hospitals
NHS Foundation Trust, Newcastle, United Kingdom,
12Department of Paediatric Neurology – Neuromuscular
Service, Evelina Children’s Hospital, Guy’s & St Thomas’
NHS Foundation Trust, London, United Kingdom, 13Ran-
dall Division of Cell and Molecular Biophysics Muscle
Signalling Section, King’s College London, London, United
Kingdom, 14Department of Basic and Clinical Neu-
roscience, Institute of Psychiatry, Psychology and Neu-
roscience, King’s College London, London, United
Kingdom, 15Divisions of Neurology and Human Genetics
of Genomic Medicine, Children’s Hospital of Philadelphia,
Philadelphia, PA, United States, 16Division of Pediatric
Neurology, The Children’s Hospital of Philadelphia,
Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States, 17William
Harvey Research Institute, Queen Mary University of
London, London, United Kingdom, 18Medical Genetics
Laboratory, Alzahra University Hospital, Isfahan Univer-
sity of Medical Sciences, Isfahan, Iran, Islamic Republic of,
19Department of neurology, Faculty of Medicine, Isfahan
University of Medical Sciences, Isfahan, Iran, Islamic
Republic of, 20Department of Pathology, University of
Gothenburg, Sahlgrenska University Hospital, Gothenburg,
Sweden, 21School of Health Science, Division Biomedicine
and Translational Medicine, University of Skovde, Skovde,
Sweden, 22Mitochondrial Medicine Frontier Program,
Division of Human Genetics, Children’s Hospital of
Philadelphia, Philadelphia, PA, United States, 23Radboud
University Medical Centre, Nijmegen, Netherlands
The extracellular matrix (ECM) comprises a network of
macromolecules such as collagens, proteoglycans and gly-
coproteins. VWA1 encodes a component of the ECM that
interacts with perlecan/collagen VI, is essential in stabiliz-
ing ECM structures and demonstrates high expression
levels in tibial nerve. Vwa1-deficient mice manifest with
abnormal peripheral nerve structure and function, however
VWA1 variants have not yet been associated with disease in
humans. Interrogation of genome sequences of 74,180
individuals from the 100K Genomes Project yielded 10
unrelated patients with rare biallelic variants in VWA1
(NM_022834.5). A single disease-associated allele
(c.62_71dup10; p.G25Rfs*74) was homozygous in 7 indi-
viduals and compound-heterozygous with other likely-
deleterious variants in another 3. Given an AF of ~1/1000,
observation of 7 homozygotes constitutes a substantial
enrichment from expectation, consistent with the variant
playing a causative role in the patients’ disease. The wide
age-range of patients (6-70 years) helps us delineate the
clinical phenotype over time. Initial assessment suggests a
consistent clinical presentation with common features
including muscle weakness, motor delay, pes cavus and
SMA-like electrophysiology. Additional families with
biallelic variants in VWA1 have been identified through
collaborative efforts and partial nonsense mediated decay of
mRNA was observed in fibroblasts. Ongoing work includes
targeted-screening of a large cohort of unsolved CMT
patients. We hypothesise that this disease gene has pre-
viously evaded detection using exome sequencing due to
high GC content, consequential low coverage and compu-
tational difficulties associated with robustly detecting
repeat-expansions. It is anticipated that review of previously
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unsolved exomes using lower QC filters may generate fur-
ther diagnoses.
A. T. Pagnamenta: None. Y. Zou: None. S. Donkervoort:
None. S. B. Neuhaus: None. R. Maroofian: None. N.
Dominik: None. H. Y. Yip: None. A. H. Nemeth: None. M.
O’Driscoll: None. F. Norwood: None. J. Rankin: None. T.
Lavin: None. C. Marini-Bettolo: None. H. Jungbluth: None.
L. Medne: None. S. Y. Yum: None. A. R. Foley: None. A.
Need: None. M. Sedghi: None. B. Ansari: None. K. Basiri:
None. A. R. Moslemi: None. H. Tajsharghi: None. C. C.
Muraresku: None. Z. Zolkipli-Cunningham: None. S.
Lassche: None. C. Marcelis: None. J. C. Taylor: None. C.
G. Bönnemann: None. H. Houlden: None.
C20.2
Mutations in the Golgi protein GBF1 as a novel cause of
distal hereditary motor neuropathy
N. Mendoza Ferreira1*, M. Karakaya1, N. Cengiz1, D.
Beijer2, N. Fuhrmann1, I. Hölker1, B. Schrank3, K. Brigatti4,
C. Gonzaga-Jauregui5, E. Puffenberger4, G. Wunderlich6,
P. De Jonghe2,7, T. Deconinck2, K. Strauss4, J. Baets2,7, B.
Wirth1
1Institute for Human Genetics, Centre for Molecular
Medicine and Center for Rare Diseases, Cologne, Ger-
many, 2Neurogenetics Group, Center for Molecular Neu-
rology (VIB), Laboratory of Neuromuscular Pathology,
Institute Born-Bunge, University of Antwerp, Antwerp,
Belgium, 3DKD HELIOS Kliniken, Department of Neurol-
ogy, Wiesbaden, Germany, 4Clinic for Special Children,
Strasburg, PA, United States, 5Regeneron Genetics Center,
Regeneron Pharmaceuticals Inc., Tarrytown, NY, United
States, 6Department of Neurology, University Hospital
Cologne, Cologne, Germany, 7Neuromuscular Reference
Centre, Department of Neurology, Antwerp University
Hospital, Antwerp, Belgium
Introduction: Distal hereditary motor neuropathies (dHMN)
are heterogeneous diseases characterized by motor neuron
degeneration and atrophy. 50% of the individuals with dHMN
have a mutation in a hitherto undiscovered gene.
Materials and Methods: WES/WGS to identify the
dHMN-causative gene. Assessment of candidate variants
consequences on splicing, protein expression, and sub-
cellular localization, using various cellular systems.
Results: We identified de novo or inherited variants
(c.2945G>A, p.C982Y; c.3410C>T, p.A1137V; c.4382G>A,
p.R1461Q and c.3524G>A, p.W1175*) in GBF1 (Golgi
Brefeldin A-Resistant Guanine Nucleotide Exchange Factor-
1) in four unrelated families with dominant or sporadic
dHMN. Other known dHMN-implicated genes were
excluded. Affected individuals show dHMN with slowly
progressive distal muscle weakness and musculoskeletal
deformities (scoliosis, pes cavus, and hammertoes). Electro-
physiological studies confirmed chronic neurogenic changes
with axonal involvement. Three patients had additionally
distal sensory loss. GBF1 plays a pivotal role in Golgi
maintenance and retrograde trafficking as well as in
mitochondrial positioning and function. Immunostaining
analyses revealed Golgi fragmentation in all patients’
fibroblasts, being more severe in W1175*. Subtle mitochon-
drial defects, including reduced mitochondrial content and
fragmentation, were observed in all fibroblast lines; except for
A1137V. These defects are in line with co-immunoprecipita-
tion studies in HEK293T cells that demonstrated reduced
GBF1-Miro2 interaction in C982Y and R1461Q. None of the
GBF1 variants affects splicing.
Conclusion: Previous studies have linked Golgi frag-
mentation and mitochondrial fusion-fission defects with
motor neuron degeneration and atrophy. Our results
emphasize the role of GBF1 in these contexts and indicate
that GBF1 mutations are a novel dHMN cause.
N. Mendoza Ferreira: None. M. Karakaya: None. N.
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C20.3
Biallelic JAM2 variants lead to early-onset recessive
primary familial brain calcification
L. V. Schottlaender1,2,3*, R. Abeti4, Z. Jaunmuktane4,5, C.
Macmillan6, V. Chelban2, B. O’Callaghan2, J. McKinley7,8,
R. Maroofian2, S. Efthymiou2, A. Fragkou2, R. Forbes9, M.
Soutar10, J. Livingston11, B. Kalmar2, O. Swayne12, G.
Hotton12, A. Pittman2, J. Mendes de Oliveira13, M. de
Grandis14, A. Richard-Loendt10, F. Launchbury10, J.
Althonayan4, G. McDonnell8, A. Carr2,12, S. Khan15, C.
Beetz15, A. Bisgin16, S. Tug Bozdogan16, A. Begtrup17, E.
Torti17, L. Greensmith2, P. Giunti4, P. Morrison18, S.
Brandner5, M. Aurrand-Lions14, H. Houlden2,12
1FLENI Neurological Research Institute, Capital federal,
Argentina, 2Department of Neuromuscular Diseases, UCL
Queen Square Institute of Neurology, Queen Square, UK,
London, United Kingdom, 3Dubowitz Neuromuscular
Centre, UCL Great Ormond Street Institute of Child
Health, London, United Kingdom, 4Department of Clinical
and Movement Neurosciences, UCL Queen Square Institute
of Neurology, London, United Kingdom, 5Division of
Neuropathology, The National Hospital for Neurology
and Neurosurgery, University College London Hospitals
NHS Foundation Trust, London, United Kingdom,
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6Department of Pediatrics, University of Chicago, Chicago,
IL, United States, 7Department of Neurology, Dublin
Neurological Institute at the Mater Misericordiae Uni-
versity Hospital, Dublin, Ireland, 8Regional Neurosciences
Centre, Royal Victoria Hospital, Belfast, United Kingdom,
9Neurology Centre, Southern HSC Trust, Craigavon Area
Hospital, Portadown, United Kingdom, 10Department of
Neurodegenerative Disease, UCL Queen Square Institute of
Neurology, London, United Kingdom, 11Paediatric Neurol-
ogy, The Leeds Teaching Hospitals NHS Trust, Leeds
General Infirmary, Leeds, United Kingdom, 12The National
Hospital for Neurology and Neurosurgery, Queen Square,
London, United Kingdom, 13Universidade Federal de
Pernambuco, Departamento de Neuropsiquiatria, Recife,
Brazil, 14Aix-Marseille University, Inserm, CNRS, Institut
Paoli-Calmettes, CRCM, Marseille, France, 15CENTO-
GENE AG, Rostock, Germany, 16Medical Genetics Depart-
ment of Medical Faculty & AGENTEM (Adana Genetic
Diseases Diagnosis and Treatment Center), Çukurova
University, Adana, Turkey, 17GeneDx, 207 Perry Parkway,
Gaithersburg, MD, United States, 18Centre for Cancer
Research and Cell Biology, Queens University Belfast,
Belfast, United Kingdom
Primary familial brain calcification (PFBC) is a rare neu-
rodegenerative disorder characterised by a combination of
neurological, psychiatric and cognitive decline associated
with calcium deposition on brain imaging. To date, muta-
tions in five genes have been linked to PFBC. However,
over 50% of individuals affected by PFBC have no mole-
cular diagnosis. We report four unrelated families present-
ing with initial learning difficulties and seizures and later
psychiatric symptoms, cerebellar ataxia, extrapyramidal
signs and extensive calcifications on brain imaging.
Through a combination of homozygosity mapping and
exome sequencing, we mapped this phenotype to chromo-
some 21q21.3 and identified biallelic variants in JAM2.
JAM2 encodes for the junctional-adhesion-molecule-2, a
key tight-junction protein in blood-brain-barrier perme-
ability. We show that JAM2 variants lead to reduction of
JAM2 mRNA expression and absence of JAM2 protein in
patient’s fibroblasts, consistent with a loss-of-function
mechanism. We show that the human phenotype is repli-
cated in the jam2 complete knockout mouse (jam2 KO).
Furthermore, neuropathology of jam2 KO mouse showed
prominent vacuolation in the cerebral cortex, thalamus,
cerebellum and particularly widespread vacuolation in the
midbrain with reactive astrogliosis and neuronal density
reduction. The regions of the human brain affected on
neuroimaging are similar to the affected brain areas in the
myorg PFBC null mouse. Along with JAM3 and OCLN,
JAM2 is the third tight-junction gene in which biallelic
variants are associated with brain calcification, suggesting
that defective cell-to-cell adhesion and dysfunction of the
movement of solutes through the paracellular spaces in the
neurovascular unit is a key mechanism in CNS calcification.
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C20.4
Loss of UGP2 in brain leads to a severe epileptic
encephalopathy, emphasizing that bi-allelic isoform
specific start-loss mutations of essential genes can cause
genetic diseases
E. Perenthaler1*, A. Nikoncuk1, S. Yousefi1, W. M.
Berdowski1, M. Alsagob2, I. Capo3, H. C. van der Linde1, P.
van den Berg1, E. H. Jacobs1, D. Putar1, M. Ghazvini1, E.
Aronica4, W. F. J. van IJcken1, W. G. de Valk1, E.
Medici–van den Herik1, M. van Slegtenhorst1, L. Brick5, M.
Kozenko5, J. N. Kohler6, J. A. Bernstein6, K. G. Monaghan7,
A. Begtrup7, R. Torene7, A. Al Futaisi8, F. Al Murshedi9, F.
Al Azri9, E. Kamsteeg10, M. Mojarrad11, A. Eslahi11, E.
Ghayoor Karimiani12, J. Vandrovcova13, F. Zafar14, N.
Rana14, K. K. Kandaswamy15, J. Hertecant16, P. Bauer15,
D. Colak2, S. Efthymiou13, H. Houlden13, A. M. Bertoli-
Avella15, R. Maroofian13, K. Retterer7, A. C. Brooks1, N.
Kaya2, T. J. van Ham1, T. Barakat1
1Erasmus MC, Rotterdam, Netherlands, 2King Faisal
Specialist Hospital and Research Centre, Riyadh, Saudi
Arabia, 3Faculty of Medicine Novi Sad, Novi Sad, Serbia,
4Amsterdam UMC, Amsterdam, Netherlands, 5McMaster
Children’s Hospital, Hamilton, ON, Canada, 6Stanford
University School of Medicine, Stanford, CA, United States,
7GeneDX, Gaithersburg, MD, United States, 8Sultan
Qaboos University, Muscat, Oman, 9Sultan Qaboos Uni-
versity Hospital, Muscat, Oman, 10Radboud University,
Nijmegen, Netherlands, 11Mashhad University of Medical
Sciences, Mashhad, Iran, Islamic Republic of, 12St.
George’s University, London, United Kingdom, 13UCL
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Queen Square Institute of Neurology, London, United
Kingdom, 14Children’s hospital and institute of Child
health, Multan, Pakistan, 15CENTOGENE AG, Rostock,
Germany, 16UAE University, Al-Ain, United Arab Emirates
Developmental and/or epileptic encephalopathies (DEEs)
are a group of devastating genetic disorders, resulting in
early onset, therapy resistant seizures and developmental
delay. Here we report on 19 individuals from 12 families
presenting with a severe form of intractable epilepsy, severe
developmental delay, progressive microcephaly and visual
disturbance. Whole exome sequencing identified a recur-
rent, homozygous variant (chr2:64083454A>G) in the
essential UDP-glucose pyrophosphorylase (UGP2) gene in
all probands. This rare variant results in a tolerable
Met12Val missense change of the longer UGP2 protein
isoform but causes a disruption of the start codon of the
shorter isoform. We show that the absence of the shorter
isoform leads to a reduction of functional UGP2 enzyme in
brain cell types, leading to altered glycogen metabolism,
upregulated unfolded protein response and premature neu-
ronal differentiation, as modelled during pluripotent stem
cell differentiation in vitro. In contrast, the complete lack of
all UGP2 isoforms leads to differentiation defects in mul-
tiple lineages in human cells. Reduced expression of Ugp2a/
Ugp2b in vivo in zebrafish mimics visual disturbance and
mutant animals show a behavioral phenotype. Our study
identifies a recurrent start codon mutation in UGP2 as a
cause of a novel autosomal recessive DEE. Importantly, it
also shows that isoform specific start-loss mutations causing
expression loss of a tissue relevant isoform of an essential
protein can cause a genetic disease, even when an organism-
wide protein absence is incompatible with life. We provide
additional examples where a similar disease mechanism
applies.
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C20.5
Human-lineage-specific genomic elements are enriched
within genes implicated in neurodegenerative diseases
Z. Chen1*, D. Zhang1, R. H. Reynolds1, J. Hardy1, J. Botía2,
S. A. Gagliano Taliun3, M. Ryten1
1Department of Neurodegenerative Diseases, UCL Queen
Square Institute of Neurology, London, United Kingdom,
2Departamento de Ingeniería de la Información y las
Comunicaciones. Universidad de Murcia, Murcia, Spain,
3Center for Statistical Genetics and Department of
Biostatistics, University of Michigan, Ann Arbor, MI,
United States
Introduction: While encephalization has had advantages
for humans, this process may predispose us to neurode-
generative disorders including Alzheimer’s and Parkinson’s
diseases, which do not occur naturally in aged non-human
primates. This suggests that genomic features specific to the
human lineage may provide insights into brain-related
diseases.
Methods: In this study, we leverage high-depth whole
genome sequencing data from ~8,000 individuals and
improved conservation metrics to generate a combined
annotation identifying regions simultaneously depleted for
genetic variation (constrained regions) and have low
conservation at ten base pair resolution. We test our
proposal that these constrained, non-conserved regions
(CNCRs) result from human-specific purifying selection
and are enriched for neurological disease risk loci.
Results: We find that CNCRs are significantly depleted
from protein-coding genes but enriched within lncRNAs.
We use stratified-linkage disequilibrium score regression to
demonstrate that CNCRs are enriched for per-SNP herit-
ability of complex human-specific phenotypes, namely
intelligence (coefficient p= 1.4e-3). We find that high
CNCR density is a feature of genes already implicated in
neurological diseases, including MAPT and APOE. Focus-
ing on APOE, we identify high CNCR density within an
unannotated intron-3 retaining non-coding transcript
reported to regulate neuronal APOE. Using human frontal
cortex RNA-sequencing data, we find the proportion of the
intron-3-retaining transcript is higher in Alzheimer’s disease
than control participants (p < 2.2e-16) and associated with
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more severe Braak pathology (adjusted r^2= 0.6778, p <
2.2e-16).
Conclusions: We generate a highly-granular annotation
that supports the importance of human-lineage-specific
sequences in neurodegenerative disorders with implications
for disease modelling and interpretation of non-coding
variants.
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C20.6
Full-length RNA sequencing of Alzheimer brain sample
using long reads reveals complex alternative splicing
patterns
J. Ekholm*, E. Tseng, T. Hon, J. Underwood
Pacific Biosciences, Menlo Park, CA, United States
Long-read mRNA sequencing such as PacBio’s Iso-Seq
method offer high-throughput transcriptome profiling that
circumvents the transcript assembly problem by sequencing
full-length cDNA. The Iso-Seq method has emerged as the
most reliable technology for fully characterizing isoforms
and, in turn, help shed light on underlying disease
mechanisms. Here, we have utilized the Iso-Seq method to
sequence an Alzheimer’s disease whole brain sample. This
is a devastating neurodegenerative disease that affects ~44
million people worldwide, making it the most common
form of dementia. Studies looking into disease mechanism
have shown that changes in gene expression due to alter-
native splicing likely contribute to the initiation and pro-
gression of Alzheimer’s disease. Hence, efforts have been
made to better understand the gene expression changes in
the Alzheimer brain by sequencing the transcriptome of
affected brain regions. In this study, complex alternative
splicing patterns emerged, with 162,290 unique transcripts
up to 14 kb in length from 17,670 genes being detected.
More than 60% of these transcripts were novel isoforms, the
vast majority of which have supporting cage peak data and
polyadenylation signals. To further investigate the sample,
we also applied the Iso-Seq solution to single cell RNA
samples. In this experiment we obtained between 150,000-
180,000 unique isoforms from 15,000-17,000 genes. Over
50% of the isoforms categorized as novel isoforms, sug-
gesting a high degree of undiscovered transcripts in the
human samples, demonstrating the utility of long-read RNA
sequencing for human disease research.
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C21 Methods and Applications of Association Studies in
Large Cohorts
C21.1
A genome-wide association study of sex at birth in 3
million individuals reveals widespread sex-differential
participation bias with potential implications for GWAS
interpretation
N. Piratsu1, M. Cordioli2, G. Mignogna3, A. Abdellaoui4, P.
Nandakumar5, B. Hollis6, M. Kanai7, V. Manikandan8, P.
Della Briotta Parolo2, N. Baya7, C. Carey7, J. Karjalainen2,
T. D. Als8, M. D. Van der Zee4, F. R. Day6, K. K. Ong6, T.
Morisaki9, E. de Geus4, R. Bellocco3, Y. Okada9, A.
Børglum8, P. Joshi1, A. Auton5, D. Hinds5, B. Neale7, R.
Walters7, Finngen Study, 23andMe Research Team,
iPSYCH Consortium, M. G. Nivard4, J. R. B. Perry6, a.
ganna2*
1University of Edinburgh, Edinburgh, United Kingdom,
2Institute for Molecular Medicine Finland, Helsinki, Fin-
land, 3University of Milano Bicocca, Milan, Italy, 4VU
amsterdam, Amsterdam, Netherlands, 523andMe Inc, Sun-
nyvale, CA, United States, 6University of Cambridge,
Cambridge, United Kingdom, 7Broad Institute, Cambridge,
MA, United States, 8Aarhus university, Aarhus, Denmark,
9University of Tokyo, Tokyo, Japan
Genetic association results are often interpreted with the
assumption that factors influencing voluntary participation
do not affect downstream analyses. Understanding the
genetic basis of this participation bias is challenging as it
involves the genotypes of unseen individuals. As a proof of
concept, we demonstrate that sex at birth becomes a heri-
table trait in the presence of sex-differential participation
bias. By performing a GWAS of sex in ~3.3M men and
women, we identify over 150 genome-wide significant loci
which highlight complex traits underpinning differences in
study participation between sexes. For example, body mass
index (BMI) raising alleles were observed at higher fre-
quency in men compared to women, suggesting that
genetically higher-weight women are less likely to partici-
pate in population studies than men. We demonstrate how
102 J. del Picchia
these biases can lead to incorrect inferences in Mendelian
Randomization analyses and propose a conceptual frame-
work for addressing these biases. Our findings highlight a
new dimension of challenges genetic studies may begin to
face as sample sizes continue to grow.
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Zee: None. F. R. Day: None. K. K. Ong: None. T. Morisaki:
None. E. de Geus: None. R. Bellocco: None. Y. Okada:
None. A. Børglum: None. P. Joshi: None. A. Auton: A.
Employment (full or part-time); Significant; 23andMe Inc.
D. Hinds: A. Employment (full or part-time); Significant;
23andMe Inc. B. Neale: None. R. Walters: None. M. G.
Nivard: None. J. R. B. Perry: None. A. ganna: None.
C21.2
A phenome-wide gene-based collapsing analysis of rare
loss-of-function and missense variation in 268,451 UK
Biobank exomes
Q. Wang, K. Carss, K. Smith, S. Petrovski*
Centre for Genomics Research (CGR), Discovery Sciences,
BioPharmaceuticals R&D, AstraZeneca, Cambridge, Uni-
ted Kingdom
Historically, the genetic basis of complex disease has been
investigated by genome-wide association studies using
genotyping arrays. This approach is cost efficient but lim-
ited to known and common variants. Via advanced access to
300K UK Biobank participant exomes, we studied the rare
protein-coding variation contribution to thousands of phe-
notypic endpoints. Containing clinical, biomarker, and other
phenotypic information, this resource is unique in breadth
and depth.
We performed collapsing analyses considering a range of
genetic architectures. In total, 12 classes of qualifying
variants were studied according to predicted protein effect,
allele frequency, and zygosity. We expanded our scope
beyond loss-of-function (LoF) variation with models
targeting missense variation predicted to be deleterious or
located in regions of missense tolerance ratio (MTR)
constraint. A synonymous genetic model was used to
define our empirical null p-value distribution.
Using exomes from 268,451 individuals, we performed a
PheWAS studying the relationships between ~19K genes
and ~15K phenotypes. Our cloud-based platform delivered
>2.5 billion analyses within 24 hours. Among study-wide
significant findings 68% are previously known, 17% are
known disease genes but novel phenotype associations, and
15% are novel disease genes. We uncovered associations
driven by missense variants clustered in genic regions that
were missed when missense constraint was not considered.
Some of these were not captured by a LoF model,
suggesting possible gain-of-function signals.
We will illustrate AstraZeneca’s use of these data to
rapidly validate and inform safety profiles of potential drug
targets, identify novel targets, predict drug repositioning
opportunities, and study prevalence of molecular diagnoses.
Q. Wang: A. Employment (full or part-time); Significant;
AstraZeneca. K. Carss: A. Employment (full or part-time);
Significant; AstraZeneca. K. Smith: A. Employment (full
or part-time); Significant; AstraZeneca. S. Petrovski: A.
Employment (full or part-time); Significant; AstraZeneca.
C21.3
FinnGen - study at its midway: already identifying
dozens of novel variants for tens of diseases and traits
M. Perola1,2,3*
1Finnish Institute for Health and Welfare (THL), Helsinki,
Finland, 2University of Helsinki, Helsinki, Finland, 3On
behalf of the FinnGen Study, Helsinki, Finland
The FinnGen project is a public-private partnership study in
Finland designed to benefit from the genetic isolation of
Finnish population to identify variants contributing to
common and rare diseases. All Finnish biobanks across the
country participate in the study. The final aim is to collect
more than 10% of the adult population of Finland, e.g. about
500.000 participants, and utilize the well validated high-
quality, lifelong health registry data for a GWAS-PheWas
setting. To date, after two and a half years of recruitment, we
have GWAS genotyped 224 578 individuals and analysed
this data against 3882 endpoints and 84 million health care
events. The current number of biobanked participants for the
project is already >340 000. Previously, we have shown that
the average Finn has more low-frequency loss-of-function
variants and complete gene knockouts as non-Finn Eur-
opeans. Following this, now in FinnGen we have so far
identified more than 400 genome-wide significant loci
(about 350 novel), which have a Finnish enriched, low fre-
quency (MAF<0.1, enrichment > 1.5) variant. More than 60
of these loci have a missense or protein truncating variant.
The longitudinal setting and inclusion of the parental cause-
of-death are producing novel insights into aetiology and
progression of hundreds of diseases. FinnGen first year
summary results of 96,499 individuals from November 2018
are now publicly released at http://r2.finngen.fi/.
M. Perola: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
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grants already received); Significant; Abbvie, Astra Zeneca,
Biogen, Celgene, Genentech, GSK, Janssen Biotech, Maze
Therapeutics, MSD, Pfizer, Sanofi.
C21.4
Discovery, estimation and prediction analysis using a
Bayesian survival model for complex traits
S. E. Ojavee1*, D. Trejo-Banos1, M. Patxot1, K. Fischer2, A.
Kousathanas1, M. R. Robinson3
1University of Lausanne, Lausanne, Switzerland, 2Univer-
sity of Tartu, Tartu, Estonia, 3Institute of Science and
Technology, Vienna, Austria
Time-to-event analysis using genotypic data may enable a
better understanding of the mechanisms and underlying
genetic architecture behind the onset and development of
common complex disease. Typically, time-to-event data are
not normally distributed, are right censored and in genomic
studies, the number of covariates strongly exceeds the
number of observations. Previous work has not adequately
addressed these issues, potentially leading to underpowered
models and biased effect size estimates.
Here, we propose a hierarchical Bayesian model which
assumes that time-to-event has a Weibull distribution,
handles sparsity with spike and slab variable selection and
variance partitioning, considers right censoring, and yields
estimates of the proportion of genetic variance explained
(SNP heritability). The model can handle datasets of
hundreds of thousands of people and millions of genetic
markers by combining synchronous parallel Gibbs sampling
and adaptive rejection sampling.
In simulations, our approach outperformed previous
approaches and provided better genetic effect estimation.
We then applied our model to UK Biobank data for a wide-
range of traits, including time-to-death, time to cardiovas-
cular disease and time-to-menopause. We achieved 68%
higher SNP heritability estimates compared to previous
results for both time-to-menopause and time-to-menarche
(SNP heritabilities of 0.26 and 0.42 respectively).
Our general framework enables more accurate discovery
and estimation of the survival-related genomic marker
effects providing novel insight into the genetic architecture
of any very large-scale time-to-event data, and unprece-
dented statistical power to predict risk for medically
important traits.
This work was funded by an SNSF Eccellenza Grant
(PCEGP3_181181) to M.R.R.
S. E. Ojavee: None. D. Trejo-Banos: None. M. Patxot:
None. K. Fischer: None. A. Kousathanas: None. M. R.
Robinson: None.
C21.5
Simultaneous estimation of bi-directional causal effects
and heritable confounding from GWAS summary
statistics
L. Darrous1,2*, N. Mounier1,2, Z. Kutalik1,2,3
1University Center for Primary Care and Public Health,
Lausanne, Switzerland, 2Swiss Institute of Bioinformatics,
Lausanne, Switzerland, 3Genetics of Complex Traits,
University of Exeter Medical School, Exeter, United
Kingdom
Introduction: Mendelian Randomisation (MR), an
increasingly popular method that estimates the causal
effects of risk factors on complex human traits, has seen
several extensions that relax its basic assumptions. How-
ever, most of these extensions suffer from two major lim-
itations; under-exploitation of genome-wide markers, and
sensitivity to the presence of a heritable confounder of the
exposure-outcome relationship. To overcome these limita-
tions, we propose a Latent Heritable Confounder MR
(LHC-MR) method applicable to association summary sta-
tistics, which simultaneously estimates bi-directional causal
effects, direct heritability, and confounder effects while
accounting for sample overlap.
Results: We demonstrate that LHC-MR outperforms
several existing MR methods in terms of bias and
variance for a wide range of simulation settings and apply
it to summary statistics of 13 complex traits. Besides
several concordant results, LHC-MR unravelled new
mechanisms (how being diagnosed for certain
diseases might lead to improved lifestyle) and revealed
potential false positive findings of standard MR
methods (apparent causal effect of body mass index on
educational attainment may be driven by a strong ignored
confounder). Phenome-wide search to identify LHC-
implied heritable confounders showed remarkable agree-
ment between the LHC-estimated causal effects of the latent
confounder and those for the potentially identified ones.
Finally, LHC-MR naturally decomposes genetic correlation
to causal effect-driven and confounder-driven contributions,
demonstrating that the genetic correlation between systolic
blood pressure and diabetes is predominantly confounder-
driven.
Conclusion: LHC-MR, a structural equation mixed effect
model, is a novel method that tackles both causal inference
with increased precision and the genetic architecture of
complex disease.
L. Darrous: None. N. Mounier: None. Z. Kutalik: None.
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C21.6
Multi-trait genome-wide association analysis of blood
pressure identifies 45 additional loci
C. P. Cabrera1,2*, R. Pazoki3,4,5, A. Giri6, J. N. Hellwege7,
E. Evangelou3,8, J. Ramírez1, L. V. Wain9,10, I. Tzoulaki3,8,
T. L. Edwards11, P. Elliott3,12,13, P. B. Munroe1,2, M. R.
Barnes1,2, M. J. Caulfield1,2, H. R. Warren1,2, on behalf of
the VA Million Veteran Program and the ICBP working
group
1William Harvey Research Institute, Barts and The London
School of Medicine and Dentistry, Queen Mary Univeristy
of London, London, United Kingdom, 2National Institute for
Health Research, Barts Cardiovascular Biomedical
Research Center, Queen Mary University of London,
London, United Kingdom, 3Department of Epidemiology
and Biostatistics, Imperial College London, London, United
Kingdom, 4Department of Life Sciences,College of Health
and Life Sciences, Brunel University, London, United
Kingdom, 5Centre for Inflammation Research and Transla-
tional Medicine, Brunel University, London, United King-
dom, 6Vanderbilt Genetics Institute,Vanderbilt
Epidemiology Center, Department of Obstetrics and
Gynecology,Vanderbilt University Medical Center, Nash-
ville, TN, United States, 7Vanderbilt Genetics Institute,
Division of Epidemiology, Department of Medicine, Insti-
tute for Medicine and Public Health,Vanderbilt University
Medical Center, Nashville, TN, United States, 8Department
of Hygiene and Epidemiology, University of Ioannina
Medical School, Ioannina, Greece, 9Department of Health
Sciences, University of Leicester, Leicester, United King-
dom, 10NIHR Leicester Biomedical Research Centre,
Glenfield Hospital, Leicester, United Kingdom, 11Vander-
bilt Genetics Institute, Division of Epidemiology, Depart-
ment of Medicine, Institute for Medicine and Public Health,
Vanderbilt University Medical Center, Nashville, TN,
United States, 12National Institute for Health Research
Imperial Biomedical Research Centre, Imperial College
Healthcare NHS Trust and Imperial College London,
London, United Kingdom, 13UK Dementia Research
Institute, Imperial College London, London, United
Kingdom
Introduction: Single-trait genome wide association studies
(GWAS) have revealed over 1,000 blood pressure (BP) loci.
However, these loci only account for less than one third of
the BP genetic variation. Multi-trait GWAS is reported to
increase discovery power by jointly analysing highly cor-
related traits. By performing the first large-scale multi-trait
BP GWAS, we aimed 1) to compare multi-trait vs single-
trait results and 2) identify additional loci.
Methods: We apply Multi-Trait Analysis of GWAS
(MTAG) software to jointly analyse systolic BP, diastolic
BP and pulse pressure traits using our recent GWAS
discovery results from ~750k individuals of European
ancestry from UK Biobank and the International Con-
sortium of Blood Pressure. To detect additional loci we
tested ~7 million imputed genetic variants applying the
same combined 1-stage and 2-stage design criteria as in the
original GWAS, with replication using MTAG results from
the US Million Veteran Program (n~220k).
Results: Single-trait GWAS yielded a higher number of
significant independent signals genome-wide. Nevertheless,
our multi-trait analysis identified 45 new BP loci that were
not detected in the equivalent GWAS, of which nine remain
novel (based on further BP loci discoveries since 2018).
Conclusions: Our multi-trait GWAS discovered addi-
tional BP loci. However, our results illustrate that the
benefits of MTAG are trait-specific, requiring high pairwise
correlation between all pairs of traits, and that more power
is gained when MTAG is also used for meta-analysis of
traits from different samples. This suggests that future BP
genetics discovery projects should focus efforts on larger
meta-analyses including new cohorts.
C. P. Cabrera: None. R. Pazoki: None. A. Giri: None. J.
N. Hellwege: None. E. Evangelou: None. J. Ramírez: None.
L. V. Wain: None. I. Tzoulaki: None. T. L. Edwards: None.
P. Elliott: None. P. B. Munroe: None. M. R. Barnes: None.
M. J. Caulfield: None. H. R. Warren: None.
C22 Immunology and Hematology
C22.1
Newborn screening for severe combined immunodefi-
ciency (SCID) using combined T cell reception excision
circles (TREC)/kappa-deleting element recombination
element (KREC) assays and next generation sequencing:
diagnostic yield from the new established Swiss
programme
M. Elgizouli1*, J. Pascal1, A. Bahr1, S. Prader2, D.
Drozdof2, J. Pachlopnik Schmid2, K. Steindl1, A. Rauch1, J.
Reichenbach2
1Institute of Medical Genetics, University Zurich, Schlieren,
Switzerland, 2Department of Immunology, University Chil-
dren’s Hospital Zurich, Zurich, Switzerland
Introduction: Infants with severe combined immunodefi-
ciency (SCID), a fatal form of primary immunodeficiency in
the absence of early definitive therapy, show an improved
outcome if diagnosed and treated within the first few
months of life, making the condition a suitable target for
newborn screening. Country-wide newborn screening for
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SCID was initiated in Switzerland in January 2019 with
about 80.000 live births per year.
Methods: DNA samples from dried blood spots of from
all neonates born in Switzerland in 2019 were assayed for
T-cell receptor excision circles (TREC) and kappa-deleting
element recombination excision circles (KREC). Cases with
low TREC and/or low KREC counts subsequently under-
went clinical genetic assessment and whole exome sequen-
cing (WES)-based mutation screening and/or high-
resolution chromosomal microarray testing. Children with
dysmorphic features suspicious of DiGeorge syndrome
were initially tested for the common 22q11.2 microdeletion.
In cases with suspected syndromes not detectable with
WES, targeted Sanger sequencing was performed.
Results: Out of 15 neonates with low TREC/KREC
counts identified through the screening procedure, we
diagnosed 5 neonates with SCID and 6 with syndromic
conditions in which a severe immunodeficiency constitutes
a component of the clinical picture. Notably, 2 of the
6 syndromic immunodeficiencies were caused by RNA-
genes and thus are not included in standard exome capture
procedures.
Conclusion: Our findings support the utility of WES as
an efficient and rapid mutation screening method in
newborns with low TREC/KREC counts and suggest a
Swiss incidence of SCID above the US incidence of 1 in
58,000 live births.
M. Elgizouli: None. J. Pascal: None. A. Bahr: None. S.
Prader: None. D. Drozdof: None. J. Pachlopnik Schmid: None.
K. Steindl: None. A. Rauch: None. J. Reichenbach: None.
C22.2
Strategies for increasing diagnostic rate in patients with
primary immunological disorders within the Genomics
England 100,000 Genomes Project
C. Camps1,2*, H. Griffin3, K. Engelhardt3, Genomics
England Research Consortium, S. Y. Patel2,4, S.
Hambleton3,5, J. C. Taylor1,2
1Wellcome Centre for Human Genetics, University of
Oxford, Oxford, United Kingdom, 2Oxford NIHR Biomedi-
cal Research Centre, Oxford, United Kingdom, 3Institute of
Cellular Medicine, Newcastle University, Newcastle upon
Tyne, United Kingdom, 4Department of Clinical Immunol-
ogy, Oxford University Hospitals NHS Foundation Trust,
Oxford, United Kingdom, 5Great North Children’s Hospi-
tal, Newcastle upon Tyne Hospitals NHS Foundation Trust,
Newcastle upon Tyne, United Kingdom
The UK’s 100,000 Genomes Project has completed its
sequencing and includes 74,180 rare disease genomes of
which 2,005 are from patients or family members with a
primary immunological diagnosis. Whilst the referring
clinical centres review variants in known genes for a
given patient’s presenting condition, the Genomics Eng-
land Clinical Interpretation partnerships (GECIPs) can
investigate the pathogenesis of ’unsolved’ cases, poten-
tially leading to the identification of novel disease genes,
phenotypes or mutation mechanisms. In the Immune
GECIP we have taken a gene-focused approach to screen
groups of subjects for whom no pathogenic mutation has
yet been confirmed, which is more efficient than analysing
results on a case-by-case basis. We started by screening
known-disease genes (n=482) for the presence of variants
with high/moderate impact and frequency ≤ 1% in popu-
lation databases across all probands. For each variant, we
counted the number of homozygotes and heterozygotes
among probands of the Immunology domain compared
with the remaining probands, and further compared the
groups at various levels to identify any enrichment.
Results from this approach include i) identification of
digenic cases among patients with complex phenotypes,
ii) detection of immune disease-causing variants in
patients outwith the Immunology domain, iii) detection of
compound heterozygotes involving structural variants.
This has paved the way for discovery of novel genes in the
remaining patients while assisting in the timely delivery
of clinically actionable findings, providing an exemplar of
how the 100K genomes dataset can be used to identify
novel disease genes and mechanisms as well as refining
disease entities.
C. Camps: None. H. Griffin: None. K. Engelhardt: None.
S. Y. Patel: None. S. Hambleton: None. J. C. Taylor: None.
C22.3
Dysregulated expression of the long intergenic non-
coding RNA (lincRNA), LINC01871, implicated in
Sjögren’s Syndrome pathogenesis
M. L. Joachims1, B. Khatri1, K. L. Tessneer1, A. M.
Stolarczyk1, G. B. Wiley1, A. Rasmussen1, J. M.
Guthridge1,2, J. A. James1,2, R. H. Scofield1,2, K. L. Sivils1, I.
Adrianto3, C. J. Lessard1,2*
1OKLAHOMA MEDICAL RESEARCH FOUNDATION,
OKLAHOMA CITY, OK, United States, 2University of
Oklahoma Health Sciences Center, Oklahoma City, OK,
United States, 3Henry Ford Health System, Detroit, MI,
United States
Introduction: Sjögren’s syndrome (SS) is an autoimmune
disease characterized by inflammatory destruction of exo-
crine glands. Here, we aimed to identify and characterize
candidate lncRNAs with potential relevance to SS
pathology.
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Results: RNA-seq was used on whole blood from SS
patients (n= 30 autoantibody negative (SSRo-); n= 27
autoantibody positive (SSRo+)) and healthy controls (HC, n
= 27) to identify differentially expressed (DE) lncRNAs (log2
fold change (FC) ≥2 or ≤0.5; padj<0.05). We identified 1054
unique DE ncRNAs between Ro+, Ro−, and a combined
analysis relative to HC. Of these, 45 (1 lincRNA, 1 antisense,
43 pseudogenes) were overexpressed in all 3 SS subsets. To
investigate the function of the novel lincRNA, LINC01871,
we performed correlation analysis of the SSRo- transcriptome
yielding several co-expressed protein coding RNAs involved
in immune regulation (THEMIS, TBX21, IL10RA, IL2RB,
etc.). Ingenuity Pathway Analysis of the SS and publicly
available RNA expression data identified shared immune-
related pathways including cytotoxic T cell, NK cell, and
T cell regulation. We used CRISPR editing to generate a
single cell LINC01871-/- clone of HSB2 cells. RNA-seq of
LINC01871-/- compared to unmodified HSB2 cells identified
1166 DE transcripts. Pathway analyses clustered DE
transcripts into similar immune regulatory, cytotoxic and T
cell pathways. Further, several T cell regulatory transcripts
correlated with LINC01871 in SSRo- were downregulation
after LINC01871 deletion: CD109 (FC=−9.7; padj=
5.3 × 10−16), IL22 (FC=−8.1; padj= 7.6 × 10−11), PDCD1
(FC=−6.2; padj= 1.1 × 10−6), THEMIS (FC=−3.8; padj=
2.7 × 10−165), TBX21 (FC=−2.1; padj= 3.3 × 10−25).
Conclusion: LINC01871 is a potential mediator of
dysregulated T cell inflammatory pathways implicated in
SS pathogenesis. Funding: NIGMS P30GM110766; Pres-
byterian Health Foundation
M. L. Joachims: None. B. Khatri: None. K. L. Tessneer:
None. A. M. Stolarczyk: None. G. B. Wiley: None. A.
Rasmussen: D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Novartis,
ThermoFisher. J. M. Guthridge: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Modest;
Dxterity. J. A. James: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Progentec
Biosciences. F. Consultant/Advisory Board; Modest; Abb-
vie, Novartis, Jannsen. R. H. Scofield: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Modest;
Pfizer. K. L. Sivils: None. I. Adrianto: None. C. J.
Lessard: None.
C22.4
Clonal myelopoiesis in the UK biobank cohort: somatic
ASXL1 mutations are strongly associated with smoking
history
A. A. Z. Dawoud*, W. J. Tapper, N. C. P. Cross
Faculty of Medicine, Southampton, United Kingdom
Age-related clonal hematopoiesis (CH) is associated with
the development of hematological malignancies and non-
hematological disorders. We sought to determine the
significance of myeloid CH in the UK Biobank cohort
(n= 502,524, median age = 58 years, median follow
up = 10.6 years). Utilizing data from single nucleotide
polymorphism arrays (n= 486,941) and whole exome
sequencing (n= 49,956), we identified 1166 (0.24%)
participants with myeloid CH, defined by myeloid-asso-
ciated mosaic chromosome abnormalities (mCA) and/or
likely somatic driver mutations in DNMT3A, TET2,
ASXL1, JAK2, SRSF2 or PPM1D. The frequency of
myeloid CH increased with age by approximately 10% per
year (OR = 1.10; P ≤ 2 × 10−16). Genome-wide associa-
tion analysis identified two distinct signals within TERT
that predisposed to CH, plus a weaker signal corre-
sponding to the JAK2 46/1 haplotype. CH and specific
mutation types were associated with several blood fea-
tures and clinical phenotypes, including an association
between TET2 mutations and chronic obstructive pul-
monary disease. Smoking history was significantly asso-
ciated with CH: 53% (n= 622) of CH cases were past or
current smokers compared to 44% (n= 13,651) of con-
trols (P= 3.38 × 10−6), a difference principally due to
current (P= 6.14 × 10−6, OR= 1.09) rather than past
smoking (P= 0.085). Strikingly, breakdown of CH by spe-
cific mutation type revealed that ASXL1 loss of function
mutations were most strongly associated with current
smoking status (P= 1.92 × 10−5, OR= 1.07), and the only
abnormality associated with past smoking (P= 2.60 × 10−3,
OR= 1.04). Indeed, 69% of participants with ASXL1 muta-
tions (n= 69) were past or current smokers. We suggest that
the inflammatory environment induced by smoking promotes
the outgrowth of ASXL1-mutant clones.
A. A. Z. Dawoud: None. W. J. Tapper: None. N. C. P.
Cross: None.
C22.5
A genome-wide meta-analysis yields 46 new loci
associating with biomarkers of iron homeostasis
E. Ferkingstad1*, M. K. Magnusson1,2, S. Bell3, A. S.
Rigas4, E. Allara3, G. Bjornsdottir1, A. Ramond3, E.
Sørensen4,5, G. H. Halldorsson1, D. S. Paul3, K. S.
Burgdorf4, H. P. Eggertsson1, S. Kristmundsdottir1, W. J.
Astle3, C. Erikstrup5, J. K. Sigurdsson1, D. Vuckovic3, V.
Tragante1, P. Surendran3, B. Vidarsson6, I. Jonsdottir1,2, T.
Hansen7, O. Sigurdardottir8, H. Stefansson1, D. Rye9,
DBDS Genomic Consortium, J. E. Peters3, D.
Westergaard7, H. Holm1, N. Soranzo10,3, K. Banasik7, G.
Thorleifsson1, W. H. Ouwehand3, U. Thorsteinsdottir1, P.
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Sulem1, A. S. Butterworth3, D. F. Gudbjartsson1,2, J.
Danesh3, S. Brunak11, E. Di Angelantonio3, H. Ullum4, K.
Stefansson1,2
1deCODE genetics/Amgen, Inc., Reykjavik, Iceland, 2Uni-
versity of Iceland, Reykjavik, Iceland, 3University of
Cambridge, Cambridge, United Kingdom, 4Copenhagen
University Hospital, Copenhagen, Denmark, 5Aarhus Uni-
versity Hospital, Aarhus, Denmark, 6The Laboratory in
Mjodd, Reykjavik, Iceland, 7University of Copenhagen,
Copenhagen, Denmark, 8Akureyri Hospital, Akureyri, Ice-
land, 9Emory University, Atlanta, GA, United States,
10Wellcome Sanger Institute, Cambridge, United Kingdom,
11Novo Nordisk Foundation Center for Protein Research,
Copenhagen, Denmark
Iron deficiency is a major public health problem affecting
maternal and child mortality, and iron overload has
important health implications due to end-organ iron
toxicity. In order to better understand the genetic regula-
tion of iron homeostasis we carried out three genome-
wide association studies in Iceland, the UK and Denmark
of blood levels of ferritin (N=246,139), total iron
binding capacity (N=135,430), iron (N=163,511) and
transferrin saturation (N=131,471), which are the bio-
markers routinely measured for clinical assessment of
iron status. In a meta-analysis we found associations
with iron homeostasis biomarkers represented by
62 sequence variants at 56 loci. Fourteen of the variants
associate with more than one biomarker, bringing the total
number of observed associations to 87. Of the identified
loci, 46 are novel and 10 are known. We assessed the
association of these variants with proteomics data and
various clinical endpoints. Five variants show sexual
dimorphism: four have stronger effects in women while
one has a stronger effect in men. The four variants with
larger effects in women also have stronger effects in pre-
menopausal than post-menopausal women, and their
effect is likely working through blood loss and primarily
menstrual bleeding. The associations implicate novel iron
regulating proteins contributing to physiological pro-
cesses involved in iron homeostasis: iron sensing and
storage, inflammation, gut iron absorption, iron recycling,
erythropoiesis and bleeding/menstruation. We further-
more identify both common and rare sequence variants
contributing to risk of iron deficiency anemia, a major
clinical entity that hitherto has not been studied thor-
oughly from a genetic point of view.
E. Ferkingstad: A. Employment (full or part-time);
Significant; deCODE genetics/Amgen, Inc. M. K. Magnus-
son: A. Employment (full or part-time); Significant;
deCODE genetics/Amgen, Inc. S. Bell: None. A. S. Rigas:
None. E. Allara: None. G. Bjornsdottir: A. Employment
(full or part-time); Significant; deCODE genetics/Amgen,
Inc. A. Ramond: None. E. Sørensen: None. G. H.
Halldorsson: A. Employment (full or part-time); Significant;
deCODE genetics/Amgen, Inc. D. S. Paul: None. K. S.
Burgdorf: None. H. P. Eggertsson: A. Employment (full or
part-time); Significant; deCODE genetics/Amgen, Inc. S.
Kristmundsdottir: A. Employment (full or part-time);
Significant; deCODE genetics/Amgen, Inc. W. J. Astle:
None. C. Erikstrup: None. J. K. Sigurdsson: A. Employ-
ment (full or part-time); Significant; deCODE genetics/
Amgen, Inc. D. Vuckovic: None. V. Tragante: A. Employ-
ment (full or part-time); Significant; deCODE genetics/
Amgen, Inc. P. Surendran: None. B. Vidarsson: None. I.
Jonsdottir: A. Employment (full or part-time); Significant;
deCODE genetics/Amgen, Inc. T. Hansen: None. O.
Sigurdardottir: None. H. Stefansson: A. Employment (full
or part-time); Significant; deCODE genetics/Amgen, Inc. D.
Rye: None. J. E. Peters: None. D. Westergaard: None. H.
Holm: A. Employment (full or part-time); Significant;
deCODE genetics/Amgen, Inc. N. Soranzo: None. K.
Banasik: None. G. Thorleifsson: A. Employment (full or
part-time); Significant; deCODE genetics/Amgen, Inc. W.
H. Ouwehand: None. U. Thorsteinsdottir: A. Employment
(full or part-time); Significant; deCODE genetics/Amgen,
Inc. P. Sulem: A. Employment (full or part-time);
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C22.6
Identification of regulators of hematopoietic stem and
progenitor cells in vivo in humans using population
genetics
A. Lopez de Lapuente Portilla1*, L. Ekhdal1, C. Cafaro1, Z.
Ali1, G. Thorleifsson2, K. Zemaitis1, N. Ugidos
Damboriena1, E. Johnsson1, G. Norddahl2, U.
Thorsteinsdottir2, J. Larsson1, K. Stefansson2, B. Nilsson1
1Lund University, Lund, Sweden, 2deCODE Genetics,
Reykjavik, Iceland
Introduction: Understanding how hematopoietic stem- and
progenitor cells (HSPCs) are regulated is of central impor-
tance for the development of new therapies for blood dis-
orders and for regenerative medicine. Traditionally,
however, HSPC regulation has been studied in model sys-
tems, and little is known about the situation in vivo in
humans.
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Methods: To learn how HSPCs are regulated under
native conditions in humans, we carried out a first large-
scale genome-wide association study on CD34+ cells,
representing HSPCs in blood. We used circulating CD34+
levels as a proxy trait to expose regulators of key
phenomena like HSPC pool size, migration, and early
differentiation. We created a unique phenotyping platform
based on high-throughput, high-resolution flow-cytometry
and machine learning-based algorithms for automated
flow data analysis, and quantified CD34+ cells in 9,936
adults.
Results: We identified 8 genome-wide (P < 5 × 10−8) and
20 suggestive loci (P < 5 × 10−6) associated with CD34+
levels. The two strongest were the HSPC migration receptor
CXCR4 and a novel protein phosphatase never previously
implicated in stem cell biology. Using eQTL, ATAC-seq,
and promoter capture Hi-C analysis in isolated HSPCs, we
pinpoint likely causal variants, including variants in distant
regulatory elements selectively active in specific HSPC
subpopulations. Furthermore, shRNA knockdown in pri-
mary CD34+ cells supports that some of the identified genes
affect CD34+ proliferation and differentiation.
Conclusions: We report the first large-scale analysis of
the genetic architecture of HSPC regulation, with potential
implications for stem cell transplantation and the treatment
of hematologic malignancies.
Grant information: European Research Council, Swed-
ish Research Council, Swedish Cancer Society.
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C23 Counselling, Communication and Deliberation
C23.1
Helping very young children understand inherited can-
cer predisposition syndromes using bibliotherapy
G. Schlub1*, A. Crook2, J. Fleming1, K. Barlow-Stewart1, J.
Kirk3, K. Tucker4, S. Greening5
1University of Sydney, Faculty of Health and Medicine,
Sydney, Australia, 2Cancer Services, Royal North Shore
Hospital, Sydney, Australia, 3Crown Princess Mary Cancer
Centre, Westmead Hospital, Sydney, Australia, 4Hereditary
Cancer Clinic, Prince of Wales Hospital, Sydney, Australia,
5Illawara Cancer Care Centre, Wollongong, Sydney,
Australia
Introduction: Communication with children about her-
editary conditions is difficult for parents. Yet, good com-
munication strategies are leading determinants of
adaptation and resilience. With inherited cancer predis-
position syndromes that can affect very young children e.g.
Li-Fraumeni Syndrome (LFS) and Hereditary Phaeochro-
mocytoma and Paraganglioma Syndrome (HPPS), genetic
testing and subsequent surveillance in at-risk children is the
optimal intervention. Given this often commences early,
providing these children and their parents appropriate
genetic counselling and communication strategies is
important. By adopting a bibliotherapeutic framework-
where stories are delivered prescriptively (i.e. ‘bib-
liotherapy’), we developed and evaluated the first psycho-
educational resource in Australia for children at risk of LFS
and HPPS.
Materials and Methods: Illustrated storybooks for
children aged 5-10 years old at risk of either LFS or HPPS
were created based on models of developmental compre-
hension. Parents were invited to participate in the study and
read the relevant storybook to their child/ren. Semi-
structured qualitative interviews were conducted and
analysed thematically using a general inductive approach
to ascertain parents’ experience reading this storybook with
their children.
Results and Conclusion: Twelve parents were inter-
viewed (total 29 children). Unanimously, parents reported
this resource would have been a useful communication tool
had it been available when their children were first tested
and/or diagnosed. Parents reported that the resource
supported them with communication without raising
emotional distress. We anticipate that by incorporating
parental views, this cost-effective and easily deployable
resource will have psycho-educational benefit and will
improve the process of communication between parents and
children about paediatric inherited cancer syndromes.
G. Schlub: None. A. Crook: None. J. Fleming: None. K.
Barlow-Stewart: None. J. Kirk: None. K. Tucker: None. S.
Greening: None.
C23.2
Towards personalized genetic counselling: exploring
subgroups among counselees based on different facets
of empowerment before the first visit
J. Voorwinden1*, E. Birnie1, M. Plantinga1, M. Ausems2, N.
Knoers1, M. Velthuizen2, A. Lucassen3, I. van Langen1, A.
Ranchor1
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Introduction: The main goal of genetic counselling is
improving empowerment (cognitive/affective outcomes).
The aim of this study is to explore subgroups among
counselees based on different facets of empowerment.
Subsequently, to examine if these subgroups are associated
with socio-demographic and clinical variables. Recognizing
the specific needs regarding genetic counselling for each
subgroup, could facilitate personalized genetic counselling.
Materials and Methods: Data from 2446 unselected
counselees from two Dutch academic centres was collected
with a validated questionnaire: the GCOS-18, which
measures six facets of empowerment (hope, knowledge
about the condition, knowledge about genetic services,
negative emotions, uncertainty about heredity, uncertainty
about the treatment). Subgroups were analysed with latent
profile analysis.
Results: Six subgroups could be distinguished. Profile 1
(n= 727) scored best on all facets of empowerment, and
consisted of more higher educated and pre-symptomatic
counselees. Profile 2 (n= 724) scored average on all facets
of empowerment. Profile 3 (n= 225) experienced less hope,
and consisted of more index patients. Profile 4 (n= 130)
experienced less hope and knowledge; parents of referred
children were overrepresented. Profile 5 (n= 491) had
strong uncertainty about heredity, these counselees were
older and more often at risk of hereditary cancer. Profile 6
(n= 149) had strong negative emotions, uncertainty about
heredity and uncertainty about the treatment. These
counselees were older and lower educated.
Conclusion: This study reveals subgroups among
counselees. The scoring on different facets of empowerment
allows to distinguish specific subgroups, each having their
own specific needs, which could be used for personalization
of the genetic counselling process.
J. Voorwinden: None. E. Birnie: None. M. Plantinga:
None. M. Ausems: None. N. Knoers: None. M. Velthuizen:
None. A. Lucassen: None. I. van Langen: None. A.
Ranchor: None.
C23.3
Exploring patient deliberation prior to predictive
genetic testing in the absence of immediate clinical utility
L. M. Ballard1*, S. Doheny2, A. M. Lucassen1, A. J. Clarke2
1University of Southampton, Southampton, United King-
dom, 2Cardiff University, Cardiff, United Kingdom
Introduction: Some patients appear to ‘know’ whether they
wish to have a genetic test or not, whilst others deliberate
extensively before deciding. Little is understood about how
patients deliberate such decisions. Previous research has
focused on the result of the deliberation process, but little
attention has been paid to the process of arriving at a
decision itself and the role medical and lifeworld frames
play in this deliberation. Our research explored both the
deliberation and eventual decision made by patients at risk
of Huntington’s disease.
Methods: We recruited 15 patients who were considering
predictive testing for Huntington’s disease from four UK
regional genetics services. We gathered qualitative data
from patients’ clinical consultations and reflective diaries to
explore deliberation and patient interviews to explore
decisions. We took an ethnographic approach to consulta-
tions, applied discourse analysis to clinic consultations and
reflective diaries, and account analysis to the final interview
with participants.
Results: Our findings show how consultations, discus-
sions with others, misconceptions, and information seeking
influence four key areas: 1. Patient knowledge of the
options available; 2. Forecasting of emotions regarding
different options; 3. Imagined futures and 4. Hypothetical
scenarios (if/then). We compared clinical consultations with
reflective diaries to further explore deliberation inside and
outside the clinical appointment.
Conclusion: Our findings illustrate how medical frames
sit alongside patient lifeworld frames and how this
influences deliberation and shared decision making. We
make recommendations regarding the development of
decision support tools for use in clinical practice. ESRC
Grant ES/R003092/1
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C23.4
Negotiating autonomy and interdependence with family:
how young people and health professionals navigate
genetic testing for Li-Fraumeni syndrome
R. Forbes Shepherd1,2*, L. A. Keogh3, A. V. Werner-Lin4,
M. B. Delatycki5,6, L. E. Forrest1,2
1Parkville Familial Cancer Centre, Peter MacCallum
Cancer Centre, Melbourne, Australia, 2Sir Peter MacCal-
lum Department of Oncology, The University of Melbourne,
Melbourne, Australia, 3Melbourne School of Population
and Global Health, The University of Melbourne, Mel-
bourne, Australia, 4School of Social Policy and Practice,
University of Pennsylvania, Philadelphia, PA, United
States, 5Victorian Clinical Genetics Service, Melbourne,
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Background/Purpose: The intersection of adolescence
and young adulthood (AYA: aged 15-39 years) with high
multi-organ cancer risk caused by Li-Fraumeni syndrome
(LFS), complicates the process and implications of
genetic testing. This research aims to investigate how
AYAs experience, and health professionals negotiate, this
process.
Methods: A multi-method approach using qualitative
interviews with AYAs together with a survey of Australa-
sian genetic and oncology health professionals examined
experiences and practice of LFS genetic testing.
Findings: Thirty AYAs (mean age 25.5; 26 TP53+ve; 4
at 50% risk) participated. Reliance on family at this life
stage complicated AYAs’ autonomous decision-making
capacity for genetic testing, with parent-driven testing being
common among adolescents. Adolescents who underwent
diagnostic testing had limited involvement in genetic testing
decisions due to a power differential between parents and
providers. Forty-three respondents completed the survey
(56% genetic counsellors), 65% had facilitated predictive
TP53 testing for AYAs, 33% had facilitated testing for
minors (<18 years). Using vignettes, respondents were more
supportive of testing for emotionally mature compared to
immature minors (p= 0.009), and more supportive of
adolescent wishes compared to parental wishes for testing
(p= 0.020) when families held discordant views on testing.
Conclusion: Despite health professionals supporting
AYA autonomy in vignettes, the reality of genetic testing
for LFS described by AYAs was more complex and subtle,
involving both developmental and familial considerations,
which require developmentally appropriate genetic
counselling.
R. Forbes Shepherd: None. L. A. Keogh: None. A. V.
Werner-Lin: None. M. B. Delatycki: None. L. E.
Forrest: None.
C23.5
Exploring outcomes from the Deciphering Developmen-
tal Disorders study
H. Copeland1,2*, E. Kivuva1, G. Hall2, T. DDD Study3, C.
Wright4
1Department of Clinical Genetics, RD&E, Exeter, United
Kingdom, 2School of Biological Sciences, University of
Manchester, Manchester, United Kingdom, 3Wellcome
Trust Sanger Institute, Wellcome Genome Campus, Cam-
bridge, United Kingdom, 4Institute of Biomedical and
Clinical Science, University of Exeter Medical School,
Exeter, United Kingdom
The Deciphering Developmental Disorders (DDD) Study is
investigating the genetic aetiology of abnormal develop-
ment in >13,500 children with severe developmental dis-
orders from across the UK and Ireland. Diagnoses have
been identified in around 35% of individuals, and over 50
genes have been newly implicated in developmental dis-
orders. We sought to investigate the clinical and psycho-
social outcomes of receiving a genetic diagnosis in a subset
of DDD participants. Individuals recruited through the
Royal Devon and Exeter NHS Trust who received a con-
firmed genetic diagnosis from the DDD study before
August 2019 were selected for inclusion (n=112). Genetics
notes were reviewed to assess pre-defined clinical out-
comes. Disease-specific treatment was indicated for seven
individuals, including Carbamazepine for seizure control in
individuals with pathogenic variants in KCNQ2, and
antenatal L-serine treatment for pregnancies at risk of
pathogenic variants in PHGDH. Additionally, 69 indivi-
duals were referred to other specialties for investigations or
ongoing screening, 25 individuals were recruited to further
genetic research studies, three families were able to access
prenatal testing techniques, and 87 families were given or
signposted to disease-specific information and/or gene-
specific patient support groups. Individuals (n=16) who had
no recorded clinical outcomes were invited to interview to
assess the psychosocial impact of the diagnosis for the
individual and wider family. Preliminary results highlight
the broad impact of a diagnosis, including clinical outcomes
for both the patient and family, as well as wider social and
psychological benefits. This presentation will discuss the
clinical and psychosocial impact of receiving a genetic
diagnosis through DDD.
H. Copeland: None. E. Kivuva: None. G. Hall: None. T.
DDD Study: None. C. Wright: None.
C23.6
Improving the communication of genomics results to
patients and families with rare diseases using Experi-
ence-Based Co-Design (EBCD)
A. Costa1,2, V. Frankova3,4*, E. Alexander5, A.
Arellanesová6, V. Bros-Facer7, J. Clayton-Smith5,8, G.
Gumus9, M. Havlovicova4, A. Hunter10, M. Macek4, A.
Metcalfe11, C. Patch12,2, R. Pourová-Kremlíková4, M.
Pritchard13, G. Robert1, L. Roberts13
1Florence Nightingale Faculty of Nursing, Midwifery &
Palliative Care King’s College, London, United Kingdom,
2Society and Ethics Research, Connecting Science, Well-
come Genome Campus, Hinxton, United Kingdom, 3Insti-
tute for Medical Humanities, Charles University, First
Faculty of Medicine, Prague, Czech Republic, 4Department
of Biology and Medical Genetics, Charles University, 2nd
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Republic, 7EURORDIS, Paris, France, 8Division of Evolu-
tion and Genomic Sciences School of Biological Sciences
University of Manchester, Manchester, United Kingdom,
9EURORDIS, Barcelona, Spain, 10Genetic Alliance UK,
London, United Kingdom, 11Sheffield Hallam University,
Sheffield, United Kingdom, 12Genomics England, Queen
Mary University of London, London, United Kingdom,
13SWAN UK, London, United Kingdom
Introduction: We present the methods and findings of a
research study aimed to improve the communication of
genomic results to families with rare diseases. The pre-
sentation will include a short video produced with family
participants.
Materials and methods: The study was set in two
genetic services, one in the United Kingdom and one in the
Czech Republic. Using EBCD, we carried out observations
of clinical appointments and interviews with families
(n=18) and health professionals (n=22). Over a series of
workshops, we worked with participants to identify
priorities for improvement and develop more appropriate
ways of communicating genomic results.
Results: Priorities for improvement identified included: i)
communication at the point testing (UK); ii) counselling on
feeling of guilt (CZ) and iii) follow up care (both sites). To
address these, participants co-designed two types of
interventions: i) educational interventions for workforce
and ii) service model improvements.
Conclusions: The results provide important evidence
on key competencies for the workforce in the new
genomic era, and practical recommendations to achieve
effective family-centred communication. They also
indicate the need for new models of service delivery
and greater attention to follow up care after results have
been shared. Finally, the study offers practical lessons
on how to enable patient and family involvement to
co-designing genomic services that can best meet
their needs.
The study is part of the larger Solve-RD project. The
Solve RD has received funding from the European Union’s
Horizon 2020 research and innovation programme under
grant agreement No 779257.
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A novel disorder involving dyshematopoiesis, inflam-
mation and HLH due to aberrant CDC42 function
S. Coppola1*, M. T. Lam2,3,4, O. H. Krumbach5, G.
Prencipe6, I. Insalaco6, C. Cifaldi7,8, I. Brigida9, E. Zara1,
S. Scala9, S. Martinelli10, M. Di Rocco10,11, A. Pascarella6,
M. Niceta12, F. Pantaleoni12, A. Ciolfi12, F. Carisey2,4, M.
Akbarzadeh5, L. Farina1,6, L. Pannone10,12, H. C.
Erichsen13, A. C. Horne14,15, Y. Bryceson16,17, L. Torralba-
Raga16, K. Ramme18,8, A. Finocchi19,8, F. Locatelli20, C.
Cancrini19,8, A. Aiuti9, M. R. Ahmadian5, J. S. Orange2, F.
De Benedetti6, M. Tartaglia12
1National center for rare diseases, Istituto Superiore di
Sanità, Rome, Italy, 2Department of Pediatrics, Columbia
University, Irving Medical Center, New York, NY, United
States, 3Translational Biology and Molecular Medicine
Graduate Program and Medical ScientistTraining Pro-
gram, Baylor College of Medicine, Houston, TX, United
States, 4Department of Pediatrics, Baylor College of
Medicine, Houston, TX, United States, 5Institute of
Biochemistry and Molecular Biology II, Medical Faculty
of the Heinrich-Heine University, Düsseldorf, Germany,
6Division of Rheumatology, Ospedale Pediatrico Bambino
Gesù, IRCCS, Rome, Italy, 7Department of Pediatrics,
Ospedale Pediatricon Bambino Gesù, IRCCS, Rome, Italy,
8Department of Systems Medicine, University of Rome Tor
Vergata, Rome, Italy, 9San Raffaele Telethon Institute for
Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific
Institute, Milan, Italy, 10Department of Oncology and
Molecular Medicine, Istituto Superiore di Sanità, Rome,
Italy, 11Department of Cellular Biotechnology and Haema-
tology, Sapienza University of Rome, Rome, Italy, 12Genet-
ics and Rare Diseases Research Division, Ospedale
Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 13Depart-
ment of Pediatric and Adolescent Medicine, Oslo University
Hospital, Oslo, Norway, 14Pediatric Rheumatology, Astrid
Lindgren Childrens Hospital, Karolinska University Hos-
pital, Stockholm, Sweden, 15Department of Women’s and
Children’s Health, Karolinska Institutet, Karolinska Uni-
versity Hospital Solna, Stockholm, Sweden, 16Department
of Medicine, Karolinska Institutet, Karolinska University
Hospital Huddinge, Stockholm, Sweden, 17Broegelmann
Research Laboratory, Institute of Clinical Sciences, Uni-
versity of Bergen, Bergen, Norway, 18Pediatric Hematol-
ogy, Immunology and HCT Section, Astrid Lindgren
Children’s Hospital, Karolinska University Hospital, Stock-
holm, Sweden, 19Department of Pediatrics, Ospedale
PediatricoBambino Gesù, IRCCS, Rome, Italy,
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Introduction: The diagnosis and delineation of novel
genetic syndromes is often difficult given the limited
availability of patients, genetic heterogeneity, and clinical
variability. Hemophagocytic lymphohistiocytosis (HLH) is
characterized by hyper-inflammation driven by excessive
activation and expansion of macrophages and defective
Natural Killer (NK) cytotoxicity; it can be fatal if untreated.
Here, we identify a previously unrecognized hematological
and autoinflammatory condition in four unrelated patients
with superimposable features, including neonatal-onset tri-
linear cytopenia with dyshematopoiesis, autoinflammation,
rash, and HLH.
Methods: To delineate this new syndrome, we performed
phenotype and whole-genome/exome analyses. In silico,
in vitro and in vivo (C. elegans) assays allowed to
characterize the impact of mutation on localization and
function.
Results: All patients shared the same de novo CDC42
mutation (Chr1:22417990C>T, p.R186C) and altered
hematopoietic compartment, immune dysregulation, and
inflammation. We documented unique effects of the p.
R186C on CDC42 localization and function. Indeed,
CDC42^R186C showed impaired interaction with known
CDC42 regulators and effectors, including RHOGDI,
IQGAP1 and WASP, leading to aberrant Golgi accumula-
tion, cytoskeleton rearrangement and reduced growth and
migration, which likely HB1underlie the distinctiveness of
the trait of this syndrome. Aberrant CDC42 function caused
defective NK cytotoxicity, which likely contributes to the
HLH phenotype. Timely therapeutic neutralization of IL-1?
and IFN? was critical to the survival of one patient, who
underwent successful bone marrow transplantation.
Conclusions: The presented data emphasize the crucial
role played by CDC42 in hematopoiesis and inflammation.
Early recognition of the disorder and establishment of
treatment followed by bone marrow transplant are important
to survival.
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Loss of costameric supervillin causes myopathy with
myofibrillar disorganization and autophagic vacuoles
C. Hedberg-Oldfors1, R. Meyer2, K. Nolte3, Y. A. Rahim1, C.
Lindberg4, K. Karason5, I. J. Thuestad6, K. Visuttijai1, M.
Geijer7,8, M. Begemann2, F. Kraft2, E. Lausberg2, L.
Hitpaß9, R. Götzl10, E. J. Luna11, H. Lochmüller12,13, S.
Koschmieder14, M. Gramlich15, B. Gess16, M. Elbracht2, J.
Weis3, I. Kurth2, A. Oldfors1, C. Knopp2*
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pathology, Medical Faculty, RWTH Aachen University,
Aachen, Germany, 4Department of Neurology, Neuromus-
cular Centre, Sahlgrenska University Hospital, Gothen-
burg, Sweden, 5 Department of Cardiology and Transplant
Institute, Sahlgrenska University Hospital, Gothenburg,
Sweden, 6Department of Pediatrics, Skane University
Hospital, Malmö, Sweden, 7Department of Radiology,
Sahlgrenska Academy, University of Gothenburg, Gothen-
burg, Sweden, 8Department of Clinical Sciences, Lund
University, Lund, Sweden, 9Institute of Human Genetics,
MeDepartment of Diagnostic and Interventional Radiology,
Medical Faculty, RWTH Aachen Universitydical Faculty,
RWTH Aachen University, Aachen, Germany, 10Department
of Plastic Surgery, Hand and Burn Surgery, Medical
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11Division of Cell Biology and Imaging, Department of
Radiology, University of Massachusetts Medical School,
Worcester, MA, United States, 12Children’s Hospital of
Eastern Ontario Research Institute, Division of Neurology,
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ON, Canada, 13Brain and Mind Research Institute, Ottawa,
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Hemostaseology and Stem Cell Transplantation, Medical
Faculty, RWTH Aachen University, Aachen, Germany,
15Department of Invasive Electrophysiology, Medical
Faculty, RWTH Aachen University, Aachen, Germany,
16Department of Neurology, Medical Faculty, RWTH
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Introduction: Archvillin, the muscle specific isoform of
supervillin encoded by the SVIL gene, is a large sarco-
lemmal protein. Despite an important role of supervillin in
muscle cell physiology has been suggested, no muscular
disease associated with SVIL mutations has been described.
We here report a new structural myopathy in four indivi-
duals of two unrelated, consanguineous families caused by
biallelic loss-of-function mutations in SVIL.
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Material and Methods: Patients were comprehensively
investigated clinically, and whole exome sequencing on
genomic DNA was performed in all affected individuals.
Skeletal muscle biopsies were morphological analyzed by
enzyme and immunohistochemical techniques and electron
microscopy.
Results: Affected patients share a distinctive phenotype
that includes a wide neck, anteverted shoulders, and a
prominent trapezius muscle together with variable contrac-
tures besides further skeletal and mild heart muscle
involvement. Muscle biopsies of both families demon-
strated complete loss of supervillin in muscle tissue by
western blot and immunohistochemical analyses. Compre-
hensive light and electron microscopical investigations of
muscle biopsies showed striking similarities between
patients and revealed a structural myopathy with prominent
lobulated type 1 fibers, myofibrillar disintegration and signs
of altered proteostasis and impaired autophagy.
Conclusions: The results underline the importance of
supervillin for the structural integrity of muscle fibers in
humans and show that recessive loss-of-function mutations
in SVIL cause a novel myopathy with distinct histological,
ultrastructural and clinical findings.
Funding: This study was supported by the Swedish
Research Council to AO (grant number 2018-02821) and by
the German Research Foundation (DFG) to IK (KU1587/4-1).
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Genome wide methylation profiling, EpiSign, as a
diagnostic test
M. Alders1*, P. Henneman1, E. Aref-Eshghi2, A. Venema1,
J. Kerkhof2, B. Sadikovic2,3, M. Mannens1
1Amsterdam UMC, Amsterdam, Netherlands, 2London
Health Sciences Centre, London, ON, Canada, 3Western
University, London, ON, Canada
A growing number of neurodevelopmental syndromes are
shown to have unique genomic DNA methylation profiles.
These episignatures can be used to diagnose patients with
such syndromes. We have recently implemented genome
wide methylation profiling as a diagnostic test in our
laboratory. This test, named EpiSign(v1), is able to recog-
nize 22 syndromes, 14 of which are syndromes with specific
episignatures, (for example for Kabuki syndrome, BAFo-
pathies and Cornelia de Lange syndrome), 6 are imprinting
disorders and 2 are repeat expansion disorders. Validation
of the test was based on 38 positive samples (with known
pathogenic variant) and 24 negative controls. All samples
were called correctly provided that the DNA was extracted
from peripheral blood and there was no low mosaicism for
the pathogenic variant. Reasons for requesting an EpiSign
clinical test were: the presence of a variant of unknown
clinical significance, clinical diagnosis without molecular
confirmation, or as a test complementary to WES/WGS,
without a prior (suspected) diagnosis. In approximately
40% of cases with a suspected (VUS present) or clinical
diagnosis, EpiSign was able to confirm this diagnosis. This
shows that EpiSign is a powerful new diagnostic tool, in
particular for patients for whom conventional genetic test-
ing was inconclusive. In March 2020 an updated version of
EpiSign will be available (EpiSignv2), allowing diagnosis
of an additional 23 syndromes (45 in total). For a current list
of syndromes detected by EpiSign see https://genomedia
gnostics.amsterdamumc.nl/
M. Alders: None. P. Henneman: None. E. Aref-Eshghi:
None. A. Venema: None. J. Kerkhof: None. B. Sadikovic:
None. M. Mannens: None.
C24.08
The landscape of BRCA1 and BRCA2 variants from
300,000 individuals in the UK Biobank population
sampling
Z. Ghazoui*
AstraZeneca, Cambridge, United Kingdom
Prior prevalence estimates of BRCA1 and BRCA2 protein-
truncating variants (PTVs) have been generally limited to
studies that have ascertained for cancer patients or indivi-
duals with a family history of cancer. The aim of this study
is to utilise one of the largest sequenced Biobank popula-
tions to investigate the prevalence of BRCA1 and BRCA2
PTVs and ClinVar pathogenic/likely pathogenic classified
missense variants. We analysed whole-exome sequence
data from 300,000 UK Biobank participants (https://www.
ukbiobank.ac.uk/), which is a prospective cohort study
linked to deep phenotypic data. Among the 300,000
exomes, we identified 1332 carriers of high confidence rare
PTVs in BRCA1/2 and another set of 62 carriers of rare
ClinVar pathogenic/likely pathogenic classified missense
variants in BRCA1/2. Of the 1394 BRCA1/2 putatively
pathogenic variant carriers, 529 (38.0%) have been diagnosed
with cancer, 455 (32.6%) have a reported family history of
cancer but are not diagnosed with cancer and 410 (29.4%)
have no reported history (or family history) of cancer. For the
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529 individuals with a cancer diagnosis we further evaluated
the contribution that they have to 100 distinct ICD10 primary
cancer phenotypes and identified that ovarian (5.3% of
reported), breast (2% of reported), prostate (1% of reported),
pancreas (1.5% of reported) and lung (1.1% of reported)
cancers are amongst the cancers that are significantly enriched
for these BRCA1/2 putatively pathogenic variants. This study
provides an unbiased summary of germline BRCA1/2 con-
tribution to various primary cancers and highlights the value
of careful variant interpretation.




ing of AML patients
F. Kraft1*, P. Krüger1, S. Koschmieder2, E. Jost2, M.
Crysandt2, I. Kurth1
1Institute of Human Genetics, University Hospital RWTH
Aachen, Aachen, Germany, 2Department of Medicine
(Hematology Oncology, Hemostaseology, and Stem Cell
Transplantation), University Hospital RWTH Aachen,
Aachen, Germany
Introduction: The current diagnostic scheme for classifi-
cation of acute myeloid leukemia (AML) patients is usually
based on cytogenetic and molecular biology methods. The
turnaround time for karyotype analysis is up to two weeks,
due to the indispensable cultivation of hematopoietic cells.
Although initial PCR or FISH-based testing for recurrent
structural variations (SV) can be carried out within few
hours, the AML classification is demanding and requires
accurate karyotyping.
Methods: We utilized nanopore-sequencing to overcome
the time-consuming karyotyping and further increase
resolution and accelerate SV analysis for AML classifica-
tion. In detail, low-coverage whole genome sequencing
(LC-WGS) was carried out in combination with a modified
SMURFseq protocol on AML bone marrow or blood
samples (?20% blasts). LC-WGS data was used to identify
classification-relevant SV in AML. Genome-wide CNV
analysis was done from SMURFSeq data.
Results: For all 16 samples the results from nanopore-
sequencing confirmed the SV identified by conventional
cytogenetic and FISH analyses. Translocations, inversions,
tandem duplications and CNVs were identified at single
base resolution. We could detect additional small CNVs in
growth regulating genes which may modify the aggressive-
ness of the leukemia. Moreover, the procedure from DNA
isolation to obtaining results requires less than 48h and is
not operator dependent. The method can also generate
karyotype data from samples for which the cell cultivation
failed.
Conclusion: We show that nanopore-sequencing can
speed-up and potentially improve the comprehensive
analysis of SV in AML. Rapid classification according to
ELN risk stratification will immediately impact on targeted
and risk adapted treatment of AML patients.
F. Kraft: None. P. Krüger: None. S. Koschmieder: None.
E. Jost: None. M. Crysandt: None. I. Kurth: None.
C24.10
Classification of ATM variants identified in Spanish
patients with suspicion of hereditary cancer
L. Feliubadaló1,2,3*, M. Santamariña Peña4,5,6, L. M.
Porras7,8, A. Moles-Fernández9, A. T. Sánchez10,11, A.
Blanco12,13,5, O. Diez9,14, S. Gutiérrez-Enríquez9, M. de la
Hoya15,16, A. Lopez-Novo17, A. Osorio18,5, M. Pineda1,2,3, D.
Rueda19,20, C. Ruiz-Ponte21,5, A. Vega12,13,5, I. J. Molina22,
X. de la Cruz7,8,23, C. Lázaro1,2,3
1Hereditary Cancer Program, Catalan Institute of Oncol-
ogy, IDIBELL, Hospitalet de Llobregat, Spain, 2Program in
Molecular Mechanisms and Experimental Therapy in
Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat,
Spain, 3Centro de Investigación Biomédica en Red de
Cáncer (CIBERONC), Madrid, Spain, 4 Grupo de Medicina
Xenómica. Instituto de Investigación Sanitaria de Santiago
de Compostela, Santiago de Compostela, Spain,
5CIBERER, Madrid, Spain, 6Universidad de Santiago de
Compostela, Santiago de Compostela, Spain, 7Research
Unit in Clinical and Translational Bioinformatics, Vall
d’Hebron Institute of Research (VHIR), Barcelona, Spain,
8Universitat Autònoma de Barcelona, Barcelona, Spain,
9Hereditary Cancer Genetics Group, Vall d’Hebron
Institute of Oncology (VHIO), Barcelona, Spain, 10Heredi-
tary Cancer Program, Catalan Institute of Oncology,
Barcelona, Spain, 11Aberystwyth University, Aberystwyth,
United Kingdom, 12Fundación Pública Galega Medicina
Xenómica-SERGAS, Santiago de Compostela, Spain,
13Instituto de Investigación Sanitaria de Santiago de
Compostela (IDIS), Santiago de Compostela, Spain, 14Area
of Clinical and Molecular Genetics, University Hospital of
Vall d’Hebron, Barcelona, Spain, 15CIBER-ONC, Instituto
de Salud Carlos III, Madrid, Spain, 16Molecular Oncology
Laboratory, Hospital Clinico San Carlos, IdISSC (Instituto
de Investigación Sanitaria del Hospital Clínico San
Carlos), Madrid, Spain, 17Fundacion Publica Galega de
Medicina Xenómica, Grupo de Medicina Xenomica-Uni-
versidade de Santiago de Compostela, Instituto de Inves-
tigacion Santiago de Compostela (E035), Santiago de
Compostela, Spain, 18Human Genetics Group, Spanish
National Cancer Research Centre (CNIO), Madrid, Spain,
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19Digestive Cancer Research Group, 12 de Octubre
Research Institute, Madrid, Spain, 20Molecular Biology
Laboratory, 12 de Octubre University Hospital, Madrid,
Spain, 21Fundacion Publica Galega de Medicina Xenomica,
Grupo de Medicina Xenomica-Universidade de Santiago de
Compostela, Instituto de Investigacion Sanitaria de San-
tiago de Compostela (E035), Santiago de Compostela,
Spain, 22Institute of Biopathology and Regenerative Med-
icine, University of Granada, Granada, Spain, 23Institució
Catalana de Recerca i Estudis Avançats (ICREA), Barce-
lona, Spain
The use of NGS gene panels for clinical testing has
increased the diagnostic yield, but also the frequency of
variants of unknown significance (VUS) per patient. With
the aim of improving and standardizing variant classifica-
tion, we’ll create a national registry of genetic variants in
cancer predisposing-genes. To that end, seven Spanish
molecular laboratory groups currently using NGS panels for
hereditary cancer diagnostics created a variant database.
Our current database gathers all variants with less than 1%
allele frequency in all GnomAD outbred populations,
starting with the ATM gene, study because of its moderate
increase in breast cancer risk and its remarkable number of
VUSes. The methodology consisted of: 1) selection and
curation of 50 representative variants from our cohort; 2)
evaluation of each by three members; and 3) discussion of
evidences for classification in monthly teleconferences. As
ATM-specific guidelines have not been published, we have
previously carried out our own ACMG/AMP criterion
adjustment. So far, 842 variants belonging to 730 tested
patients with different hereditary cancer conditions. Among
the 265 unique variants, 97 appeared more than once, and
35 had differences in classification among groups. Our new
ATM-specific criteria have allowed us to improve and
standardize the classification of the 50 pilot variants. We’ll
next submit our classifications to international databases
and extend our database to other Spanish participants and
hereditary cancer genes. Grant support: Carlos III National
Health Institute - FEDER funds [PI19/00553; PI16/00563;
PI16/01898; SAF2015-68016-R and CIBERONC]; the
Government of Catalonia [PERIS_MedPerCan and URD-
Cat projects, 2017SGR1282 and 2017SGR496].
L. Feliubadaló: None. M. Santamariña Peña: None. L. M.
Porras: None. A. Moles-Fernández: None. A. T. Sánchez:
None. A. Blanco: None. O. Diez: None. S. Gutiérrez-
Enríquez: None. M. de la Hoya: None. A. Lopez-Novo:
None. A. Osorio: None. M. Pineda: None. D. Rueda: None.
C. Ruiz-Ponte: None. A. Vega: None. I. J. Molina: None. X.
de la Cruz: None.
C24.12
Reduced male reproductive success drives selective
constraint on human genes
E. J. Gardner1*, M. D. C. Neville1, K. E. Samocha1, M. E.
K. Niemi1, K. J. Barclay2, M. Kolk3, G. Kirov4, H. C.
Martin1, M. E. Hurles1
1Wellcome Sanger Institute, Hinxton, United Kingdom,
2Max Planck Institute for Demographic Research, Rostock,
Germany, 3Stockholm University, Stockholm, Sweden,
4School of Medicine, Cardiff University, Cardiff, United
Kingdom
Sequencing of human populations has revealed highly
variable patterns of natural selection acting on human
genes, with a minority of genes appearing to be under
strong selection against heterozygous variants that abolish
the function of the encoded protein. Although these selec-
tively constrained genes are strongly enriched for dominant
single gene disorders, for most of these genes the nature of
the selective constraint is unknown. We called large dele-
tions from SNP genotyping data on 500K UK Biobank
participants and analysed protein truncating variants from
exome data on 50K UK Biobank participants. We deter-
mined the cumulative burden of likely loss-of-function
variants in each UK Biobank participant, weighted
according to the degree of selective constraint of the
impacted gene(s), which we term their Shet burden. We
found that increasing Shet burden results in substantially
reduced male reproductive success, driven by an increased
risk of childlessness (p= 4x10-15). This reduction in
reproductive success is much weaker in females (p=
0.0026). Shet burden is also associated with reduced fluid
intelligence, educational attainment and household income,
but without strong sex-bias. We present evidence that this
reduced male reproductive success is most likely mediated
by cognitive and behavioural traits, which, due to female
preferences for mating partners likely to invest resources in
their offspring, renders male carriers of such variants less
able to find mating partners. Our findings support a sub-
stantial role for sexual selection due to mate choice pre-
ferences shaping the recent evolution of human genes.
E. J. Gardner: None. M. D. C. Neville: None. K. E.
Samocha: None. M. E. K. Niemi: None. K. J. Barclay: None.
M. Kolk: None. G. Kirov: None. H. C. Martin: None. M. E.
Hurles: E. Ownership Interest (stock, stock options, patent or
other intellectual property); Modest; Congenica.
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C24.13
Widespread sexual differences in genetic architecture in
UK Biobank
E. Bernabeu1*, O. Canela-Xandri2, K. Rawlik1, A. Talenti1,
J. Prendergast1, A. Tenesa1,2
1The Roslin Institute, University of Edinburgh, Edinburgh,
United Kingdom, 2MRC Human Genetics Unit, University
of Edinburgh, Edinburgh, United Kingdom
Despite males and females sharing nearly identical gen-
omes, there are differences between the sexes in complex
traits and in the risk, incidence, and prevalence of a wide
array of diseases. Gene by sex interactions (GxS) are
thought to underlie some of this sexual dimorphism.
However, the extent and basis of these interactions are
poorly understood. Here we provide insights into both the
scope and mechanism of GxS across the genome of circa
450,000 individuals of European ancestry and 530 complex
traits in UK Biobank. We report sex differences in herit-
ability for 71 traits, through genetic correlations for 69
traits, and in associations of genetic variants located in the
autosome and X-chromosome for 103 traits. We also show
that sex specific polygenic risk scores may lead to a modest
improvement of phenotypic prediction and highlight how
sex agnostic analyses could be missing loci of interest.
Finally, we studied the potential functional role of this
dimorphism through sex-biased eQTL and gene-level ana-
lyses. This study marks the largest examination of the
genetics of sexual dimorphism to date. Our findings parallel
previous reports, proving the widespread presence of sexual
genetic heterogeneity across complex traits, though be it of
generally modest magnitude. This warrants the need for
future studies to consider sex-stratifying analyses, in order
to both shed light into possible sex-specific molecular
mechanisms as well as improve prediction of high-level
phenotypes.
E. Bernabeu: None. O. Canela-Xandri: None. K. Rawlik:
None. A. Talenti: None. J. Prendergast: None. A.
Tenesa: None.
C24.14
Profiling the chromatin landscape of early neurodeve-
lopment using scATAC-seq
C. C. Mannens*, L. Hu, E. P. Braun, P. Lönnerberg, S.
Linnarsson
Karolinska institutet, Solna, Sweden
Understanding the molecular processes underlying healthy
development of the human brain is crucial in the modelling
and investigation of neurodevelopmental disorders. While
many evolutionarily conserved developmental processes are
well studied in mouse models, our understanding of human-
specific neurodevelopmental processes is limited. Our lab
aims to provide transcriptomic and epigenomic reference
atlases with single-cell resolution. In this ongoing project,
we are characterizing chromatin accessibility of cell types in
the human brain during early development (5 - 13 p.c.w.)
using single-cell ATAC-sequencing. So far, we have
sequenced a few tens of thousands of cells and will profile
up to one million individual human cells, identifying both
region- and cell lineage-specific enhancers as well as enri-
ched motifs and gene accessibility. We use a two-step
approach to feature identification, first performing super-
ficial decomposition and clustering on binned genomic
ranges to stratify peak calling and then performing Hier-
archical Poisson Factorization on more detailed PeakxCell
data to identify lineages and cell types. We have identified
29 clusters and 325.484 unique peaks. 115.048 of these
peaks are intergenic and 28.622 of these peaks (25%) don’t
align to any known element in the GENCODE GRCh38
reference, indicating the presence of unannotated cell line-
age specific enhancers. To validate the cluster identities and
lineages, our scATAC-seq data will be integrated with the
scRNA-seq data that has been acquired as part of the
Human Developmental Cell Atlas initiative. This combined
resource may serve as a reference for future studies relating
to development of the human nervous system. European
Union - H2020-SC1-BHC-2018-2020 - BRAINTIME
C. C. Mannens: None. L. Hu: None. E. P. Braun: None.
P. Lönnerberg: None. S. Linnarsson: None.
C25 Late Breaking Session
C25.1
Deciphering genomic inversions
C. M. Grochowski1*, M. Pettersson2, J. Eisfeldt2, M.
Gandhi1,3, D. Pehlivan1, C. Gonzaga-Jauregui4, M.
Withers1, P. Stankiewicz1,5, A. C. V. Krepischi6, J. R.
Lupski1, A. Lindstrand2, C. M. B. Carvalho1
1Baylor College of Medicine, Houston, TX, United States,
2Karolinska Institutet, Stockholm, Sweden, 3University of
Texas MD Anderson Cancer Center, Houston, TX, United
States, 4Regeneron, Tarrytown, NY, United States, 5Baylor
Genetics, Houston, TX, United States, 6University of São
Paulo, SP, Brazil
Genomic inversions are a class of structural variation (SV)
relevant in evolution, speciation and disease but challenging
to detect/resolve. Copy number neutral inversions contain
two breakpoints in cis, often located within repetitive
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regions. Contrastingly, inversions accompanied by copy
number variation (CNV, deletions/duplications/triplica-
tions) may have more than two breakpoints. Those features
contribute to the high error rates that characterize inversion
detection resulting in many events being overlooked.
We hypothesize that proper detection/investigation of
inversions require a strategy utilizing multiple methodolo-
gies including cytogenetics and next-generation sequencing.
We applied karyotyping, short-read WGS, linked-read
WGS, droplet digital PCR, array CGH, long-read WGS
(ONT) or optical mapping (OM) in two cohorts of inversion
carriers: 1. paracentric or pericentric inversions (N=18) and
2. inversions accompanied with complex rearrangements
(N=3) and one individual with multiple de novo inversions.
For cohort 1, we achieved nucleotide-resolution of inver-
sion for 13/18 (72%) samples studied by WGS providing
mechanistic insights and challenging the dogma of how
most inversions are formed. Remarkably, we observed that
~17% of apparently neutral inversions are accompanied by
CNVs. For cohort 2, we observed that ONT/OM resolved
the complex inversion structure through the use of single
molecules preserving the architecture, enabling identifica-
tion of multiple junctions within repetitive segments missed
by WGS.
No single technology solves all SVs. While short-read
WGS can resolve a proportion of neutral inversions, those
mediated by repeats or accompanied by CNVs remain
challenging. Utilization of multiple technologies and
visualization of unbroken DNA through OM/ONT sequen-
cing facilitates detection/resolution of structures containing
multiple breakpoint junctions.
C. M. Grochowski: None. M. Pettersson: None. J.
Eisfeldt: None. M. Gandhi: None. D. Pehlivan: None. C.
Gonzaga-Jauregui: A. Employment (full or part-time);
Significant; Regeneron Genomics Center. M. Withers:
None. P. Stankiewicz: None. A. C. V. Krepischi: None. J.
R. Lupski: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; 23 and Me. F.
Consultant/Advisory Board; Modest; Regeneron Pharma-
ceuticals, Novartis. A. Lindstrand: None. C. M. B.
Carvalho: None.
C25.2
Polymorphic inversions underlie the shared genetic
susceptibility of obesity-related diseases
J. R. Gonzalez1*, C. Ruiz1, A. Caceres1, I. Moran2, M.
Lopez1, L. Alonso2, I. Tolosana1, M. Guindo-Martinez3, J.
M. Mercader3, T. Esko4, D. Torrents2, J. Gonzalez5, L. A.
Perez-Jurado5
1Barcelona Institute for Global Health, BARCELONA,
Spain, 2Barcelona Supercomputing Center, BARCELONA,
Spain, 3Broad Institute, BOSTON, MA, United States,
4University of Tartu, BARCELONA, Estonia, 5Universitat
Pompeu Fabra, BARCELONA, Spain
Background: The burden of several common diseases
including obesity, diabetes, hypertension, asthma, and
depression is increasing in most world populations. The
mechanisms underlying the numerous epidemiological and
genetic correlations among these disorders remain largely
unknown. Genomic inversions can alter the function of
genes by multiple mechanisms affecting several diseases. Its
impact remained largely unknown because they were dif-
ficult to genotype in large cohorts.
Methods: We performed an inversion association
analysis including 21 inversions and 25 obesity-related
traits, on a total of 408,898 Europeans, and validated the
results in 67,299 independent individuals. Inversion calling
was performed using our scoreInvHap tool that uses exiting
GWAS data.
Results: Seven inversions were associated with multiple
diseases while inversions and inversions 8p23.1, 16p11.2
and 11q13.2 were strongly associated with the co-
occurrence of obesity with other common diseases.
Transcriptome analysis across numerous tissues revealed
strong candidate genes of obesity-related traits. Analyses in
human pancreatic islets indicated the potential mechanism
of inversions in the susceptibility of diabetes by disrupting
the cis-regulatory effect of SNPs from their target genes.
Conclusions: We report the largest association study of
genomic inversions and human traits that represents a
breakthrough for genomic association of comorbid dis-
orders. Inversions have major genetic contribution into the
joint susceptibility to common diseases. The results in
obesity and diabetes reveal a mechanism in which cis-
regulatory SNPs are separated from their target genes by
inversion breakpoints. Future studies in other diseases are
now accessible to the research community thanks to our
inversion genotyping tool.
J. R. Gonzalez: None. C. Ruiz: None. A. Caceres: None.
I. Moran: None. M. Lopez: None. L. Alonso: None. I.
Tolosana: None. M. Guindo-Martinez: None. J. M.
Mercader: None. T. Esko: None. D. Torrents: None. J.
Gonzalez: None. L. A. Perez-Jurado: None.
C25.3
Discovery of rare variants associated with blood
pressure regulation through meta-analysis of 1.3 million
individuals
E. V. Feofanova*, the Blood Pressure-International
Consortiumof Exome chip Studies (BP‐ICE), CHARGE
consortium, CHD Exome+, Exome BP, GoT2D:T2Dgenes,
deCODE, the Million Veteran Program (MVP)
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Human Genetics Center, The University of Texas Health
Science Center at Houston, Houston, TX, United States
Elevated blood pressure (BP) is a major risk-factor for
cardiovascular disease worldwide. Most prior genetic stu-
dies of BP explored Single Nucleotide Variants (SNVs)
with minor allele frequency [MAF]>0.01. The majority of
identified BP-SNVs are non-coding and the corresponding
causal genes remain unknown. We explored the role of rare
variants (MAF<=0.01) on BP and elucidated candidate
causal BP genes, to further our understanding of BP
regulation.
The Exome array facilitates analyses of rare coding
variants with potential functional consequences. Over 80%
of SNVs on the array are rare and ~80% are missense,
implicating a candidate causal gene. We performed an
Exome Array-Wide Association Study (EAWAS) of
~247,000 SNVs in ~1.32 million participants (95 studies)
to identify SNVs associated with SBP, DBP, pulse pressure
and hypertension. We additionally performed a rare-variant
Genome-Wide Association Study (RV-GWAS) of ~29
million imputed and genotyped SNVs in ~670,000
participants (UKBiobank, MVP).
We discovered 105 new BP-associated genomic regions,
containing nine rare SNV-BP associations in the EAWAS
and 23– in the RV-GWAS (P<5x10−8); 55 additional rare
variants were distinct novel SNVs within known BP-
associated loci. Many BP-associated rare variants highlight
potential candidate causal genes (e.g. GATA5, PLCB3),
with 17% located in or near potentially druggable genes
(e.g. NR3C2, NPPA).
Our study is the largest analysis of rare variants to date,
revealing candidate genes at new and previously reported
BP loci, highlighting potential therapeutic targets. We also
report new observations from both rare and common loci
enriching our understanding of genetic BP regulation in
health and disease.
E. V. Feofanova: None.
C25.4
Multi-Omics integration for molecular diagnostics of
mendelian disorders
R. Kopajtich1,2*, D. Smirnov1,2, S. Loipfinger3, C. Meng4,
D. Ghezzi5, K. Murayama6, J. A. Mayr7, P. Freisinger8, M.
D. Metodiev9, A. Rötig9, T. Klopstock10, G. F. Hoffmann11,
R. Santer12, F. Distelmaier13, R. Olsen14, D. Piekutowska-
Abramczuk15, P. Verloo16, C. Lamperti5, J. Gagneur3, C.
Ludwig4, H. Prokisch1,2
1Institute of Human Genetics, Technical University Munich,
München, Germany, 2Institute of Neurogenomics, Helm-
holtz Center Munich, Munich, Germany, 3Department of
Informatics, Technical University Munich, Garching, Ger-
many, 4Bavarian Center for Biomolecular Mass Spectro-
metry, BayBioMS, Technical University Munich, Freising,
Germany, 5Unit of Molecular Neurogenetics, Istituto
Neurologico ‘Carlo Besta, Milan, Italy, 6Department of
Metabolism, Chiba Children’s Hospital, Chiba, Japan,
7Department of Paediatrics, Paracelsus Medical University,
Salzburg, Austria, 8Department of Pediatrics, Klinikum
Reutlingen, Reutlingen, Germany, 9INSERM U1163, Uni-
versité Paris, Institut Imagine, Paris, France, 10Department
of Neurology, Friedrich-Baur-Institute, Ludwig-Maximi-
lians-University, Munich, Germany, 11Department of Gen-
eral Pediatrics, University Hospital Heidelberg,
Heidelberg, Germany, 12University Medical Center Eppen-
dorf, Hamburg, Germany, 1313Department of General
Pediatrics, Heinrich-Heine-University Düsseldorf, Düssel-
dorf, Germany, 1414Research Unit for Molecular Medicine,
Aarhus University and University Hospital, Aarhus N,
Denmark, 15Department of Medical Genetics, The Chil-
dren’s Memorial Health Institute, Warsaw, Poland,
16Department of Internal Medicine and Paediatrics, Ghent
University Hospital, Ghent, Belgium
With genomic advancement, came the shift from variant
discovery to interpretation, which must be rigorous to avoid
misinterpretation. Here, we analyzed 150 fibroblast cell lines
from undiagnosed patients with suspected mitochondrial
disorders. Transcriptome analysis facilitates genome-wide
DNA variant interpretation on the RNA level, for both coding
and non-coding variants. Proteomics allows quantification of
proteins in one assay, removing the need for individual
Western blot analyses. Missense variants accounting for over
50% of all mutations reported in HGMD. They may have no
functional consequence or may exercise their pathogenicity
by disrupting interactions or destabilizing the protein structure
which can be detected by proteomics as aberrantly low
expression. We established a protocol for quantitative deep
proteome analysis allowing us to quantify a median of 7,500
proteins per sample. Discarding lowly expressed genes,
around 13,000 transcripts are detectable. For the diagnosis of
Mendelian disease, we analyzed three aberrant events: 1)
aberrant splicing, 2) low expression, 3) monoallelic expres-
sion, and variants often present as a combination of these
events. Combining DNA and RNA sequencing we increase
the diagnostic yield by 15%. Proteomics allowed us to vali-
date 12/27 missense VUS (44%). In additional 12 cases, we
were able to reach a diagnosis by detecting low protein levels
of known disease genes which have not been prioritized by
WES. In 14 of those cases, we were able to validate the
pathogenic character by the impact on additional proteins
functionally associated. In summary, we established a multi-
omics integration pipeline and propose its application to
advanced molecular diagnostics.
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C25.5
Impaired complex I repair causes recessive Leber’s
hereditary optic neuropathy
S. L. Stenton1,2*, N. Sheremet3, C. Catarino4, N. Andreeva3,
Z. Assouline5, P. Barboni6, O. Barel7, I. Bychkov8, L.
Caporali9, P. Charbel Issa10, P. Freisinger11, S. Gerber12,
D. Ghezzi13, J. Heidler14, M. Hempel15, E. Heon16, Y.
Itkis17, E. Javasky7, J. Kaplan12, R. Kopajtich1,2, C.
Kornblum18, R. Kovacs-Nagy19,1, T. Krylova8, W. Kunz20,
C. La Morgia9, C. Lamperti13, C. Ludwig21, P.
Malacarne22, J. Mayr23, J. Meisterknecht14, T. Nevinitsyna3,
F. Palombo9, B. Pode-Shakked24, M. Shmelkova3, M.
Tzadok24, A. van der Ven15, C. Vignal-Clermont25, M.
Wagner1, E. Zakharova8, N. Zhorzholadze3, J. Rozet12, V.
Carelli9, P. Tsygankova8, T. Klopstock4, I. Wittig14, H.
Prokisch1,2
1Institute of Human Genetics, Technische Universität
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Canada, 17Research Centre for Medical Genetics, Moscow,
Moscow, Russian Federation, 18Department of Neurology,
University Hospital Bonn, Bonn, Germany, 19Department of
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Research, University of Bonn, Bonn, Germany, 21Bavarian
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Technische Universität München, München, Germany,
22Institute for Cardiovascular Physiology, Goethe-Univer-
sity, Frankfurt am Main, Germany, 23Department of
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mologie des Qinze-Vingts, Paris, France
Leber’s hereditary optic neuropathy (LHON) is one of the
most frequent and first genetically defined mitochondrial
diseases. The majority of LHON cases are caused by
mutations in mitochondrial DNA-encoded complex I (CI)
genes and are characterized by a mild CI defect. However, a
significant number still remain genetically undefined. Uti-
lizing human genetics and tracking of protein turnover in
mitochondrial supercomplexes, we delineate the role of an
orphan chaperone protein in a novel mechanism of CI
function and describe a recessive form of LHON resulting
from defects in this protein. Biallelic recessive DNAJC30
mutations were discovered in LHON cases from 29 famil-
ies, breaking the longstanding dogma of exclusive maternal
inheritance. In 27 of the families, the variant is ascribed to
an Eastern European founder event. Moreover, incomplete
penetrance and male predominance hallmarking maternally
inherited LHON are recapitulated, indicating that these
features originate downstream of the genetic defect. Given
the combination of variable penetrance and higher than
expected allele frequency of the founder variant, the dis-
covery proved challenging to current diagnostic approaches.
Our experimental data from patient-derived fibroblast cell
lines indicate that the pathology underpinning the disease, a
mild but consistent CI defect, is due to reduced exchange of
subunits of the CI N-module, responsible for the first part of
electron transport and exposed to higher risk of damage.
The identification of this repair system is of general biolo-
gical importance, and may open promising avenues for
future therapeutic interventions for defective CI. Grant
references: 01GM1906D, 01GM1906A, 01GM1603, SFB
815/Z1, GR-2016-02361449, EXC2026.
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C25.6
WES profiling of COVID-19
A. Renieri1,2*, E. Benetti3, F. Montagnani3,4, R. Tita2, C.
Fallerini1, S. Amitrano2, M. Bruttini2, G. Doddato1, A.
Giliberti1, F. Valentino1, S. Croci1, L. Di Sarno1, F. Fava1,2,
M. Baldassarri1, A. Tommasi1,2, M. Palmieri1, A.
Emiliozzi3,4, M. Fabbiani4, B. Rossetti4, G. Zanelli3,4, L.
Bergantini5, M. D’Alessandro5, P. Cameli5, D. Bennet5, F.
Anedda6, S. Marcantonio6, S. Scolletta6, F. Franchi6, M.
Mazzei7, E. Conticini8, L. Cantarini9, B. Frediani10, D.
Tacconi11, M. Feri12, R. Scala13, A. Ognibene14, G.
Spargi15, C. Nencioni16, G. Caldarelli17, M. Spagnesi18, A.
Canaccini19, E. Frullanti1, I. Meloni1, M. Mencarelli2, C.
Lo Rizzo2, A. Pinto2, E. Bargagli5, M. Mandalà20, S.
Furini3, F. Mari1,2
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Medicine, University of Siena, Siena, Italy, 6Dept of
Emergency and Urgency, Medicine, Surgery and Neuros-
ciences, Unit of Intensive Care Medicine, Siena University
Hospital, Siena, Italy, 7Dept of Medical, Surgical and
Neuro Sciences, Diagnostic Imaging, University of Siena,
Azienda Ospedaliera Universitaria Senese, Siena, Italy,
8Rheumatology Unit, Department of Medicine, Surgery and
Neurosciences, University of Siena, Policlinico Le Scotte,
Siena, Italy, 9Dept of Medical Sciences, University of Siena,
Siena, Italy, 10Research Center of Systemic Autoinflamma-
tory Diseases and Behçet’s Disease and Rheumatology-
Ophthalmology Collaborative Uveitis Center, Department
of Medical Sciences, Surgery and Neurosciences, Univer-
sity of Siena, Siena, Italy, 11Dept of Specialized and Internal
Medicine, Infectious Diseases Unit, San Donato Hospital
Arezzo, Arezzo, Italy, 12Dept of Emergency, Anesthesia
Unit, San Donato Hospital, Arezzo, Italy, 13Dept of
Specialized and Internal Medicine, Pneumology Unit and
UTIP, San Donato Hospital, Arezzo, Italy, 14Clinical
Chemical Analysis Laboratory, San Donato Hospital,
Arezzo, Italy, 15Dept of Emergency, Anesthesia Unit,
Misericordia Hospital, Grosseto, Italy, 16Dept of Specia-
lized and Internal Medicine, Infectious Diseases Unit,
Misericordia Hospital, Grosseto, Italy, 17Clinical Chemical
Analysis Laboratory, Misericordia Hospital, Grosseto,
Italy, 18Dept of Prevention, ASL South-East Tuscany, ASL
South-East Tuscany, Italy, 19Territorial Scientific Techni-
cian Department, ASL South-East Tuscany, ASL South-East
Tuscany, Italy, 20Otolaryngology Unit, University of Siena,
Siena, Italy
Introduction: Italy has been the first European Country
experiencing the epidemic wave of SARS-CoV-2 infection
reaching 200,000 cases. On March 16, we started the GEN-
COVID project (https://sites.google.com/dbm.unisi.it/gen-
covid) aiming to collect 2,000 COVID-19 patients all over
Italy, the first 500 being already collected.
Material and Methods: A first cohort of 130 Tuscanian
COVID-19 patients (100 of which hospitalised) was
subjected to clinical and molecular characterisation by
Whole Exome Sequencing (WES).
Results: Searching for common genes by Collapsing
Methods against 300 WES controls of Italian population
failed to give straightforward statistically significant results
with the exception of a pair of genes, one belonging to the
Olfactory Receptor families with many paralogs in the
genome. This result is not unexpected since we are facing
the most challenging common disorder triggered by
environmental factor with a strong underlying heritability
(50%). Learning the lesson of Autism Spectrum Disorder,
we started to re-analyse the cohort treating each patient as an
independent case, following a Mendelian-like model. We
identified for each patient an average of 3 pathogenic
mutations involved in virus infection susceptibility and
pinpoint to one or more rare disorder(s); the number being
higher in the most severely affected cases. To our knowl-
edge, this is the first report on WES and COVID-19. Our
results pinpoint to a combined model for COVID-19
susceptibility with a number of, yet unknown, common
susceptibility genes which represent the favorite background
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in which additional rare mutations confer to the host the best
environment for virus growth and organ damage.
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C26 New Technologies and Approaches
C26.1
Electrical impedance detection based GenapSys
sequencer enables diverse genomic applications
S. Paliwal*, A. Nabi, M. Fallahi, M. R. Barmi, M. Jouzi, S.
Stern, X. Gomes, H. Nezamfar, E. LoPrete, B. Dong, P.
Kenney, K. B. Parizi, H. Rategh, S. Sankar, H.
Esfandyarpour
Genapsys Inc, Redwood City, CA, United States
Next Generation Sequencing (NGS) technologies have
made rapid strides in the throughput and accuracy of DNA
sequencing in recent years. These advances have revolu-
tionized biomedical and clinical research. Here, Genapsys
presents a novel, scalable, low cost, and high accuracy NGS
platform, which enables wide-ranging genomic
applications.
The GenapSys NGS platform is based on accurate
detection of electrical impedance changes resulting from
single base incorporations during sequencing-by-synthesis.
We show that impedance changes measure a steady state
dNTP incorporation signal, leading to higher accuracy. The
core of the technology is a CMOS-based electronic chip that
enables scalability and low instrument and consumable
costs. Chips with 1M, 16M and 144M sensors can be run on
the same GenapSys instrument, giving a lab flexibility in
NGS assay design and sample multiplexing. We demon-
strate that a single run with a 16M sensor chip generates up
to 2 Gb of high accuracy data, with greater than 99% raw
accuracy and average read lengths of 150 bp.
We demonstrate wide-ranging genomic applications of
the GenapSys platform, which include whole genome
sequencing of small genomes such as bacteria and viruses,
whole exome sequencing of human samples, and transcrip-
tomic applications. We also demonstrate that the high
accuracy of the GenapSys platform makes it ideal for
germline and somatic variant calling for inherited diseases
and cancer. Thus, the GenapSys NGS platform is an
accurate, scalable, and low cost solution for genomics
research and clinical applications.
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C26.2
A bespoke gene-to-patient approach uplifts novel gene
discovery for rare disease diagnostics
E. G. Seaby1,2*, D. Smedley3, R. Scott3, M. Caulfield3, D.
Baralle1, H. L. Rehm2, A. O’Donnell-Luria2, S. Ennis1
1University of Southampton, Southampton, United Kingdom,
2Broad Institute of MIT and Harvard, Cambridge, MA,
United States, 3Genomics England, London, United Kingdom
Next generation sequencing has revolutionised rare disease
diagnostics. Concomitant with advancing technologies has
been a rise in novel disease-gene discoveries. However,
diagnostic rates remain suboptimal at ~30%. Novel gene
discovery is still hindered by vast quantities of variants of
uncertain significance found in genes of undetermined
biological function. This necessitates intensive functional
experiments on genes of equally-predicted causality that is
proving a major bottleneck. Herein we propose a bespoke
method that reverses the traditional approach of novel gene
discovery. We apply the LOEUF metric of intolerance to
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gene inactivation to curate a list of predicted haploinsuffi-
cient disease genes. By leveraging genomic and phenotypic
data from the 100,000 Genomes Project, we adopt a gene-
to-patient approach that matches de novo loss-of-function
variants in constrained genes to rare disease patients, thus
reducing most of the analytical noise that currently pre-
cludes novel discoveries. Preliminary data reveal the most
constrained LOEUF genes (n=1044) are highly correlated
with OMIM disease genes. Yet, 70% have no disease
association, leaving many probable disease genes yet to be
discovered. Pilot data from the 100,000 Genomes Project
(n=28,000) reveal 655 rare (MAF <0.001), de novo loss-of-
function events in 1044 LOEUF-constrained genes. 476 are
in known OMIM genes and 179 are in novel genes (174
cases involving 138 genes). Of these, 27 genes have more
than one kindred affected and 17 have the same/similar
phenotypes. Therefore, rethinking current practices by uti-
lising large cohorts and adopting gene-based approaches
can accelerate novel gene discovery and target the most
appropriate genes for functional validation.
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C26.3
Analysis of Mendelian phenotypes through mouse
embryo viability screening
P. Cacheiro1*, S. A. Murray2, V. Muñoz-Fuentes3, H.
Westerberg4, M. E. Dickinson5, A. Mallon4, T. F. Meehan3,
D. Smedley1, the International Mouse Phenotyping
Consortium
1William Harvey Research Institute, Queen Mary University
of London, London, United Kingdom, 2The Jackson
Laboratory, Bar Harbor, ME, United States, 3European
Molecular Biology Laboratory, European Bioinformatics
Institute, Hinxton, United Kingdom, 4Medical Research
Council Harwell, Mammalian Genetics Unit and Mary
Lyon Centre, Harwell, United Kingdom, 5Department of
Molecular Physiology and Biophysics, Baylor College of
Medicine, Houston, TX, United States
We have recently described a gene classification across the
Full Spectrum of Intolerance to Loss-of-function (LoF)
(FUSIL) by combining mouse viability screens and human
cell proliferation assays, and showing specific enrichment
of disease genes in discrete categories. Here, we further
dissect this spectrum by assessing the embryonic stage at
which homozygous LoF results in lethality in mice, and
explore the correlation with human phenotypes.
Four hundred mouse lethal genes identified by the
International Mouse Phenotyping Consortium were
additionally classified into one of three windows of
embryonic lethality: early, mid or late gestation. Early
lethal genes showed a lower percentage of genes with
abnormal phenotypes reported in the human orthologues
when compared to late lethal genes (40% vs 51%,
P=0.048), while the percentage of disease genes associated
with autosomal recessive inheritance was significantly
higher (74 % vs 46%, P= 0.0005). Consistent with this
observation, we found higher pRec scores among the early
lethals (median pRec for early, mid and late windows: 0.80,
0.50 and 0.36; median pLI: 0.004, 0.07 and 0.32).
Neurological and neurodevelopmental were the most
frequent type of diseases across windows (19%, 24% and
27%). Skeletal disorders were the second most frequent
class among those genes lethal at mid-gestation, which
correlates with the organogenesis phase of embryonic
development. Conversely, early lethal disease genes were
highly enriched for metabolic disorders (OR 4.27,
P=0.0003).
The mouse embryonic development stage where LoF
leads to lethality allows us to establish associations with
human disease features. This knowledge may assist the
prioritisation of candidate genes.
P. Cacheiro: None. S. A. Murray: None. V. Muñoz-
Fuentes: None. H. Westerberg: None. M. E. Dickinson:
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C26.4
Patient-derived retinal organoids to model retinitis
pigmentosa 1 (RP1)
P. Berber*, A. Milenkovic, C. Brandl, B. H. F. Weber
University of Regensburg, Regensburg, Germany
Introduction: Human induced pluripotent stem cells
(hiPSC) are an excellent starting point for generating 3D
retinal organoids, which contain many cell types native to
the retina. Still, retinal organoids lack critical physiological
contact between photoreceptors and retinal pigment epi-
thelium (RPE) cells. Nevertheless, retinal organoids offer
exciting new pathways of scientific discovery, including
modeling retinal dystrophies such as Retinitis Pigmentosa 1
(RP1, OMIM #180100), where vision loss is caused by the
degeneration of photoreceptors. Here, we have differ-
entiated retinal organoids from healthy controls and RP1
patients harboring autosomal dominant mutations in the
RP1 gene (OMIM # 603937).
Materials and Methods: Human dermal fibroblasts were
obtained from skin biopsies of six RP1 patients and healthy
controls, and reprogrammed into hiPSCs. An organoid
differentiation protocol was adapted from published
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protocols. A novel method to harvest and expand RPE cells
as byproducts from the organoid differentiation protocol,
was also established.
Results: Successful retinal organoid differentiation was
confirmed, via immunocytochemistry staining for ganglion
and photoreceptor markers. Photoreceptor differentiation
was improved by culturing the organoids on an orbital
shaker, facilitating the redistribution of fresh media and
waste. Organoids differentiated from RP1 patient hiPSC
showed a dramatic reduction in cells expressing recoverin, a
developing photoreceptor marker (13 ± 4.35 vs 80.3 ± 4.51,
p-value= 4.92*10−05). RPE cells were used to establish a
co-culture with the organoids, to induce physiological
contact between photoreceptors and RPE.
Conclusions: Retinal organoids can be differentiated from
hiPSC, and provide an exciting new avenue of research to
model inherited retinal dystrophies, including RP1.
P. Berber: None. A. Milenkovic: None. C. Brandl: None.
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C26.6
Next generation cytogenetics: genome-imaging improves
structural variant detection for constitutional chromo-
somal aberrations
K. Neveling*, T. Mantere, E. Kater-Baats, R. van Beek, M.
Oorsprong, S. Vermeulen, M. Pauper, D. Olde Weghuis, M.
Stevens-Kroef, G. van der Zande, D. Smeets, A. Hoischen
Department of Human Genetics, Nijmegen, Netherlands
Recently, we raised the question whether the Bionano genome-
imaging technology would have potential to replace all, FISH,
karyotyping and CNV-microarray studies, in the analysis of
somatic aberrations for different kind of leukemia samples.1
Here we aimed to test the clinical utility of this technology for
the analysis of constitutional aberrations in DNA derived from
various tissues. We analyzed samples with known aberrations
of patients with infertility, recurrent abortions or intellectual
disability, as well as prenatal samples by genome imaging.
For 30 samples, ultra-high molecular weight gDNA was
isolated either from blood (EDTA/Heparin) or cell lines
(fibroblasts/amniotic fluid/chorionic villi). DNA was pro-
cessed and imaged on the Saphyr instrument (Bionano
Genomics).1 For each sample at least 100x genome
coverage was obtained. Using Bionano Access software,
de novo genome assembly, SV and CNV variant calling and
annotation was performed.
Sample preparation for all different materials was successful.
Data analysis on average resulted in ~50 rare SVs and ~20 high
confidence CNVs per sample. In the analyzed cases, all
previously clinically reported structural aberrations were
detected except for Robertsonian translocations, as expected
for the current technology. Correctly detected aberrations
included 8 microdeletions and 8 duplications, 11 translocations,
1 inversion and 4 aneuploidies.
Bionano genome-imaging is a promising technology with
potential to become a generic cytogenetic test for all types of
(molecular-)cytogenetic aberrations. The 10.000-time higher
resolution as compared to standard karyotyping thereby
enables precise breakpoint mapping and strikingly, even
balanced translocations and inversions are picked up easily.
1. Neveling et al. (2020). bioRxiv-https://doi.org/10.
1101/2020.02.06.935742
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C27 Genome Variation and Architecture
C27.1
NCBI ALFA: Providing Sequence Variation Resource
from 1 Million dbGaP Subjects
L. Phan*, NCBI dbSNP, NCBI dbGaP
NCBI, Bethesda, MD, United States
The aim of the NCBI Allele Frequency Aggregator (ALFA)
project (https://go.usa.gov/xdNvF) is to make frequency data
from over 1M subjects in the database of Genotype and Phe-
notype (dbGaP), previously under authorized access, available
for open-access to facilitate discoveries and interpretations of
variants with biological impacts or causing diseases. The
ALFA project will compute allele frequency for variants across
approved un-restricted dbGaP studies. This involved harmo-
nizing and normalizing Heterogeneous data and file formats
from GWAS chip array genotyping, exomes, and whole gen-
omes. were QC and transformed into standard VCF format as
input into an automated pipeline using the new SPDI notation
(Holmes et al., 2019) to aggregate, remap and cluster to
existing dbSNP rs, and computed allele frequency. Allele fre-
quencies are computed for 12 major populations including
European, Hispanic, African, Asian, and other diverse popu-
lation ancestries that were determined using GRAF-pop soft-
ware developed by dbGaP (Jin et al., 2019). The data is
integrated with dbSNP 680 million Reference SNP (rs) and
existing allele frequency reported for over 500 million rs from
various projects including 1000Genomes, ExAc, GnomAD,
TopMed, and many other population studies. The initial ALFA
aggregate data release is from 110 thousand dbGaP subjects,
~10% of available data. Aggregated from 677 billion geno-
types, the results included allele counts and frequency for 531
million known dbSNP rs site and 18 million novel ones.
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Subsequent quarterly releases will include additional new
dbGaP studies and combined can reach over a billion variants
from millions of subjects.
L. Phan: None.
C27.2
Predicting the effects of structural variants in the
human genome
P. Kleinert*, M. Kircher
Berlin Institute of Health (BIH), Berlin, Germany
In recent years, we saw rapid technological advances in the
identification of structural variants (SVs). However, the
interpretation of these variants remains challenging. Several
methods were developed that utilize individual mechanistic
principles like the deletion of coding sequence or 3D gen-
ome architecture disruptions. However, a comprehensive
tool that uses the broad spectrum of available annotations
for estimating the effect of SVs and prioritize functional
variants in health and disease is missing. Here we describe
CADD-SV, a method to retrieve and integrate a wide set of
annotations across the range and in the vicinity of SVs for
functional scoring. So far, supervised learning approaches
were of very limited power for this kind of application, due
to a very small number of functionally annotated (e.g.
pathogenic/benign) SV sets. We overcome this problem by
using a surrogate training-objective, the combined annota-
tion dependent depletion (CADD) of functional variants in
evolutionary derived variant sets. Our tool computes sum-
mary statistics and uses a trained linear model to differ-
entiate deleterious from neutral structural variants. We use
human and chimpanzee derived alleles as proxy-neutral and
contrast them with matched simulated variants as proxy-
pathogenic, an approach that has proven powerful in the
interpretation of SNVs and short InDels (Kircher & Witten
et al, 2014). In a proof-of-principle study, we show that
CADD-SV scores correlate with known pathogenic variants
in individual genomes as well as allelic diversity observed
across the population. The ability of the current model to
prioritize functionally relevant and pathogenic variants is
unmatched by existing methods.
P. Kleinert: None. M. Kircher: None.
C27.3
RNA secondary structure mediated by Alu insertion as a
novel disease-causing mechanism
E. Masson1,2, S. Maestri1,2, D. N. Cooper3, C. Férec1,2, J.
M. Chen1*
1Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France,
2CHRU Brest, Service de Génétique Médicale et de Biologie
de la Reproduction, Brest, France, 3Institute of Medical
Genetics, School of Medicine, Cardiff University, Cardiff,
United Kingdom
We have recently reported a homozygous Alu insertion var-
iant (termed Alu_Ins) within the 3′-untranslated region (3′-
UTR) of the SPINK1 gene as the cause of a new pediatric
disease entity. Although Alu_Ins had been shown, by means
of a cell culture-based full-length gene expression assay
(FLGEA; expression vector contained SPINK1’s ~7-kb entire
coding and intronic sequences), to result in the complete loss
of SPINK1 mRNA expression, the precise underlying
mechanism(s) has remained elusive. Herein, we filled this
knowledge gap by adopting a hypothesis-driven approach.
Employing RepeatMasker, we identified two Alu elements
(termed Alu1 and Alu2) within the SPINK1 locus; both are
located deep within intron 3 and, most importantly, reside in
the opposite orientation to Alu-Ins. We then performed the
cell culture-based FLGEA on a total of 7 full-length SPINK1
expression vectors (i.e., wild-type (WT), mutant (Mut),
WT_delAlu1, Mut_delAlu1, WT_delAlu2, Mut_delAlu2 and
inversion of Alu_Ins) in the presence of a nonsense-mediated
mRNA decay inhibitor, cycloheximide. The results clearly
demonstrated that Alu_Ins disrupts splicing by forming RNA
secondary structures with Alu1 in the pre-mRNA sequence
rather than by its primary sequence. This is the first time that
an Alu insertion variant has been shown to exert its effect via
such a mechanism causing human genetic disease. Given the
abundance of pre-existing Alu elements within the human
genome and the potential insertion of new Alu elements into
virtually any site, our findings have important implications for
the detection and interpretation of Alu elements in human
disease genes. (This work was supported by INSERM).
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C27.4
Increased mutation rates and genome variation at active
spermatogonial regulatory sites
V. B. Kaiser*, L. Talmane, Y. Kumar, F. Semple, M.
MacLennan, Deciphering Developmental Disorders Study,
D. R. FitzPatrick, M. S. Taylor, C. A. Semple
MRC Human Genetics Unit, Edinburgh, United Kingdom
Introduction: The germline is the ultimate source of
genetic variation, but we know little about the influence of
germline chromatin structure on the processes that give rise
to mutations. Here, we use germline epigenomic data to
study the influence of transcription factor binding sites
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(TFBSs) in the germline on the patterns of different classes
of mutation across the human genome.
Materials and Methods: We use novel spermatogonial
ATAC-seq data to infer the locations of TFBSs and meiotic
recombination initiation sites (PRDM9 binding sites). We
then relate these sites to structural variants in the DDD
(Deciphering Developmental Disorders) cohort, very rare
(gnomAD database) variants from extant human popula-
tions, and de novo mutations.
Results: Germline TFBSs are impacted by significantly
increased rates of structural variant breakpoints: 32% of
singleton DDD breakpoints are within 1KB of an ATAC-
Seq peak, and particular testis-active factors are enriched.
Both de novo and rare gnomAD short insertions are
enriched at the same TFBSs, suggesting these sites are
particularly susceptible to mutation and that they employ an
unusual DNA repair mechanism. The increased mutation
rates associated with germline TF binding disproportio-
nately affect a class of enhancers active in human
neurodevelopment, since these enhancers overlap TFBSs
active in spermatogonia (odds ratio of mutation = 6.82,
95% CI = [5.34,8.71] for deletion breakpoints).
Conclusion: Spermatogonial TFBSs drive genome
increased mutation rates and regulatory redundancy may
lead to neurodevelopmental disease.
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C27.5
Resolving complex structural variants in recurrent
brain tumors
K. Okonechnikov1,2, J. Hübner1,2, O. Chapman3, A.
Chakraborty4, M. Pagadal3, R. Bumb5, S. Chandran5, K.
Kraft6, R. Hidalgo7, S. Mundlos7, R. Wechsler-Reya8, N.
Coufal9, M. Levy10, J. Crawford11, K. Pajtler1,2,12, D.
Reid13, A. Schmitt13, H. Carter3, F. Ay4, J. Dixon5, J.
Mesirov3,14, S. M. Pfister1,2,12, M. Kool1,2, L. Chavez3,14*
1Hopp Children’s Cancer Center at the NCT Heidelberg
(KiTZ), Heidelberg, Germany, 2Division of Pediatric
Neurooncology, German Cancer Research Center (DKFZ),
Heidelberg, Germany, 3Department of Medicine, University
of California San Diego (UCSD), San Diego, CA, United
States, 4Division of Vaccine Discovery, La Jolla Institute for
Allergy and Immunology, La Jolla, CA, United States, 5Salk
Institute for Biological Studies, La Jolla, CA, United States,
6Center for Personal Dynamic Regulomes, Stanford Uni-
versity, Stanford, Stanford, CA, United States, 7Max Planck
Institute for Molecular Genetics, Berlin, Germany, 8Tumor
Initiation and Maintenance Program, NCI-Designated
Cancer Center, Sanford Burnham Prebys Medical Research
Discovery Institute, La Jolla, CA, United States, 9Depart-
ment of Pediatrics, University of California, San Diego, San
Diego, CA, United States, 10Department of Neurosurgery,
University of California San Diego – Rady Children’s
Hospital, Sam Diego, CA, United States, 11Department of
Neurosciences, University of California San Diego – Rady
Children’s Hospital, San Diego, CA, United States,
12Department of Pediatric Oncology, Hematology and
Immunology, Heidelberg University Hospital, Heidelberg,
Germany, 13Arima Genomics, Inc, San Diego, CA, United
States, 14Moores Cancer Center, University of California
San Diego (UCSD), La Jolla, CA, United States
Introduction: Brain and other tumors of the CNS are the
most common cancers in children aged 0-14 years in the
USA. Ependymoma is the third most common pediatric
brain tumor and a leading cause of death in childhood
cancer patients. The most common and aggressive sub-
group, posterior fossa ependymoma group A (PFA), occurs
in young children and frequently leads to recurrences.
Despite extensive DNA sequencing studies, the only
molecular marker associated with particularly poor survival
is gain of chromosome 1q.
Materials and Methods: Through profiling enhancers in
ependymoma tumors, we have recently identified putative
oncogenes, molecular targets, and functional pathways
(Mack et al, Nature 2018). Complementary to the analysis
of enhancers, we have now mapped the 3D organization of
tumor chromatin in primary and relapse ependymoma
tumors using HiC.
Results: By an integrative analysis of enhancer and gene
expression in the context of the newly derived HiC data, we
identify new tumor-dependency genes activated by tumor-
specific chromatin clusters of regulatory elements. We have
also leveraged the HiC data for resolving structural variants
(SVs) underlying copy number alterations. As a result, we
identify complex inter-chromosomal SVs that result in the
formation of new topologically associated domains (‘neo-
TADs’) leading to transcriptional activation of putative
oncogenes.
Conclusions: We propose a new molecular mechanism
by which chromosome 1q gains lead to complex inter-
chromosomal SVs. By forming neo-TADs, these SVs lead
to the transcriptional activation of oncogenes and thus
potentially contribute to resistance in a subgroup of very
aggressive pediatric brain tumors.
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C28 Neurodevelopment
C28.1
Pathogenic variants in RLIM/RNF12 lead to syndromic
X-linked intellectual disability and congenital, neurolo-
gic and behavior disorders
S. G. M. Frints1,2*, A. Ozanturk3, G. Rodriguez Criado4, U.
Grasshoff5, M. Field6, S. Manouvrier-Hanu7,8, S. Hickey9,10,
K. Gripp11, C. Bauer5, C. Schroeder5, A. Toutain12,13, T.
Mihalic Mosher9,14, B. J. Kelly14, P. White9,14, A. Dufke5, S.
Moon3, D. C. Koboldt9,14, E. Gerkes15, A. van Haeringen16,
C. Ruivenkamp16, C. Mignot17, B. Keren18, A. Müller5, S.
Waldmüller5, M. Blandfort19, U. Kordaß20, K. Gardner21, A.
Trimouille22, K. E. P. van Roozendaal1,2, S. A. Haas23, L.
Murray6, E. Haan24,25, R. Carroll24, J. Liebelt25, L.
Hobson26, M. De Rademaeker27, H. Brunner1,2,28, J.
Glatz1,2, K. Devriendt29, J. Vermeesch29, M. Raynaud12,13,30,
O. Riess5, J. Gribnau31, N. Katsanis3, P. Bauer5, J.
Gecz25,32, C. Golzio33, C. Gontan34, V. Kalscheuer35
1Department of Clinical Genetics, Maastricht University
Medical Center+, MUMC+, azM, Maastricht, Netherlands,
2Department of Genetics and Cell Biology, FHML,
Maastricht University, Maastricht, Netherlands, 3Center
for Human Disease Modeling and Departments of Pedia-
trics and Psychiatry, Duke University, Durham, NC, United
States, 4Unidad de Genética Clínica, Hospital Virgen del
Rocío, Sevilla, Spain, 5Institute of Medical Genetics and
Applied Genomics, University of Tübingen, Tübingen,
Germany, 6GOLD (Genetics of Learning and Disability)
Service, Hunter Genetics, Waratah, Australia, 7Clinique de
Génétique médicale Guy Fontaine, Centre de référence
maladies rares Anomalies du développement Hôpital
Jeanne de Flandre, Lille, France, 8Département Universi-
taire de Génétique, EA RADEME Maladies Rares du
Développement et du Métabolisme, Faculté de Médecine,
Université Lille 2, Lille, France, 9Division of Molecular &
Human Genetics, Nationwide Children’s Hospital, Colum-
bus, OH, United States, 10Department of Pediatrics, The
Ohio State University College of Medicine, Ohio, OH,
United States, 11Alfred I. duPont Hospital for Children
Nemours, Wilmington, DE, United States, 12Service de
Génétique, Hôpital Bretonneau, CHU de Tours, Tours,
France, 13UMR INSERM U930, Faculté de Médecine,
Université François Rabelais, Tours, France, 14The Insti-
tute for Genomic Medicine, Nationwide Children’s Hospi-
tal, Columbus, OH, United States, 15Department of Clinical
Genetics, University Medical Center Groningen, UMCG,
Groningen, Netherlands, 16Department of Clinical
Genetics, Leiden University Medical Center, LUMC,
Leiden, Netherlands, 17Unité Génétique Clinique, Hôpital
Armand-Trousseau, Paris, France, 18Genetic Department,
Pitié-Salpêtrière Hospital, APHP. Sorbonne Université,
Paris, France, 19Praxis für Neuropädiatrie und humangen-
etische Beratung, Landau, Germany, 20MVZ für Human-
genetik und Molekularpathologie GmbH, Greifswald,
Germany, 21RareREACH Research Patient Liaison, Rare
Genomics Institute, 4859 West Slauson Avenue #573, Los
Angeles, CA 90056, USA, Los Angeles, CA, United States,
22Service de Génétique Médicale, CHU Bordeaux, Labor-
atoire MRGM, INSERM U1211, Univ., Bordeaux, France,
23Department of Computational Molecular Biology, Max
Planck Institute for Molecular Genetics, Berlin, Germany,
24Adelaide Medical School and Robinson Research Insti-
tute, The University of Adelaide, Adelaide, Australia,
25South Australian Clinical Genetics Service, SA Pathology
(at Royal Adelaide Hospital), Adelaide, Australia, 26Genet-
ics and Molecular Pathology, SA Pathology, Adelaide,
Australia, 27Centre for Medical Genetics, Reproduction and
Genetics, Reproduction Genetics and Regenerative Medi-
cine, Free University Brussel (VUB), UZ Brussel, Brussels,
Belgium, 28Radboud University Medical Center, Depart-
ment of Human Genetics, Nijmegen, Netherlands, 29Center
for Human Genetics, University Hospitals Leuven, Leuven,
Belgium, 30Inserm U930 "Imaging and Brain", Tours,
France, 31Department of Developmental Biology, Oncode
Institute, Erasmus MC, University Medical Center, Rotter-
dam, Netherlands, 32South Australian Health and Medical
Research Institute, Adelaide, Australia, 33U964; Université
de33Institut de Génétique et de Biologie Moléculaire et
Cellulaire, Centre National de la Recherche Scientifique,
Université de Strasbourg, Illkirch-Graffenstaden, France,
34Department of Developmental Biology, Oncode Institute,
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Introduction: RLIM/RNF12 is an X-linked E3 ubiquitin
ligase acting as a negative regulator of LIM-domain con-
taining transcription factors and participates in X-chromo-
some inactivation (XCI) in mice.
Material and Methods:We performed exome sequencing,
in vitro and in vivo studies. Clinical genetic (re)evaluation was
performed using a Human Phenotype Ontology scoring list.
Methylation-based assays were used for determining X-
chromosome inactivation in carrier females.
Results: We will provide a review on affected males and
carrier females from 9 families which we published recently
and on 10 novel families who have unique missense
variants in RLIM. All surviving affected males presented
with X-linked intellectual disability (XLID) disorders. Ten
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Oral Presentations 127
percent of the heterozygous carrier females showed mild
physical features. X-chromosome inactivation was skewed
in >91% of the carrier females. Most of the RLIM variants
identified are predicted to affect protein function. Nine
altered amino acids are conserved and lie within a domain
essential for binding interacting proteins or in the C-
terminal RING-finger catalytic domain. In vitro experiments
revealed that the amino acid changes investigated impaired
RLIM ubiquitin ligase activity. In vivo experiments in rlim
mutant zebrafish showed that wild-type RLIM rescued the
zebrafish rlim microcephaly phenotype, whereas the so far
9/9 patient-specific missense variants tested failed to rescue
the phenotype and thus represent likely severe loss of
function mutations.
Conclusions: The identified spectrum of functionally
investigated pathogenic RLIM missense variants (9/9) cause
related XLID disorders and impaired ubiquitin ligase
activity, suggesting that proper function of RLIM is
required for normal development, cognition and behavior.
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C28.2
De-novo and Biallelic pathogenic variants in NARS1
cause neurodevelopmental delay due to dominant
negative and partial loss of function effect
E. O’Connor1, A. Manole1, S. Efthymiou1*, M. Mendes2, M.
Jennings3, D. Jenkins4, M. Lopez5, R. Maroofian1, V.
Salpietro1, S. Antonarakis6, J. Vincent7, T. B. Haack8, F.
Distelmaier9, R. Horvath3, J. Gleeson10, H. Becker11, J.
Mandel12, D. Koolen13, H. Houlden1
1UCL Institute of Neurology, London, United Kingdom,
2Amsterdam University Medical Centers, Amsterdam,
Netherlands, 3University of Cambridge, Cambridge, United
Kingdom, 4Institute of Child Health, London, United
Kingdom, 5Institute of Healthy Aging, London, United
Kingdom, 6University of Geneva, Geneva, Switzerland,
7Centre for Addiction and Mental Health, Ontario, ON,
Canada, 8University of Tuebingen, Tuebingen, Germany,
9Heinrich-Heine-University, Dusseldorf, Germany,
10Howard Hughes Medical Institute, California, CA, United
States, 11University of Strasbourg, Strasbourg, France,
12IGBMC, Strasbourg, France, 13Radboud University
Medical Center, Nijmegen, Netherlands
Aminoacyl-tRNA-synthetases (ARSs) are ubiquitous, ancient
enzymes that charge amino-acids to cognate tRNA molecules,
the essential first-step of protein translation. Here, we describe
20 families consisting of 31 individuals with de-novo hetero-
zygous and biallelic mutations in the asparaginyl-tRNA-syn-
thetase gene (NARS1), with a phenotype characterised by
microcephaly, neurodevelopmental delay, seizures, peripheral
neuropathy and ataxia. NARS1 mRNA and protein expression
from both patient fibroblasts and induced neural progenitor
cells (iNPCs) were reduced; NARS1 enzyme levels in these
tissues were also significantly reduced. Yeast complementation
assay on the recessive p.Arg545Cys mutation was not detri-
mental, but molecular modelling of this mutation showed
weaker spatial positioning and tRNA selectivity. Zebrafish
modelling of the prevalent p.Arg534* de-novo mutation gave a
severely abnormal locomotor phenotype. Here, we show that
de-novo and biallelic mutations in NARS1 are a prevalent cause
of abnormal neurodevelopment, where the mechanism for de-
novo mutations is dominant negative and for recessive muta-
tions partial loss-of-function. MRC Centre grant (G0601943)
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C28.3
Biallelic loss-of-function variants in TBC1D2B cause a
neurodevelopmental disorder with seizures and gingival
overgrowth
F. L. Harms1*, P. Parthasarathy2, D. Zorndt1, M. Alawi3, S.
Fuchs1, B. J. Halliday2, C. McKeown4, H. Sampaio5,6, N.
Radhakrishnan7, S. K. Radhakrishnan8, R. Sachdev4, S. P.
Robertson2, S. Nampoothiri9, K. Kutsche1
1Institute of Human Genetics, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, 2Department of
Women’s and Children’s Health, Dunedin School of
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3Bioinformatics Core, University Medical Center Hamburg-
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Genetics, Sydney Children’s Hospital, Randwick, Australia,
5Department of Women and Children’s Health, Randwick
Campus, University of New South Wales, Randwick,
Australia, 6Sydney Children’s Hospital, Randwick, Austra-
lia, 7Department of Ophthalmology, Amrita Institute of
Medical Sciences & Research Centre, Cochin, India,
8Department of Neurology, Amrita Institute of Medical
Sciences & Research Centre, Cochin, India, 9Department of
Pediatric Genetics, Amrita Institute of Medical Sciences &
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The family of Tre2-Bub2-Cdc16 (TBC)-domain con-
taining GTPase activating proteins (RABGAPs) is not
only known as key regulators of RAB GTPase activity,
but also has GAP-independent functions. RAB GTPases
are implicated in membrane trafficking pathways, such
as vesicular trafficking. We report biallelic loss-of-
function variants in TBC1D2B, encoding a member of
the TBC/RABGAP family with yet unknown function, as
the underlying cause of cognitive impairment, seizures,
and gingival overgrowth in two individuals from unre-
lated families. TBC1D2B mRNA amount was drastically
reduced and the protein was absent in fibroblasts of one
patient. In immunofluorescence analysis, ectopically
expressed TBC1D2B co-localized with vesicles positive
for RAB5, a small GTPase orchestrating early endocytic
vesicle trafficking. In two independent TBC1D2B
CRISPR/Cas9 knockout HeLa cell lines that serve as
cellular model of TBC1D2B deficiency, epidermal
growth factor internalization was significantly reduced
compared with the parental HeLa cell line suggesting a
role of TBC1D2B in early endocytosis. Serum depriva-
tion of TBC1D2B-deficient HeLa cell lines caused a
decrease in cell viability and an increase in apoptosis.
Our data reveal that loss of TBC1D2B causes a neuro-
developmental disorder with gingival overgrowth, pos-
sibly by deficits in vesicle trafficking and/or cell
survival.
F. L. H. was supported by the Research Promotion Fund
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Medical Center Hamburg-Eppendorf. This work was
supported by grants from the Deutsche Forschungsge-
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New Zealand to S.P.R.
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C28.4
De novo pathogenic variants in CSNK2B cause a new
intellectual disability-craniodigital syndrome distin-
guished from Poirier-Bienvenu neurodevelopmental
syndrome
M. Asif1,2,3*, E. Kaygusuz1,2,4, M. Shinawi5, A. Nickelsen6,
J. Hochscherf7, D. Lindenblatt7, A. A. Noegel1,3, S.
Tinschert8, K. Niefind7, P. Fortugno9, J. Jose6, F.
Brancati9,10, P. Nürnberg1,3, M. S. Hussain1,2,3
1Cologne Center for Genomics, University of Cologne,
Cologne, Germany, 2Institute of Biochemistry I, Medical
Faculty, University of Cologne, Cologne, Germany, 3Center
for Molecular Medicine Cologne (CMMC), University of
Cologne, Cologne, Germany, 4Institute of Human Genetics,
University Medical Center Göttingen, Göttingen, Germany,
5Division of Genetics and Genomic Medicine, Department
of Pediatrics, Washington University School of Medicine,
St. Louis, MO, United States, 6Institute of Pharmaceutical
and Medicinal Chemistry, Westphalian Wilhelms-Univer-
sity, Münster, Germany, 7Department of Chemistry, Insti-
tute of Biochemistry, University of Cologne, Cologne,
Germany, 8Zentrum Medizinische Genetik, Medizinische
Universität, Innsbruck, Austria, 9Istituto Dermopatico
dell’Immacolata (IDI) IRCCS, Rome, Italy, 10Medical
Genetics, Department of Life, Health and Environmental
Science, University of L’Aquila, L’Aquila, Italy
Introduction: In a cohort of patients with intellectual dis-
ability, microcephaly, growth failure, facial and digital
anomalies, we recently identified mutations in CKAP2L as a
cause of Filippi syndrome (FS). One of these patients was
tested negative for CKAP2L and had a slightly different
phenotype.
Materials and Methods: To identify the causal variants,
trio whole-exome sequencing was performed. To further
explore the consequences of identified variants, pulldown
assays, microscale thermophoresis, immunofluorescence
and whole transcriptome and whole phosphoproteome
(WPP) profiling were conducted.
Results: A pathogenic de novo CSNK2B variant was
identified in the proband, while a second patient recruited
through GeneMatcher showing similar phenotype harbored
a de novo CSNK2B variant on same codon. Both variants, p.
(Asp32Asn) and p.(Asp32His), caused an up-regulation of
CSNK2B expression at transcript and protein level, which
resulted in impaired cross talk between α and β subunits of
casein kinase 2 (CK2). The effect of p.(Asp32His) was
observed in the canonical Wnt signaling (CWS) and DNA
damage response (DDR) pathways. In CWS, an impaired
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interaction of DVL3 with mutant CK2β and up-regulation
as well as mislocalization of β-catenin in mutant LCLs was
found. In DDR, γH2AX, 53BP1 and CHK1 was substan-
tially increased in mutant LCLs. Additionally, RNA-seq
data confirmed differential expression of genes involved in
the aforementioned pathways. Finally, WPP showed
hypophosphorylation of 344 substrates of CK2.
Conclusions: Our findings suggest that CSNK2B is a
novel candidate gene for a rare distinguished craniodigital
syndrome. The underlying pathogenic variants exert their
pleiotropic effects through a dysregulation of CWS
and DDR.
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C28.5
Biallelic and monoallelic variants in PLXNA1 cause a
syndromic disorder with neurodevelopmental and
oculo-cerebral anomalies
G. C. Dworschak1,2,3*, J. Punetha4, J. C. Kalanithy1, E.
Mingardo1, H. B. Erdem5, Z. C. Akdemir4, E. Karaca6, T.
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Valkanas21, L. B. Waddell22, K. J. Jones22, E. C. Oates22, S.
T. Cooper22, D. MacArthur23, R. E. Schnur24, G. E.
Hoganson25, J. E. Burton25, M. McEntagart26, D. Pehlivan4,
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PMAS – Arid Agriculture University, Rawalpindi, Pakistan,
16Cologne Center for Genomics, University of Cologne,
Cologne, Germany, 17Institute of Human Genetics, Klini-
kum rechts der Isar, School of Medicine, Technical
University of Munich, Munich, Germany, 18Department of
Medical Genetics, Centre for Applied Neurogenetics,
University of British Columbia, Vancouver, BC, Canada,
19Division of Neurology, Department of Pediatrics, Uni-
versity of British Columbia and BC Children’s Hospital,
Vancouver, BC, Canada, 20AP-HP, Hôpital Pitié-Salpê-
trière, Département de Génétique, Paris, France, 21Center
for Mendelian Genomics, The Broad Institute of MIT and
Harvard, Cambridge, MA, United States, 22Kids Neu-
roscience Centre, Kids Research, The Children’s Hospital
at Westmead, Sydney, Australia, 23Broad Institute of
Harvard and Massachusetts Institute of Technology, Cam-
bridge, MA, United States, 24GeneDx, Gaithersburg, MD,
United States, 25Department of Pediatrics, University of
Illinois, College of Medicine, Chicago, IL, United States,
26South West Thames Regional Genetics Centre, St.
George’s Healthcare NHS Trust, St. George’s, University
of London, London, United Kingdom, 27Department of
Neonatology and Pediatric Intensive Care, University
Hospital of Bonn, Bonn, Germany
PLXNA1 encodes plexin-A1, a neuronal transmembrane
receptor for semaphorin signaling in the central nervous
system that is suggested to play a key role in axon guidance.
Here, we describe rare and novel potentially deleterious
variants in PLXNA1 identified by exome sequencing in five
families with biallelic variants and four families with
monoallelic variants. Shared phenotypic features among
affected individuals include global developmental delay
(11/12), congenital brain anomalies (7/12), craniofacial
dysmorphisms (7/12), and ocular anomalies (7/12). Nota-
bly, seizures were almost exclusively reported in indivi-
duals with monoallelic variants. Structural modeling of all
missense variants in PLXNA1 suggests distortion in the
native protein. Knockdown of the zebrafish homolog
plxna1a in zebrafish larvae caused anomalies of the central
nervous system and the eye supporting our observations in
affected individuals. Our human genetic and functional
studies in zebrafish indicate that PLXNA1 plays an
130 J. del Picchia
indispensable role in neurodevelopment and implicate it in a
syndromic disorder with neurodevelopmental and oculo-
cerebral anomalies. Grant: BONFOR grant O-120.0001 and
Herbert-Reeck foundation (2019) to GCD
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C28.6
Mutations in Gemin5 cause developmental delay, motor
dysfunction and cerebellar atrophy
U. Pandey*
University of Pittsburgh Medical Center, Pittsburgh, PA,
United States
GEMIN5, an RNA-binding protein is essential for assembly
of the SMN complex. It facilitates the formation of small
nuclear ribonucleoproteins (snRNPs), the building blocks of
spliceosomes. GEMIN5 is involved in regulating the spli-
cing of pre-mRNAs and has been shown to bind snRNA-
binding protein of the SMN complex. Here we show
identification of novel autosomal recessive variants in the
GEMIN5 gene in 5 unrelated patient families with total 7
affected individuals. These variants have not been reported
in any publicly available databases. The probands present
with developmental delay, central hypotonia, ataxia and
cerebellar hypoplasia. In addition to this, we found novel
compound heterozygote variants including deletions and
frameshift mutations in 14 additional unrelated families
with 17 affected individuals sharing overlapping clinical
symptoms. We observed that patient iPSC-derived neurons
expressing GEMIN5 variants drastically reduced the
expression of snRNP components (SMN, Gemin2, Gemin4
and Gemin6) as compared to controls suggesting a potential
disruption in snRNP complex. Pathogenic mutations in
GEMIN5 as well as shRNA mediated knockdown of
endogenous GEMIN5 perturbed snRNP complex assembly.
Importantly, knocking down rigor mortis, fly homologue of
human GEMIN5, showed a reduced lifespan and motor
dysfunction similar to human patients. Furthermore, we
identified transcriptomic changes that are caused by
pathogenic mutations in GEMIN5 in patients. Here, we
provide the first evidence that, patients carrying autosomal
recessive mutations in GEMIN5 display neurological
symptoms. Our data suggests that pathogenic mutations in
GEMIN5 perturb the physiological functions by potential
loss-of-function of GEMIN5 protein.
U. Pandey: None.
C29 Skin & Bones
C29.1
Homozygous loss-of-function mutations in CCDC134 are
responsible for a severe form of osteogenesis imperfecta
J. Dubail1*, P. Brunelle1, G. Baujat1, C. Huber1, M.
Doyard1, C. Michot1, P. Chavassieux2, A. Khairouni3, V.
Topouchian4, S. Monnot1, E. Koumakis1,5, V. Cormier-
Daire1
1Institut Imagine INSERM U1163, Paris, France, 2Univer-
sité de Lyon, INSERM UMR 1033, Lyon, France, 3Pediatric
Orthopedics, Casablanca, Morocco, 4Necker-Enfants
Malades Hospital, Paris, France, 5Cochin Hospital,
Rheumatology department, Paris, France
Osteogenesis Imperfecta (OI) is a primary bone fragility
disorder with an estimated prevalence of 1/15 000 births.
The majority of OI cases are inherited in an autosomal-
dominant manner, while five to ten percent have recessive
or X-linked inheritance. Up to now, approximately 10% of
OI cases remain without mutation demonstrated, supporting
the involvement of other genes in the disease spectrum. By
whole exome sequencing, we identified a homozygous
variant (c.2T>C) in CCDC134 gene in three patients from
two unrelated families, with bisphosphonate-resistant severe
bone fragility, short stature, gracile long bones with pseu-
darthroses, but no dentinogenesis imperfecta. CCDC134
encodes a secreted protein widely expressed, implicated in
the regulation of some mitogen-activated protein kinases
(MAPK) signaling pathway. Western blot and immuno-
fluorescence analyses confirmed the absence of CCDC134
protein in patient cells, compared to controls. Furthermore,
we demonstrated that CCDC134 mutations are associated
with increased Erk1/2 phosphorylation and decreased
COL1A1 and OPN mRNA expression in patient osteoblasts
compared to controls. These data support that CCDC134 is
a new gene involved in severe progressive deforming
recessive osteogenesis imperfecta (type III).
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C29.2
Hypomorphic variants in the replication complex
member GINS3 result in a Meier Gorlin phenotype
P. Kannu1*, E. Campos1, H. Wurtele2, K. Ahmed1, R.
Shaheen3, M. McQuaid2, K. Kernohan4, K. Boycott5, Z.
Alhassnan3, F. Alkuraya3
1The Hospital for Sick Children, Toronto, ON, Canada,
2Université de Montréal, Montreal, QC, Canada, 3King
Faisal Specialist Hospital, Riyadh, Saudi Arabia, 4Chil-
dren’s Hospital of Eastern Ontario, Toronto, ON, Canada,
5Children’s Hospital of Eastern Ontario, Ottawa, ON,
Canada
Introduction: Meier-Gorlin syndrome (MGORS) is a rare
genetic disorder characterized by primordial dwarfism,
microtia, and patellar aplasia//hypoplasia, which is caused
by impaired DNA replication. Here we report the identifi-
cation of four individuals from two unrelated families pre-
senting a MGORS like phenotype, characterized by
unreported recessive hypomorphic variants in the GINS3
gene, which encodes a subunit of the CMG helicase. The
evolutionarily conserved CDC45/MCM2-7/GINS1-4
(CMG) protein complex is an essential helicase that
unwinds DNA during DNA replication.
Results:We found that variants in GINS3 limit origin of
replication firing, hence slowing cellular proliferation,
providing a potential mechanism for the dwarfism
phenotype. Furthermore, the variants destabilize the GINS
subcomplex, thereby affecting the entire DNA replication
fork altogether. Cells with the GINS3 variants accumulate
in the S and G2-phases of the cell cycle. Infection of
patient cells with a lentivirus expressing wt GINS3
rescues the origin of firing of replication forks and
proliferation rates. We also show that the GINS3 variants
alter protein-protein interactions within components of the
replication machinery and are hypersensitive to DNA
damage.
Conclusions: In summary, we have identified variants in
GINS3 as a new cause of MGORS and established GINS3
as a critical component required for efficient DNA
replication and genome stability.
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Campos: None. H. Wurtele: None. K. Ahmed: None. R.
Shaheen: None. M. McQuaid: None. K. Kernohan:
None. K. Boycott: None. Z. Alhassnan: None. F.
Alkuraya: None.
C29.3
Homozygous EMILIN1 loss-of-function variants impair
both elastin and collagen fiber formation and cause a
novel entity with arterial tortuosity and osteopenia
A. Beyens1,2*, C. Adamo3,4, E. Yilmaz Gulec5, A. Gezdirici5,
P. Bonaldo6, H. Bornaun7, E. Brauchle8, J. Brinckmann9,
W. P. Devine10, B. Gangaram11, T. Sasaki12, K. Schenke-
Layland8,13, S. Symoens1, A. Tam11, G. Sengle3,4,14, B.
Callewaert1
1Center for Medical Genetics Ghent and Department of
Biomolecular Medicine, Ghent University Hospital, Ghent,
Belgium, 2Department of Dermatology, Ghent University
Hospital, Ghent, Belgium, 3Center for Biochemistry,
Faculty of Medicine, University of Cologne, Cologne,
Germany, 4Department of Pediatrics and Adolescent
Medicine, Faculty of Medicine, University Hospital of
Cologne, Cologne, Germany, 5Department of Medical
Genetics, Kanuni Sultan Suleyman Training and Research
Hospital, Health Sciences University, Istanbul, Turkey,
6Department of Molecular Medicine, University of Padova,
Padova, Italy, 7Department of Pediatric Cardiology,
Kanuni Sultan Suleyman Training and Research Hospital,
Health Sciences University, Istanbul, Turkey, 8Research
Centre for Women’s Health, University of Tübingen,
Tübingen, Germany, 9Institute of Virology and Cell
Biology, University of Lübeck, Lübeck, Germany, 10Pathol-
ogy Department, University of California San Francisco,
San Francisco, CA, United States, 11Department of
Pediatrics, University of California San Francisco, San
Francisco, CA, United States, 12Department of Biochem-
istry II, Faculty of Medicine, Oita University, Oita, Japan,
13NMI Tübingen, University of Tübingen, Tübingen,
Germany, 14Center for Molecular Medicine Cologne
(CMMC), University of Cologne, Cologne, Germany
Introduction: EMILIN1 belongs to the Elastin Microfibril
Interface-Located Proteins (EMILINs), a family of structu-
rally related extracellular glycoproteins. It is found in var-
ious tissues characterized by pronounced resilience and
elastic recoil, such as skin and arteries, where it associates
with elastic fibers and preferentially targets fibrillin micro-
fibrils. EMILIN1 has been reported to bind and co-localize
with fibulin-4 in the extracellular matrix. Fibulin-4 is a
known carrier of lysyl oxidase (LOX), an enzyme involved
in elastin and collagen crosslinking. Arterial tortuosity can
be found in several connective tissue disorders, such as
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FBLN4-related cutis laxa and arterial tortuosity syndrome
(ATS), caused by SLC2A10 mutations.
Results: Exome sequencing in two unrelated families
with arterial tortuosity revealed homozygous loss-of-func-
tion mutations in EMILIN1. Patients exhibit widespread
arterial tortuosity and fractures of ribs and long bones.
Immunofluorescence of patient fibroblasts reveals a direct
dependence of fibulin-4 fiber assembly on EMILIN1
deposition. Western blotting and mass spectrometry analy-
sis show altered levels of LOX and collagen 1. Raman
microspectroscopy analysis carried out in in Emilin1-/- mice
shows structural changes in the collagen and elastic fiber
networks. Biochemical analysis of human fibroblast cul-
tures and Emilin1-/- mice skin demonstrates a disturbed
collagen crosslinking pattern. Transmission electron micro-
scopy of patient skin displays a frayed and moth-eaten
aspect of the elastin with disorganization of microfibrillar
structures. Collagen fibrils show increased and more
variable diameters.
Conclusion: This study describes a novel syndrome
associated with arterial tortuosity and suggests a mechanism
through which altered elastic fiber homeostasis affects
collagen fiber formation. (Grant Reference BOF01N04516)
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C29.4
Transcriptional single-cell atlas of human limb mal-
formation candidate genes
C. A. Prada-Medina1*, G. Cova1, J. Glaser1, C. Dietrich1,
J. Henck1, S. Mundlos1,2, M. A. Mensah2, M. Spielmann1,2
1Max Planck Institute for Molecular Genetics, Berlin,
Germany, 2Institute for Medical Genetics and Human
Genetics Charité, Berlin, Germany
The extensive clinical and genetic heterogeneity of con-
genital limb malformation requires a comprehensive ana-
lysis of genome-wide genetic variation. Large exome and
genome sequencing studies have led to the identification of
hundreds of candidate genes. However, few variants have
been functionally characterized. The sheer number of these
candidate genes makes traditional functional analyses e.g.,
in animal models almost impossible. Therefore, for the vast
majority of patients, the molecular mechanism is still
unknown. In our study, we used high throughput single-cell
transcriptomics to create a reference atlas of candidate genes
during embryonic limb development. We characterized
gene expression of over fifty thousand cells from four cri-
tical days of mouse early limb development (E9.5, E10.5,
E11.5, and E12.5) by performing a single-cell RNA
sequencing. We implemented an unsupervised approach to
identify the general transcriptional patterns of disease-
causing genes during mouse embryonic limb development.
We curated a gene-set of over 1400 genes that are asso-
ciated with limb malformation in mice. 25% of these genes
ranked among the topmost informative gene expression
variances during early limb development. Over sixty of
these genes present cell-type-specific gene expression pat-
terns, mainly in the ectoderm and the apical ectodermal
ridge. We show that mutations in genes expressed during
early limb development are particularly prone to give rise to
limb malformation. Our study provides an atlas of candidate
genes that are co-expressed with known limb disease genes
and represents a resource to study cell-types and molecular
mechanisms involved in limb malformation.
C. A. Prada-Medina: None. G. Cova: None. J. Glaser:
None. C. Dietrich: None. J. Henck: None. S. Mundlos:
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C29.5
Tendon-to-bone attachment cells are bi-fated <and> are
regulated by shared enhancers <and> KLF transcrip-
tion factors
S. Kult1, T. Olender1*, M. Osterwalder2, S. Krief1, R.
Blecher-Gonen1, S. Ben-Moshe1, L. Farack1, H. Keren-
Shaul1, D. Leshkowitz1, T. M. Salame1, T. D. Capellini3, S.
Itzkovitz1, I. Amit1, A. Visel2, E. Zelzer1
1The Weizmann Instiute of Science, Rehovot, Israel, 2Lawr-
ence Berkeley National Laboratory, Berkeley, CA, United
States, 3Harvard University, Cambridge, MA, United States
The mechanical challenge of attaching elastic tendons to
stiff bones is solved by the formation of a unique transi-
tional tissue, the enthesis. A comprehensive molecular
signature of the developing enthesis cells has yet been
uncovered. Here, we show that tendon-to-bone attachment
cells are bi-fated, activating a mixture of chondrocyte and
tenocyte transcriptomes, under regulation of shared reg-
ulatory elements and Krüppel-like factors transcription
factors (KLFs). RNA and ATAC sequencing of embryonic
attachment cells, chondrocytes and tenocytes revealed
expression of both chondrogenic and tenogenic genes by
attachment cells. Indeed, in situ hybridization and single-
molecule ISH showed that attachment cells co-express
tenocyte and chondrocyte markers. ATAC-Seq analyses
combined with ENCODE histone mark data, conservation,
and other datasets revealed that attachment cells are regu-
lated by putative enhancers that are shared with either
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tenocytes or chondrocytes. Transgenic mouse enhancer
reporter assay verified the shared activity of three enhan-
cers, supporting the notion that the mixed transcriptome of
attachment cells is regulated by sharing enhancers with
tenocytes or chondrocytes. Combining over-represented
transcription factor analysis with transcriptome results
suggested a regulatory role for KLFs in attachment cells.
Indeed, blocking expression of Klf2 and Klf4 in the devel-
oping limb mesenchyme impaired attachment cell differ-
entiation, establishing that KLFs are key regulators of the
fate of these cells. Overall, we provide the first molecular
overview of the developing transitional tissue, connecting
tendon to bone, showing that activation of a combination of
cartilage and tendon transcriptomes by the bi-fated attach-
ment cells leads to the formation of a new, intermediate
cell fate.
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C29.6
Identifying targets for osteoporosis via whole exome
sequencing and CRISPR-Cas9
S. Zhou1*, L. Laurent1, J. P. Kemp2, V. Forgetta1, J.
Morris3, A. Pramatarova4, P. I. Croucher5, J. Bassett6, D.
Goltzman7, D. M. Evans2, J. Richards1
1McGill University, Jewish General Hospital, Montreal,
QC, Canada, 2University of Queensland Diamantina
Institute, Translational Research Institute, Brisbane, Aus-
tralia, 3New York Genome Center, New York, NY, United
States, 4McGill University and Genome Quebec Innovation
Centre, Montreal, QC, Canada, 5Garvan Institute of
Medical Research, Sydney, Australia, 6Molecular Endocri-
nology Laboratory, Department of Medicine, Imperial
College London, London, United Kingdom, 7Research
Institute of the McGill University Health Centre, Montreal,
QC, Canada
New drug targets are needed for osteoporosis. It is not
known whether whole exome sequencing (WES) or GWAS
followed by target gene mapping can better identify causal
genes for this disease. To compare these approaches, we
first identified a set of 54 positive control genes whose
perturbation causes a Mendelian form of osteoporosis, or
which act as drug targets for approved therapies. We
undertook sequence kernel association tests (SKATO) to
associate 18,350 autosomal protein-coding genes with
estimated bone mineral density (eBMD), using WES data
of 42,404 white British participants from UK Biobank
and performed a GWAS in the same sample. We
found that WES identified genes were more strongly enri-
ched for positive control genes (odds ratio [OR] = 119,
P= 5.2 × 10−6), and this enrichment was 5-fold higher
compared to enrichment of GWAS-identified genes (OR=
22.5, P= 5 × 10−5). From WES data, we identified 38 genes
with exonic variants with functional impact that collectively
associated with eBMD, one of the most prominent genes
was CADM1 (SKATO, P= 1.8 × 10−9). We used CRISPR-
Cas9 to knockout (KO) CADM1 in SaOS-2 osteoblast cell
lines, suppressing protein abundance at the cell surface,
which resulted in increased expression of early bone mar-
kers: RUNX2, COL1A1/2 and ALPL. We previously
demonstrated that Cadm1 KO mice had reduced bone
mineral content (-3.2 standard deviations [SD]) and strength
(-2.0 SD) compared to wildtype. These findings demon-
strate that WES is a powerful approach to identify genes
influencing bone density, such as CADM1, which could
serve as targets for osteoporosis therapies.
S. Zhou: None. L. Laurent: None. J. P. Kemp: None. V.
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C30 Polygenic Risk Scores: From Tool to Practice
C30.1
Using reference-fixed principal components to improve
polygenic risk score prediction
O. Naret*, J. Fellay
École polytechnique fédérale de Lausanne, Lausanne,
Switzerland
Genome-wide association studies (GWAS) have identified
multiple genetic variants associated with traits or diseases.
They confirmed that most common diseases have a strong
genetic component coming from many genetic variants,
each having a small effect size on disease risk. Using the
summary statistics from highly powered GWAS, it is now
possible to build polygenic risk scores (PRS) that can help
predict the individual risk of common diseases. We here
propose to improve PRS prediction by leveraging popula-
tion stratification due to demographic history, which is a
typical confounding factor removed during GWAS. We
provide a tool that 1) map a discovery cohort to the prin-
cipal component (PC) space of the 1000 Genomes Project
cohort and train a model to associate the phenotype dis-
tribution to this PC space; 2) map a target patient to the
same PC space and use the previously trained model to
compute its PC score. We compared two disease risk
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models, one using PRS only and one using PRS and PC
score jointly. Applying this method to UK Biobank data, we
demonstrate improvement for all tested phenotypes: <10%
for menarche age, blood pressure, BMI, baldness, and
height), 14% for menopause age, 50% for diabetes, 59% for
bone mineral density and 455% for skin color. This
approach has the potential to allow ethnically diverse
populations to benefit from genomic medicine.(Grant:
SNF:175603)
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C30.2
The Polygenic Score (PGS) Catalog: an open database to
enable reproducibility and systematic evaluation
S. A. Lambert1,2,3*, L. GIl2,4, S. Jupp3, M. Chapman2,1,4, H.
Parkinson3,2, J. Danesh1,2,5,4, J. A. L. MacArthur3, M.
Inouye1,2,5,6,7
1University of Cambridge, Cambridge, United Kingdom,
2Health Data Research UK-Cambridge, Wellcome Genome
Campus, Hinxton, United Kingdom, 3European Molecular
Biology Laboratory, European Bioinformatics Institute,
Wellcome Genome Campus, Hinxton, United Kingdom,
4Wellcome Sanger Institute, Wellcome Genome Campus,
Hinxton, United Kingdom, 5National Institute for Health
Research Cambridge Biomedical Research Centre at the
Cambridge University Hospitals NHS Foundation Trust,
Cambridge, United Kingdom, 6Baker Heart and Diabetes
Institute, Melbourne, Australia, 7The Alan Turing Institute,
London, United Kingdom
Introduction: Polygenic [risk] scores (PGS), which
aggregate hundreds-to-millions of genomic variant’s effects
into a single score, can enhance prediction and under-
standing of common diseases and traits. Rapidly-evolving
research into PGS and their potential clinical utility has,
however, been limited by inadequate and/or incomplete
reporting, heterogeneity in evaluation techniques, and
variable performance in populations of non-European
ancestry.
Objective: An accurate understanding of each PGS and
its predictive value is necessary for its application.
Collaborating with the NHGRI-EBI GWAS Catalog, we
have developed the PGS Catalog to provide an open
resource of consistently annotated PGS, to increase their
reproducibility and availability.
Methods: We developed a framework to summarise and
represent PGS. For each PGS we extract metadata
describing the score (rsID, effect allele & weight), its
development and application details, links to GWAS
Catalog summary statistics employed, characteristics of
training/validation cohorts (phenotyping, sample size,
ancestry), and reported performance metrics.
Results: The current PGS Catalog contains over 100
consistently annotated PGS for 43 different traits, distrib-
uted in an open database (www.PGSCatalog.org), initially
focusing on purpose-built PGS developed after 2010 for
cardiometabolic diseases and cancers. The Catalog is
regularly updated to broaden its coverage, and we invite
researchers to submit their PGS to maximize their utility.
We aim to provide a comprehensive resource of available
PGS along with a complete picture of their predictive
accuracy - to this end we outline our upcoming efforts to
systematically evaluate the cataloged PGS in diverse
external cohorts, in order to distribute directly comparable
measures of PGS performance.
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C30.3
Polygenic risk, breast cancer susceptibility genes, and
breast cancer over the life course
N. Mars1*, E. Widén1, T. Meretoja2,3, S. Kerminen1, M.
Pirinen1,4,5, P. Palta1,6, A. Palotie1,7,8, J. Kaprio1,5, H.
Joensuu9,3, M. Daly1,8, S. Ripatti1,5,8
1Institute for Molecular Medicine Finland (FIMM),
HiLIFE, University of Helsinki, Helsinki, Finland, 2Breast
Surgery Unit, Comprehensive Cancer Center, Helsinki
University Hospital, Helsinki, Finland, 3University of
Helsinki, Helsinki, Finland, 4Helsinki Institute for Informa-
tion Technology HIIT and Department of Mathematics and
Statistics, University of Helsinki, Helsinki, Finland,
5Department of Public Health, University of Helsinki,
Helsinki, Finland, 6Estonian Genome Center, Institute of
Genomics, University of Tartu, Tartu, Estonia, 7Psychiatric
& Neurodevelopmental Genetics Unit, Department of
Psychiatry, Analytic and Translational Genetics Unit,
Department of Medicine, and the Department of Neurology,
Massachusetts General Hospital, Boston, MA, United
States, 8Broad Institute of the Massachusetts Institute of
Technology and Harvard University, Cambridge, MA,
United States, 9Comprehensive Cancer Center, Helsinki
University Hospital, Helsinki, Finland
Breast cancer is the most common cancer in women, with
both monogenic and polygenic germline inheritance.
Among 99,969 women in FinnGen, we set out to evaluate
how breast cancer polygenic risk score (PRS) and high-
impact frameshift variants jointly impact the risk of breast
cancer. Secondly, we evaluated whether PRS impacts breast
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cancer mortality in the population, and the risk of recur-
rence and mortality among breast cancer patients.
The lifetime risk of breast cancer (by age 80) for carriers
of two Finnish-enriched frameshift variants, c.1592delT in
PALB2 (242-fold enrichment in Finland, 270 carriers) and
c.1100delC in CHEK2 (3.7-fold enrichment, 1,543 carriers)
was 57% and 32%, respectively. The PRS modifies the
breast cancer risk conferred by the two variants. Women
with PALB2 and average PRS (20-80th percentile) had a
lifetime risk of 56%, which increased to 85% with high PRS
(>90th percentile), and decreased to 27% with low PRS
(<20th percentile). For CHEK2, these lifetime risks were
27%, 59%, and 18%.
We move beyond the simple binary definition of breast
cancer: the PRS was associated with a more severe disease,
both in the population (HR 2.25, 95%CI 1.72-2.95 for
breast cancer-related mortality with a PRS >90th percentile),
and in breast cancer cases (HR 1.21, 95%CI 1.09-1.34 for
risk of breast cancer recurrence; similar results adjusting for
surgery type, age, and stage at diagnosis).
We demonstrate opportunities to improve genetic risk
assessment in breast cancer, both using PRS alone and for
facilitating better management of women carrying muta-
tions in breast cancer susceptibility genes.
N. Mars: None. E. Widén: None. T. Meretoja: None. S.
Kerminen: None. M. Pirinen: None. P. Palta: None. A.
Palotie: None. J. Kaprio: None. H. Joensuu: None. M. Daly:
None. S. Ripatti: None.
C30.4
Genetic assessment of age-associated fracture risk
C. Medina-Gomez1*, K. Trajanoska1, C. Fan2, O. A.
Andreassen3, M. Zillikens1, A. M. Dale2, A. G.
Uitterlinden1, T. M. Seibert2, F. Rivadeneira1
1ErasmusMC, Rotterdam, Netherlands, 2University of
California, San Diego, CA, United States, 3University of
Oslo, Oslo, Norway
Aim: Identifying individuals at risk of early-onset osteo-
porosis is of outmost importance. The largest GWAS to
date, identified 1,103 genetic variants associated with
ultrasound-derived Bone Mineral density (eBMD). We
investigated whether a genetic risk score (GRS) from these
variants would associate with fracture incidence and predict
time to fracture.
Methods: We included in this study 11,351 participants
of the Rotterdam Study with up to 20 years of follow-up.
Incident non-vertebral fractures were reported in 2,153
(19%) individuals. GRS was constructed as a weighted sum
of the number of putative eBMD-decreaser alleles at 1,031
genetic variants. Cox regression and Weibull survival
analysis were implemented adjusting for sex.
Results: An increment of one standard deviation (SD) in
the GRS represented an increase of 1.20 (pv< 2 × 10−16) in
the hazard ratio of fracture. When analyzed in quintiles,
individuals in the highest quintile had 1.52 HR of fracture
(95%CI 1.09-2.11) as compared to these individuals in the
middle quintile, despite their similitude in anthropometric
characteristics (Table 1). In addition, fracture occurred
significantly earlier in the former group (event time ratio=
0.95, 95%CI 0.91-0.99).
Conclusion: Our results suggest that GRS can be used for
personalized genetic risk estimates that can predict for age
at fracture. We show how a suboptimal epidemiological
predictive tool, as ultrasound measurements for fracture
prediction, is leveraged within the genetic framework.
Table 1
Quintiles GRS 1 N=54 2N=1758 3N=6497 4N=2892 5N=150 P
Fracture % 9.2% 14.1% 18.7% 22.4% 24.7% 1.8E-11
HR 0.6 0.7 Ref 1.2 1.5 <2E-16
ETR 1.07 1.04 Ref 0.97 0.95 <2E-16
FN-BMD (g/cm2) 1.00 0.94 0.91 0.87 0.83 <2E-16
Female% 64.0% 58.0% 57.0% 59.0% 58.0% 0.47
Age (yrs) 63.0 65.5 65.2 65.4 65.2 0.86
Weight (kg) 76.5 75.8 76.1 76.5 77.0 0.23
Height (m) 1.67 1.68 1.68 1.68 1.69 0.51
C. Medina-Gomez: None. K. Trajanoska: None. C. Fan:
None. O. A. Andreassen: None. M. Zillikens: None. A. M.
Dale: None. A. G. Uitterlinden: None. T. M. Seibert: None.
F. Rivadeneira: None.
C30.5
Integrative analysis of the plasma proteome and
polygenic risk of cardiometabolic disease
S. C. Ritchie1*, Y. Liu2, S. A. Lambert1, B. G. Drew2, A. C.
Calkin2, A. S. Butterworth1, J. Danesh1, M. Inouye1,2
1University of Cambridge, Cambridge, United Kingdom,
2Baker Heart and Diabetes Institute, Melbourne, Australia
Introduction: Polygenic risk scores (PRSs) capture the
genetic architecture of common diseases by aggregating
genome-wide genetic variation into a single score that
reflects an individual’s disease risk. These present new
opportunities to identify molecular pathways involved in
disease pathogenesis.
Materials and Methods: We performed association
analysis between PRSs and 3,442 plasma proteins using
linear regression models in 3,175 healthy individuals to
identify proteins whose levels associated with PRSs for
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atrial fibrillation, coronary artery disease, chronic kidney
disease, stroke, or type 2 diabetes. Mendelian Randomisa-
tion analysis was used to test whether levels of PRS-
associated proteins were causal of disease risk. Tissue-
specific gene expression levels of PRS-associated proteins
were tested for correlations with cardiometabolic pheno-
types in mouse models. We investigated potential drug
repurposing opportunities by overlaying PRS to protein
associations with drug target information.
Results: We identified 48 proteins whose levels asso-
ciated with PRSs for coronary artery disease, chronic
kidney disease, or type 2 diabetes, including well-known
disease-associated proteins along with novel associations.
Mendelian Randomisation supported a causal effect for
changes in levels of three PRS-associated proteins on
disease. Mouse models revealed strong correlations with
relevant cardiometabolic traits for tissue-specific expression
of seven PRS associated proteins with no previous known
link to cardiometabolic disease. Finally, we identified three
promising potential drug repurposing opportunities where
the effect of on-market drugs on protein levels were
consistent with PRS to protein associations.
Conclusions: Overall, our study provides a framework
for polygenic association studies, demonstrating the power
of PRSs to identify and prioritise novel disease biology.
S. C. Ritchie: None. Y. Liu: None. S. A. Lambert: None.
B. G. Drew: None. A. C. Calkin: None. A. S. Butterworth:
None. J. Danesh: None. M. Inouye: None.
C30.6
Genotyping On ALL patients (GOALL); clinical imple-
mentation of high-throughput genotyping arrays
J. van Rooij*, A. Verkerk, B. Sedaghati-khayat, L. Broer, J.
de Vries, G. van Dijk, J. van Meurs, A. Uitterlinden
Erasmus Medical Centre, Rotterdam, Netherlands
Introduction: Genetic testing is increasingly used in stan-
dard clinical practice. Dense genotyping arrays cover a large
portion of known clinically relevant genetic variation and
provide a cost-effective, high-throughput and highly stan-
dardized alternative. In the GOALL project, we are deter-
mining the clinical utility and applications of genotyping
arrays.
Methods: We investigate the clinical utility of the
GSAMD_v2 and PMDA arrays by: 1) technical validation
of common and rare variants 2) offering polygenic risk
scores (PRS) as primary utility in clinical practice, 3)
prospectively counseling and testing eligibility of feeding
back secondary findings (pharmacogenomics, ACMG
mutations) using array based genotyping. We are piloting
these applications in collaboration with multiple depart-
ments at the Erasmus MC.
Results: Our preliminary results suggest that >90% of the
mutations routinely determined in our hospital are covered
by the array design. We have selected 240 known breast
cancer mutation carriers for array genotyping to check
concordance. Comparison of array vs. WES of 197
population samples shows an overall non-reference con-
cordance of 98%, and 95% for singletons. Population pilot
results demonstrate significant primary case stratification by
PRS for breast cancer, coronary artery disease, myocardial
infarction, osteoarthritis and age-related macular
degeneration.
Discussion: Our preliminary results suggest that a portion
of hospital-wide clinical genetic testing can cost-effectively
be replaced by array-based genotyping. In addition to
reporting highly concordant results, array-based genotyping
allows additional reporting of several PRS, HLA- and
ancestry-typing and pharmacogenomics. This data can
easily be stored and re-analyzed, or unblinded when a
patient requires further (secondary) genetic testing.
J. van Rooij: None. A. Verkerk: None. B. Sedaghati-
khayat: None. L. Broer: None. J. de Vries: None. G. van
Dijk: None. J. van Meurs: None. A. Uitterlinden: None.
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C31.1
"It’s probably nothing, but⋯" Couples’ experiences of
pregnancy following a uncertain prenatal genetic result
S. Lou1,2*, K. Lomborg3, C. Lewis4, S. Riedijk5, O.
Petersen6, I. Vogel1,7
1Center for Prenatal Diagnostics, Aarhus University
Hospital, Aarhus, Denmark, 2Defactum - Public Health &
Health Services Research, Aarhus, Denmark, 3Steno
Diabetes Center Copenhagen, Copenhagen, Denmark,
4London North Genomic Laboratory Hub, Great Ormond
Street Hospital, London, United Kingdom, 5Erasmus
Medical Center, Rotterdam, Netherlands, 6Fetal Medicine
Unit, Department of Obstetrics & Gynecology, Rigshospi-
talet Copenhagen University Hospital, Copenhagen, Den-
mark, 7Department of Clinicial Genetics, Aarhus University
Hospital, Aarhus, Denmark
Introduction: The introduction of Chromosomal Micro-
Array in prenatal testing includes the potential identification
of uncertain copy number variants (CNV) where sig-
nificance and implications for the unborn child can be dif-
ficult or impossible to predict. The aim of this study was to
explore how prospective parents manage uncertainty and
experience pregnancy in light of an uncertain CNV result.
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Material and methods: Qualitative interviews with 16
women and 10 partners who had received a prenatally
diagnosed, uncertain CNV. Participants were interviewed 1-
14 weeks after birth. Data were analyzed using thematic
analysis.
Results: Following the CNV diagnosis, some couples
focused on the severe syndromes ruled out by the result,
while others were more concerned with the new potential
risks, e.g. learning disabilities. During pregnancy, the
couples used various strategies to reduce worry such as
limiting information seeking, reducing talk of the CNV and
deferring thoughts of potential consequences. Furthermore,
additional ultrasound was appreciated by all. Inherited
CNVs caused relief, but also feelings of responsibility for
the child’s potential challenges. After birth, worry
decreased considerably. However, all couples paid extra
attention to the child’s development, while also being alert
to the risk wrongfully interpreting the child’s development
in terms of the CNV. Eleven couples appreciated knowing
about the child’s CNV. Five couples would rather not
have known.
Conclusions: Health professionals should be mindful of
terminology, remember to point out what has been ruled out
by the CNV result, and discuss potential coping strategies
with the couple. Funding: Novo Nordisk Foundation (Grant
NNF16OC0018722)
S. Lou: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; Novo Nordisk Founda-
tion. K. Lomborg: None. C. Lewis: None. S. Riedijk: None.
O. Petersen: None. I. Vogel: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Novo Nordisk
Foundation.
C31.2
Additional Genomic Findings: towards a feasible,
effective model of care
E. Lynch1,2,M. Martyn1,3,4*, L. Lee1,3,4, A. Kanga-Parabia2,
R. Weerasuriya1,3,4, R. Tytherleigh1,3, C. L. Gaff1,3,4
1Melbourne Genomics Health Alliance, Parkville, Austra-
lia, 2Victorian Clinical Genetics Services, Parkville,
Australia, 3Murdoch Children’s Research Institute, Park-
ville, Australia, 4Department of Paediatrics, University of
Melbourne, Parkville, Australia
Genomic sequencing for diagnosis makes possible deliber-
ate analysis for variants predictive of future health risk
(‘additional findings’). Challenges to provision of AF in
public health systems exist but evidence to guide develop-
ment of a feasible, effective model of care is lacking. When
available, AF are offered concurrently with diagnostic
testing. To examine decisions about AF and investigate
other models of care, we offered AF to 200 adults at a
separate genetic counselling appointment after completion
of diagnostic testing (i.e. after results)Patients completed
surveys after AF genetic counselling, after AF result return
and 6 months following last contact with the service.
Consultations were recorded and analysed. Participating
genetic counsellors were interviewed. Eighty three (83/200,
42%) patients attended pre-test counselling with 81 (98%)
accepting AF. Patients felt supported in decision making:
79/83 (95%) agreed the level of information they received
was ‘about right’ and 73/78 (94%) reported counselling was
helpful. Participants and counsellors identified valuable
elements of counselling, including establishing a relation-
ship. Genetic counsellors also reported addressing concerns
and misconceptions yet, despite relatively intensive coun-
selling, 34% (28/83) of participants mistakenly believed the
test was for all known genetic conditions or would provide
information about their primary condition. All respondents
to the post-result survey correctly recalled their AF result
(49/49) but confusion about its implications was evident.
Research is needed to identify communication strategies
that effectively address common AF misconceptions and are
achievable in public health systems in order to realise the
ideal of a feasible, effective service for AF.
E. Lynch: None. M. Martyn: None. L. Lee: None. A.
Kanga-Parabia: None. R. Weerasuriya: None. R. Tyther-
leigh: None. C. L. Gaff: None.
C31.3
Analysis of laboratory exome sequencing reporting
practices using a ‘virtual patient’
D. F. Vears1,2,3,4*, M. G. Elferink5, M. Kriek6, P. Borry1,4,
K. L. van Gassen7
1Centre for Biomedical Ethics and Law, Department of
Public Health and Primary Care,KU Leuven, Leuven,
Belgium, 2University of Melbourne, Carlton, Australia,
3Murdoch Children’s Research Institute, Parkville, Austra-
lia, 4Leuven Institute for Human Genomics and Society,
Leuven, Belgium, 5University of Utrecht, Utrecht, Nether-
lands, 6Leiden University Medical Center, Leiden, Nether-
lands, 7University Medical Center Utrecht, Utrecht,
Netherlands
Studies have suggested that laboratories performing exome
sequencing return different types of results to clinicians.
While some report variants of uncertain significance,
unsolicited findings, and/or secondary findings, others do
not. To investigate the degree of variation in reporting, we
created a ‘virtual patient-parent trio’ by in silico merging
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eight disease-causing variants from patients into “normal”
background exomes. We sent the sequence data and details
of the patient’s phenotype (developmental delay, dys-
morphic features, cardiac hypertrophy), to laboratories
worldwide and asked them to issue a diagnostic report.
Participating laboratories completed a questionnaire to
explain their rationale for (not) reporting each of the var-
iants integrated. Of the 39 participating laboratories, 30
reported the X-linked dominant inherited variant in the
HDAC8 gene, which was the partial cause of the patient’s
phenotype, and 26 reported the de novo BICD2 variant,
which explained another component of the phenotype.
Laboratories who did not report these variants explained
they used either a filter or a targeted gene panel that
excluded the variant, or they did not consider the variant to
be responsible for the phenotype. There was also variation
in reporting associated with the cardiac phenotype; 30
reported MYBPC3 and only 16 reported PLN, often due to
the filtering strategies used. Reporting of unsolicited/sec-
ondary findings also varied widely. We identified con-
siderable variability in reporting of disease-causing variants,
primarily due to different analysis strategies. This sig-
nificantly impacts whether causative variants are identified,
with important implications for patients. Analysis strategy
best-practice guidelines may help reduce variability and
improve patient care.
D. F. Vears: None. M. G. Elferink: None. M. Kriek:
None. P. Borry: None. K. L. van Gassen: None.
C31.4
Knowledge, attitudes and preparedness for polygenic
risk testing in clinical practice: a cross-sectional survey
of health professionals
A. K. Smit1*, A. E. Cust1, K. Dunlop1, M. Young2, B.
Meiser3, J. Tiller4, T. Yanes5,3
1The University of Sydney, Sydney, Australia, 2Garvan
Institute of Medical Research, Sydney, Australia, 3Univer-
sity of New South Wales, Sydney, Australia, 4Monash
University, Melbourne, Australia, 5University of Queens-
land, Woolloongabba, Australia
Introduction: Strategies to prepare and support health
professionals for the potentialimplementation of polygenic
risk scores (PRS) into clinical practice are required.
Materials and Methods: An anonymous questionnaire
was distributed online byprofessional organisations in
Australia, New Zealand, Canada and the US. Eligibleparti-
cipants were health professionals who provide cancer risk
assessments. Knowledge,perceived self-efficacy, concerns,
benefits and expectations for the future clinical
applicationof PRS were described. Content analysis was
undertaken of free-text responses.
Results: A total of 128 health professionals took part in
the questionnaire (geneticcounsellors n=86%; oncologists
n=5%; clinical geneticists n=4%; other n=5%). Many
haddiscussed PRS with a patient (61%), but only 20%
reported having ordered a test. Over half(69%) reported that
the use of PRS in future clinical practice was certain or
likely. Many(49%) reported that general practitioners would
have a primary role in the provision of PRS,supported by
genetics health professionals. Overall, confidence in
explaining PRS to patientswas low, and participants
reported concern about insufficient health professional
resources,uncertainty about individual risk and barriers to
obtaining life insurance. Perceived benefitsof PRS included
greater incentive for patients to engage in preventive
behaviours and accessto increased or tailored surveillance
and screening.
Conclusions: Our findings demonstrate that health
professionals are already providingpolygenic risk informa-
tion, although fewer are ordering testing, and there is a need
foreducational and point-of-contact resources to support this
process. These findings will informthe development of
implementation strategies for incorporating PRS into
clinical practice.
A. K. Smit: None. A. E. Cust: None. K. Dunlop: None.
M. Young: None. B. Meiser: None. J. Tiller: None. T.
Yanes: None.
C31.5
Impact of the discussion of uncertainty on former
counselees’ outcomes. An experimental vignettes study
N. Medendorp1*, M. Hillen1, C. Aalfs2, A. Stiggelbout3, E.
Smets1
1Amsterdam UMC, Amsterdam, Netherlands, 2University
Medical Center Utrecht, Utrecht, Netherlands, 3Leiden
University Medical Center, Leiden, Netherlands
Introduction: Uncertainty increasingly needs to be dis-
cussed during cancer genetic counseling due to technolo-
gical developments. How discussions about uncertainty
affect counselees may depend on communication style.
Ideally, counselees are enabled to deal with uncertainty and
make well-informed decisions. We tested the impact of
different ways of conveying uncertainty and addressing
counselees’ uncertainty on counselees’ outcomes, and
explored moderating effects of counselees’ characteristics.
Materials and methods: Former counselees viewed one
(out of six) randomly assigned video depicting a consultation
involving the discussion of a multigene panel test. In a 2x3
design geneticists’ communication of uncertainty
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(comprehensive vs. gist) and responses to counselees’
uncertainty expressions (providing information vs. providing
space vs. balancing uncertainty) were systematically manipu-
lated. Before and after watching, participants completed
questionnaires. Primary outcome was feelings of uncertainty.
Results: Preliminary analyses were performed on 91%
(n=178) of the required sample. Communication of
uncertainty was successfully manipulated: the comprehen-
sive version was perceived as more detailed (p=. 099).
However, differences in how responses to counselees’
uncertainty expressions were not perceived (p=.303). No
effects on feelings of uncertainty were found for geneticists’
communication about uncertainty (p=.323), or response
style (p=.630). Statistical analysis on the complete dataset,
including effects on secondary outcomes and moderating
effects of counselees’ characteristics will be performed and
discussed.
Conclusions: Preliminary analysis showed that different
manners of communicating uncertainty and addressing
counselees’ uncertainty expressions did not lead to
differences in feelings of uncertainty. Findings will inform
a training intervention to support geneticists in discussing
uncertainty.
Funding: Dutch Cancer Society (KWF Kankerbestrijding;
UvA 2015-7607)
N. Medendorp: None. M. Hillen: None. C. Aalfs: None.
A. Stiggelbout: None. E. Smets: None.
C31.6
Primary Care Genomics: A roadmap for curriculum
change and educational resource development
J. Hayward1,2,3, I. Rafi1, S. Simpson2, E. Miller2, A. Seller2,
M. Bishop2*
1Royal College of General Practitioners, London, United
Kingdom, 2Genomics Education Programme, Birmingham,
United Kingdom, 3Yorkshire and Humber Genomics
Medicine Centre, Leeds, United Kingdom
Health Education England’s Genomics Education Pro-
gramme (GEP) has developed a roadmap for defining
General Practitioners’ (GPs) learning needs and identifying
priorities for resource development, suitable for adoption by
other specialties. With the implementation of England’s
National Health Service’s (NHS) Genomic Medicine Ser-
vice, genomic information will be used within routine
clinical care by an increasing number of specialties. The
GEP exists to ensure NHS staff are prepared for the inte-
gration of genomics into clinical practice. With the Royal
College of General Practitioners (RCGP), the GEP devised
a three-stage process - plan; develop; deliver - to identify
GPs’ learning requirements and appropriate interventions.
Using the Delphi method, an expert working group (n=30),
comprising GPs, genetic specialists, patients and educa-
tionalists, identified 22 themes around the knowledge, skills
and behaviours GPs require to manage clinical activities
involving genomics (stage 1). Alongside this, a desktop
exercise (stage 2) mapped genetic/genomic education
resources relevant to GPs through targeted searches of
organisational websites, supplemented by web searches.
From these, resources from 21 organisations were identi-
fied. Next, a gap analysis (stage 3) mapped resources from
stage 2 against the knowledge, skills and behaviours from
stage 1, establishing a list of resources requiring develop-
ment. These resources, with those identified in stage 2,
formed the foundation of an education toolkit, hosted on the
RCGP website. Findings from stage 1 also informed the
revised RCGP training curriculum for GPs. The toolkit has
become a go-to destination for GPs learning about geno-
mics, and its development roadmap can be adopted by other
specialties.
J. Hayward: None. I. Rafi: None. S. Simpson: None. E.
Miller: None. A. Seller: None. M. Bishop: None.
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